NZ618079B2 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives - Google Patents
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives Download PDFInfo
- Publication number
- NZ618079B2 NZ618079B2 NZ618079A NZ61807912A NZ618079B2 NZ 618079 B2 NZ618079 B2 NZ 618079B2 NZ 618079 A NZ618079 A NZ 618079A NZ 61807912 A NZ61807912 A NZ 61807912A NZ 618079 B2 NZ618079 B2 NZ 618079B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkylene
- ome
- substituted
- group
- alkyl
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 553
- AMRJKAQTDDKMCE-UHFFFAOYSA-N Dolastatin Chemical class CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title description 55
- 229920001184 polypeptide Polymers 0.000 claims abstract description 342
- -1 amino acid dolastatin analogs Chemical class 0.000 claims abstract description 189
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 93
- 125000004989 dicarbonyl group Chemical group 0.000 claims abstract description 66
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims abstract description 38
- 150000002923 oximes Chemical class 0.000 claims abstract description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 255
- 150000001875 compounds Chemical class 0.000 claims description 255
- 125000000217 alkyl group Chemical group 0.000 claims description 181
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 146
- 229920000023 polynucleotide Polymers 0.000 claims description 129
- 239000002157 polynucleotide Substances 0.000 claims description 129
- 229910020008 S(O) Inorganic materials 0.000 claims description 109
- 125000004450 alkenylene group Chemical group 0.000 claims description 103
- 125000005647 linker group Chemical group 0.000 claims description 99
- 239000011347 resin Substances 0.000 claims description 88
- 229920005989 resin Polymers 0.000 claims description 88
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 85
- 150000003839 salts Chemical class 0.000 claims description 72
- 239000011780 sodium chloride Substances 0.000 claims description 72
- 150000002148 esters Chemical class 0.000 claims description 67
- 229910052739 hydrogen Chemical group 0.000 claims description 67
- 108090001123 antibodies Proteins 0.000 claims description 64
- 102000004965 antibodies Human genes 0.000 claims description 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 63
- 125000000732 arylene group Chemical group 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 55
- 150000002367 halogens Chemical class 0.000 claims description 55
- 125000005549 heteroarylene group Chemical group 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 51
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 49
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 47
- 125000006239 protecting group Chemical group 0.000 claims description 45
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 42
- 150000001299 aldehydes Chemical class 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 239000001257 hydrogen Chemical group 0.000 claims description 38
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 36
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
- 150000002576 ketones Chemical class 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 229940035295 Ting Drugs 0.000 claims description 26
- 230000002378 acidificating Effects 0.000 claims description 26
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 25
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 25
- 150000007970 thio esters Chemical class 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims description 23
- 125000004419 alkynylene group Chemical group 0.000 claims description 23
- 150000004985 diamines Chemical class 0.000 claims description 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 150000002500 ions Chemical class 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 150000001345 alkine derivatives Chemical class 0.000 claims description 17
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 16
- 150000002466 imines Chemical class 0.000 claims description 16
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 150000001409 amidines Chemical class 0.000 claims description 13
- 108010010691 Trastuzumab Proteins 0.000 claims description 12
- 229960000575 trastuzumab Drugs 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 11
- 150000003973 alkyl amines Chemical class 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 150000003568 thioethers Chemical class 0.000 claims description 8
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims description 7
- 125000005907 alkyl ester group Chemical group 0.000 claims description 7
- 150000007860 aryl ester derivatives Chemical class 0.000 claims description 7
- 150000002825 nitriles Chemical class 0.000 claims description 7
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 150000001350 alkyl halides Chemical class 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical group C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 101710019694 COR8 Proteins 0.000 claims 6
- 125000004416 alkarylalkyl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 43
- 238000006011 modification reaction Methods 0.000 abstract description 31
- 230000004048 modification Effects 0.000 abstract description 29
- 230000001225 therapeutic Effects 0.000 abstract description 27
- 235000001014 amino acid Nutrition 0.000 description 543
- 125000000547 substituted alkyl group Chemical group 0.000 description 93
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 74
- 229920000642 polymer Polymers 0.000 description 72
- 210000004027 cells Anatomy 0.000 description 44
- 150000004676 glycans Polymers 0.000 description 39
- 229920001282 polysaccharide Polymers 0.000 description 39
- 239000005017 polysaccharide Substances 0.000 description 39
- 150000004804 polysaccharides Polymers 0.000 description 39
- 239000003814 drug Substances 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 33
- 239000000126 substance Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 229940079593 drugs Drugs 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 229920001223 polyethylene glycol Polymers 0.000 description 27
- 239000002202 Polyethylene glycol Substances 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 25
- 125000000524 functional group Chemical group 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 230000002588 toxic Effects 0.000 description 24
- 231100000331 toxic Toxicity 0.000 description 24
- 230000036499 Half live Effects 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 125000004427 diamine group Chemical group 0.000 description 21
- 239000000651 prodrug Substances 0.000 description 21
- 229940002612 prodrugs Drugs 0.000 description 21
- 125000003544 oxime group Chemical group 0.000 description 20
- 125000004429 atoms Chemical group 0.000 description 18
- 230000001965 increased Effects 0.000 description 18
- 125000003107 substituted aryl group Chemical group 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 210000002966 Serum Anatomy 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- 230000000051 modifying Effects 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 230000004481 post-translational protein modification Effects 0.000 description 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 101710008209 FBLIM1 Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 150000004982 aromatic amines Chemical class 0.000 description 11
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000002609 media Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000010511 deprotection reaction Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000002194 synthesizing Effects 0.000 description 10
- 229920003169 water-soluble polymer Polymers 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 229940022353 Herceptin Drugs 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 9
- 230000002708 enhancing Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 9
- 230000000670 limiting Effects 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000004473 Threonine Substances 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 125000005842 heteroatoms Chemical group 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 230000036912 Bioavailability Effects 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000001588 bifunctional Effects 0.000 description 7
- 230000035514 bioavailability Effects 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 230000001413 cellular Effects 0.000 description 7
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000206602 Eukaryota Species 0.000 description 6
- 229920000272 Oligonucleotide Polymers 0.000 description 6
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 239000003398 denaturant Substances 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 229940093476 ethylene glycol Drugs 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229940020899 hematological Enzymes Drugs 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Natural products C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 5
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 230000035071 co-translational protein modification Effects 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000000269 nucleophilic Effects 0.000 description 5
- 150000002482 oligosaccharides Polymers 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001515 polyalkylene glycol Polymers 0.000 description 5
- 229920000570 polyether Polymers 0.000 description 5
- 230000001323 posttranslational Effects 0.000 description 5
- 239000003638 reducing agent Substances 0.000 description 5
- 125000005017 substituted alkenyl group Chemical group 0.000 description 5
- 125000005415 substituted alkoxy group Chemical group 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 229960001230 Asparagine Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 229960002989 Glutamic Acid Drugs 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 230000037165 Serum Concentration Effects 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000006352 cycloaddition reaction Methods 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229930003347 taxol Natural products 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-Hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- DHIGSAXSUWQAEI-UHFFFAOYSA-N Hydrazine azide Chemical compound NNN=[N+]=[N-] DHIGSAXSUWQAEI-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- SHTFZHTWSLHVEB-BDNRQGISSA-N Lineatin Chemical compound O1C(C)(C)[C@H]2[C@@]3(C)C[C@@H]1O[C@@H]2C3 SHTFZHTWSLHVEB-BDNRQGISSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229920002521 Macromolecule Polymers 0.000 description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 3
- 230000035633 Metabolized Effects 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 229960005190 Phenylalanine Drugs 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 229920001451 Polypropylene glycol Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229940055619 Selenocysteine Drugs 0.000 description 3
- ZKZBPNGNEQAJSX-REOHCLBHSA-N Selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 3
- FDKWRPBBCBCIGA-UWTATZPHSA-N Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- UNXHWFMMPAWVPI-QWWZWVQMSA-N Threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000007801 affinity label Substances 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 108010044540 auristatin Proteins 0.000 description 3
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001615 biotins Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 229920001002 functional polymer Polymers 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atoms Chemical group O* 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 230000002441 reversible Effects 0.000 description 3
- 235000016491 selenocysteine Nutrition 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000004434 sulfur atoms Chemical group 0.000 description 3
- 125000005309 thioalkoxy group Chemical group 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 229960005261 Aspartic Acid Drugs 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N Dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000205062 Halobacterium Species 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 229960004716 Idoxuridine Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229960004961 Mechlorethamine Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- ADJJYEZPSBDGGL-UHFFFAOYSA-N N'-[3-[(2-methoxyphenyl)methyl-methylamino]propyl]-N'-methylpropane-1,3-diamine Chemical group COC1=CC=CC=C1CN(C)CCCN(C)CCCN ADJJYEZPSBDGGL-UHFFFAOYSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000772415 Neovison vison Species 0.000 description 2
- 108091005503 Nucleic proteins Proteins 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 241000143392 Oar Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N Pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010928 TGA analysis Methods 0.000 description 2
- 229960001967 Tacrolimus Drugs 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- QWDZADMNIUIMTC-UHFFFAOYSA-N Uranyl nitrate Chemical compound [O-][N+](=O)O[U-2](=O)(=O)O[N+]([O-])=O QWDZADMNIUIMTC-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N aminothiourea Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 230000000259 anti-tumor Effects 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 108010045524 dolastatin 10 Proteins 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 125000000879 imine group Chemical group 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000005291 magnetic Effects 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GNRSAWUEBMWBQH-UHFFFAOYSA-N nickel(II) oxide Inorganic materials [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 238000005935 nucleophilic addition reaction Methods 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 230000003285 pharmacodynamic Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2S)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- DVOOWDFPPNOBFV-UHFFFAOYSA-N (3E)-penta-1,3-diene Chemical group C=C[CH]C=C DVOOWDFPPNOBFV-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- PMMURAAUARKVCB-YLZRJQLMSA-N (4R,5R)-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound OCC1OC(O)C[C@@H](O)[C@H]1O PMMURAAUARKVCB-YLZRJQLMSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- CRPTXKKKIGGDBX-UHFFFAOYSA-N (Z)-but-2-ene Chemical group [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N 2-[dodecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- PMMURAAUARKVCB-CERMHHMHSA-N 2-deoxy-D-glucopyranose Chemical compound OC[C@H]1OC(O)C[C@@H](O)[C@@H]1O PMMURAAUARKVCB-CERMHHMHSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- WGLQHUKCXBXUDV-UHFFFAOYSA-L 3-aminophthalate Chemical compound NC1=CC=CC(C([O-])=O)=C1C([O-])=O WGLQHUKCXBXUDV-UHFFFAOYSA-L 0.000 description 1
- PCXDJQZLDDHMGX-UHFFFAOYSA-O 3-ammoniopropanal Chemical compound [NH3+]CCC=O PCXDJQZLDDHMGX-UHFFFAOYSA-O 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 description 1
- QUHGSDZVAPFNLV-UHFFFAOYSA-N 4-[(5-acetamidofuran-2-carbonyl)amino]-N-[3-(dimethylamino)propyl]-1-propylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCCN(C)C)N(CCC)C=C1NC(=O)C1=CC=C(NC(C)=O)O1 QUHGSDZVAPFNLV-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N 6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-Yl)-3-Methylquinoline-4-Carboxylic Acid Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M AC1L4ZKD Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229940023040 Acyclovir Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- QGAVSDVURUSLQK-UHFFFAOYSA-N Ammonium heptamolybdate Chemical compound N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo] QGAVSDVURUSLQK-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000205042 Archaeoglobus fulgidus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 241000770536 Bacillus thermophilus Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N Benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 229950010231 Brequinar Drugs 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
- 229920002574 CR-39 Polymers 0.000 description 1
- OKIIEJOIXGHUKX-UHFFFAOYSA-L Cadmium iodide Chemical compound [Cd+2].[I-].[I-] OKIIEJOIXGHUKX-UHFFFAOYSA-L 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 Carbenicillin Drugs 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N Carbohydrazide Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 229950009017 Cemadotin Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 229960000724 Cidofovir Drugs 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovirum Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- ZDLBNXXKDMLZMF-UHFFFAOYSA-N Cinitapride Chemical compound CCOC1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1CCN(CC2CC=CCC2)CC1 ZDLBNXXKDMLZMF-UHFFFAOYSA-N 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 229940099500 Cystamine Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229940119025 Cysteamine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N DAPTOMYCIN Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 101700061444 DDX25 Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960005484 Daptomycin Drugs 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 229960003109 Daunorubicin Hydrochloride Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960000633 Dextran Sulfate Drugs 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UVYVLBIGDKGWPX-SPPYGRLSSA-N Digitonin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H](O)C[C@]3(C)[C@@H]4[C@H]([C@@H]5[C@H](O)[C@@H]6O[C@]7([C@@H](C)[C@@H]6[C@@]5(C)CC4)OC[C@H](C)CC7)CC[C@H]3C2)O[C@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1 UVYVLBIGDKGWPX-SPPYGRLSSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N Dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 108010009858 Echinomycin Proteins 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N Eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N Furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920002391 Guide RNA Polymers 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- FXNFULJVOQMBCW-JWNPXFETSA-N Halichondrin B Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-JWNPXFETSA-N 0.000 description 1
- 241000204933 Haloferax volcanii Species 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 229940042795 Hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- WEVJJMPVVFNAHZ-RRKCRQDMSA-N Ibacitabine Chemical compound C1=C(I)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 WEVJJMPVVFNAHZ-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- PSCMQHVBLHHWTO-UHFFFAOYSA-K Indium(III) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 1
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N Isatin Chemical class C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- RLJMLMKIBZAXJO-UHFFFAOYSA-N Lead(II) nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003151 Mercaptamine Drugs 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- 241001302042 Methanothermobacter thermautotrophicus Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O Methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 229960003152 Metisazone Drugs 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N Moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OKPYIWASQZGASP-UHFFFAOYSA-N N-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 description 1
- AUJXLBOHYWTPFV-CVLRASHMSA-N N-[(1R,4R,7R,11S,14R,17R,20R,24S)-2,4,12,15,17,25-hexamethyl-29-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-7-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-20-yl]quinoxaline-2-carbo Chemical compound C([C@H](C(=O)N[C@H](C)C(=O)N1C)NC(=O)C=2N=C3C=CC=CC3=NC=2)OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]1CSC2SC AUJXLBOHYWTPFV-CVLRASHMSA-N 0.000 description 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N N-[(2R,3R,4S,5R)-4,5,6-trihydroxy-1-oxo-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 1
- CMEGANPVAXDBPL-INIZCTEOSA-N N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N N-methylidenehydroxylamine Chemical group ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- IDBIFFKSXLYUOT-UHFFFAOYSA-N Netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- 229960000689 Nevirapine Drugs 0.000 description 1
- 229910003301 NiO Inorganic materials 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N O(4)-phospho-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229960001699 Ofloxacin Drugs 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- TVIDEEHSOPHZBR-AWEZNQCLSA-N PARA-(BENZOYL)-PHENYLALANINE Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C(=O)C1=CC=CC=C1 TVIDEEHSOPHZBR-AWEZNQCLSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N Phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229950008646 Pirozadil Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229920001748 Polybutylene Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229940072288 Prograf Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000522615 Pyrococcus horikoshii Species 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N RIFABUTIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N RIFAXIMIN Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N Rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N Sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 241001111950 Sonora Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 229960001203 Stavudine Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N Telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 229960005240 Telavancin Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N Tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- 229950001353 Tretamine Drugs 0.000 description 1
- 229960003962 Trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 229940008349 Truvada Drugs 0.000 description 1
- 101700013217 U312 Proteins 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclover Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960002110 Vincristine Sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- 229960001028 Zanamivir Drugs 0.000 description 1
- DLGSOJOOYHWROO-WQLSENKSSA-N [(Z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001388 anti-tubulin Effects 0.000 description 1
- 229940045695 antineooplastic Colchicine derivatives Drugs 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 238000001593 atomic mass spectrometry Methods 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- 230000001851 biosynthetic Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940075417 cadmium iodide Drugs 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229960001411 chlormethine Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- DRXGWTUAIWQOKN-UHFFFAOYSA-L dihydroxy(dioxo)molybdenum;phosphonic acid Chemical compound OP(O)=O.O[Mo](O)(=O)=O DRXGWTUAIWQOKN-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000007337 electrophilic addition reaction Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229930013349 epothilone B Natural products 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940112424 fosfonet Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000000855 fungicidal Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 125000005252 haloacyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium(0) Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960000374 ibacitabine Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- MCEUZMYFCCOOQO-UHFFFAOYSA-L lead diacetate trihydrate Chemical compound O.O.O.O1C(C)=O[Pb]21O=C(C)O2 MCEUZMYFCCOOQO-UHFFFAOYSA-L 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- NMKUAEKKJQYLHK-KRWDZBQOSA-N methyl (7S)-7-acetamido-1,2,3-trimethoxy-6,7-dihydro-5H-dibenzo[5,3-b:1',2'-e][7]annulene-9-carboxylate Chemical compound CC(=O)N[C@H]1CCC2=CC(OC)=C(OC)C(OC)=C2C2=CC=C(C(=O)OC)C=C21 NMKUAEKKJQYLHK-KRWDZBQOSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000004971 nitroalkyl group Chemical class 0.000 description 1
- FYWSTUCDSVYLPV-UHFFFAOYSA-N nitrooxythallium Chemical compound [Tl+].[O-][N+]([O-])=O FYWSTUCDSVYLPV-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 230000005298 paramagnetic Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical class NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 238000001907 polarising light microscopy Methods 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- MIMJFNVDBPUTPB-UHFFFAOYSA-N potassium hexacyanoferrate(3-) Chemical compound [K+].[K+].[K+].N#C[Fe-3](C#N)(C#N)(C#N)(C#N)C#N MIMJFNVDBPUTPB-UHFFFAOYSA-N 0.000 description 1
- OCPOWIWGGAATRP-UHFFFAOYSA-N potassium hexacyanoferrate(4-) Chemical compound [K+].[K+].[K+].[K+].N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N OCPOWIWGGAATRP-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001603 reducing Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- ZXYSDUPLHOJIOR-UHFFFAOYSA-H ruthenium red Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[NH3+][Ru-3]([NH3+])([NH3+])([NH3+])([NH3+])O[Ru-2]([NH3+])([NH3+])([NH3+])([NH3+])O[Ru-3]([NH3+])([NH3+])([NH3+])([NH3+])[NH3+] ZXYSDUPLHOJIOR-UHFFFAOYSA-H 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- IXPWAPCEBHEFOV-UHFFFAOYSA-J sodium tetrachloroaurate Chemical compound [Na+].Cl[Au-](Cl)(Cl)Cl IXPWAPCEBHEFOV-UHFFFAOYSA-J 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- NRUKOCRGYNPUPR-PSZSYXFXSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4OC(OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-PSZSYXFXSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000005730 thiophenylene group Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 229960001234 valaciclovir Drugs 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
- 238000002460 vibrational spectroscopy Methods 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 125000002256 xylenyl group Chemical group C1(C(C=CC=C1)C)(C)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Abstract
The disclosure relates to non-natural amino acids and dolastatin analogs (formula (I)) that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Further disclosed are methods for using such non-natural amino aciddolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use. ve at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Further disclosed are methods for using such non-natural amino aciddolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
Description
COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL
AMINO ACID LINKED DOLASTATIN DERIVATIVES
CROSS REFERENCE
This application claims priority to US. Provisional Application No. 61/491,146, entitled,
“Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin
tives,” filed May 27, 2011, the contents of Which are incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
The ability to incorporate non-genetically encoded amino acids (i.e., “non-natural amino )
into proteins permits the introduction of al functional groups that could provide valuable
alternatives to the naturally-occurring onal groups, such as the epsilon —NH2 of , the
sulfliydryl —SH of cysteine, the imino group of histidine, etc. Certain chemical functional groups are
known to be inert to the functional groups found in the 20 common, genetically-encoded amino acids but
react cleanly and efficiently to form stable linkages With functional groups that can be orated onto
non-natural amino acids.
Methods are now available to selectively introduce al functional groups that are not found
in proteins, that are chemically inert to all of the functional groups found in the 20 common, genetically-
d amino acids and that may be used to react efficiently and selectively with reagents comprising
certain functional groups to form stable covalent linkages.
SUMMARY OF THE INVENTION
Disclosed herein are toxic moieties with one or more linker(s), toxic groups linked to non-natural
amino acids, and methods for making such non-natural amino acids and polypeptides.
Some embodiments of the present invention describe a compound, or salt f, comprising
Formula (1):
may,R70 /\ Me OMeO
wherein:
Z has the structure of:
€Yé\(KAr
R5 ;
R5 is H, CORg, C1-C6alkyl, or thiazole;
R8 is OH or —NH—(alkylene—O)n—NH2;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
Y is selected from the group consisting of an hydroxylamine, methyl, aldehyde, ted
aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, amidine, imine,
diamine, azide, keto-amine, keto-alkyne, alkyne, cycloalkyne, and ene-dione;
L is a linker selected from the group consisting of —alkylene—, —alkylene—C(O)—, lene—O)n—
alkylene—, —(alkylene—O)n—alkylene—C(O)—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nv~
—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, —(alkylene—O)n—alkylene—W—, —
alkylene—C(O)—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, and lene—O)n—
alkylene—U—alkylene—;
W has the structure of:
ILWJUCVJK;
U has the structure of:
COZH
,nmiwr
or L is absent, Y is methyl, R5 is CORg, and R8 is —NH—(alkylene—O)n—NH2; and
each n, n', n", n'" and nH" are independently integers greater than or equal to one.
In some embodiments, R5 is le. In other embodiments, R6 is H. In n embodiments, Ar
is phenyl. In further or additional embodiments, R7 is methyl. In some embodiments, n is an integer from
Ot020,0to 10 orOtoS.
In some embodiments, a compound is described comprising Formula (II):
Me Me
H2N\ /L\ N
O N a N
R7 0 /_\ Me OMeO
Me Me MeO NH
In certain embodiments, L is —(alkylene—O)n—alkylene—. In specific embodiments, each alkylene is —
CHQCH2—, n is equal to 3, and R7 is methyl. In other embodiments, L is —alkylene—. In specific
embodiments, each alkylene is —CH2CH2— and R7 is methyl or hydrogen. In certain embodiments, L is —
(alkylene—O)n—alkylene—C(O)—. In certain specific embodiments, each alkylene is 2—, n is equal
to 4, and R7 is methyl. In further or alternative embodiments, L is —(alkylene—O)n—(CH2)nv—NHC(O)—
(CH2)nu—C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—. In specific ments, each
alkylene is —CH2CH2—, n is equal to l, n' is equal to 2, n" is equal to l, n '" is equal to 2, n"" is equal to 4,
and R7 is methyl.
In some embodiments, Y is azide. In other ments, Y is ctyne. In specific
embodiments, the cyclooctyne has a structure of:
|©—§
(R19)q
each R19 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, ester,
ether, thioether, aminoalkyl, halogen, alkyl ester, aryl ester, amide, aryl amide, alkyl halide,
alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, halosulfonyl, nitrile,
alkyl nitrile, and nitro; and
qis 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10 or 11.
Some embodiments of the present invention be a compound, or salt thereof, comprising
Formula (III), (IV), (V) or (VI):
L2—N:[IfeN\)J\18%:0 “'9
R7 0 MAMeMe OMeOM
Y’ (III)
L3—N:[IMfNfiJJi/IN Me
R7 0 Me/_\MeMe OMeOM
Me\N MeNjN Me
Me O Me OMeO
MeO NH O
348%HN—L2
Me (IV)
Me\N MeNjLN
Me O Me/\MeMe OMeOM
mNHHN—L3
Rw¥Q>R70 /\ Me OMeO
Y] Me
L3_N meNi/IN Me
R7 0 Me/\MeMe OMeOM N\H
J o 2
L4—N Mai/IN Me
R7 0 Me/\MeMe OMeOM NH
/\ Me OMe O
Me Me MeO NH HN—L4
wherein:
Z has the structure of:
€Yé\(KAr
R5 ;
R5 is H, CORg, C1-C6alkyl, or thiazole;
R8 is OH;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
Y and V are each selected from the group consisting of an ylamine, methyl, aldehyde,
protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, amidine,
imine, diamine, azide, keto-arnine, lkyne, alkyne, lkyne, and ene-dione;
L1, L2, L3, and L4 are each linkers independently selected from the group consisting of a bond, —
alkylene—, —(alkylene—O)n—alkylene—J—, ene'—J—(alkylene—O)n—alkylene—, —J—
(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—J—(alkylene—O)n'—alkylene—J'—, —
(alkylene—O)n—alkylene—J—alkylene'—, —W—, —alkylene—W—, alkylene'—J—(alkylene—NMe)n—
alkylene—W—, —J—(alkylene—NMe)n—alkylene—W—, —J—alkylene—NMe—alkylene'—NMe—
alkylene"—W—, and —alkylene— —alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
Me Me k5;
o KW\H
04;\NH2 ;
each I and J' independently have the structure of:
zit/iiN/‘Zi fiNiO/‘Zi or ‘fiNié’;
H H H
, , ,mm
each n and n' are independently integers greater than or equal to one.
In n embodiments, a compound is described sing a (VII):
Me Me 0M9
M H
e\'\ll ; ".1 Me
Me O /_\ Me OMeO
Me Me MeO NHoHNL2
”Mgr“?fry WU)
Me O Me/\MeMe OMeOM
NHeReoL1>7VHN—L3
In certain embodiments, L1 is —(alkylene—O)n—alkylene—J—, L2 is —alkylene'—J'—(alkylene—O)n'—
alkylene—, L3 is —J"—(alkylene—O)n"—alkylene—, alkylene is 2—, alkylene' is —(CH2)4—, n is l, n' and
jiNfl; J5:
NiO/EL
n" are 3, J has the structure of H J' and J" have the structure of H and R7 is methyl.
, ,
In other embodiments, L1 is —J—(alkylene—O)n—alkylene—, L2 is —(alkylene—O)nbalkylene—J'—alkylene'—, L3
is —(alkylene—O)nu—alkylene—J"—, alkylene is —CH2CH2—, alkylene' is —(CH2)4—, n is l, n' and n" are 4, and
all;
I, J' and I" have the ure of H
In some embodiments, Y is azide. In other embodiments, Y is cyclooctyne. In specific
embodiments, the cyclooctyne has a structure of:
|©—§
(R19)q
each R19 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, ester,
ether, thioether, aminoalkyl, n, alkyl ester, aryl ester, amide, aryl amide, alkyl halide,
alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, halosulfonyl, nitrile,
alkyl e, and nitro; and
qis 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10 or 11.
Certain ments of the present invention describe a compound comprising Formula (VIII) or
(IX):
(VIII)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
lkylene, substituted lower cycloalkylene, lower alkenylene, substituted lower
alkenylene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
substituted aralkylene,
B is optional, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower
alkylene, substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -
S-, -S-(alkylene or substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or
substituted ne)-, , -C(O)-(alkylene or tuted alkylene)-, -C(S)-, -C(S)-
(alkylene or substituted alkylene)-, -N(R’)-, -NR’-(alkylene or substituted alkylene)-,
-C(O)N(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene
or substituted alkylene)-, -N(R’)CO-(alkylene or substituted ne)-, -N(R’)C(O)O-,
-S(0)kN(R’)-, C(O)N(R’)-, _N(R’)C(S)N(R’)_a -N(R’)S(O)kN(R’)-, -N(R’)-N=, -
C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where
each R’ is independently H, alkyl, or substituted alkyl,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or cleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R3 and R4 are each independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4
or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
Z has the ure of:
€Yé\(KAr
R5 ;
R5 is H, COZH, C1-C6alkyl, or thiazole;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
L is a linker selected from the group consisting of ene—, —alkylene—C(O)—, —(alkylene—O)n—
alkylene—, —(alkylene—O)n—alkylene—C(O)—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nv~
C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, lene—O)n—alkylene—W—, —
alkylene—C(O)—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, and —(alkylene—O)n—
ne—U—alkylene—;
W has the structure of:
Lwflfifk“;
U has the structure of:
COZH
Mimi
2012/039472
each n, n', n", n'" and nH" are independently integers greater than or equal to one;
or an active metabolite, or a pharmaceutically acceptable prodrug or solvate thereof.
In some embodiments, R1 is a polypeptide. In specific embodiments, the ptide is an
antibody. In certain specific embodiments, the antibody is herceptin. In other embodiments, R2 is a
polypeptide. In specific embodiments, the polypeptide is an antibody. In n specific embodiments,
the antibody is herceptin.
Some embodiments of the present invention describe a nd, or salt thereof, comprising
Formula (X), (XI), (XII) or (XIII):
._Mag,
RrSLNltwfifir
B\A R7 0 /\ Me OMeO
R3 R04
R3 R2
Me O Me/_\MeMe OMeO OMeOAMfLMfl—Z R2 31
L (XI)
1 R4
\ R3
(I) ’i‘ R3
Me\NWNJLN NYE
Me o Me/KMeMe OMeO OMeOA R
L_NIM;H91:];WNMNR7 0 Me/\MeMe OMeOM
9 Me MeH 0 Me
R / N NyLM -“H \r N (X11)
L3_M Me
B\A 0 R7 0 /\ Me OMeO
R4 Me Me MeO N\H
R3 2 Me Me 9
HN1 H
R1 N N
Lrw $N Me
R7 O /\ Me
Me Me MeO NH
0 Z ;
Me Me Me
Me Me 0
Me\ NHi N N
'1“ ; N
R7 0 eMe OMeO OMe OArfiM_L2
R6 R2 81
|_ (XHD
Me 1 R4
(P A
| R3
R7 OMe/\MeMe OMeO OMeOA R
Me Me Me
e\M ; N
R7 O /\ R 12 OMeO Nj\)R:N_L4H
Me Me OMeOAr R6
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
cycloalkylene, substituted lower cycloalkylene, lower alkenylene, substituted lower
alkenylene, alkynylene, lower heteroalkylene, substituted alkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, tuted alkarylene, aralkylene, or
substituted aralkylene;
B is optional, and when t is a linker selected from the group consisting of lower alkylene,
tuted lower alkylene, lower alkenylene, substituted lower alkenylene, lower
heteroalkylene, substituted lower heteroalkylene, -O-, kylene or substituted alkylene)-, -
S-, -S-(alkylene or substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or
substituted alkylene)-, -C(O)—, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-
(alkylene or substituted alkylene)-, -, -NR’-(alkylene or substituted alkylene)-,
-C(O)N(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene
or substituted ne)-, -N(R’)CO-(alkylene or substituted alkylene)-, -N(R’)C(O)O-,
-S(0)kN(R’)-, -N(R’)C(O)N(R’)-, _N(R’)C(S)N(R’)_a -N(R’)S(O)kN(R’)-, -N(R’)-N=, -
C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where
each R’ is independently H, alkyl, or tuted alkyl,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester ting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R3 and R4 are each independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4
or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
Z has the structure of:
€Yé\(KAr
R5 ;
R5 is H, COZH, C1-C6alkyl, or le;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
L1, L2, L3, and L4 are each linkers independently selected from the group consisting of a bond, —
alkylene—, —(alkylene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —J—
(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—J—(alkylene—O)n'—alkylene—J'—, —
ene—O)n—alkylene—J—alkylene'—, —W—, —alkylene—W—, alkylene'—J—(alkylene—NMe)n—
alkylene—W—, —J—(alkylene—NMe)n—alkylene—W—, —J—alkylene—NMe—alkylene'—NMe—
alkylene"—W—, and —alkylene—J—alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
Lwflfifk“;
o NH2
each J and J' independently have the structure of:
1 éiNiO/E‘ or J’S\Nj\e§
H H
, , ; and
each n and n' are independently integers greater than or equal to one.
In some embodiments, R1 is a polypeptide. In specific embodiments, the polypeptide is an
antibody. In certain specific embodiments, the antibody is tin. In other embodiments, R2 is a
polypeptide. In specific embodiments, the ptide is an antibody. In certain c embodiments,
the antibody is herceptin.
In some embodiments, provided herein is a method for derivatizing a dolastatin analog
comprising a (I), (III), (IV), (V), or (VI), the method comprising contacting the dolastatin analog
with a reagent of Formula (XXXVII), wherein Formula (I), (III), (IV), (V), or (VI) correspond to:
Italian}R7 0 /\ Me OMeO
L2—NMeNjLM;:E|\/WNeOO
R7 0 MAMeMe OMeOM
Y! filwwk (H1)
R7 0 Me/\MeMe OMeOM NH
Me\NMeN\_)0J\NINWA/I/WNeOO
Me O Me/\MeMe OMeOM
NHOHN—L2
(IV)
|\/|e\NIrreNjLN Me L1
Me O Me/\MeMe OMeO
MO NH HN—L3
Ar 0
Lena;R70 /\ Me OMeO
Y] IWNJQ;W (W
JL4<3e Me
R7 0 Me/\MeMe OMeOM N\H
0 Z
_NIWNJ1]:JW Me
R7 0 Me/\MeMe OMeOM NH
0 Z ;
MeleeWi/I
Me O MAMeMe OMeOM
floHN—L2
JigsJ1: R6
Me L1
_ V
0Me/\ Me
Me OMeOM NH HN—L3
Ar 0
MeganJ1: R6
0Me/:\ Me
Me OMeOM NH HN—L4
Ar 0
wherein:
Z has the ure of:
€Yé\(KAr
R5 ;
R5 is H, CORg, C1-C6a1kyl, 0r thiazole;
R8 is OH or —NH—(a1kylene—O)n—NH2;
R6 is OH or H;
Ar is phenyl or pyridine;
WO 66560
R7 is C1-C6 alkyl or en;
Y is NHg—O— or methyl;
L, L1, L2, L3, and L4 are each linkers selected from the group consisting of a bond, —alkylene—, —
alkylene—C(O)—, —(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—C(O)—, —(alkylene—
O)n—(CH2)n~NHC(O) (CH2)nu C(Me)2 S S (CH2)nm NHC(O)—(alkylene—O)nmv—alkylene—, —
(alkylene—O)n—alkylene—W—, —alkylene—C(O)—W—, —(alkylene—O)n—alkylene—J—, —alkylene'—
J—(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—J—alkylene', —J—(alkylene—O)n—
alkylene—, —(alkylene—O)n—alkylene—J—(alkylene—O)n'—alkylene—J'—, —W—, —alkylene—W—,
alkylene'—J— (alkylene—NMe)n—alkylene—W—, and J— (alkylene—NMe)n—alkylene—W—, —
(alkylene—O)n—alkylene—U—alkylene—C(O)—, —(alkylene—O)n—alkylene—U—alkylene—; —J—
alkylene—NMe—alkylene'—NMe—alkylene"—W—, and —alkylene—J—alkylene'—NMe—alkylene"—
NMe—alkylene'"—W—;
W has the structure of:
flLWJUCVk;
U has the ure of:
COZH
Mink
each J and J' independently have the structure of:
agiN/ksz éiNiO/E‘ or fimief
H H
or L is absent, Y is methyl, R5 is CORg, and R8 is lkylene—O)n—NH2; and
eachn n' n" n'" andnH" are inde endentl inte ers eater than or e ual to one‘
7 7 7 7
wherein Formula (XXXVII) corresponds to:
R3 A‘B’K‘R
RbN R2
H R40
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower alkenylene,
substituted lower alkenylene, e, substituted arylene, heteroarylene, substituted
heteroarylene, alkarylene, substituted alkarylene, aralkylene, or substituted aralkylene;
B is optional, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, -O-, -O-(alkylene
or substituted alkylene)-, -S-, -S-(alkylene or tuted alkylene)-, -S(O)k- where k is 1, 2, or
3, -S(O)k(alkylene or substituted ne)-, , -C(O)-(alkylene or substituted alkylene)-,
-C(S)-, -C(S)-(alkylene or substituted alkylene)-, -N(R’)-, -NR’-(alkylene or substituted
alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, ’)-,
-CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene or substituted alkylene)-,
-N(R’)C(0)0-, -S(0)kN(R’)-, -N(R’)C(0)N(R’)-, _N(R’)C(S)N(R’)_a S(O)kN(R’)-,
-N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, 2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl,
each R’ is independently H, alkyl, or substituted alkyl,
My S ”L
Ki, 120%“ 1‘?"ka X i: $5? “ah/[ko/L“L.
R is H, alkyl, substituted alkyl, cycloalkyl, or tuted cycloalkyl;
R1 is H, an amino protecting group, resin, at least one amino acid, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, or polynucleotide; and
R3 and R4 are each independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4
or two R3 groups ally form a cycloalkyl or a heterocycloalkyl.
In some embodiments, the derivatized dolastatin analog comprises at least one oxime containing
amino acid haVing the structure of Formula (VIII), (IX), (X), (XI), (XII), or (XIII):
Me O MAMeMe OMeO OMeOO R3 R3 31
A)ZNH| R4
“#30 R2
Me Me 0M9 Me
H_ .\\H
L2—| N Me
R7 0 Me/\MeMe OMeOM NH
,L1 Z
<9 Me (X)
R /N
\l/ L3—N MeNfi/IN
B\A 0 R7 0 Me/\MeMe OMeOM
RRMRZR4 NH
3 o z
HNNR
Me\NR1J1N HMOYKWH5:th
Me O Me/\MeMe OMeO OMeOAAr R2 81
Me b R3
I I R3
Me\ MHJ1: HOW/CNNNfiwN N\ B
N Y
Me O Me OMeO OMeOAAr
L_N MHjL:
R7 0 Me/\MeMe OMeOM
, Me
9 Me MeH 0 Me
R / N -“H
\r (X11) N
L3—N NyLM Me
B\A 2\
0 R7 0 Me OMeO
Me Me MeO N\H
R3RMRzR4
J o z
Me Me 0M9 Me
HN\ H
\\ H R1 N N
Lrw $N He
R7 0 A Me OMeO
Me e MeO NH
0 Z ;
R7 OMe/\M 6Me 0MeO OMeOA R2 81
|_ (XHD
Me 1 R3 Me
Q 4‘ R3
M A”OH/Mpg 3\ N\ B
N Y
R eMe OMeO OMeoA R
Me Me Me
MeMMETNflNwe%$:fifi
R7 OMe/\MeMe OMeO OMeOA
In specific embodiments, the dolastatin analog is contacted With the reagent of Formula
(XXXVH) in aqueous solution under mildly acidic conditions.
Certain embodiments of the present invention describe a compound comprising Formula (XXV),
(XXVI), , (XXVIH), (XXIX), orM(XXX):M
(R16)nl— H '
\7/ N\ R7
R 0Me/\MeMe OMeoM (XXV)
0 R2
R7 OMe/\MeMe OMeO OMeOO
L\—H _’
N \I—/) RO4
(R16)n
Me MeH Me
0 Me
NA “‘ H H
N N\
L2—N
g I?!
R7 0Me/\MeMe OMeO OMe O
(R 16) @NVMI— (XXVII) WKNRL, H MIN“J1Mpg/WW“ W
R4 _N N\z
0 R2 R7 OMe/\MeMe OMeO OMeO
UmmfimJim—L2
R7 OMe/\MeMe OMeO OMeOA R
, 1
LNAC/H _ (XXVIH)
Me R40
Me\l\|l MeNjLN (R16)n
R7 0Me/\MeMe OMeO OMeOAWEN—L3 _
RENE“?WAT/WR7 OMe/\MeMe OMeOM
(Rush—(y Hv1L M9
V N\ (XXIX)
R4 L3_N
0 R2 R7 eMe OMeOM NH
J Z
LEZIWMUENQW
R7 OMe/\M Me OMeO
MUL: H
R7 OMe/\MeMe OMeO OMeOAr R6 R1
HN R2
L1 —
Me Me \_ R O Me 0 4
Me\ “vii H N9H
N a fiMfl—s (R16)n (XXX)
R7 0 /_\ Me OMeO OMeO
Me e Ar R5
Me Me
Me 0
‘ H
Me\ N ‘
I}! 3 ”_L4
R7 OMe/\MeMe OMe O OMe OAr
R6 -
wherein:
Z has the structure of:
‘7;\KKAr
R5 ;
R5 is H, COZH, C1-C6alkyl, or thiazole;
R6 is OH or H;
Ar is phenyl, or pyridine;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R4 is H, halogen, lower alkyl, or substituted lower alkyl;
R7 is C1-C6alkyl or hydrogen;
L, L1, L2, L3, and L4 are each linkers selected from the group consisting of a bond, —alkylene—, —
alkylene—C(O)—, —alkylene—J—, —(alkylene—O)n—alkylene—, lene—O)n—alkylene—C(O)—, —
ene—O)n—J—, —(alkylene—O)n—J—alkylene—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nu—
C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, —(alkylene—O)n—alkylene—W—, —
alkylene—C(O)—W—, —(alkylene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —
(alkylene—O)n—alkylene—J—alkylene', —J—(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—
ylene—O)n'—alkylene—J'—, —W—, ene—W—, alkylene'—J—(alkylene—NMe)n—alkylene—
W—, —J—(alkylene—NMe)n—alkylene—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, —
(alkylene—O)n—alkylene—U—alkylene—; —J—alkylene—NMe—alkylene'—NMe—alkylene"—W—, and
—alkylene—J—alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
LWJLKTJK“;
U has the structure of:
COZH
QM”?
each I and J' independently have the structure of:
Erin/571 fiNiO/‘zi or Jimif
each n and n' are independently integers greater than or equal to one; and
each R16 is independently selected from the group consisting of hydrogen, halogen, alkyl, N02,
CN, and substituted alkyl.
In some embodiments, R1 is a polypeptide. In specific embodiments, the polypeptide is an
dy. In certain specific ments, the dy is herceptin. In other embodiments, R2 is a
ptide. In specific embodiments, the polypeptide is an antibody. In certain specific embodiments,
the antibody is herceptin.
Some embodiments of the present invention describe a compound comprising Formula (XXXI),
(XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI):
RNf,B\/L\:gf\)J\RRH 33
R7 O /\ Me OMeO
R2 MeO NH 0000)
WMSLrHflMI%%N Ar
(XXXH)
R7 OMe/\MeMe OMeO OM30 :ro
IH R3 R3 H
L\ / \
D B\A)ZN R1
Me Me Me
Me M6
H "‘H
N H
Lz—w ; N \2
R7 0 /_\ Me OMeO OMeO
Me Me
H R3 R3
N /B\
R1/ /L1
A D Me Me Me
R4 Me (XXXIH)
H 3
NNxH H
L3—'\Il ; N Z
R7 OMe/\MeMe OMeO OMeO
NeNN
R7 NMHJ1M;%@\J§NI:N_LZOMe/\MeMe OMeO OMeOA
R3 R3N
L1\ DA/B\
Me H|V|e%NNfLWI—s AR4 NR1 I)
R7 OMe/\MeMe OMeO OMeOA
_NIMMN:NJfiwR7 OMe/\MeMe R3 R3 OMeOM
R1/HfA31D/L1
L_:W%%OMe/\MeMe OMeOM
R7 OMe/\M Me OMeO
“AelfilflN .\
NfiNH
R7 OMe/\MeMe OMeO OMeO
r R5
R3 R3 H
L1\ /B\ N\
Me 0 R4
N 0 R2
u—Ls
OM6 0
Ar R5 (XXXVI)
i Me O
_\ H
R7 OMe/\MeMe OMe 0 OMe OAr
R6 -
wherein:
Z has the structure of:
‘7;\KKAr
R5 ;
R5 is H, COZH, C1-C6alkyl, or thiazole;
R6 is OH or H;
Ar is phenyl or pyridine;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R4 is H, halogen, lower alkyl, or substituted lower alkyl;
R7 is lkyl or hydrogen;
L, L1, L2, L3, and L4 are each s selected from the group consisting of a bond, —alkylene—, —
alkylene—C(O)—, —alkylene—J—, —(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—C(O)—, —
(alkylene—O)n—J—, —(alkylene—O)n—J—alkylene—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nu—
C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, —(alkylene—O)n—alkylene—W—, —
alkylene—C(O)—W—, —(alkylene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —
(alkylene—O)n—alkylene—J—alkylene', —J—(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—
ylene—O)n'—alkylene—J'—, —W—, —alkylene—W—, alkylene'—J—(alkylene—NMe)n—alkylene—
W—, —J—(alkylene—NMe)n—alkylene—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, —
(alkylene—O)n—alkylene—U—alkylene—; —J—alkylene—NMe—alkylene'—NMe—alkylene"—W—, and
—alkylene—J—alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
LWJLKTJK“;
U has the structure of:
COZH
QM”?
each J and J' independently have the structure of:
Erin/571 fiNiO/‘zi or Jimif
! a
each n and n' are independently integers greater than or equal to one;
D has the structure of:
each R17 is ndently selected from the group consisting of H, alkyl, substituted alkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy,
alkylalkoxy, substituted lkoxy, polyalkylene oxide, substituted polyalkylene oxide,
aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted l,
aralkyl, tuted l, -(alkylene or substituted alkylene)-ON(R”)2, -(alkylene or
substituted alkylene)-C(O)SR”, -(alkylene or substituted alkylene)-S-S-(aryl or
tuted aryl), -C(O)R”, -C(O)2R”, or -C(O)N(R”)2, Wherein each R” is independently
hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy,
aryl, substituted aryl, heteroaryl, alkaryl, substituted alkaryl, aralkyl, or substituted
aralkyl;
each 21 is a bond, CR17R17, O, S, NR’, CR17R17-CR17R17, CR17R17-O, O-CR17R17, CR17R17-S,
S-CR17R17, 7-NR’, or NR’-CR17R17;
each R’ is H, alkyl, or substituted alkyl;
each 22 is selected from the group consisting of a bond, -C(O)-, -C(S)-, optionally substituted
C1-C3 alkylene, optionally tuted C1-C3 alkenylene, and optionally substituted
heteroalkyl;
each 23 are independently selected from the group consisting of a bond, optionally substituted
C1-C4 alkylene, optionally substituted C1-C4 alkenylene, optionally substituted
heteroalkyl, -O-, -S-, , , and -N(R’)-;
each T3 is a bond, C(R”)(R”), O, or S; With the proviso that When T3 is O or S, R” cannot be
halogen;
each R” is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
m and p are 0, l, 2, or 3, provided that at least one ofm or p is not 0;
(b) (b)
| ‘A'I'V‘ /R3 if; nlnr
/C\— E03) /C—C\(b—E)
(577R4 /C=C\—E(b) mlnn (b) /C\—5—§ (b)
M2 is (a) R3 R4 (a5; R4 M3 (201K:
(b) (b) (b)
(b) M J‘ri R fi R
3 3
m R3 I / /
R3/i—d—é
/C=C—E (b) O—T—E (b) s—T—E (b) (b)
\R4 >44“ R4 mIJu‘ w m
(a) (a) (a) or (a) Where (a) indicates
a , , ,
bonding to the B group and (b) tes bonding to respective positions Within the
heterocycle group;
(b) (b) (b) (b) “if” /R3
mi: 3(1)) —c/R3—§(b) T—o——(b)§ c—s—E (b) (f—ng (b) / / R M3 is (3)3? (a)$??/||— CR\R4 (352% (3)3/ 4
Where (a) indicates bonding to the B group and (b) indicates bonding to respective
positions Within the heterocycle group;
(b) (b) ”$3“ (b) (b)
“I: “l” R—c'2—c=§ I— —g '— :31)
/C\_q=g (b) 3 (b) 0
1|?4 >5: C}; (b) S
/C—§(b) CE‘Nm)
R3 M41s (3)19 (a) R3 (a) (a) or (a)
, , a , 7
Where (a) indicates bonding to the B group and (b) indicates bonding to respective
ons Within the heterocycle group;
each R19 is ndently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy,
ester, ether, thioether, lkyl, n, alkyl ester, aryl ester, amide, aryl amide,
alkyl halide, alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester,
halosulfonyl, nitrile, alkyl nitrile, and nitro;
qis 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10 or 11; and
each R16 is ndently selected from the group consisting of hydrogen, halogen, alkyl, N02,
CN, and substituted alkyl.
In some embodiments, R1 is a polypeptide. In specific embodiments, the polypeptide is an
antibody. In certain specific embodiments, the antibody is herceptin. In other embodiments, R2 is a
polypeptide. In specific embodiments, the polypeptide is an antibody. In certain specific ments,
the antibody is herceptin.
In some embodiments, a|Vlcompound is described comprising Formula (XXXI-A):
=N R7 MeMe OMeO
MeO N\H (XXXI'A)
R 0
40 Z
R1 R2
In certain embodiments, a pharmaceutical composition is provided comprising any of the
compounds described and a pharmaceutically acceptable carrier, excipient, or binder.
In further or alternative embodiments are s for detecting the presence of a polypeptide in a
patient, the method comprising administering a polypeptide comprising at least one heterocyclecontaining
non—natural amino acid and the resulting cycle-containing non-natural amino acid
polypeptide modulates the immunogenicity of the polypeptide relative to the homologous naturally-
occurring amino acid polypeptide.
It is to be understood that the methods and compositions described herein are not limited to the
particular ology, protocols, cell lines, constructs, and reagents described herein and as such may
vary. It is also to be understood that the terminology used herein is for the purpose of describing particular
embodiments only, and is not intended to limit the scope of the methods and compositions bed
herein, which will be limited only by the appended claims.
As used herein and1n the appended claims, the singular forms 44a 39 ccan,” and “the” include plural
nce unless the context clearly indicates otherwise.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as
commonly understood to one of ry skill in the art to which the inventions described herein belong.
Although any methods, devices, and materials similar or equivalent to those bed herein can be used
in the ce or testing of the inventions described herein, the preferred methods, deVices and materials
are now described.
All publications and patents mentioned herein are incorporated herein by reference in their
entirety for the e of describing and sing, for example, the constructs and methodologies that
are described in the publications, which might be used in connection with the presently described
ions. The publications discussed herein are provided solely for their disclosure prior to the filing
date of the present application. g herein is to be construed as an admission that the inventors
described herein are not entitled to te such disclosure by virtue of prior invention or for any other
reason.
The terms “aldol-based linkage” or “mixed aldol-based linkage” refers to the acid— or base-
catalyzed condensation of one carbonyl nd with the enolate/enol of another carbonyl compound,
which may or may not be the same, to generate a B-hydroxy carbonyl compound—an aldol.
The term “affinity label,” as used herein, refers to a label which reversibly or irreversibly binds
another molecule, either to modify it, destroy it, or form a compound with it. By way of example, affinity
labels include enzymes and their substrates, or antibodies and their antigens.
The terms “alkoxy,” “alkylamino” and “alkylthio” (or thioalkoxy) are used in their conventional
sense, and refer to those alkyl groups linked to molecules via an oxygen atom, an amino group, or a sulfur
atom, respectively.
The term “alkyl,” by itself or as part of r molecule means, unless otherwise stated, a
straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully
saturated, mono- or polyunsaturated and can include di- and alent radicals, having the number of
carbon atoms designated (Le. C1-C10 means one to ten carbons). Examples of saturated hydrocarbon
radicals e, but are not limited to, groups such as methyl, ethyl, n-propyl, pyl, l, t-butyl,
isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for
example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one
or more double bonds or triple bonds. Examples of unsaturated alkyl groups e, but are not limited
to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl,
1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. The term “alkyl,” unless otherwise
noted, is also meant to include those derivatives of alkyl defined in more detail , such as
“heteroalkyl”, “haloalkyl” and “homoalkyl”.
The term “alkylene” by itself or as part of another molecule means a divalent radical derived from
an alkane, as exemplified, by (—CH2—)n, wherein n may be 1 to about 24. By way of example only, such
groups include, but are not limited to, groups having 10 or fewer carbon atoms such as the structures —
CH2CH2— and —CH2CH2CH2CH2—. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or
alkylene group, generally having eight or fewer carbon atoms. The term “alkylene,” unless ise
noted, is also meant to include those groups described herein as “heteroalkylene.”
The term “amino acid” refers to lly occurring and tural amino acids, as well as amino
acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino
acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine,
aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine,
methionine, phenylalanine, proline, serine, ine, phan, ne, and valine) and pyrolysine and
selenocysteine. Amino acid analogs refers to compounds that have the same basic chemical structure as a
naturally occurring amino acid, by way of example only, an (x-carbon that is bound to a hydrogen, a
carboxyl group, an amino group, and an R group. Such analogs may have modified R groups (by way of
example, norleucine) or may have modified e backbones while still retaining the same basic
chemical structure as a naturally occurring amino acid. Non-limiting examples of amino acid analogs
include homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
Amino acids may be referred to herein by either their name, their commonly known three letter
symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature
Commission. Additionally, nucleotides, may be referred to by their commonly accepted single-letter
codes.
An “amino terminus modification group” refers to any molecule that can be ed to a terminal
amine group. By way of example, such al amine groups may be at the end of polymeric les,
wherein such polymeric molecules include, but are not limited to, polypeptides, polynucleotides, and
polysaccharides. Terminus modification groups include but are not limited to, various water soluble
polymers, peptides or proteins. By way of example only, terminus modification groups include
polyethylene glycol or serum n. Terminus modification groups may be used to modify therapeutic
teristics of the polymeric molecule, including but not limited to increasing the serum half-life of
peptides.
By “antibody fragment” is meant any form of an antibody other than the full-length form.
Antibody nts herein include dies that are smaller components that exist within ength
antibodies, and antibodies that have been engineered. dy fragments include but are not limited to
Fv, Fc, Fab, and (Fab')2, single chain Fv (scFv), diabodies, triabodies, tetrabodies, bifunctional hybrid
antibodies, CDRl, CDR2, CDR3, combinations of CDR’s, variable regions, framework regions, constant
regions, heavy chains, light chains, and variable regions, and ative scaffold non-antibody molecules,
bispecific antibodies, and the like rd & Georgiou, 2000, Annu. Rev. Biomed. Eng. 2:339-76;
Hudson, 1998, Curr. Opin. Biotechnol. 9:395-402). Another functional ucture is a single chain Fv
(scFv), comprised of the variable regions of the immunoglobulin heavy and light chain, covalently
connected by a e linker (S-z Hu et al., 1996, Cancer Research, 56, 3055-3061). These small (Mr
,000) proteins generally retain specificity and affinity for antigen in a single polypeptide and can
provide a convenient building block for larger, antigen-specific molecules. Unless cally noted
otherwise, statements and claims that use the term “antibody” or “antibodies” specifically includes
ody fragment” and “antibody fragments.”
By ody-drug conjugate, or “ADC”, as used herein, refers to an antibody molecule, or
fragment thereof, that is covalently bonded to one or more biologically active molecule(s). The
biologically active molecule may be conjugated to the antibody through a linker, polymer, or other
covalent bond.
The term “aromatic” or “aryl”, as used herein, refers to a closed ring ure which has at least
one ring haVing a conjugated pi electron system and includes both carbocyclic aryl and heterocyclic aryl
(or oaryl” or “heteroaromatic”) groups. The carbocyclic or heterocyclic aromatic group may contain
from 5 to 20 ring atoms. The term includes clic rings linked covalently or fused-ring polycyclic
(i.e., rings which share nt pairs of carbon atoms) groups. An ic group can be unsubstituted or
substituted. Non-limiting examples of “aromatic” or “aryl”, groups include , 1-naphthyl, 2-
naphthyl, 4-biphenyl, anthracenyl, and thracenyl. Substituents for each of the above noted aryl and
aryl ring systems are selected from the group of acceptable tuents described herein.
For brevity, the term “aromatic” or “aryl” when used in combination with other terms (including
but not limited to, aryloxy, arylthioxy, aralkyl) includes both aryl and heteroaryl rings as defined above.
Thus, the term yl” or yl” is meant to include those radicals in which an aryl group is ed
to an alkyl group (including but not limited to, benzyl, phenethyl, pyridylmethyl and the like) ing
those alkyl groups in which a carbon atom (including but not limited to, a methylene group) has been
replaced by a heteroatom, by way of example only, by an oxygen atom. Examples of such aryl groups
include, but are not limited to, phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the
like.
The term “arylene”, as used herein, refers to a divalent aryl radical. Non-limiting examples of
“arylene” include phenylene, pyridinylene, pyrimidinylene and thiophenylene. Substituents for arylene
groups are selected from the group of acceptable substituents described herein.
A “bifunctional polymer”, also referred to as a “bifunctional linker”, refers to a polymer
comprising two functional groups that are capable of reacting specifically with other moieties to form
covalent or non-covalent linkages. Such moieties may include, but are not limited to, the side groups on
l or non-natural amino acids or peptides which contain such natural or tural amino acids. The
other moieties that may be linked to the bifunctional linker or bifunctional polymer may be the same or
different moieties. By way of example only, a bifunctional linker may have a functional group reactive
with a group on a first peptide, and another onal group which is reactive with a group on a second
peptide, whereby forming a conjugate that includes the first peptide, the bifunctional linker and the second
peptide. Many procedures and linker molecules for ment of various compounds to peptides are
known. See, e.g., European Patent Application No. 188,256; US. Patent Nos. 4,671,958, 4,659,839,
4,414,148, 784; 4,680,338; and 4,569,789 which are incorporated by reference herein in their
entirety. A “multi-functional polymer” also referred to as a “multi-functional linker”, refers to a polymer
comprising two or more functional groups that are capable of ng with other es. Such moieties
may include, but are not limited to, the side groups on natural or non-natural amino acids or peptides
which contain such natural or non-natural amino acids. (including but not limited to, amino acid side
groups) to form covalent or non-covalent linkages. A bi-functional polymer or multi-functional polymer
2012/039472
may be any desired length or molecular weight, and may be selected to provide a ular desired
spacing or conformation between one or more molecules linked to a nd and molecules it binds to
or the compound.
The term “bioavailability,” as used herein, refers to the rate and extent to which a substance or its
active moiety is delivered from a pharmaceutical dosage form and becomes available at the site of action
or in the general circulation. Increases in bioavailability refers to increasing the rate and extent a
substance or its active moiety is delivered from a pharmaceutical dosage form and becomes available at
the site of action or in the general circulation. By way of e, an increase in bioavailability may be
indicated as an increase in concentration of the substance or its active moiety in the blood when compared
to other substances or active moieties. A non-limiting example of a method to evaluate increases in
bioavailability is given in examples 21-25. This method may be used for evaluating the bioavailability of
any polypeptide.
The term “biologically active molecule”, gically active moiety” or “biologically active
agent” when used herein means any nce which can affect any physical or biochemical properties of
a biological , pathway, molecule, or interaction relating to an sm, including but not limited
to, viruses, bacteria, bacteriophage, transposon, prion, insects, fungi, plants, animals, and humans. In
particular, as used herein, ically active molecules include but are not limited to any nce
intended for diagnosis, cure, mitigation, treatment, or tion of disease in humans or other animals, or
to otherwise enhance physical or mental well-being of humans or animals. Examples of biologically
active molecules e, but are not limited to, peptides, proteins, enzymes, small molecule drugs, hard
drugs, soft drugs, prodrugs, ydrates, inorganic atoms or molecules, dyes, lipids, nucleosides,
radionuclides, oligonucleotides, toxins, cells, viruses, liposomes, microparticles and micelles. Classes of
biologically active agents that are le for use with the methods and compositions described herein
include, but are not limited to, drugs, prodrugs, radionuclides, imaging agents, polymers, antibiotics,
fungicides, anti-viral agents, anti-inflammatory agents, anti-tumor agents, cardiovascular agents, anti-
y agents, hormones, grth s, steroidal agents, microbially derived , and the like.
By “modulating ical activity” is meant increasing or decreasing the reactivity of a
polypeptide, altering the selectivity of the polypeptide, enhancing or decreasing the substrate selectivity of
the polypeptide. Analysis of modified biological activity can be performed by comparing the biological
activity of the non-natural polypeptide to that of the natural polypeptide.
The term “biomaterial,” as used herein, refers to a biologically-derived material, including but not
limited to material obtained from bioreactors and/or from recombinant methods and techniques.
The term “biophysical probe,” as used herein, refers to probes which can detect or monitor
ural changes in les. Such molecules include, but are not limited to, proteins and the
“biophysical probe” may be used to detect or monitor interaction of ns with other macromolecules.
Examples of biophysical probes include, but are not limited to, spin-labels, a fluorophores, and
photoactivatible groups.
The term nthetically,” as used herein, refers to any method utilizing a translation system
(cellular or non-cellular), including use of at least one of the following components: a polynucleotide, a
codon, a tRNA, and a ribosome. By way of example, tural amino acids may be “biosynthetically
orated” into non-natural amino acid ptides using the methods and techniques described
herein, “In vivo tion of polypeptides comprising non-natural amino acids”, and in the non-limiting
example 20. onally, the methods for the selection of useful non-natural amino acids which may be
“biosynthetically incorporated” into non-natural amino acid polypeptides are described in the non-limiting
examples 20.
The term “biotin analogue,” or also referred to as “biotin mimic”, as used herein, is any molecule,
other than biotin, which bind with high affinity to avidin and/or streptavidin.
The term “carbonyl” as used herein refers to a group containing at a moiety selecting from the
group consisting of -C(O)-, -S(O)-, -S(O)2—, and —C(S)-, including, but not limited to, groups containing a
least one ketone group, and/or at least one aldehyde groups, and/or at least one ester group, and/or at least
one carboxylic acid group, and/or at least one thioester group. Such carbonyl groups include ketones,
aldehydes, carboxylic acids, esters, and thioesters. In addition, such groups may be part of linear,
branched, or cyclic molecules.
The term “carboxy terminus modification group” refers to any molecule that can be attached to a
terminal carboxy group. By way of example, such terminal carboxy groups may be at the end of
polymeric molecules, wherein such polymeric molecules include, but are not d to, polypeptides,
polynucleotides, and polysaccharides. Terminus modification groups include but are not limited to,
various water soluble polymers, peptides or ns. By way of example only, terminus modification
groups include polyethylene glycol or serum n. Terminus modification groups may be used to
modify therapeutic characteristics of the polymeric molecule, including but not d to increasing the
serum half-life of peptides.
The term “chemically cleavable group,” also referred to as “chemically labile”, as used herein,
refers to a group which breaks or cleaves upon exposure to acid, base, oxidizing , reducing agents,
chemical inititiators, or radical initiators.
The term “chemiluminescent group,” as used herein, refers to a group which emits light as a result
of a chemical reaction without the on of heat. By way of e only, luminol (5-amino-2,3-
dihydro-l,4-phthalazinedione) reacts with oxidants like hydrogen peroxide (H202) in the presence of a
base and a metal catalyst to produce an excited state product (3-aminophthalate, 3-APA).
The term “chromophore,” as used herein, refers to a molecule which absorbs light of visible
wavelengths, UV ngths or IR wavelengths.
The term tor,” as used herein, refers to an atom or molecule essential for the action of a
large molecule. Cofactors include, but are not limited to, inorganic ions, coenzymes, proteins, or some
other factor necessary for the activity of enzymes. Examples include, heme in obin, magnesium in
phyll, and metal ions for proteins.
ding,” as used herein, refers to refolding processes, reactions, or methods which employ at
least two molecules which interact with each other and result in the transformation of unfolded or
improperly folded molecules to properly folded molecules. By way of example only, “cofolding,” employ
at least two ptides which interact with each other and result in the transformation of unfolded or
improperly folded polypeptides to native, properly folded polypeptides. Such ptides may contain
natural amino acids and/or at least one non-natural amino acid.
A “comparison window,” as used herein, refers a segment of any one of contiguous positions used
to compare a sequence to a reference ce of the same number of uous positions after the two
sequences are optimally aligned. Such uous positions e, but are not d to a group
consisting of from about 20 to about 600 sequential units, including about 50 to about 200 sequential
units, and about 100 to about 150 sequential units. By way of example only, such sequences include
polypeptides and polypeptides containing non-natural amino acids, with the sequential units include, but
are not limited to l and tural amino acids. In addition, by way of example only, such
sequences include polynucleotides with nucleotides being the corresponding sequential units. Methods of
alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for
comparison can be conducted, including but not limited to, by the local homology algorithm of Smith and
Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and
Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988)
Proc. Nat’l. Acad. Sci. USA 852444, by computerized entations of these algorithms (GAP,
BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer
Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e. g., Ausubel
et al., Current Protocols in Molecular Biology (1995 supplement)).
By way of e, an algorithm which may be used to determine percent sequence identity and
ce similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al.
(1997) Nuc. Acids Res. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively.
Software for performing BLAST analyses is publicly available through the National Center for
hnology ation. The BLAST algorithm parameters W, T, and X determine the sensitivity and
speed of the alignment. The BLASTN program (for tide ces) uses as defaults a wordlength
(W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid
sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the
BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915)
alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLAST
algorithm is typically performed with the “low complexity” filter turned off.
The BLAST algorithm also performs a statistical analysis of the similarity between two sequences
(see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of
similarity ed by the BLAST algorithm is the smallest sum probability (P(N)), which provides an
indication of the probability by which a match between two nucleotide or amino acid sequences would
occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest
sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2,
or less than about 0.01, or less than about 0.001.
The term “conservatively modified variants” s to both natural and non-natural amino acid
and natural and non-natural nucleic acid sequences, and ations thereof. With respect to particular
nucleic acid sequences, “conservatively modified variants” refers to those natural and non-natural nucleic
acids which encode identical or essentially identical natural and tural amino acid sequences, or
where the natural and non-natural nucleic acid does not encode a natural and non-natural amino acid
sequence, to ially cal sequences. By way of example, because of the racy of the genetic
code, a large number of onally identical nucleic acids encode any given protein. For instance, the
codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an
alanine is specified by a codon, the codon can be altered to any of the corresponding codons described
without altering the d polypeptide. Such nucleic acid variations are “silent variations,” which are
one species of conservatively modified ions. Thus by way of example every natural or non-natural
nucleic acid sequence herein which encodes a natural or tural polypeptide also describes every
possible silent variation of the natural or non-natural nucleic acid. One of ordinary skill in the art will
recognize that each codon in a natural or non-natural nucleic acid (except AUG, which is ordinarily the
only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified
to yield a functionally identical molecule. Accordingly, each silent variation of a natural and non-natural
nucleic acid which encodes a natural and non-natural polypeptide is implicit in each described sequence.
As to amino acid sequences, individual substitutions, deletions or additions to a nucleic acid,
peptide, polypeptide, or protein ce which alters, adds or deletes a single natural and non-natural
amino acid or a small percentage of l and non-natural amino acids in the encoded sequence is a
rvatively modified variant” where the alteration results in the deletion of an amino acid, addition of
an amino acid, or substitution of a natural and non-natural amino acid with a ally similar amino
acid. Conservative substitution tables providing functionally similar natural amino acids are well known
in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic
variants, interspecies homologs, and alleles of the methods and itions described herein.
Conservative substitution tables ing functionally similar amino acids are known to those of
ordinary skill in the art. The following eight groups each contain amino acids that are vative
substitutions for one another:
1) Alanine (A), Glycine (G);
2) Aspartic acid (D), Glutamic acid (E);
3) Asparagine (N), Glutamine (Q);
4) Arginine (R), Lysine (K);
) lsoleucine (I), Leucine (L), Methionine (M), Valine (V);
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
7) Serine (S), Threonine (T); and
8) Cysteine (C), Methionine (M)
(see, e.g., ton, Proteins:Structures and Molecular Properties (W H Freeman & Co.; 2nd edition
(December 1993)
The terms alkyl” and “heterocycloalkyl”, by themselves or in combination with other
terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Thus,
a cycloalkyl or heterocycloalkyl include saturated, partially unsaturated and fully unsaturated ring
linkages. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the
heterocycle is attached to the remainder of the molecule. The heteroatom may include, but is not limited
to, oxygen, nitrogen or sulfur. Examples of cycloalkyl include, but are not limited to, cyclopentyl,
cyclohexyl, l-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl
include, but are not limited to, l—(l,2,5,6-tetrahydropyridyl), l-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-
morpholinyl, 3-morpholinyl, tetrahydrofuran—2-yl, tetrahydrofuran—3-yl, tetrahydrothienyl,
tetrahydrothien—3-yl, l—piperazinyl, 2-piperazinyl, and the like. Additionally, the term encompasses
multicyclic structures, ing but not limited to, bicyclic and tricyclic ring ures. Similarly, the
term “heterocycloalkylene” by itself or as part of another molecule means a divalent radical derived from
heterocycloalkyl, and the term “cycloalkylene” by itself or as part of another molecule means a divalent
radical derived from cycloalkyl.
The term dextrin,” as used herein, refers to cyclic carbohydrates consisting of at least six to
eight glucose molecules in a ring formation. The outer part of the ring contains water e ; at
the center of the ring is a relatively nonpolar cavity able to accommodate small molecules.
The term “cytotoxic,” as used herein, refers to a compound which harms cells.
“Denaturing agent” or “denaturant,” as used , refers to any compound or material which
will cause a reversible unfolding of a polymer. By way of example only, “denaturing agent” or
“denaturants,39 may cause a reversible unfolding of a protein. The strength of a denaturing agent or
denaturant will be determined both by the properties and the concentration of the particular denaturing
agent or denaturant. By way of example, ring agents or denaturants include, but are not limited to,
chaotropes, detergents, c, water miscible solvents, phospholipids, or a combination thereof. Nonlimiting
examples of chaotropes include, but are not limited to, urea, guanidine, and sodium anate.
Non-limiting examples of ents may include, but are not limited to, strong detergents such as sodium
dodecyl sulfate, or polyoxyethylene ethers (e. g. Tween or Triton detergents), Sarkosyl, mild non-ionic
detergents (e. g., digitonin), mild ic detergents such as N—>2,3-(Dioleyoxy)-propyl-N,N,N—
trimethylammonium, mild ionic detergents (e. g. sodium cholate or sodium deoxycholate) or zwitterionic
ents including, but not limited to, sulfobetaines (Zwittergent), 3-(3-
midopropyl)dimethylammonio-l -propane e (CHAPS), and 3 -(3 -
chlolamidopropyl)dimethylammoniohydroxy-l-propane sulfonate (CHAPSO). miting examples
of organic, water miscible ts include, but are not limited to, acetonitrile, lower alkanols (especially
C2 - C4 ls such as ethanol or isopropanol), or lower alkandiols (C2 - C4 alkandiols such as
ethylene-glycol) may be used as denaturants. Non-limiting examples of olipids include, but are not
limited to, naturally occurring phospholipids such as phosphatidylethanolamine, phosphatidylcholine,
phosphatidylserine, and phosphatidylinositol or tic olipid derivatives or variants such as
dihexanoylphosphatidylcholine or diheptanoylphosphatidylcholine.
The term ed functionality” as used herein refers to any group selected from a label; a dye; a
polymer; a water-soluble polymer; a tive of polyethylene glycol; a photocrosslinker; a cytotoxic
compound; a drug; an affinity label; a ffmity label; a reactive compound; a resin; a second protein
or polypeptide or polypeptide analog; an antibody or antibody fragment; a metal chelator; a cofactor; a
fatty acid; a carbohydrate; a cleotide; a DNA; a RNA; an antisense polynucleotide; a saccharide, a
water-soluble dendrimer, a cyclodextrin, a biomaterial; a nanoparticle; a spin label; a fluorophore; a
metal-containing moiety; a ctive moiety; a novel functional group; a group that covalently or
noncovalently interacts with other molecules; a photocaged moiety; an actinic radiation excitable moiety;
a ligand; a photoisomerizable moiety; biotin; a biotin analogue; a moiety incorporating a heavy atom; a
chemically cleavable group; a photocleavable group; an ted side chain; a carbon-linked sugar; a
redox-active agent; an amino id; a toxic moiety; an isotopically labeled moiety; a biophysical probe;
a phosphorescent group; a chemiluminescent group; an electron dense group; a magnetic group; an
intercalating group; a chromophore; an energy transfer agent; a biologically active agent (in which case,
the biologically active agent can include an agent with therapeutic activity and the non-natural amino acid
polypeptide or modified tural amino acid can serve either as a co-therapeutic agent with the
ed therapeutic agent or as a means for delivery the therapeutic agent to a desired site within an
organism); a detectable label; a small molecule; an inhibitory ribonucleic acid; a radionucleotide; a
neutron-capture agent; a derivative of biotin; quantum dot(s); a ansmitter; a radiotransmitter; an
, an activated complex activator, a Virus, an adjuvant, an aglycan, an allergan, an angiostatin, an
antihormone, an antioxidant, an aptamer, a guide RNA, a saponin, a shuttle vector, a macromolecule, a
mimotope, a receptor, a reverse micelle, and any combination thereof.
The term “diamine,”as used herein, refers to groups/molecules comprising at least two amine
functional groups, including, but not d to, a hydrazine group, an amidine group, an imine group, a
l,l-diamine group, a 1,2-diamine group, a 1,3-diamine group, and a l,4-diamine group. In addition, such
groups may be part of linear, branched, or cyclic molecules.
The term “detectable label,” as used herein, refers to a label which may be observable using
analytical techniques including, but not limited to, fluorescence, chemiluminescence, electron-spin
resonance, ultraviolet/visible absorbance spectroscopy, mass spectrometry, nuclear magnetic resonance,
magnetic resonance, and electrochemical methods.
The term bonyl” as used herein refers to a group containing at least two moieties selected
from the group consisting of -C(O)-, -S(O)-, -S(O)2-, and , including, but not limited to, 1,2-
dicarbonyl groups, a 1,3-dicarbonyl groups, and l,4-dicarbonyl groups, and groups containing a least one
ketone group, and/or at least one aldehyde groups, and/or at least one ester group, and/or at least one
carboxylic acid group, and/or at least one thioester group. Such dicarbonyl groups include diketones,
ketoaldehydes, ketoacids, ketoesters, and ketothioesters. In addition, such groups may be part of linear,
branched, or cyclic molecules. The two moieties in the dicarbonyl group may be the same or different, and
may include substituents that would produce, by way of example only, an ester, a ketone, an aldehyde, a
thioester, or an amide, at either of the two moieties.
The term “drug,” as used herein, refers to any nce used in the prevention, diagnosis,
alleviation, treatment, or cure of a disease or condition.
The term “dye,” as used herein, refers to a soluble, coloring substance which contains a
chromophore.
The term “effective amount,” as used herein, refers to a sufficient amount of an agent or a
compound being administered which will relieve to some extent one or more of the symptoms of the
disease or condition being d. The result can be ion and/or alleviation of the signs, symptoms,
or causes of a e, or any other desired alteration of a biological system. By way of example, an agent
or a compound being administered includes, but is not limited to, a natural amino acid polypeptide, non-
natural amino acid polypeptide, modified natural amino acid ptide, or modified non-amino acid
ptide. Compositions containing such natural amino acid polypeptides, non-natural amino acid
ptides, modified natural amino acid polypeptides, or modified tural amino acid ptides
can be administered for prophylactic, enhancing, and/or therapeutic treatments. An riate “effective”
amount in any individual case may be determined using techniques, such as a dose escalation study.
The term “electron dense group,” as used herein, refers to a group which scatters electrons when
irradiated with an electron beam. Such groups include, but are not d to, ammonium molybdate,
h subnitrate cadmium iodide, 99%, carbohydrazide, ferric chloride hexahydrate, thylene
tetramine, 98.5%, indium trichloride anhydrous, lanthanum e, lead acetate trihydrate, lead citrate
trihydrate, lead nitrate, ic acid, phosphomolybdic acid, phosphotungstic acid, potassium
ferricyanide, potassium ferrocyanide, ruthenium red, silver nitrate, silver proteinate (Ag Assay: 80-85%)
“Strong”, silver tetraphenylporphin (S-TPPS), sodium chloroaurate, sodium tungstate, thallium nitrate,
thiosemicarbazide (TSC), uranyl acetate, uranyl nitrate, and vanadyl sulfate.
The term “energy transfer ” as used herein, refers to a molecule which can either donate or
accept energy from another molecule. By way of example only, fluorescence resonance energy er
(FRET) is a dipole-dipole coupling s by which the excited-state energy of a fluorescence donor
molecule is non-radiatively transferred to an unexcited acceptor molecule which then fluorescently emits
the donated energy at a longer wavelength.
The terms “enhance” or “enhancing” means to increase or prolong either in potency or duration a
desired effect. By way of example, “enhancing” the effect of therapeutic agents refers to the ability to
increase or g, either in potency or duration, the effect of therapeutic agents on during ent of a
disease, disorder or condition. An “enhancing-effective amount,” as used herein, refers to an amount
adequate to enhance the effect of a therapeutic agent in the treatment of a disease, disorder or condition.
When used in a patient, amounts effective for this use will depend on the severity and course of the
disease, disorder or condition, previous therapy, the patients health status and response to the drugs, and
the judgment of the treating physician.
As used herein, the term “eukaryote” refers to sms belonging to the phylogenetic domain
Eucarya, ing but not limited to animals (including but not limited to, mammals, insects, reptiles,
birds, etc.), ciliates, plants (including but not limited to, ts, dicots, and algae), fungi, yeasts,
flagellates, microsporidia, and protists.
The term “fatty acid,” as used , refers to carboxylic acids with about C6 or longer
hydrocarbon side chain.
The term “fluorophore,” as used herein, refers to a molecule which upon excitation emits photons
and is y fluorescent.
The terms “functional 9 ccactive moiety:9 ccactivating 9 cc ccreactive
, , , leaving group:9 ,
site”, “chemically reactive group” and “chemically reactive ,” as used herein, refer to portions or
units of a molecule at which al reactions occur. The terms are somewhat synonymous in the
chemical arts and are used herein to indicate the portions of molecules that perform some function or
activity and are reactive with other molecules.
The term “halogen” includes fluorine, chlorine, iodine, and e.
The term “haloacyl,” as used herein, refers to acyl groups which contain halogen moieties,
including, but not limited to, -C(O)CH3, F3, H20CH3, and the like.
The term “haloalkyl,” as used herein, refers to alkyl groups which contain halogen moieties,
including, but not limited to, -CF3 and —CH2CF3 and the like.
The term oalkyl,” as used herein, refers to straight or branched chain, or cyclic hydrocarbon
radicals, or combinations thereof, consisting of an alkyl group and at least one heteroatom selected from
the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be
oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S and Si
may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group
is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2-CH2-O-CH3, -
CHZ-CHZ-NH-CHg, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2,-S(O)-CH3, -CH2-CH2-S(O)2-
CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, and —CH=CH-N(CH3)-CH3. In addition, up to two
atoms may be consecutive, such as, by way of e, H-OCH3 and —CH2-O-Si(CH3)3.
The terms “heterocyclic-based linkage” or “heterocycle linkage” refers to a moiety formed from
the reaction of a dicarbonyl group with a diamine group. The resulting reaction product is a cycle,
including a heteroaryl group or a heterocycloalkyl group. The resulting heterocycle group serves as a
chemical link between a non-natural amino acid or non-natural amino acid polypeptide and another
functional group. In one ment, the heterocycle linkage includes a nitrogen-containing heterocycle
linkage, including by way of example only a pyrazole linkage, a pyrrole e, an indole linkage, a
benzodiazepine linkage, and a pyrazalone linkage.
rly, the term “heteroalkylene” refers to a divalent radical derived from heteroalkyl, as
exemplified, but not limited by, -CH2-CH2-S-CH2-CH2- and —CH2-S-CH2-CH2-NH-CH2-. For
heteroalkylene groups, the same or different heteroatoms can also occupy either or both of the chain
termini (including but not limited to, alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino,
aminooxyalkylene, and the like). Still further, for ne and heteroalkylene linking groups, no
orientation of the linking group is implied by the direction in which the formula of the g group is
written. By way of e, the formula —C(O)2R’- represents both —C(O)2R’- and —R’C(O)2-.
The term “heteroaryl” or “heteroaromatic,” as used herein, refers to aryl groups which contain at
least one heteroatom selected from N, O, and S; wherein the nitrogen and sulfur atoms may be optionally
ed, and the nitrogen atom(s) may be optionally quatemized. Heteroaryl groups may be substituted
or unsubstituted. A heteroaryl group may be attached to the remainder of the molecule through a
heteroatom. Non-limiting examples of heteroaryl groups include l-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-
pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyloxazolyl, 5-oxazolyl,
3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-
l, 2-pyridyl, 3-pyridyl, 4-pyridyl, midyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-
benzimidazolyl, 5-indolyl, l-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-
quinolyl.
The term “homoalkyl,” as used herein refers to alkyl groups which are hydrocarbon groups.
The term “identical,” as used herein, refers to two or more sequences or subsequences which are
the same. In addition, the term “substantially identical,” as used herein, refers to two or more sequences
which have a percentage of tial units which are the same when compared and aligned for maximum
correspondence over a ison window, or designated region as measured using comparison
algorithms or by manual alignment and Visual inspection. By way of example only, two or more
sequences may be “substantially identical” if the sequential units are about 60% cal, about 65%
identical, about 70% cal, about 75% identical, about 80% identical, about 85% identical, about 90%
cal, or about 95% cal over a ied region. Such percentages to describe the “percent
identity” of two or more sequences. The identity of a sequence can exist over a region that is at least about
75-100 sequential units in length, over a region that is about 50 sequential units in length, or, where not
specified, across the entire ce. This definition also refers to the complement of a test sequence. By
way of example only, two or more polypeptide sequences are identical when the amino acid residues are
the same, while two or more polypeptide sequences are “substantially identical” if the amino acid es
are about 60% identical, about 65% identical, about 70% identical, about 75% cal, about 80%
identical, about 85% identical, about 90% identical, or about 95% identical over a specified region. The
identity can exist over a region that is at least about 75 to about 100 amino acids in length, over a region
that is about 50 amino acids in length, or, where not ed, across the entire ce of a polypeptide
sequence. In addition, by way of e only, two or more polynucleotide sequences are identical when
the nucleic acid es are the same, while two or more polynucleotide sequences are “substantially
cal” if the nucleic acid residues are about 60% identical, about 65% identical, about 70% identical,
about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95%
identical over a specified region. The identity can exist over a region that is at least about 75 to about 100
nucleic acids in length, over a region that is about 50 nucleic acids in length, or, where not specified,
across the entire sequence of a polynucleotide sequence.
For sequence comparison, lly one sequence acts as a reference sequence, to which test
sequences are compared. When using a sequence comparison thm, test and reference sequences are
entered into a computer, subsequence coordinates are designated, if ary, and sequence algorithm
program parameters are designated. Default program parameters can be used, or alternative parameters
can be designated. The sequence comparison thm then calculates the percent sequence identities for
the test sequences relative to the reference sequence, based on the program parameters.
The term “immunogenicity,” as used herein, refers to an antibody response to administration of a
therapeutic drug. The immunogenicity toward therapeutic non-natural amino acid polypeptides can be
obtained using quantitative and qualitative assays for detection of anti-non-natural amino acid
ptides dies in biological fluids. Such assays include, but are not limited to,
Radioimmunoassay (RIA), Enzyme-linked immunosorbent assay ( ELISA), luminescent immunoassay
(LIA), and fluorescent immunoassay (FIA). Analysis of immunogenicity toward therapeutic non-natural
amino acid ptides involves ing the dy response upon administration of therapeutic
non-natural amino acid ptides to the antibody response upon administration of therapeutic natural
amino acid polypeptides.
The term calating agent,” also referred to as calating group,” as used herein, refers to a
chemical that can insert into the intramolecular space of a molecule or the intermolecular space n
molecules. By way of example only an intercalating agent or group may be a molecule which inserts into
the stacked bases of the DNA double helix.
The term “isolated,” as used herein, refers to separating and removing a ent of interest
from components not of interest. Isolated substances can be in either a dry or semi-dry state, or in
solution, including but not limited to an aqueous solution. The isolated component can be in a
homogeneous state or the isolated ent can be a part of a pharmaceutical composition that
ses additional pharmaceutically acceptable carriers and/or excipients. Purity and homogeneity may
be determined using analytical chemistry techniques including, but not limited to, polyacrylamide gel
electrophoresis or high performance liquid chromatography. In addition, when a component of interest is
isolated and is the predominant species present in a preparation, the ent is described herein as
substantially purified. The term “purified,” as used herein, may refer to a component of interest which is
at least 85% pure, at least 90% pure, at least 95% pure, at least 99% or greater pure. By way of example
only, nucleic acids or proteins are “isolated” when such nucleic acids or proteins are free of at least some
2012/039472
of the cellular components with which it is associated in the natural state, or that the nucleic acid or
n has been concentrated to a level greater than the concentration of its in vivo or in vitro production.
Also, by way of example, a gene is isolated when separated from open reading frames which flank the
gene and encode a protein other than the gene of interest.
The term “label,” as used herein, refers to a substance which is incorporated into a compound and
is y detected, whereby its physical distribution may be detected and/or monitored.
The term “linkage,” as used herein to refer to bonds or chemical moiety formed from a chemical
reaction between the functional group of a linker and another molecule. Such bonds may include, but are
not limited to, covalent linkages and non-covalent bonds, while such chemical es may include, but
are not limited to, esters, carbonates, imines phosphate esters, hydrazones, acetals, sters, peptide
linkages, and oligonucleotide linkages. Hydrolytically stable es means that the linkages are
ntially stable in water and do not react with water at useful pH values, including but not limited to,
under physiological conditions for an extended period of time, perhaps even indefinitely. Hydrolytically
unstable or degradable linkages mean that the es are degradable in water or in aqueous ons,
ing for e, blood. Enzymatically unstable or able linkages mean that the linkage can be
degraded by one or more enzymes. By way of example only, PEG and related polymers may e
degradable linkages in the polymer backbone or in the linker group between the polymer backbone and
one or more of the terminal fimctional groups of the polymer molecule. Such degradable linkages include,
but are not limited to ester linkages formed by the reaction of PEG carboxylic acids or activated PEG
carboxylic acids with alcohol groups on a biologically active agent, wherein such ester groups generally
hydrolyze under physiological conditions to release the biologically active agent. Other hydrolytically
degradable linkages include but are not limited to carbonate linkages; imine linkages resulted from
reaction of an amine and an aldehyde; phosphate ester linkages formed by ng an alcohol with a
phosphate group; hydrazone linkages which are on product of a hydrazide and an aldehyde; acetal
linkages that are the reaction product of an aldehyde and an l; orthoester linkages that are the
reaction product of a formate and an alcohol; peptide linkages formed by an amine group, including but
not limited to, at an end of a polymer such as PEG, and a yl group of a peptide; and ucleotide
linkages formed by a oramidite group, including but not limited to, at the end of a polymer, and a
' hydroxyl group of an oligonucleotide.
The terms “medium” or “media,” as used herein, refer to any culture medium used to grow and
harvest cells and/or products expressed and/or secreted by such cells. Such “medium” or ” include,
but are not limited to, solution, solid, semi-solid, or rigid supports that may support or contain any host
cell, including, by way of example, bacterial host cells, yeast host cells, insect host cells, plant host cells,
eukaryotic host cells, mammalian host cells, CHO cells, prokaryotic host cells, E. coli, or Pseudomonas
host cells, and cell contents. Such “medium” or “media” includes, but is not limited to, medium or media
in which the host cell has been grown into which a polypeptide has been secreted, including medium
either before or after a proliferation step. Such “medium” or “media” also includes, but is not limited to,
buffers or reagents that contain host cell lysates, by way of example a polypeptide produced intracellularly
and the host cells are lysed or disrupted to release the polypeptide.
The term “metabolite,” as used herein, refers to a derivative of a compound, by way of example
natural amino acid ptide, a non-natural amino acid polypeptide, a modified natural amino acid
polypeptide, or a modified non-natural amino acid polypeptide, that is formed when the compound, by
way of example natural amino acid ptide, non-natural amino acid polypeptide, modified natural
amino acid polypeptide, or modified non-natural amino acid polypeptide, is lized. The term
“pharmaceutically active metabolite” or “active metabolite” refers to a biologically active derivative of a
nd, by way of example natural amino acid polypeptide, a non-natural amino acid polypeptide, a
modified natural amino acid ptide, or a modified non-natural amino acid polypeptide, that is
formed when such a compound, by way of example a natural amino acid polypeptide, non-natural amino
acid polypeptide, modified natural amino acid polypeptide, or modified non-natural amino acid
polypeptide, is lized.
The term “metabolized,” as used , refers to the sum of the processes by which a particular
substance is changed by an organism. Such processes include, but are not limited to, hydrolysis reactions
and ons catalyzed by enzymes. Further information on metabolism may be obtained from The
Pharmacological Basis of Therapeutics, 9th Edition, McGraw—Hill (1996). By way of example only,
metabolites of natural amino acid polypeptides, non-natural amino acid polypeptides, modified l
amino acid polypeptides, or modified non-natural amino acid polypeptides may be fied either by
administration of the natural amino acid ptides, tural amino acid polypeptides, modified
natural amino acid polypeptides, or modified non-natural amino acid ptides to a host and analysis
of tissue samples from the host, or by incubation of natural amino acid polypeptides, non-natural amino
acid polypeptides, d natural amino acid polypeptides, or d non-natural amino acid
polypeptides with hepatic cells in vitro and analysis of the resulting nds.
The term “metal chelator,” as used herein, refers to a molecule which forms a metal complex with
metal ions. By way of example, such molecules may form two or more coordination bonds with a central
metal ion and may form ring structures.
The term “metal-containing moiety,” as used herein, refers to a group which contains a metal ion,
atom or particle. Such es include, but are not limited to, cisplatin, chelated metals ions (such as
nickel, iron, and platinum), and metal nanoparticles (such as , iron, and platinum).
The term “moiety incorporating a heavy atom,” as used , refers to a group which
incorporates an ion of atom which is usually heavier than carbon. Such ions or atoms include, but are not
limited to, silicon, tungsten, gold, lead, and uranium.
The term “modified,” as used herein refers to the presence of a change to a natural amino acid, a
non-natural amino acid, a natural amino acid polypeptide or a non-natural amino acid polypeptide. Such
changes, or modifications, may be obtained by post synthesis modifications of natural amino acids, non-
natural amino acids, natural amino acid polypeptides or non-natural amino acid polypeptides, or by co-
translational, or by post-translational modification of natural amino acids, non-natural amino acids,
natural amino acid polypeptides or non-natural amino acid polypeptides. The form “modified or
unmodified” means that the natural amino acid, non-natural amino acid, natural amino acid polypeptide or
non-natural amino acid polypeptide being sed are optionally d, that is, he natural amino
acid, non-natural amino acid, natural amino acid polypeptide or non-natural amino acid polypeptide under
discussion can be modified or unmodified.
As used , the term “modulated serum half-life” refers to positive or negative changes in the
circulating half-life of a modified biologically active molecule relative to its non-modified form. By way
of example, the modified biologically active molecules include, but are not limited to, natural amino acid,
non-natural amino acid, natural amino acid polypeptide or non-natural amino acid ptide. By way of
e, serum half-life is ed by taking blood samples at various time points after stration
of the biologically active molecule or modified biologically active molecule, and determining the
tration of that molecule in each sample. Correlation of the serum concentration with time allows
calculation of the serum half-life. By way of example, modulated serum half-life may be an increased in
serum half-life, which may enable an improved dosing regimens or avoid toxic effects. Such ses in
serum may be at least about two fold, at least about three-fold, at least about five-fold, or at least about
ten-fold. A non-limiting example of a method to te ses in serum half-life is given in example
33. This method may be used for ting the serum half-life of any polypeptide.
The term “modulated therapeutic half-life,” as used herein, refers to positive or negative change in
the half-life of the therapeutically effective amount of a modified biologically active molecule, relative to
its non-modified form. By way of example, the modified biologically active molecules include, but are not
limited to, natural amino acid, non-natural amino acid, natural amino acid polypeptide or non-natural
amino acid polypeptide. By way of example, therapeutic half-life is measured by measuring
pharmacokinetic and/or pharmacodynamic properties of the molecule at various time points after
administration. Increased therapeutic half-life may enable a particular beneficial dosing n, a
particular beneficial total dose, or avoids an undesired effect. By way of example, the increased
therapeutic half-life may result from increased potency, increased or decreased binding of the modified
molecule to its target, an increase or decrease in another parameter or mechanism of action of the non-
modified molecule, or an increased or sed breakdown of the molecules by enzymes such as, by way
of example only, proteases. A non-limiting example of a method to evaluate increases in therapeutic half-
life is given in example 33. This method may be used for evaluating the therapeutic half-life of any
polypeptide.
] The term “nanoparticle,” as used herein, refers to a le which has a particle size between
about 500 nm to about 1 nm.
The term “near-stoichiometric,’ 9 as used , refers to the ratio of the moles of nds
participating in a al reaction being about 0.75 to about 1.5.
As used , the term “non-eukaryote” refers to non-eukaryotic organisms. By way of
example, a non-eukaryotic organism may belong to the Eubacteria, (which includes but is not d to,
Escherichia coli, Thermus thermophilus, or Bacillus thermophilus, Pseudomonas fluorescens,
Pseudomonas aeruginosa, Pseudomonas putida), phylogenetic domain, or the Archaea, which es,
but is not limited to, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Archaeoglobus
fulgidus, ccus furiosus, Pyrococcus horikoshii, Aeuropyrum pemix, or Halobacterium such as
Haloferax volcanii and Halobacterium species NRC-1, or phylogenetic domain.
A “non-natural amino acid” refers to an amino acid that is not one of the 20 common amino acids
or pyrolysine or selenocysteine. Other terms that may be used synonymously with the term “non-natural
amino acid” is “non-naturally encoded amino acid,” “unnatural amino acid,” “non-naturally-occurring
amino acid,” and variously hyphenated and non-hyphenated versions thereof. The term “non-natural
amino acid” includes, but is not d to, amino acids which occur naturally by modification of a
lly encoded amino acid (including but not limited to, the 20 common amino acids or ysine
and selenocysteine) but are not themselves incorporated into a growing polypeptide chain by the
translation complex. Examples of naturally-occurring amino acids that are not naturally-encoded include,
but are not limited to, N—acetylglucosaminyl-L-serine, N—acetylglucosaminyl-L-threonine, and O-
phosphotyrosine. Additionally, the term “non-natural amino acid” includes, but is not limited to, amino
acids which do not occur naturally and may be obtained synthetically or may be obtained by modification
of non-natural amino acids.
The term “nucleic acid,” as used herein, refers to deoxyribonucleotides, deoxyribonucleosides,
ribonucleosides or ribonucleotides and polymers thereof in either single- or double-stranded form. By way
of example only, such c acids and nucleic acid polymers include, but are not limited to, (i)
ues of natural nucleotides which have similar binding properties as a reference nucleic acid and are
metabolized in a manner similar to naturally ing nucleotides; (ii) oligonucleotide analogs including,
but are not limited to, PNA donucleic acid), analogs of DNA used in antisense technology
(phosphorothioates, phosphoroamidates, and the like); (iii) conservatively modified variants thereof
ding but not limited to, degenerate codon substitutions) and complementary sequences and sequence
explicitly indicated. By way of example, rate codon substitutions may be achieved by generating
ces in which the third position of one or more selected (or all) codons is substituted with mixed-
base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 ; Ohtsuka et al., J.
Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 ).
The term “oxidizing agent,” as used herein, refers to a compound or material which is capable of
removing an electron from a compound being oxidized. By way of example oxidizing agents include, but
are not limited to, oxidized glutathione, e, cystamine, oxidized threitol, oxidized erythreitol,
and oxygen. A wide variety of oxidizing agents are suitable for use in the methods and compositions
described herein.
The term “pharmaceutically acceptable”, as used herein, refers to a material, including but not
d, to a salt, carrier or diluent, which does not abrogate the biological activity or properties of the
compound, and is relatively nontoxic, i.e., the material may be administered to an individual without
causing rable biological effects or interacting in a deleterious manner with any of the components
of the composition in which it is contained.
The term “photoaffinity label,” as used herein, refers to a label with a group, which, upon
exposure to light, forms a linkage with a molecule for which the label has an affinity. By way of e
only, such a linkage may be covalent or non-covalent.
The term caged moiety,” as used herein, refers to a group which, upon illumination at
certain wavelengths, covalently or non-covalently binds other ions or molecules.
The term “photocleavable group,” as used herein, refers to a group which breaks upon exposure to
light.
The term “photocrosslinker,” as used herein, refers to a compound comprising two or more
functional groups which, upon exposure to light, are reactive and form a covalent or non-covalent linkage
with two or more monomeric or polymeric molecules.
The term “photoisomerizable moiety,” as used herein, refers to a group wherein upon illumination
with light changes from one ic form to another.
The term “polyalkylene glycol,” as used herein, refers to linear or branched polymeric polyether
s. Such polyalkylene glycols, including, but are not limited to, polyethylene glycol, polypropylene
glycol, polybutylene glycol, and derivatives thereof. Other exemplary embodiments are listed, for
example, in commercial supplier catalogs, such as ater Corporation's catalog “Polyethylene Glycol
and Derivatives for Biomedical Applications” (2001). By way of example only, such polymeric polyether
s have average molecular weights between about 0.1 kDa to about 100 kDa. By way of example,
such polymeric polyether s include, but are not d to, between about 100 Da and about 100,000
Da or more. The molecular weight of the polymer may be between about 100 Da and about 0 Da,
including but not limited to, about 100,000 Da, about 95,000 Da, about 90,000 Da, about 85,000 Da,
about 80,000 Da, about 75,000 Da, about 70,000 Da, about 65,000 Da, about 60,000 Da, about 55,000 Da,
about 50,000 Da, about 45,000 Da, about 40,000 Da, about 35,000 Da, about 30,000 Da, about 25,000 Da,
about 20,000 Da, about 15,000 Da, about 10,000 Da, about 9,000 Da, about 8,000 Da, about 7,000 Da,
about 6,000 Da, about 5,000 Da, about 4,000 Da, about 3,000 Da, about 2,000 Da, about 1,000 Da, about
900 Da, about 800 Da, about 700 Da, about 600 Da, about 500 Da, 400 Da, about 300 Da, about 200 Da,
and about 100 Da. In some embodiments molecular weight of the polymer is n about 100 Da and
about 50,000 Da. In some embodiments, the molecular weight of the polymer is between about 100 Da
and about 40,000 Da. In some embodiments, the molecular weight of the polymer is between about 1,000
Da and about 40,000 Da. In some embodiments, the molecular weight of the r is between about
2,000 to about 50,000 Da. In some embodiments, the molecular weight of the r is between about
,000 Da and about 40,000 Da. In some embodiments, the molecular weight of the polymer is between
about 10,000 Da and about 40,000 Da. In some embodiments, the poly(ethylene glycol) molecule is a
branched polymer. The molecular weight of the ed chain PEG may be between about 1,000 Da and
about 100,000 Da, including but not limited to, about 100,000 Da, about 95,000 Da, about 90,000 Da,
about 85,000 Da, about 80,000 Da, about 75,000 Da, about 70,000 Da, about 65,000 Da, about 60,000 Da,
about 55,000 Da, about 50,000 Da, about 45,000 Da, about 40,000 Da, about 35,000 Da, about 30,000 Da,
about 25,000 Da, about 20,000 Da, about 15,000 Da, about 10,000 Da, about 9,000 Da, about 8,000 Da,
about 7,000 Da, about 6,000 Da, about 5,000 Da, about 4,000 Da, about 3,000 Da, about 2,000 Da, and
about 1,000 Da. In some embodiments, the molecular weight of the branched chain PEG is between about
1,000 Da and about 50,000 Da. In some embodiments, the molecular weight of the branched chain PEG is
between about 1,000 Da and about 40,000 Da. In some embodiments, the molecular weight of the
branched chain PEG is between about 5,000 Da and about 40,000 Da. In some embodiments, the
molecular weight of the branched chain PEG is between about 5,000 Da and about 20,000 Da. In other
embodiments, the molecular weight of the branched chain PEG is between about 2,000 to about 50,000
The term “polymer,” as used herein, refers to a molecule composed of repeated subunits. Such
molecules include, but are not limited to, polypeptides, cleotides, or polysaccharides or
polyalkylene glycols.
The terms eptide,” “peptide” and “protein” are used interchangeably herein to refer to a
polymer of amino acid residues. That is, a description directed to a ptide applies equally to a
description of a e and a description of a protein, and vice versa. The terms apply to naturally
occurring amino acid rs as well as amino acid polymers in which one or more amino acid residues
is a non-natural amino acid. Additionally, such “polypeptides,39 66peptides” and “proteins” include amino
acid chains of any length, including full length proteins, n the amino acid es are linked by
covalent peptide bonds.
The term “post-translationally modified” refers to any cation of a natural or non-natural
amino acid which occurs after such an amino acid has been translationally incorporated into a polypeptide
chain. Such modifications include, but are not d to, co-translational in vivo modifications, co-
translational in vitro modifications (such as in a cell-free translation ), post-translational in vivo
modifications, and post-translational in vitro ations.
The terms “prodrug” or “pharmaceutically acceptable prodrug,” as used herein, refers to an agent
that is converted into the parent drug in vivo or in vitro, wherein which does not abrogate the biological
activity or properties of the drug, and is relatively nontoxic, i.e., the material may be administered to an
individual without causing undesirable biological effects or interacting in a deleterious manner with any
of the ents of the composition in which it is contained. Prodrugs are generally drug precursors
that, following administration to a subject and subsequent absorption, are converted to an active, or a
more active species via some process, such as sion by a metabolic pathway. Some prodrugs have a
chemical group present on the prodrug that renders it less active and/or confers solubility or some other
property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the
active drug is ted. Prodrugs are converted into active drug within the body through enzymatic or
non-enzymatic reactions. gs may provide improved physiochemical properties such as better
solubility, enhanced delivery characteristics, such as specifically targeting a particular cell, tissue, organ
or ligand, and improved therapeutic value of the drug. The benefits of such prodrugs include, but are not
limited to, (i) ease of administration compared with the parent drug; (ii) the prodrug may be bioavailable
by oral stration whereas the parent is not; and (iii) the prodrug may also have improved solubility
in ceutical compositions ed with the parent drug. A pro-drug includes a pharmacologically
inactive, or reduced-activity, derivative of an active drug. Prodrugs may be designed to modulate the
amount of a drug or biologically active molecule that reaches a desired site of action through the
manipulation of the properties of a drug, such as physiochemical, biopharmaceutical, or pharmacokinetic
properties. An example, without limitation, of a prodrug would be a non-natural amino acid ptide
which is administered as an ester (the “prodrug”) to facilitate transmittal across a cell membrane where
water solubility is detrimental to ty but which then is metabolically hydrolyzed to the carboxylic
acid, the active , once inside the cell where water solubility is ial. Prodrugs may be designed
as reversible drug tives, for use as modifiers to enhance drug transport to site-specific tissues.
The term “prophylactically effective amount,” as used herein, refers that amount of a composition
containing at least one tural amino acid polypeptide or at least one modified non-natural amino
acid polypeptide prophylactically applied to a patient which will relieve to some extent one or more of the
symptoms of a disease, condition or disorder being treated. In such prophylactic applications, such
s may depend on the patient's state of health, weight, and the like. It is considered well within the
skill of the art for one to determine such prophylactically effective amounts by routine experimentation,
including, but not limited to, a dose escalation al trial.
The term “protected,” as used herein, refers to the presence of a “protecting group” or moiety that
prevents reaction of the chemically reactive onal group under certain reaction conditions. The
protecting group will vary depending on the type of chemically reactive group being protected. By way of
example only, (i) if the chemically reactive group is an amine or a hydrazide, the protecting group may be
selected from tert-butyloxycarbonyl ) and 9-fluorenylmethoxycarbonyl (Fmoc); (ii) if the
chemically reactive group is a thiol, the protecting group may be orthopyridyldisulfide; and (iii) if the
chemically reactive group is a carboxylic acid, such as butanoic or propionic acid, or a hydroxyl group,
the ting group may be benzyl or an alkyl group such as methyl, ethyl, or tert-butyl.
By way of e only, blocking/protecting groups may be selected from:
:2 0
H (1312 O \ C\O El ,0
\El/ \ O \(+312 Y
Hzc/, “39/
2 O
allyl Bn Cbz alloc Me
H2 H3C\ [CH3 0
ch/c\ (HsC)sC/ (Hsc)3<:’s'\ (HsC>sSi\/\OJ\
Et t—butyl TBDMS
T900
H2 )1
0/ o HZC’O
(CH3)3C/ \n/ (C6H5)3C‘
H ck
° 3 O.0
B00 pMBn trityl acetyl
Fmoc
Additionally, protecting groups include, but are not limited to, including photolabile groups such
as Nvoc and MeNvoc and other protecting groups known in the art. Other protecting groups are described
in Greene and Wuts, Protective Groups in Organic sis, 3rd Ed., John Wiley & Sons, New York,
NY, 1999, which is incorporated herein by reference in its entirety.
The term active moiety,” as used herein, refers to a group whose nuclei spontaneously give
off nuclear radiation, such as alpha, beta, or gamma les; wherein, alpha particles are helium nuclei,
beta particles are electrons, and gamma particles are high energy photons.
The term ive nd,” as used herein, refers to a compound which under appropriate
conditions is reactive toward another atom, molecule or compound.
The term “recombinant host cell,” also referred to as “host cell,” refers to a cell which includes an
exogenous polynucleotide, n the methods used to insert the exogenous polynucleotide into a cell
include, but are not limited to, direct uptake, transduction, f-mating, or other methods known in the art to
create recombinant host cells. By way of example only, such exogenous polynucleotide may be a
nonintegrated vector, including but not limited to a plasmid, or may be integrated into the host genome.
The term “redox-active ” as used herein, refers to a molecule which oxidizes or reduces
another molecule, whereby the redox active agent becomes reduced or oxidized. Examples of redox active
2+/3+ complexes, and
agent include, but are not limited to, ferrocene, quinones, Ruw3+ complexes, Co
Osw3+ complexes.
The term “reducing agent,” as used herein, refers to a compound or material which is capable of
adding an on to a compound being reduced. By way of example reducing agents e, but are not
d to, threitol (DTT), 2-mercaptoethanol, dithioerythritol, cysteine, cysteamine (2-
thanethiol), and reduced glutathione. Such reducing agents may be used, by way of example only,
to maintain sulfhydryl groups in the reduced state and to reduce intra- or intermolecular disulfide bonds.
“Refolding,” as used herein describes any process, reaction or method which transforms an
improperly folded or unfolded state to a native or properly folded conformation. By way of example only,
refolding transforms disulfide bond containing polypeptides from an improperly folded or unfolded state
to a native or properly folded conformation with respect to de bonds. Such disulfide bond
ning polypeptides may be natural amino acid polypeptides or non-natural amino acid ptides.
The term “resin,” as used herein, refers to high molecular , ble polymer beads. By
way of example only, such beads may be used as supports for solid phase e synthesis, or sites for
attachment of molecules prior to purification.
The term “saccharide,” as used , refers to a series of carbohydrates including but not limited
to sugars, ccharides, accharides, and polysaccharides.
The term “safety” or “safety profile,” as used herein, refers to side effects that might be related to
administration of a drug relative to the number of times the drug has been administered. By way of
example, a drug which has been administered many times and produced only mild or no side effects is
said to have an ent safety profile. A non-limiting example of a method to evaluate the safety profile
is given in example 26. This method may be used for evaluating the safety profile of any polypeptide.
The phrase tively hybridizes to” or “specifically hybridizes to,” as used herein, refers to the
binding, duplexing, or hybridizing of a molecule to a particular nucleotide sequence under stringent
hybridization conditions when that sequence is present in a complex mixture including but not limited to,
total cellular or library DNA or RNA.
The term “spin label,” as used herein, refers to molecules which contain an atom or a group of
atoms exhibiting an unpaired electron spin (i.e. a stable paramagnetic group) that can be detected by
electron spin resonance spectroscopy and can be attached to another molecule. Such spin-label molecules
include, but are not limited to, nitryl radicals and nitroxides, and may be single spin-labels or double spin-
labels.
The term “stoichiometric,” as used , refers to the ratio of the moles of compounds
participating in a chemical on being about 0.9 to about 1.1.
The term “stoichiometric-like,” as used herein, refers to a chemical reaction which becomes
stoichiometric or near-stoichiometric upon changes in reaction ions or in the presence of additives.
Such s in reaction conditions include, but are not limited to, an increase in temperature or change
in pH. Such additives include, but are not limited to, accelerants.
The phrase “stringent hybridization conditions” refers to hybridization of sequences of DNA,
RNA, PNA or other nucleic acid mimics, or combinations thereof, under conditions of low ionic th
and high temperature. By way of example, under stringent conditions a probe will hybridize to its target
subsequence in a complex mixture of nucleic acid (including but not limited to, total cellular or library
DNA or RNA) but does not hybridize to other ces in the complex mixture. Stringent conditions are
sequence-dependent and will be different in different circumstances. By way of example, longer
sequences ize specifically at higher temperatures. Stringent ization conditions include, but
are not limited to, (i) about 5-10 0C lower than the thermal melting point (Tm) for the specific sequence at
a defined ionic strength and pH; (ii) the salt concentration is about 0.01 M to about 1.0 M at about pH 7.0
to about pH 8.3 and the temperature is at least about 30 0C for short probes (including but not limited to,
about 10 to about 50 nucleotides) and at least about 60 0C for long probes (including but not d to,
greater than 50 nucleotides); (iii) the addition of destabilizing agents including, but not limited to,
formamide, (iv) 50% formamide, 5X SSC, and 1% SDS, incubating at 42 0C, or 5X SSC, about 1% SDS,
incubating at 65 0C, with wash in 0.2X SSC, and about 0.1% SDS at 65 0C for between about 5 s to
about 120 minutes. By way of e only, detection of selective or ic hybridization, includes, but
is not limited to, a positive signal at least two times background. An extensive guide to the hybridization
of nucleic acids is found in Tijssen, Laboratory ques in Biochemistry and Molecular Biology--
Hybridization with Nucleic Probes, “Overview of principles of hybridization and the strategy of nucleic
acid assays” (1993).
The term ct” as used herein, refers to an animal which is the object of treatment,
observation or experiment. By way of example only, a subject may be, but is not limited to, a mammal
ing, but not limited to, a human.
The term “substantially purified,” as used herein, refers to a component of interest that may be
substantially or essentially free of other components which ly accompany or interact with the
component of st prior to cation. By way of example only, a component of interest may be
“substantially purified” when the preparation of the component of st contains less than about 30%,
less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%,
less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of
contaminating components. Thus, a “substantially purified” component of interest may have a purity level
of about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about
98%, about 99% or greater. By way of example only, a natural amino acid polypeptide or a non-natural
amino acid polypeptide may be purified from a native cell, or host cell in the case of recombinantly
produced natural amino acid polypeptides or non-natural amino acid polypeptides. By way of example a
preparation of a natural amino acid polypeptide or a tural amino acid polypeptide may be
“substantially purified” when the preparation contains less than about 30%, less than about 25%, less than
about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than
about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating al. By way of
example when a natural amino acid polypeptide or a non-natural amino acid polypeptide is recombinantly
produced by host cells, the natural amino acid polypeptide or non-natural amino acid polypeptide may be
t at about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%,
about 2%, or about 1% or less of the dry weight of the cells. By way of example when a natural amino
acid polypeptide or a non-natural amino acid polypeptide is recombinantly produced by host cells, the
natural amino acid polypeptide or non-natural amino acid polypeptide may be present in the culture
medium at about 5g/L, about 4g/L, about 3g/L, about 2g/L, about 1g/L, about 750mg/L, about 500mg/L,
about 250mg/L, about 100mg/L, about 50mg/L, about 10mg/L, or about 1mg/L or less of the dry weight
of the cells. By way of e, “substantially purified” natural amino acid polypeptides or non-natural
amino acid polypeptides may have a purity level of about 30%, about 35%, about 40%, about 45%, about
50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%,
about 95%, about 99% or greater as determined by appropriate s, including, but not limited to,
SDS/PAGE is, RP-HPLC, SEC, and capillary electrophoresis.
The term “substituents” also referred to as “non-interfering substituents39 66refers to groups which
may be used to replace another group on a molecule. Such groups include, but are not limited to, halo, C1-
C10 alkyl, C2-C10 alkenyl, C2-C10 l, C1-C10 alkoxy, C5-C12 aralkyl, C3-C12 cycloalkyl, C4-C12
cycloalkenyl, , substituted phenyl, toluolyl, xylenyl, biphenyl, C2-C12 alkoxyalkyl, C5-C12
aryl, C5-C12 aryloxyalkyl, C7-C12 oxyaryl, C1-C6 alkylsulfmyl, C1-C10 alkylsulfonyl, -(CH2)m-O-(C1-
C10 alkyl) wherein m is from 1 to 8, aryl, substituted aryl, tuted alkoxy, fluoroalkyl, heterocyclic
radical, substituted heterocyclic radical, nitroalkyl, -N02, -CN, -NRC(O)-(C1-C10 alkyl), (C1-C10
alkyl), C2-C10 oalkyl, -C(O)O-(C1-C10 , -OH, -S02, =S, -COOH, -NR2, carbonyl, -C(O)-(C1-
C10 alkyl)-CF3, -C(O)-CF3, -C(O)NR2, -(C1-C10 aryl)-S-(C6-C10 aryl), -C(O)-(C6-C10 aryl), -(CH2)m-O-
(CH2)m-O-(C1-C10 alkyl) wherein each m is from 1 to 8, -C(O)NR2, -C(S)NR2, -S02NR2, -NRC(O)NR2, -
NRC(S)NR2, salts thereof, and the like. Each R group in the ing list includes, but is not limited to,
H, alkyl or substituted alkyl, aryl or substituted aryl, or alkaryl. Where substituent groups are specified by
their conventional chemical formulas, written from left to right, they equally encompass the chemically
identical substituents that would result from writing the structure from right to left; for example, -CH20-
is equivalent to —OCH2-.
By way of example only, substituents for alkyl and heteroalkyl radicals (including those groups
referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
cycloalkenyl, and heterocycloalkenyl) includes, but is not limited to: -OR, =0, =NR, =N—OR, -NR2, -SR, -
halogen, -SiR3, -OC(O)R, -C(O)R, -C02R, -CONR2, -OC(O)NR2, -NRC(O)R, -NRC(O)NR2, -NR(O)2R, -
NR-C(NR2)=NR, -S(O)R, -S(O)2R, -S(O)2NR2, -NRS02R, -CN and —N02. Each R group in the ing
list includes, but is not limited to, hydrogen, tuted or unsubstituted heteroalkyl, substituted or
unsubstituted aryl, including but not limited to, aryl substituted with 1-3 halogens, substituted or
unsubstituted alkyl, alkoxy or thioalkoxy groups, or aralkyl groups. When two R groups are attached to
the same nitrogen atom, they can be ed with the nitrogen atom to form a 5-, 6-, or 7-membered
ring. For example, -NR2 is meant to e, but not be d to, l-pyrrolidinyl and 4-morpholinyl.
By way of example, substituents for aryl and aryl groups include, but are not limited to, -
OR, =0, =NR, =N-OR, -NR2, -SR, -halogen, -SiR3, -OC(O)R, -C(O)R, -C02R, -CONR2, NR2, -
NRC(O)R, -NRC(O)NR2, -NR(O)2R, -NR-C(NR2)=NR, -S(O)R, -S(O)2R, -S(O)2NR2, -NRS02R, -CN, —
N02, -R, -N3, -CH(Ph)2, C1-C4)alkoxy, and fluoro(C1-C4)alkyl, in a number ranging from zero to
the total number of open valences on the aromatic ring system; and where each R group in the preceding
list includes, but is not limited to, hydrogen, alkyl, heteroalkyl, aryl and heteroaryl.
The term “therapeutically effective amount,” as used , refers to the amount of a composition
containing at least one non-natural amino acid polypeptide and/or at least one modified non-natural amino
acid polypeptide administered to a patient already suffering from a disease, condition or disorder,
sufficient to cure or at least partially arrest, or e to some extent one or more of the symptoms of the
disease, disorder or condition being treated. The effectiveness of such compositions depend conditions
including, but not limited to, the severity and course of the disease, er or condition, us
therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.
By way of example only, therapeutically effective amounts may be determined by routine
experimentation, ing but not limited to a dose escalation clinical trial.
The term “thioalkoxy,” as used herein, refers to sulfur containing alkyl groups linked to les
Via an oxygen atom.
The term “thermal melting point” or Tm is the temperature (under def1ned ionic strength, pH, and
nucleic concentration) at Which 50% of probes complementary to a target hybridize to the target sequence
at equilibrium.
The term “toxic moiety” or “toxic group” as used herein, refers to a compound Which can cause
harm, disturbances, or death. Toxic moieties include, but are not limited to, auristatin, DNA minor groove
binding agent, DNA minor groove alkylating agent, enediyne, lexitropsin, duocarmycin, taxane,
puromycin, dolastatin, maytansinoid, Vinca alkaloid, AFP, MMAF, MMAE, AEB, AEVB, atin E,
paclitaxel, docetaxel, CC-1065, SN—38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-
doxorubicin, dolastatin-lO, echinomycin, combretatstatin, chalicheamicin, maytansine, DM-l, netropsin,
podophyllotoxin (e.g. etoposide, teniposide, etc.), baccatin and its tives, anti-tubulin agents,
cryptophysin, combretastatin, auristatin E, Vincristine, Vinblastine, Vindesine, Vinorelbine, VP-l6,
camptothecin, lone A, epothilone B, zole, colchicines, colcimid, ustine, cemadotin,
discodermolide, maytansine, eleutherobin, mechlorethamine, cyclophosphamide, lan, carmustine,
lomustine, semustine, streptozocin, chlorozotocin, uracil mustard, chlormethine, ifosfamide, chlorambucil,
pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, dacarbazine, and
temozolomide, ytarabine, cytosine arabinoside, fluorouracil, floxuridine, 6-thioguanine, 6-
mercaptopurine, pentostatin, 5-fluorouracil, methotrexate, lO-propargyl-5,8-dideazafolate, 5,8-
dideazatetrahydrofolic acid, leucovorin, fludarabine phosphate, pentostatine, gemcitabine, Ara-C,
paclitaxel, docetaxel, deoxycoformycin, cin—C, raginase, azathioprine, brequinar, antibiotics
(e. g., anthracycline, gentamicin, cefalotin, vancomycin, telavancin, daptomycin, azithromycin,
erythromycin, rocithromycin, furazolidone, illin, ampicillin, carbenicillin, acillin,
methicillin, penicillin, ciprofloxacin, moxifloxacin, ofloxacin, doxycycline, minocycline, racycline,
tetracycline, streptomycin, rifabutin, ethambutol, rifaximin, etc.), ral drugs (e. g., abacaVir, acyclovir,
ampligen, cidofovir, rdine, didanosine, efavirenz, entecaVir, fosfonet, ganciclovir, ibacitabine,
imunovir, idoxuridine, inosine, lopinaVir, methisazone, r, neVirapine, miVir, penciclovir,
stavudine, trifluridine, truvada, valaciclovir, zanamiVir, etc.), daunorubicin hydrochloride, ycin,
rubidomycin, cerubidine, icin, doxorubicin, epirubicin and morpholino derivatives, phenoxizone
biscyclopeptides (e.g., dactinomycin), basic glycopeptides (e.g., bleomycin), anthraquinone glycosides
WO 66560
(e. g., plicamycin, mithramycin), anthracenediones (e. g., mitoxantrone), azirinopyrrolo indolediones (e. g.,
mitomycin), macrocyclic immunosuppressants (e.g., cyclosporine, FK-506, tacrolimus, prograf,
rapamycin etc.), navelbene, CPT-ll, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide,
ifosamide, droloxafine, allocolchicine, Halichondrin B, colchicine, colchicine derivatives , maytansine,
rhizoxin, paclitaxel, paclitaxel derivatives, docetaxel, thiocolchicine, trityl cysterin, Vinblastine sulfate,
Vincristine sulfate, cisplatin, carboplatin, hydroxyurea, N—methylhydrazine, epidophyllotoxin,
procarbazine, mitoxantrone, leucovorin, and tegafur. “Taxanes” e paclitaxel, as well as any active
taxane derivative or ug.
The terms “treat,” “treating” or “treatment”, as used herein, include alleviating, abating or
ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or
preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g.,
arresting the development of the disease or condition, ing the disease or condition, causing
regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping
the symptoms of the e or condition. The terms “treat,39 66treating” or “treatment”, include, but are not
d to, lactic and/or therapeutic treatments.
As used herein, the term “water soluble polymer” refers to any polymer that is soluble in aqueous
ts. Such water e polymers include, but are not limited to, hylene glycol, hylene
glycol propionaldehyde, mono C1-C10 alkoxy or aryloxy tives thereof (described in US. Patent No.
,252,714 which is incorporated by reference herein), monomethoxy—polyethylene glycol, polyvinyl
pyrrolidone, polyvinyl alcohol, polyamino acids, diVinylether maleic anhydride, N—(2-Hydroxypropyl)-
methacrylamide, dextran, dextran derivatives including dextran sulfate, polypropylene glycol,
polypropylene oxide/ethylene oxide copolymer, polyoxyethylated , heparin, n fragments,
polysaccharides, oligosaccharides, glycans, cellulose and cellulose derivatives, including but not limited
to methylcellulose and carboxymethyl cellulose, serum albumin, starch and starch derivatives,
ptides, polyalkylene glycol and tives thereof, copolymers of polyalkylene glycols and
derivatives thereof, polyvinyl ethyl ethers, and alpha-beta-poly[(2-hydroxyethyl)-DL-aspartamide, and the
like, or mixtures thereof By way of example only, coupling of such water soluble polymers to natural
amino acid polypeptides or non-natural ptides may result in changes including, but not limited to,
increased water solubility, increased or modulated serum half-life, sed or modulated therapeutic
half-life relative to the unmodified form, increased bioavailability, modulated biological ty, extended
ation time, modulated immunogenicity, modulated physical association characteristics including, but
not limited to, aggregation and multimer formation, altered receptor binding, altered binding to one or
more binding partners, and altered receptor dimerization or multimerization. In addition, such water
soluble polymers may or may not have their own biological ty.
Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein
try, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art are
employed.
WO 66560 2012/039472
Compounds, (including, but not d to non-natural amino acids, non-natural amino acid
polypeptides, modified non-natural amino acid polypeptides, and reagents for producing the
aforementioned compounds) presented herein include isotopically—labeled compounds, which are identical
to those recited in the various formulas and structures presented herein, but for the fact that one or more
atoms are replaced by an atom haVing an atomic mass or mass number ent from the atomic mass or
mass number usually found in nature. Examples of es that can be incorporated into the present
compounds include isotopes of en, carbon, en, oxygen, fluorine and chlorine, such as 2H, 3H,
13C, 14C, 15N, 18O, 17O, 35
S, 18F, 36Cl, respectively. Certain isotopically-labeled compounds described
herein, for example those into which ctive isotopes such as 3H and 14C are incorporated, are useful
in drug and/or substrate tissue distribution assays. Further, substitution with isotopes such as deuterium,
i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example
increased in Vivo half-life or reduced dosage requirements.
Some of the compounds herein (including, but not limited to tural amino acids, non-natural
amino acid polypeptides and modified non-natural amino acid polypeptides, and reagents for producing
the aforementioned compounds) have asymmetric carbon atoms and can therefore exist as omers or
diastereomers. Diasteromeric mixtures can be separated into their indiVidual diastereomers on the basis of
their physical chemical differences by methods known, for example, by chromatography and/or fractional
crystallization. Enantiomers can be separated by ting the omeric mixture into a
diastereomeric mixture by reaction with an appropriate optically active compound (e. g., alcohol),
separating the diastereomers and converting (e. g., hydrolyzing) the dual diastereomers to the
ponding pure enantiomers. All such isomers, including diastereomers, enantiomers, and mixtures
thereof are considered as part of the compositions described herein.
In additional or further embodiments, the compounds described herein (including, but not limited
to tural amino acids, non-natural amino acid polypeptides and modified non-natural amino acid
polypeptides, and reagents for producing the aforementioned compounds) are used in the form of prodrugs.
In additional or further embodiments, the compounds described herein ((including, but not limited
to tural amino acids, non-natural amino acid polypeptides and modified non-natural amino acid
polypeptides, and reagents for producing the aforementioned compounds) are metabolized upon
stration to an organism in need to produce a metabolite that is then used to produce a desired effect,
including a desired therapeutic effect. In further or additional embodiments are active metabolites of non-
natural amino acids and “modified or unmodified” non-natural amino acid polypeptides.
The methods and formulations described herein include the use of es, crystalline forms
(also known as polymorphs), or pharmaceutically acceptable salts of non-natural amino acids, non-natural
amino acid ptides and modified non-natural amino acid polypeptides. In certain embodiments, non-
natural amino acids, non-natural amino acid polypeptides and modified non-natural amino acid
polypeptides may exist as tautomers. All tautomers are ed within the scope of the non-natural amino
acids, non-natural amino acid polypeptides and modified non-natural amino acid ptides presented
herein. In addition, the non-natural amino acids, non-natural amino acid polypeptides and modified non-
natural amino acid polypeptides described herein can exist in unsolvated as well as solvated forms with
pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the non-
natural amino acids, non-natural amino acid polypeptides and modified non-natural amino acid
polypeptides presented herein are also considered to be disclosed herein.
] Some of the compounds herein (including, but not limited to non-natural amino acids, non-natural
amino acid polypeptides and d non-natural amino acid polypeptides and ts for producing
the aforementioned nds) may exist in several tautomeric forms. All such tautomeric forms are
considered as part of the compositions described herein. Also, for example all eto forms of any
compounds (including, but not limited to tural amino acids, non-natural amino acid polypeptides
and d non-natural amino acid polypeptides and reagents for producing the aforementioned
compounds) herein are considered as part of the compositions described herein.
Some of the compounds herein (including, but not limited to non-natural amino acids, non-natural
amino acid ptides and modified non-natural amino acid polypeptides and reagents for producing
either of the entioned compounds) are acidic and may form a salt with a pharmaceutically
acceptable cation. Some of the nds herein (including, but not limited to non-natural amino acids,
non-natural amino acid polypeptides and modified non-natural amino acid polypeptides and reagents for
ing the aforementioned compounds) can be basic and accordingly, may form a salt with a
pharmaceutically able anion. All such salts, including di-salts are within the scope of the
compositions described herein and they can be prepared by conventional methods. For example, salts can
be prepared by contacting the acidic and basic es, in either an s, non-aqueous or partially
aqueous medium. The salts are recovered by using at least one of the following techniques: filtration,
precipitation with a non-solvent followed by filtration, evaporation of the solvent, or, in the case of
aqueous solutions, lyophilization.
Pharmaceutically acceptable salts of the non-natural amino acid polypeptides disclosed herein
may be formed when an acidic proton present in the parent non-natural amino acid polypeptides either is
replaced by a metal ion, by way of example an alkali metal ion, an alkaline earth ion, or an aluminum ion;
or coordinates with an organic base. In addition, the salt forms of the disclosed non-natural amino acid
polypeptides can be prepared using salts of the ng materials or intermediates. The tural amino
acid polypeptides described herein may be prepared as a pharmaceutically acceptable acid addition salt
(which is a type of a pharmaceutically acceptable salt) by reacting the free base form of non-natural amino
acid polypeptides described herein with a pharmaceutically acceptable inorganic or organic acid.
Alternatively, the non-natural amino acid polypeptides described herein may be prepared as
pharmaceutically acceptable base addition salts (which are a type of a ceutically acceptable salt)
by reacting the free acid form of non-natural amino acid polypeptides described herein with a
pharmaceutically acceptable inorganic or organic base.
The type of pharmaceutical acceptable salts, include, but are not limited to: (1) acid addition salts,
formed With inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid, and the like; or formed With c acids such as acetic acid, propionic acid, hexanoic
acid, cyclopentanepropionic acid, ic acid, c acid, lactic acid, malonic acid, succinic acid,
malic acid, maleic acid, fumaric acid, ic acid, citric acid, benzoic acid, ydroxybenzoyl)benzoic
acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid,
2-hydroxyethanesulfonic acid, benzenesulfonic acid, thalenesulfonic acid, 4-methylbicyclo-
[2.2.2]octene-l-carboxylic acid, glucoheptonic acid, 4,4’-methylenebis-(3-hydroxyene-l -carboxylic
acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary cetic acid, lauryl sulfuric acid, gluconic
acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; (2)
salts formed When an acidic proton present in the parent compound either is replaced by a metal ion, e. g.,
an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates With an organic base.
Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-
methylglucamine, and the like. Acceptable inorganic bases e aluminum hydroxide, calcium
hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
The corresponding counterions of the non-natural amino acid polypeptide pharmaceutical
acceptable salts may be analyzed and identified using various methods ing, but not limited to, ion
exchange chromatography, ion chromatography, capillary electrophoresis, inductively coupled plasma,
atomic absorption spectroscopy, mass spectrometry, or any combination thereof. In addition, the
therapeutic ty of such non-natural amino acid polypeptide pharmaceutical acceptable salts may be
tested using the techniques and methods described in es 87-91.
It should be tood that a reference to a salt includes the solvent addition forms or crystal
forms thereof, ularly solvates or polymorphs. Solvates contain either stoichiometric or non-
stoichiometric amounts of a solvent, and are often formed during the process of crystallization With
ceutically acceptable solvents such as water, l, and the like. Hydrates are formed When the
solvent is water, or alcoholates are formed When the solvent is alcohol. Polymorphs include the different
crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually
have ent X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape,
optical and electrical properties, stability, and solubility. Various factors such as the recrystallization
solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate.
The ing and characterization of non-natural amino acid polypeptide pharmaceutical
acceptable salts polymorphs and/or solvates may be accomplished using a variety of techniques including,
but not limited to, thermal analysis, x-ray diffraction, spectroscopy, vapor sorption, and microscopy.
Thermal analysis methods address thermo chemical degradation or thermo al processes including,
but not d to, polymorphic transitions, and such methods are used to analyze the relationships
between polymorphic forms, determine weight loss, to find the glass transition temperature, or for
excipient compatibility studies. Such methods include, but are not limited to, ential scanning
calorimetry (DSC), Modulated Differential ng Calorimetry (MDCS), Thermogravimetric analysis
(TGA), and Thermogravi-metric and Infrared analysis (TG/IR). X-ray diffraction methods include, but are
not limited to, single crystal and powder ctometers and synchrotron sources. The various
spectroscopic techniques used include, but are not limited to, Raman, FTIR, UVIS, and NMR (liquid and
solid state). The various microscopy techniques include, but are not limited to, polarized light microscopy,
Scanning Electron Microscopy (SEM) with Energy sive X-Ray Analysis (EDX), Environmental
Scanning Electron Microscopy with EDX (in gas or water vapor atmosphere), IR copy, and Raman
microscopy.
BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with particularity in the appended claims. A
better understanding of the features and advantages of the present invention will be ed by reference
to the following detailed description that sets forth illustrative embodiments, in which the principles of the
invention are utilized, and the accompanying drawings of which:
Figure 1 presents a graphical illustration of Her-Tox binding to the Her2 receptor.
Figure 2 presents a graphical illustration of the expression of Anti-Her2 variants determined by
ELISA analysis.
Figure 3 presents a cal ration of the expression of Anti-Her2 variants determined by
ELISA analysis.
Figure 4 presents a graphical illustration of the cell proliferation assay with HCC 1954 breast
cancer cell line and dolastatin linker derivatives.
Figure 5 presents a graphical ration of the analysis of the cell eration assay with HCC
1954 breast cancer cell line and trastuzumab-tox conjugates.
Figure 6 presents a cal illustration of the analysis of the cell proliferation assay with
SKOV-3 ovarian cancer cell line and dolastatin linker derivatives.
Figure 7 presents a graphical illustration of the analysis of the cell eration assay with
SKOV-3 ovarian cancer cell line and trastuzumab-tox conjugates.
Figure 8 presents a graphical illustration of the analysis of the cell proliferation assay with MDA-
MB-468 breast cancer cell line and dolastatin linker derivatives.
Figure 9 presents a graphical illustration of the analysis of the cell proliferation assay with MDA-
MB-468 breast cancer line and trastuzumab-tox conjugates.
Figure 10 presents a cal ration of tumor volume measurement (mm3) after a single IC
dose (3.3 mg/kg, 10 mg/kg, g) of trastuzumab-linked dolastatin tives.
Figure 11 presents assay formats used to measure trastuzumab-linked dolastatin tives
tration in SD rat serum
Figure 12 presents graphical illustrations of serum concentrations (ng/mL) of trastuzumab-linked
dolastatin derivatives after single IV injections.
Figure 13 presents a graphical illustration of serum concentrations (ng/mL) of trastuzumab-linked
dolastatin derivatives after single IV injections. This assay detects antibody binding to the ErbB2
Figure 14 presents a graphical illustration of of serum concentrations (ng/mL) of trastuzumab-
linked dolastatin derivatives after IV ion. The in Vivo stability measurements detect at least two
dolastatin derivatives linked to umab.
Figure 15 presents graphical illustrations of the change in rat body weight and tumor volume after
treatment with trastuzumab-linked dolastatin derivatives.
Figure 16 presents graphical illustrations of anti-tumor efficacy of trastuzumab, Her2-HSl22-
NCDl and Her2-HSl22/LK145-HCD1 against established tumors of HCC1954 in SCID-bg mice. Mice
were administered a single IV ion on day l ). Data points ent group e tumor
volume and error bars represent standard error of the mean (SEM).
Figure 17 presents graphical rations of umor efficacy of dolastatin linker derivatives in
the MDA361DYT2 Breast (2--) Xenograft model.
Figure 18 presents graphical illustrations of anti-tumor efficacy of dolastatin linker derivatives in
the MDA361DYT2 Breast (2--) Xenograft model.
DETAILED DESCRIPTION OF THE INVENTION
While preferred embodiments of the present invention have been shown and described herein, it
will be obvious to those d in the art that such embodiments are provided by way of example only.
Numerous variations, changes, and substitutions will now occur to those skilled in the art without
departing from the invention. It should be understood that various alternatives to the embodiments of the
invention described herein may be employed in practicing the invention. It is intended that the following
claims define the scope of the invention and that s and structures within the scope of these claims
and their equivalents be covered thereby.
I. Introduction
Recently, an entirely new technology in the n sciences has been ed, which promises to
overcome many of the limitations associated with site-specific cations of proteins. Specifically,
new components have been added to the protein biosynthetic machinery of the prokaryote Escherichia
coli (E. 6011') (e. g., L. Wang, et al., (2001), m 292:498-500) and the eukaryote Sacchromyces
cerevisiae (S. cerevisiae) (e. g., J. Chin et al., m 301 :964-7 (2003)), which has enabled the
incorporation of non-natural amino acids to proteins in vivo. A number of new amino acids with novel
chemical, physical or biological ties, including ff1nity labels and somerizable amino
acids, keto amino acids, and glycosylated amino acids have been incorporated efficiently and with high
fidelity into proteins in E. coli and in yeast in response to the amber codon, TAG, using this methodology.
See, e.g., J. W. Chin et al., (2002), Journal of the American Chemical Society 124:9026-9027
(incorporated by reference in its entirety); J. W. Chin, & P. G. Schultz, (2002), ChemBioChem
3(1 1):] 135-1 137 (incorporated by reference in its entirety); J. W. Chin, et al., (2002), PNAS United States
of America 99(17):]1020-11024 (incorporated by reference in its entirety); and, L. Wang, & P. G.
Schultz, (2002), Chem. Comm. l-ll (incorporated by reference in its ty). These studies have
demonstrated that it is possible to selectively and routinely introduce al functional groups that are
not found in ns, that are chemically inert to all of the functional groups found in the 20 common,
genetically-encoded amino acids and that may be used to react ently and selectively to form stable
covalent linkages.
II. Overview
]At one level, described herein are the tools ds, itions, techniques) for creating and
using atin linker derivatives or analogs comprising at least one carbonyl, dicarbonyl, oxime,
hydroxylamine, de, protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl,
hydrazine, azide, amidine, imine, diamine, keto-amine, keto-alkyne, alkyne, cycloalkyne, or ene-dione.
At another level, described herein are the tools (methods, compositions, techniques) for creating and using
dolastatin linker derivatives or analogs comprising at least one non-natural amino acid or modified non-
l amino acid With an oxime, aromatic amine, cycle (e. g., indole, quinoxaline, phenazine,
pyrazole, triazole, etc.).
.Such dolastatin linker derivatives comprising non-natural amino acids may contain further
functionality, ing but not limited to, a polymer; a water-soluble polymer; a derivative of
polyethylene glycol; a second protein or polypeptide or polypeptide analog; an antibody or antibody
fragment; and any combination thereof Note that the various aforementioned functionalities are not meant
to imply that the members of one functionality cannot be classified as members of another functionality.
Indeed, there Will be overlap depending upon the particular circumstances. By way of example only, a
soluble polymer overlaps in scope With a derivative of polyethylene glycol, however the overlap is
not complete and thus both functionalities are cited above.
Provided herein in some embodiments, is a toxic group linker derivative comprising a yl,
dicarbonyl, oxime, hydroxylamine, aldehyde, protected de, ketone, protected ketone, thioester,
ester, dicarbonyl, hydrazine, azide, amidine, imine, diamine, keto-amine, keto-alkyne, alkyne,
cycloalkyne, or ene-dione. In some embodiments, the toxic group derivative comprises any of the linkers
disclosed herein. In other embodiments, described herein are the tools (methods, compositions,
techniques) for creating and using toxic group derivatives or s comprising at least one non-natural
amino acid or modified tural amino acid With an oxime, aromatic amine, heterocycle (e. g., indole,
quinoxaline, phenazine, pyrazole, triazole, etc.).
] In some embodiments, such toxic tives comprising non-natural amino acids may contain
further functionality, including but not limited to, a polymer; a water-soluble polymer; a derivative of
polyethylene glycol; a second protein or polypeptide or polypeptide ; an antibody or dy
fragment; and any combination thereof In specific embodiments, the toxic group is dolastatin or
auristatin. In certain specific embodiments, the toxic group is dolastatin-10. Note that the various
aforementioned functionalities are not meant to imply that the members of one functionality cannot be
classified as members of another functionality. Indeed, there will be overlap depending upon the particular
circumstances. By way of e only, a soluble polymer overlaps in scope with a derivative of
polyethylene glycol, however the p is not complete and thus both functionalities are cited above.
Certain embodiments of the present invention describe preparations of certain toxic moieties with
linkers that reduce the toxicity of the moiety in vivo while the toxic moiety retains pharmacological
activity. In some embodiments, the toxicity of the linked toxic group, when administered to an animal or
human, is reduced or eliminated compared to the free toxic group or toxic group derivatives comprising
labile linkages, while retaining pharmacological activity. In some embodiments, increased doses of the
linked toxic group (e. g., atin linker derivatives, non-natural amino acid linked dolastatin tives)
may be administered to animals or humans with greater safety. In certain embodiments, the non-natural
amino acid ptides linked to a toxic moiety (e. g., dolastatin derivative) provides in vitro and in vivo
stability. In some embodiments, the non-natural amino acid ptides linked to a toxic moiety (e. g.,
dolastatin-10 derivative) are efficacious and less toxic compared to the free toxic moiety (e. g., dolastatin-
).
III. Dolastatin Linker Derivatives
]At one level, described herein are the tools (methods, compositions, techniques) for creating and
using a dolastatin linker tives or analogs sing at least one non-natural amino acid or modified
non-natural amino acid with a carbonyl, dicarbonyl, oxime or hydroxylamine group. Such dolastatin
linker derivatives comprising non-natural amino acids may contain further functionality, including but not
limited to, a polymer; a soluble polymer; a derivative of polyethylene ; a second n or
polypeptide or polypeptide analog; an antibody or antibody fragment; and any ation thereof Note
that the various aforementioned functionalities are not meant to imply that the members of one
onality cannot be classified as members of another functionality. Indeed, there will be overlap
depending upon the particular circumstances. By way of example only, a water-soluble polymer overlaps
in scope with a tive of polyethylene glycol, however the overlap is not complete and thus both
functionalities are cited above.
In one aspect are methods for selecting and designing a dolastatin linker derivative to be d
using the methods, compositions and techniques described herein. The new dolastatin linker derivative
may be designed de novo, including by way of example only, as part of high-throughput screening s
(in which case numerous polypeptides may be designed, synthesized, characterized and/or tested) or based
on the interests of the researcher. The new dolastatin linker derivative may also be designed based on the
structure of a known or partially characterized polypeptide. By way of example only, dolastatin has been
the subject of intense study by the scientific community; a new compound may be designed based on the
structure of dolastatin. The ples for selecting which amino acid(s) to substitute and/or modify are
described separately herein. The choice of which modification to employ is also described , and can
be used to meet the need of the experimenter or end user. Such needs may include, but are not limited to,
manipulating the therapeutic iveness of the polypeptide, improving the safety profile of the
ptide, adjusting the pharmacokinetics, pharmacologics and/or pharmacodynamics of the
polypeptide, such as, by way of example only, increasing water solubility, bioavailability, increasing
serum half-life, increasing therapeutic half-life, modulating immunogenicity, modulating biological
actiVity, or extending the circulation time. In addition, such modifications include, by way of example
only, providing additional functionality to the polypeptide, incorporating an antibody, and any
combination of the aforementioned modifications.
Also described herein are dolastatin linker derivatives that have or can be modified to contain an
oxime, carbonyl, dicarbonyl, or hydroxylamine group. Included with this aspect are methods for
producing, purifying, characterizing and using such atin linker tives
] The dolastatin linker derivative may contain at least one, at least two, at least three, at least four,
at least five, at least six, at least seven, at least eight, at least nine, or ten or more of a carbonyl or
dicarbonyl group, oxime group, hydroxylamine group, or protected forms thereof. The dolastatin linker
derivative can be the same or different, for e, there can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
, 16, 17, 18, 19, 20, or more different sites in the derivative that se 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, or more different ve groups.
A. Structure and Synthesis of Dolastatin Linker Derivatives: Electrophilic and
Nucleophilic Groups
Dolastatin derivatives with linkers containing a hydroxylamine (also called an aminooxy) group
allow for reaction with a variety of electrophilic groups to form conjugates (including but not limited to,
with PEG or other water soluble rs). Like hydrazines, hydrazides and semicarbazides, the
enhanced nucleophilicity of the aminooxy group permits it to react efficiently and selectively with a
variety of molecules that contain carbonyl- or dicarbonyl-groups, including but not d to, s,
aldehydes or other functional groups with similar chemical reactivity. See, e. g., Shao, J. and Tam, J., J.
Am. Chem. Soc. 117:3893-3899 (1995); H. Hang and C. Bertozzi, Acc. Chem. Res. 34(9): 727-736
(2001). Whereas the result of reaction with a hydrazine group is the corresponding hydrazone, however,
an oxime results generally from the reaction of an aminooxy group with a carbonyl- or dicarbonyl-
ning group such as, by way of example, a ketones, aldehydes or other functional groups with similar
chemical reactiVity. In some embodiments, dolastatin derivatives with linkers comprising an azide, alkyne
or lkyne allow for linking of molecules Via cycloaddition reactions (e. g., polar cycloadditions,
azide-alkyne Huisgen cycloaddition, etc.). ibed in US. Patent No. 7,807,619 which is incorporated
by reference herein to the extent relative to the reaction).
Thus, in certain embodiments described herein are dolastatin derivatives with linkers comprising
a hydroxylamine, de, protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl,
hydrazine, amidine, imine, diamine, keto-amine, keto-alkyne, and one hydroxylamine group, a
ylamine-like group (which has reactiVity similar to a hydroxylamine group and is structurally
similar to a hydroxylamine group), a masked hydroxylamine group (which can be readily converted into a
hydroxylamine group), or a protected hydroxylamine group (Which has vity r to a
hydroxylamine group upon deprotection). In some embodiments, the dolastatin derivatives with linkers
comprise azides, alkynes or cycloalkynes. Such dolastatin linker tives include compounds having
the structure of Formula (I), (III), (IV), (V), and (VI):
Y N NdLLT/W e (1)
R7 0 Me/_\MeMe OMeOM
LZ—N
| Mtg
R7 0 Me/\MeMe OMeOM
v' _N MULN (111)
R7 0 MAMeMe OMeOM
Me\NMeN\_)0J\MNWA/I/WNeOO
Me O Me/\MeMe OMeOM
+1r4-[.2NH0
(1‘1)
|\/|e\NfireNjLN Me L1
Me O Me/\MeMe OMeOM NH HN—L3
Ar 0
_NIMNQHAfiNNKN
R7 0 /\ Me OMeO
v' INVL W
J4<LMMeR7 0 Me/\MeMe OMeOM
_NIMN8H¢LNgi:
R7 0 Me/\MeMe OMeOM
MeMe:grNET
Me O Me/\MeMe OMeOM
HN—L2
Me O /\ Me
Me Me OMeOM NH HN_’ L3
04H (VD
M3\NMeNjL%
OMe MeM/:\ OMeOM NH HN—L4
Arfie
wherein:
Z has the structure of:
R5 ;
R5 is H, CORg, C1-C6a1kyl, 0r thiazole;
R8 is OH or —NH—(a1ky1ene—O)n—NH2;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6a1kyl or hydrogen;
Y and V are each selected from the group ting of an hydroxylamine, methyl, aldehyde,
protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, azide,
e, imine, diamine, keto-amine, keto-alkyne, alkyne, cycloalkyne, and ene-dione;
L, L1, L2, L3, and L4 are each linkers ed from the group consisting of a bond, —alkylene—, —
alkylene—C(O)—, —alkylene—J—, —(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—C(O)—, —
(alkylene—O)n—J—, —(alkylene—O)n—J—alkylene—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nu—
C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, —(alkylene—O)n—alkylene—W—, —
alkylene—C(O)—W—, —(alkylene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —
(alkylene—O)n—alkylene—J—alkylene', —J—(alkylene—O)n—alkylene—, lene—O)n—alkylene—
J—(alkylene—O)n'—alkylene—J'—, —W—, —alkylene—W—, alkylene'—J—(alkylene—NMe)n—alkylene—
W—, —J—(alkylene—NMe)n—alkylene—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, —
(alkylene—O)n—alkylene—U—alkylene—g —J—alkylene—NMe—alkylene'—NMe—alkylene"—W—, and
—alkylene—J—alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
ILWJUCVJK;
U has the ure of:
COZH
mink
each I and J' independently have the structure of:
agiN/ksz éiNiO/E‘ or fimief
H H
each n, n' n", n'" and n"" are independently integers greater than or equal to one; and
or L is absent, Y is methyl, R5 is CORg, and R8 is —NH—(alkylene—O)n—NH2.
Such dolastatin linker tives may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, r, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In certain embodiments of compounds of Formula (I), (III), and (V), R5 is thiazole or ylic
acid. In certain embodiments of compounds of Formula (I), (III), and (V), R5 is hydrogen. In certain
embodiments of compounds of Formula (I), (III), and (V), R5 is methyl, ethyl, propyl, iso-propyl, butyl,
iso-butyl, sec-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of Formula (I),
(III), and (V), R5 is —NH—(alkylene—O)n—NH2, n alkylene is —CH2—, —CH2CH2—, —CH2CH2CH2—, —
CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—
, —CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CHQCHQCHZCH2—,
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CHZCHZCHZCHZCHZCHZCH2CH2CH2CH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In certain embodiments of compounds of Formula
(IV) and (VI), R5 is —NH—(alkylene—O)n—NH2, Wherein n is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,
43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, or 100.
In some embodiments, Y is azide. In other embodiments, Y is cycloalkyne. In specific
embodiments, the cyclooctyne has a structure of:
|©—§
(R19)q
each R19 is ndently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, ester,
ether, thioether, lkyl, halogen, alkyl ester, aryl ester, amide, aryl amide, alkyl ,
alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, lfonyl, nitrile,
alkyl nitrile, and nitro; and
qis 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10 or 11.
In certain embodiments of compounds of Formula (I), (III), and (V), R6 is H. In some
ments of compounds of Formula (I), (III), and (V), R6 is hydroxy.
In certain embodiments of nds of Formula (I), (III), and (V), Ar is phenyl.
In certain embodiments of nds of Formula (I), (III), (IV), (V), and (VI), R7 is methyl,
ethyl, propyl, iso-propyl, butyl, sec-butyl iso-butyl, tert-butyl, pentyl, or hexyl. In n embodiments of
compounds of Formula (I), (III), (IV), (V), and (VI), R7 is hydrogen.
] In n embodiments of compounds of Formula (I), (III), and (V), Y is hydroxylamine,
aldehyde, protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, amidine,
imine, diamine, keto-amine, keto-alkyne, or ene-dione.
In certain embodiments of compounds of Formula (IV) and (VI), V is a hydroxylamine, ,
aldehyde, protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, amidine,
imine, diamine, keto-amine, keto-alkyne, and ene-dione.
In certain embodiments of compounds of Formula (I), (III), (IV), (V), and (VI), each L, L1, L2, L3,
and L4 is independently a cleavable linker or non-cleavable linker. In certain embodiments of compounds
WO 66560
of Formula (I), (III), (IV), (V), and (VI), each L, L1, L2, L3, and L4 is independently a oligo(ethylene
) derivatized linker.
In certain embodiments of compounds of Formula (I), (III), (IV), (V), and (VI), each alkylene,
ne', alkylene", and alkylene'" independently is —CH2—, —CH2CH2—, —CH2CH2CH2—, —
CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, 2CH2CH2CH2CH2CH2—
—CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In certain embodiments of compounds of Formula
(XIV), (XV), (XVI), (XVII), and (XVIII), each n, n', n", n'", and n"" is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68,
69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, or 100.
B. Structure and Synthesis 0fDolastatin Linker Derivatives: ylamine Groups
Thus, in certain embodiments described herein are dolastatin derivatives with linkers comprising
a hydroxylamine group, a hydroxylamine-like group (Which has reactivity similar to a hydroxylamine
group and is structurally similar to a ylamine group), a masked hydroxylamine group (Which can
be readily converted into a hydroxylamine group), or a protected hydroxylamine group (which has
reactivity similar to a hydroxylamine group upon deprotection). Such dolastatin linker derivatives include
compounds having the structure of Formula (I):
mm,R70 /\ Me OMeO
wherein:
Z has the structure of:
R5 ;
R5 is H, CORg, C1-C6alkyl, or thiazole;
R8 is OH or —NH—(alkylene—O)n—NH2;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
Y is NHg—O— or methyl;
2012/039472
L is a linker selected from the group consisting of —alkylene—, —alkylene—C(O)—, —(alkylene—O)n—
alkylene—, —(alkylene—O)n—alkylene—C(O)—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nv~C(Me)2—
S—S—(CH2)nm—NHC(O)—(alkylene—O)nvm—alkylene—, —(alkylene—O)n—alkylene—W—, —alkylene—
C(O)—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, and —(alkylene—O)n—alkylene—U—
alkylene—;
W has the ure of:
ILWJUCVJK;
U has the structure of:
COZH
or L1s absent, Y1s methyl, R5 is CORg, and R8 is —NH—(alkylene—O)n—NH2; and
each n, n', n", n'" and n"H are independently integers greater than or equal to one. Such dolastatin linker
derivatives may be in the form of a salt, or may be incorporated into a non-natural amino acid
polypeptide, polymer, polysaccharide, or a polynucleotide and ally post translationally modified.
In certain embodiments of compounds of Formula (I), R5 is thiazole. In certain embodiments of
compounds of Formula (I), R5 is hydrogen. In certain embodiments of compounds of Formula (I), R5 is
methyl, ethyl, , iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, or hexyl. In certain
embodiments of compounds of Formula (I), R5 is —NH—(alkylene—O)n—NH2, wherein alkylene is —CH2—, —
CHZCH2—, 2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —
CHZCHZCHZCHZCHZCHZCHE —CH2CHZCHZCHZCHZCHZCHZCH2—, —
CHZCHZCHZCHZCHZCHZCHZCHZCHE —CH2CHZCHZCHZCHZCHZCHZCHZCHZCH2—, —
CHZCHZCHZCHZCHZCHZCHZCHZCHZCHZCHE or —CH2CH2CH2CH2CHZCHZCHZCHZCHZCHZCHZCHF
In n embodiments of compounds of Formula (I), R5 is —NH—(alkylene—O)n—NH2, wherein n is O, 1,
2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
In n ments of compounds of Formula (I), R6 is H. In some embodiments of
compounds of a (1), R6 is hydroxy.
In certain embodiments of compounds of Formula (I), Ar is phenyl.
In n ments of compounds of Formula (1), R7 is , ethyl, propyl, iso—propyl,
butyl, tyl iso-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of Formula
(1), R7 is hydrogen.
In certain embodiments of compounds of Formula (I), Y is hydroxylamine, de, protected
aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, e, imine, diamine, keto-
amine, keto-alkyne, or ene-dione. In certain ments of compounds of Formula (I), V is a
hydroxylamine, methyl, aldehyde, protected aldehyde, ketone, protected ketone, ter, ester,
dicarbonyl, hydrazine, amidine, imine, diamine, keto-amine, keto-alkyne, and ene-dione.
In certain ments of compounds of Formula (I), each L is independently a cleavable linker
or non-cleavable linker. In certain embodiments of compounds of Formula (I), each L is independently a
oligo(ethylene glycol) derivatized .
In certain embodiments of compounds of Formula (I), alkylene is —CH2—, -—CH2CH2—, -—
CH2CH2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CHZCH2CH2CHZCHZCHZCHZCHZCHZCH2—, or —CH2CH2CH2CHZCH2CHZCHZCHZCHZCHZCHZCH2—.
In certain embodiments of compounds of Formula (I), each n, n', n", n'", and n"" is O, 1, 2, 3, 4, 5, 6, 7, 8,
9, 10,11,12, 13, 14, 15, 16, 17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, 99, or 100.
In certain embodiments, dolastatin linker derivatives e compounds haVing the
structure of Formula (II):
H2N\O/L\NMeNfi-JLNI:§WNO
R7 0 Me/\MeMe OMeOM
OK/s
In some embodiments of compounds of Formula (11), L is —(alkylene—O)n—alkylene—. In some
embodiments, each alkylene is 2—, n is equal to 3, and R7 is methyl. In some embodiments, L is —
alkylene—. In some embodiments of compounds of Formula (11), each alkylene is —CH2CH2— and R7 is
methyl or hydrogen. In some embodiments of compounds of a (II), L is —(alkylene—O)n—alkylene—
C(O)—. In some embodiments of compounds of Formula (11), each alkylene is —CH2CH2—, n is equal to 4,
and R7 is . In some embodiments of compounds of Formula (II), L is —(alkylene—O)n—(CH2)n~
NHC(O) (CH2)nu C(Me)2 S S (CH2)nm NHC(O)—(alkylene—O)nmv—alkylene—. In some embodiments of
2012/039472
nds of Formula (11), each alkylene is —CH2CH2—, n is equal to 1, n' is equal to 2, n" is equal to 1, n
'" is equal to 2, "H '
n 1s equal to 4, and R7 is methyl. Such dolastatin linker derivatives may be in the form of
a salt, or may be incorporated into a non-natural amino acid polypeptide, polymer, polysaccharide, or a
polynucleotide and optionally post translationally modified.
In certain embodiments of compounds of Formula (11), each L is independently a cleavable linker
or non-cleavable linker. In certain ments of compounds of Formula (11), each L is independently a
oligo(ethylene glycol) derivatized linker.
] In certain embodiments of compounds of Formula (11), R7 is , ethyl, propyl, iso-propyl,
butyl, sec-butyl tyl, tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of Formula
(II), R7 is hydrogen.
In certain embodiments of compounds of Formula (II), alkylene is —CH2—, -—CH2CH2—, -—
CH2CH2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CHZCH2CH2CHZCHZCHZCHZCHZCHZCH2—, or —CH2CH2CH2CHZCH2CHZCHZCHZCHZCHZCHZCH2—.
In certain embodiments of nds of Formula (II), each n, n', n", n'", and n"" is O, 1, 2, 3, 4, 5, 6, 7, 8,
9, 10,11,12, 13, 14, 15, 16, 17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, 99, or 100.
Such dolastatin linker derivatives include compounds having the ure of Formula (111), (IV),
(V) or (VI):
L_NI“”;N51”;];WNO N.
R7 0 MAMeMe OMeOM
Y’ (111)
L3—N:[IMfNfiJJi/IN Me
R7 0 Me/\MeMe OMeOM
Me\N MeNjN Me
Me O Me/\MeMe OMeO
MeO NH O
348%HN—L2
Me (IV)
Me\N MeNjLN
Me O Me/\MeMe OMeOM
mNHHN—L3
NI?“$§WQF§F
R7 0 /\ Me OMeO
Yl Me
L3—N meNJN Me
R7 0 Me OMeOM NNH
J o 2
L4_N “Ami/IN Me
R7 0 Me/\MeMe OMeOM NH
wherein:
Z has the structure of:
€Yé\(KAr
R5 ;
R5 is H, CORg, C1-C6alkyl, or thiazole;
R8 is OH;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
Y is NH2—0—;
V is —O—NH2
L1, L2, L3, and L4 are each linkers ndently selected from the group consisting of a bond, —
alkylene—, —(alkylene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —J—
(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—J—(alkylene—O)n'—alkylene—J'—, —
(alkylene—O)n—alkylene—J—alkylene'—, —W—, ene—W—, alkylene'—J—(alkylene—NMe)n—
alkylene—W—, —J—(alkylene—NMe)n—alkylene—W—, —J—alkylene—NMe—alkylene'—NMe—
alkylene"—W—, and ene— —alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
each I and J' independently have the structure of:
zit/iiN/‘Zi ‘Zi or ‘fiNié’;
H H H
, , ,and
each n and n' are independently integers r than or equal to one.
Such dolastatin linker derivatives may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a cleotide and optionally post translationally
modified.
In certain embodiments of compounds of Formula (III), (IV), (V) or (VI), R5 is thiazole. In
certain embodiments of nds of Formula (III), (IV), (V) or (VI), R6 is H. In certain embodiments
of compounds of Formula (III), (IV), (V) or (VI), Ar is phenyl. In certain embodiments of nds of
Formula (III), (IV), (V) or (VI), R7 is methyl. In certain embodiments of compounds of Formula (III),
(IV), (V) or (VI), n and n' are integers from O to 20. In certain embodiments of compounds of a
(III), (IV), (V) or (VI), n and n' are integers from O to 10. In certain embodiments of compounds of
a (III), (IV), (V) or (VI), n and n' are integers from O to 5.
In certain embodiments of nds of Formula (III) and (V), R5 is thiazole or carboxylic acid.
In certain embodiments of compounds of Formula (III) and (V), R5 is hydrogen. In certain ments
of compounds of Formula (III) and (V), R5 is methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl,
tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of Formula (III) and (V), R5 is —NH—
(alkylene—O)n—NH2, Wherein alkylene is —CH2—, -—CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In certain embodiments of compounds of Formula
(III) and (V), R5 is lkylene—O)n—NH2, Wherein n is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
or 100.
In certain embodiments of compounds of Formula (III), (IV), (V) and (VI), R6 is H. In some
embodiments of compounds of Formula (III), (IV), (V) and (VI), R6 is hydroxy.
In certain embodiments of compounds of Formula (III), (IV), (V) and (VI), Ar is phenyl.
In certain embodiments of compounds of Formula (III), (IV), (V) and (VI), R7 is methyl, ethyl,
propyl, opyl, butyl, sec-butyl iso-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of
compounds of Formula (III), (IV), (V) and (VI), R7 is en.
In certain embodiments of compounds of Formula (III) and (V), Y is hydroxylamine, aldehyde,
protected aldehyde, ketone, ted ketone, thioester, ester, dicarbonyl, hydrazine, amidine, imine,
diamine, keto-amine, lkyne, or ene-dione. In certain embodiments of compounds of Formula (IV)
and (VI), V is a hydroxylamine, methyl, aldehyde, ted aldehyde, ketone, protected , thioester,
ester, dicarbonyl, hydrazine, amidine, imine, diamine, keto-amine, keto-alkyne, and ene-dione.
In certain embodiments of compounds of a (XIV), (XV), (XVI), (XVII), and (XVIII), each
L, L1, L2, L3, and L4 is independently a cleavable linker or non-cleavable linker. In certain embodiments
of compounds of Formula (XIV), (XV), (XVI), (XVII), and (XVIII), each L, L1, L2, L3, and L4 is
independently a oligo(ethylene glycol) tized linker.
] In certain embodiments of nds of Formula (III), (IV), (V) and (VI), each alkylene,
alkylene', alkylene", and alkylene'" independently is —CH2—, -—CH2CH2—, -—CH2CH2CH2—, —
CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, 2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—
, —CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2—,
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In n embodiments of compounds of Formula
(III), (IV), (V) and (VI), alkylene is methylene, ethylene, propylene, butylenes, pentylene, hexylene, or
heptylene.
In certain embodiments of nds of Formula (III), (IV), (V) and (VI), each n and n'
independently is 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,]3,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
In certain embodiments, dolastatin linker derivatives include nds having the
structure of Formula (VII):
_ I
Me O /\ Me OMeO
Me Me MeO NHOHN‘L2
Me (VII)
Me\ "
Ii] 3 I
Me O /\ Me
Me Me OMeOM
In certain embodiments of compounds of Formula (VII), L1 is —(alkylene—O)n—alkylene—J—, L2 is
—alkylene'—J'—(alkylene—O)n'—alkylene—, L3 is —J"—(alkylene—O)n"—alkylene—, alkylene is —CH2CH2—,
swig
alkylene' is —(CH2)4—, n is 1, n' and n" are 3, J has the structure of H J' and I" have the structure
§é\Ni0/15.
of H and R7 is methyl. In certain embodiments of compounds of Formula (VII), L1 is —J—
(alkylene—O)n—alkylene—, L2 is —(alkylene—O)n~alkylene—J'—alkylene'—, L3 is —(alkylene—O)nv~alkylene—
J"—, alkylene is —CH2CH2—, alkylene' is —(CH2)4—, n is l, n' and n" are 4, and J, J' and I" have the ure
of H
. Such atin linker derivatives may be in the form of a salt, or may be incorporated into
a non-natural amino acid ptide, polymer, polysaccharide, or a polynucleotide and ally post
translationally modified.
In certain embodiments, compounds of Formula (I)-(VII) are stable in aqueous solution for at
least 1 month under mildly acidic conditions. In certain embodiments, compounds of Formula (I)-(VII)
are stable for at least 2 weeks under mildly acidic conditions. In certain embodiments, compound of
Formula (I)-(VII) are stable for at least 5 days under mildly acidic conditions. In certain embodiments,
such acidic conditions are pH 2 to 8.
The methods and compositions provided and described herein e polypeptides comprising
dolastatin linker derivative containing at least one carbonyl or onyl group, oxime group,
hydroxylamine group, or protected or masked forms f. Introduction of at least one ve group
into a dolastatin linker derivative can allow for the application of conjugation chemistries that involve
specific al reactions, ing, but not limited to, With one or more dolastatin linker derivative(s)
While not reacting With the commonly occurring amino acids. Once incorporated, the dolastatin linker
derivative side chains can also be modified by utilizing chemistry methodologies described herein or
suitable for the particular functional groups or substituents present in the dolastatin linker derivative.
2012/039472
The dolastatin linker derivative methods and compositions described herein provide conjugates of
substances having a wide variety of functional , substituents or moieties, with other substances
including but not limited to a polymer; a soluble polymer; a derivative of polyethylene glycol; a
second protein or polypeptide or polypeptide analog; an antibody or antibody fragment; and any
combination thereof.
In certain embodiments, the dolastatin linker derivatives, linkers and reagents described herein,
including compounds of Formulas (I)-(VII) are stable in aqueous solution under mildly acidic ions
(including but not limited to pH 2 to 8). In other embodiments, such compounds are stable for at least one
month under mildly acidic conditions. In other embodiments, such compounds are stable for at least 2
weeks under mildly acidic ions. In other ments, such compounds are stable for at least 5
days under mildly acidic conditions.
In another aspect of the compositions, methods, techniques and strategies described herein are
methods for studying or using any of the aforementioned “modified or unmodified” non-natural amino
acid dolastatin linker derivatives. Included within this aspect, by way of example only, are therapeutic,
diagnostic, assay-based, industrial, cosmetic, plant biology, environmental, energy-production, consumer-
products, and/or military uses which would benefit from a dolastatin linker derivative comprising a
“modified or unmodified” non-natural amino acid ptide or protein.
Non—limiting examples of dolastatin linker derivatives include:
WO 66560
H2N\O/Vo\/\NW/SWNMo/Vowo/VowMENfiRQI/RKHUS
OMe O OMe O
HzN—O
,wwwwwéxfigw
OMe o OMe o
N/NS\:/
Mbwmwxnxama
OMe O OMe O
—/ N,_,3
wowowowcmo$KHf%go051w”fi%%“OMe O OMe O
CF3COOH \:/
HNJ/
o NH2
i 21
o O O N .
H | ; |
N O /\ OMeO OMeO
H N’0 N N
2 N/
H i H \_7$
H of
O NH2
o O 0
H 'I‘
OMe O
H N/o\/\O/\)J\N N\)J\N
H :
CF3COOH of
o NH2
HZINOJKN\_/U\N/©/\00 OMeO OMeON
CF23C00H HNf
0 NH2
COZH
0 0 0
HZN,O\/\o/\/N\n/\NJJ\/\/\/U\NH 3 NgLNH El: 5?2::
H I I
o o A
”ZN/OwONNEN/ELA/mc02H ARI/g1" E: if2::
PCT/US 12/39472 072012
HOf 0*:Ao El M” 2‘
a zra-o VOW3;;3 W4);
K H
«0% NOWN" N N
H_N7 o ‘4’]; hat/0v:
s 0 NH2 0
f”” 5 ° HJL cal? = ?
[JO HNYVNV‘NA/H‘N NE N A
H H
HEN-D 0 of
O‘LNHZ
SUBSTITUTE SHEET (RULE 26)
PCT/U312/39472 032012
IV. Non-Natural Amino Acid Derivatives
The non-natural amino acids used in the s and compositions described herein have at
least one of the following four properties: (1) at least one functional group on the sidechain of the non-
natural amino acid has at least one characteristics and/or activity and/or reactivity orthogonal to the
chemical reactivity of the 20 common, cally-encoded amino acids (i.e., alanine, arginine,
asparagine, ic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine,
lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and ), or at least
orthogonal to the chemical reactivity of the naturally occurring amino acids present in the ptide
that includes the non-natural amino acid; (2) the introduced non-natural amino acids are substantially
chemically inert toward the 20 common, genetically-encoded amino acids; (3) the non-natural amino acid
can be stably incorporated into a polypeptide, preferably With the stability commensurate With the
naturally-occurring amino acids or under typical physiological conditions, and further preferably such
oration can occur via an in vivo system; and (4) the tural amino acid includes an oxime
SUBSTITUTE SHEET (RULE 26)
functional group or a functional group that can be ormed into an oxime group by reacting with a
reagent, preferably under conditions that do not y the biological properties of the polypeptide that
includes the tural amino acid (unless of course such a destruction of biological properties is the
purpose of the modif1cation/transformation), or where the transformation can occur under aqueous
conditions at a pH between about 4 and about 8, or where the reactive site on the non-natural amino acid
is an electrophilic site. Any number of non-natural amino acids can be introduced into the polypeptide.
tural amino acids may also include protected or masked oximes or protected or masked groups that
can be transformed into an oxime group after deprotection of the protected group or unmasking of the
masked group. Non-natural amino acids may also e protected or masked yl or dicarbonyl
groups, which can be transformed into a carbonyl or dicarbonyl group after ection of the ted
group or unmasking of the masked group and thereby are available to react with hydroxylamines or
oximes to form oxime groups.
Non-natural amino acids that may be used in the methods and compositions bed herein
include, but are not limited to, amino acids comprising a amino acids with novel functional groups, amino
acids that covalently or noncovalently interact with other molecules, glycosylated amino acids such as a
sugar substituted serine, other carbohydrate modified amino acids, keto-containing amino acids, aldehyde-
containing amino acids, amino acids comprising polyethylene glycol or other polyethers, heavy atom
substituted amino acids, chemically cleavable and/or photocleavable amino acids, amino acids with an
elongated side chains as compared to natural amino acids, including but not limited to, polyethers or long
chain arbons, including but not limited to, greater than about 5 or greater than about 10 carbons,
carbon-linked sugar-containing amino acids, redox-active amino acids, amino id containing amino
acids, and amino acids comprising one or more toxic moiety.
In some embodiments, non-natural amino acids comprise a saccharide moiety. Examples of
such amino acids include N—acetyl-L-glucosaminyl-L-serine, N—acetyl-L-galactosaminyl-L-serine, N-
acetyl-L-glucosaminyl-L-threonine, N—acetyl-L-glucosaminyl-L-asparagine and O-mannosaminyl-L-
serine. Examples of such amino acids also e examples where the naturally-occurring N— or O-
linkage between the amino acid and the saccharide is replaced by a covalent linkage not commonly found
in nature — including but not limited to, an alkene, an oxime, a thioether, an amide and the like. Examples
of such amino acids also include saccharides that are not commonly found in naturally-occurring proteins
such as 2-deoxy-glucose, 2-deoxygalactose and the like.
] The chemical moieties incorporated into polypeptides Via incorporation of non-natural amino
acids into such polypeptides offer a y of advantages and manipulations of polypeptides. For
example, the unique reactivity of a carbonyl or dicarbonyl onal group ding a keto- or
aldehyde- functional group) allows selective modification of proteins with any of a number of hydrazine-
or hydroxylamine-containing reagents in vivo and in vitro. A heavy atom tural amino acid, for
example, can be useful for phasing x-ray structure data. The site-specific introduction of heavy atoms
using non-natural amino acids also provides selectiVity and flexibility in choosing positions for heavy
2012/039472
atoms. Photoreactive non-natural amino acids (including but not limited to, amino acids with
benzophenone and arylazides (including but not limited to, phenylazide) side chains), for example, allow
for efficient in vivo and in vitro photocrosslinking of polypeptides. Examples of photoreactive non-natural
amino acids include, but are not limited to, p-azido-phenylalanine and p-benzoyl—phenylalanine. The
polypeptide with the photoreactive non-natural amino acids may then be crosslinked at will by excitation
of the photoreactive group-providing temporal control. In a non-limiting example, the methyl group of a
non-natural amino can be substituted with an ically labeled, including but not limited to, with a
methyl group, as a probe of local structure and dynamics, including but not limited to, with the use of
nuclear magnetic resonance and vibrational spectroscopy.
A. Structure and Synthesis ofNon-Natural Amino Acid Derivatives: Carbonyl, yl
like, Masked Carbonyl, and Protected Carbonyl Groups
] Amino acids with an electrophilic reactive group allow for a variety of reactions to link molecules
via s chemical reactions, ing, but not d to, nucleophilic addition reactions. Such
electrophilic reactive groups include a carbonyl- or onyl-group ding a keto- or aldehyde
group), a carbonyl-like- or dicarbonyl-like-group (which has reactivity similar to a carbonyl- or
dicarbonyl-group and is urally similar to a carbonyl- or dicarbonyl-group), a masked carbonyl- or
masked dicarbonyl-group (which can be readily converted into a carbonyl- or dicarbonyl-group), or a
protected carbonyl- or ted dicarbonyl-group (which has reactivity r to a carbonyl- or
dicarbonyl-group upon deprotection). Such amino acids include amino acids having the structure of
Formula (XXXVH):
R3 A\ , K \
R3 B R
o<xxv11)
R1\N R2
H R4o
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted alkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
tuted alkarylene, aralkylene, or tuted aralkylene,
B is al, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene,
substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, -S(O)k- where k is 1, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -, -NR’-(alkylene or tuted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
0 120%?“ s E" 5:" 0R" SR" Ff" a. ”\l/
“A, o fikwfiwks,thaw/”\o/imkf.
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
each R” is independently H, alkyl, substituted alkyl, or a ting group, or when more than one R”
group is present, two R” optionally form a cycloalkyl;
R1 is H, an amino ting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or cleotide;
each of R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4 or two
R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
or the —A-B-K-R groups together form a bicyclic or tricyclic cycloalkyl or heterocycloalkyl comprising at
least one carbonyl group, including a dicarbonyl group, protected carbonyl group, including a
protected dicarbonyl group, or masked carbonyl group, ing a masked dicarbonyl group;
or the —K-R group together forms a monocyclic or bicyclic lkyl or heterocycloalkyl comprising at
least one carbonyl group, including a dicarbonyl group, protected carbonyl group, including a
protected dicarbonyl group, or masked carbonyl group, ing a masked dicarbonyl group;
with a proviso that when A is phenylene and each R3 is H, B is present; and that when A is —(CH2)4- and
each R3 is H, B is not —NHC(O)(CH2CH2)-; and that when A and B are absent and each R3 is H, R is not
methyl. Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-
natural amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post
translationally d.
] In certain ments, compounds of Formula (XXXVII) are stable in aqueous solution for
at least 1 month under mildly acidic conditions. In certain embodiments, compounds of Formula
(XXXVII) are stable for at least 2 weeks under mildly acidic conditions. In certain embodiments,
compound of Formula (XXXVII) are stable for at least 5 days under mildly acidic conditions. In certain
embodiments, such acidic conditions are pH 2 to 8.
In certain embodiments of nds of Formula (XXXVII), B is lower alkylene, substituted
lower alkylene, -O-(alkylene or substituted alkylene)-, -C(R’)=N—N(R’)-, -N(R’)CO-, , -C(R’)=N—,
-C(O)-(alkylene or substituted alkylene)-, ’)-(alkylene or substituted alkylene)-, -S(alkylene or
substituted alkylene)-, -S(O)(alkylene or substituted alkylene)-, or -S(O)2(alkylene or substituted
alkylene)-. In certain embodiments of compounds of Formula (XXXVII), B is —O(CH2)-, -CH=N—,
-CH=N—NH-, -NHCH2-, -NHCO-, -C(O)-, -C(O)-(CH2)-, -CONH-(CH2)-, -SCH2-, -S(=O)CH2-, or -
S(O)2CH2-. In certain embodiments of compounds of Formula (XXXVII), R is C1_6 alkyl or lkyl. In
certain embodiments of compounds of Formula (XXXVII) R is —CH3, -CH(CH3)2, or cyclopropyl. In
certain embodiments of compounds of Formula (XXXVII), R1 is H, tert-butyloxycarbonyl (Boc), 9-
Fluorenylmethoxycarbonyl , N—acetyl, tetrafluoroacetyl (TFA), or benzyloxycarbonyl (Cbz). In
certain ments of compounds of Formula (XXXVII), R1 is a resin, amino acid, polypeptide,
antibody, or polynucleotide. In certain embodiments of nds of Formula I), R2 is OH, 0-
methyl, O-ethyl, or O-t—butyl. In certain embodiments of compounds of Formula (XXXVII), R2 is a resin,
amino acid, polypeptide, antibody, or polynucleotide. In certain embodiments of compounds of Formula
(XXXVII), R2 is a polynucleotide. In certain embodiments of compounds of Formula (XXXVII), R2 is
ribonucleic acid (RNA).
In certain embodiments of nds of Formula (XXXVII), flog/A is selected
from the group ting of:
(i) A is tuted lower ne, C4-arylene, substituted arylene, heteroarylene, substituted
arylene, alkarylene, substituted alkarylene, aralkylene, or substituted aralkylene,
B is optional, and when present is a divalent linker selected from the group consisting of
lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower
alkenylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S(O)-, -S(O)2-, -NS(O)2-, -
OS(O)2-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -N(R’)-, -C(O)N(R’)-,
’)-(alkylene or tuted alkylene)-, -CSN(R’)-, -N(R’)CO-(alkylene or
substituted alkylene)-, -N(R’)C(O)O-, -N(R’)C(S)-, (R’), -S(O)2N(R’),
-N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-, -N(R’)S(0)N(R’)-, -N(R’)S(O)2N(R’)-, -N(R’)-
N=, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-;
(ii) A is optional, and when present is substituted lower alkylene, C4-arylene, substituted
arylene, heteroarylene, substituted heteroarylene, lene, substituted alkarylene,
aralkylene, or substituted aralkylene,
B is a nt linker selected from the group consisting of lower alkylene, substituted
lower ne, lower alkenylene, substituted lower alkenylene, -O-, -O-(alkylene or
tuted alkylene)-, -S-, -S(O)-, -S(O)2-, -NS(O)2-, -OS(O)2-, -C(O)-, -C(O)-(alkylene
or substituted alkylene)-, -C(S)-, -N(R’)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -N(R’)CO-(alkylene or tuted alkylene)-,
-N(R’)C(0)O-, -N(R’)C(S)-, (R’), -S(O)2N(R’), -N(R’)C(O)N(R’)-,
-N(R’)C(S)N(R’)-, -N(R’)S(O)N(R’)-, -N(R’)S(O)2N(R’)-, -N(R’)-N=, -C(R’)=N—N(R’)-,
-C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-;
(iii) A is lower alkylene;
B is optional, and when present is a divalent linker selected from the group consisting of
lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower
lene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S(O)-, -S(O)2-, -NS(O)2-, -
OS(O)2-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -N(R’)-, -C(O)N(R’)-,
-CSN(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, -N(R’)C(O)O-, -N(R’)C(S)-,
-S(0)N(R’), -S(0)2N(R’), _N(R’)C(O)N(R’)_a -N(R’)C(S)N(R’)-, _N(R’)S(O)N(R’)_a -
(O)2N(R’)-, -N(R’)-N=, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
-C(R’)2-N(R’)-N(R’)-; and
(iV) A is phenylene;
B is a nt linker selected from the group consisting of lower alkylene, substituted
lower alkylene, lower alkenylene, substituted lower alkenylene, -O-, kylene or
substituted alkylene)-, -S-, -S(O)-, -, -NS(O)2-, 2-, -C(O)-, -C(O)-(alkylene
or substituted alkylene)-, -C(S)-, -N(R’)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -N(R’)CO-(alkylene or substituted alkylene)-,
-N(R’)C(O)O-, -N(R’)C(S)-, -S(O)N(R’), -S(0)2N(R’), -N(R’)C(O)N(R’)-,
-N(R’)C(S)N(R’)-, -N(R’)S(O)N(R’)-, -N(R’)S(O)2N(R’)-, -N(R’)-N=, -C(R’)=N—N(R’)-,
-C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-;
:le SR'
O a. S / \ OR' R.
A: art/wL
7 7 ,or
O\ /R
la rr"
each R’ is independently H, alkyl, or substituted alkyl,
R1 is optional, and when present, is H, an amino protecting group, resin, amino acid, polypeptide,
or polynucleotide; and
R2 is optional, and when present, is OH, an ester protecting group, resin, amino acid, polypeptide,
or polynucleotide; and
each R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
In addition, amino acids haVing the structure of Formula (XXXVHI) are included:
0 (XXXVHI),
wherein:
A is optional, and when present is lower alkylene, tuted lower alkylene, lower lkylene,
substituted lower cycloalkylene, lower lene, substituted lower alkenylene, alkynylene, lower
alkylene, substituted heteroalkylene, lower cycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene;
B is optional, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene,
substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, - where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, , -C(S)-(alkylene or substituted
alkylene)-, -N(R’)-, -NR’-(alkylene or tuted alkylene)-, (R’)-, -CON(R’)-(alkylene or
substituted ne)-, -CSN(R’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted ne)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
with a proviso that when A is phenylene, B is present; and that when A is 4-, B is not —
(CH2CH2)-; and that when A and B are , R is not methyl. Such non-natural amino acids
may be in the form of a salt, or may be incorporated into a non-natural amino acid polypeptide, polymer,
polysaccharide, or a polynucleotide and optionally post translationally modified.
In on, amino acids having the structure of Formula (XXXIX) are included:
Ra BTR
R1 \ R2
O (XXXIX),
wherein:
B is a linker selected from the group consisting of lower alkylene, substituted lower alkylene, lower
alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene, -O-,
-O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or substituted alkylene)-, -S(O)k- where k is l,
2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-, -NS(O)2-, -OS(O)2-, -C(O)-(alkylene or
substituted ne)-, -C(S)-, -C(S)-(alkylene or substituted alkylene)-, -N(R’)-, -NR’-(alkylene or
substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, -CSN(R’)-,
-CSN(R’)-(alkylene or tuted alkylene)-, -N(R’)CO-(alkylene or substituted alkylene)-,
-N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-, -N(R’)S(O)kN(R’)-, -N=,
=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where each
R’ is independently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each Ra is independently selected from the group consisting of H, halogen, alkyl, substituted alkyl, -
N(R’)2, -C(O)kR’ where k is l, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’, where each R’ is
independently H, alkyl, or substituted alkyl. Such non-natural amino acids may be in the form of a
salt, or may be incorporated into a non-natural amino acid polypeptide, polymer, polysaccharide, or a
polynucleotide and optionally post translationally modified.
In addition, the following amino acids are included:
0 O
OQK H
\N/NY \N
OH H OH
H2N H N H2N
O H2N COOH 0 O
7 7 7 7
Qt O O
0 NJKH
OH H OH
H2N H2N H2N
H2N COOH o o and
, , ,
Such non-natural amino acids may be are optionally amino protected group, carboxyl protected and/or in
the form of a salt, or may be incorporated into a non-natural amino acid polypeptide, polymer,
polysaccharide, or a polynucleotide and optionally post translationally modified.
In addition, the following amino acids haVing the structure of Formula (XXXX) are included:
(CR8 n)\B)J\R
R1\N R2
(XXXX)
wherein
-NS(O)2-, -OS(O)2-, optional, and when t is a linker ed from the group consisting of lower
alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower
heteroalkylene, substituted lower heteroalkylene, -O-, -O-(alkylene or substituted ne)-, -S-, -S-
(alkylene or tuted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or substituted
alkylene)-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -, -NR’-(alkylene or substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, ’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
2-N(R’)-N(R’)-, where each R’ is ndently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or tuted lkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each R5 is independently selected from the group consisting of H, halogen, alkyl, substituted alkyl, -
N(R’)2, -C(O)kR’ where k is l, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’, where each R’ is
independently H, alkyl, or substituted alkyl; and n is O to 8;
with a proviso that when A is —(CH2)4-, B is not —NHC(O)(CH2CH2)-. Such non-natural amino acids may
be in the form of a salt, or may be incorporated into a non-natural amino acid polypeptide, polymer,
polysaccharide, or a polynucleotide and ally post translationally modified.
In addition, the following amino acids are included:
5
55555555
5 5 5
w,herein such compounds are ally amino
protected, optionally carboxyl protected, optionally amino protected and carboxyl ted, or a
salt thereof, or may be incorporated into a non-natural amino acid ptide, polymer,
ccharide, or a polynucleotide and optionally post translationally modified.
] In addition, the following amino acids haVing the structure of Formula (XXXXI) are
included:
0 (XXXXI),
wherein,
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, tuted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene;
B is optional, and when present is a linker selected from the group consisting of lower alkylene,
tuted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene,
substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or substituted ne)-, -C(O)-,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -N(R’)-, -NR’-(alkylene or tuted alkylene)-, (R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene or tuted alkylene)-, -N(R’)CO-(alkylene
or tuted alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
R1 is H, an amino protecting group, resin, amino acid, ptide, or cleotide; and
R2 is OH, an ester ting group, resin, amino acid, polypeptide, or polynucleotide.
Such tural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids haVing the structure of Formula (XXXXH) are
included:
Ra BYOOJ
R1 \ R2
0 (XXXXII),
wherein,
B is optional, and when present is a linker selected from the group ting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene,
substituted lower heteroalkylene, -O-, kylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, ,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -N(R’)-, -NR’-(alkylene or substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, =N—N=, 2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
WO 66560
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
wherein each Ra is independently ed from the group consisting of H, n, alkyl,
tuted alkyl, -N(R’)2, -C(O)kR’ where k is l, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’,
where each R’ is ndently H, alkyl, or substituted alkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, ccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids are included:
Wfiww
”it?<53”? 1?”
wherein such compounds are optionally amino protected, optionally carboxyl protected, optionally amino
protected and carboxyl protected, or a salt thereof, or may be incorporated into a non-natural amino acid
polypeptide, polymer, polysaccharide, or a polynucleotide and ally post translationally modified.
In addition, the following amino acids haVing the structure of Formula (XXXXIV) are
included:
(CRa)n\BA?
R1\ R2
0 (XXXXIV),
wherein,
B is al, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower lene, substituted lower alkenylene, lower alkylene,
substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -N(R’)-, -NR’-(alkylene or substituted ne)-, (R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each R21 is independently selected from the group consisting of H, n, alkyl, substituted alkyl, -
, -C(O)kR’ where k is l, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’, where each R’ is
independently H, alkyl, or tuted alkyl; and n is O to 8.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids are included:
(E3 (E3 (E3 003 003 /—\
o o
HzNJ:,(0'4 ’HzNLVfOH ’HzNji'fOH O
0“ 0“
H2N HZN HEN/gOH
O O O and
, , , ,
n such compounds are optionally amino protected, optionally carboxyl protected, optionally amino
protected and carboxyl protected, or a salt thereof, or may be incorporated into a non-natural amino acid
polypeptide, r, polysaccharide, or a polynucleotide and optionally post translationally modified.
In addition to monocarbonyl structures, the non-natural amino acids described herein may
include groups such as dicarbonyl, dicarbonyl like, masked dicarbonyl and protected dicarbonyl groups.
For example, the following amino acids haVing the structure of Formula (XXXXV) are included:
A\B)H(R
R1\ R2
0 (XXXXV),
wherein,
A is optional, and when present is lower alkylene, substituted lower ne, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
tuted alkarylene, aralkylene, or substituted lene;
B is optional, and when t is a linker selected from the group ting of lower alkylene,
substituted lower alkylene, lower alkenylene, tuted lower alkenylene, lower heteroalkylene,
substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -N(R’)-, -NR’-(alkylene or substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, ’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, C(O)O-, N(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester ting group, resin, amino acid, polypeptide, or polynucleotide.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a cleotide and optionally post translationally
modified.
In addition, the following amino acids haVing the structure of a I) are
included:
Ra B
R1\ R2
0 (XXXXVI),
wherein,
B is al, and when present is a linker ed from the group ting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene,
substituted lower alkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or
substituted alkylene)-, - where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-,
-NS(O)2-, -OS(O)2-, (alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
alkylene)-, -N(R’)-, -NR’-(alkylene or substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is ndently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or tuted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
wherein each R21 is independently ed from the group consisting of H, halogen, alkyl,
substituted alkyl, -N(R’)2, -C(O)kR’ where k is l, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’,
where each R’ is ndently H, alkyl, or substituted alkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, r, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids are included:
o o o
(W m HWA
(Cr 0 o
+H3N 000- +H3N 000' +H3N 000- and+H3N coo-
7 7 7
wherein such compounds are optionally amino protected and carboxyl protected, or a salt thereof. Such
non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural amino
acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
] In addition, the following amino acids haVing the ure of Formula (XXXXVH) are
included:
(CRa)n\ R
R1\ R2 0
O (XXXXVH),
wherein,
B is optional, and when present is a linker ed from the group consisting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene,
substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, kylene or
substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, -C(O)-,
-NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted
ne)-, -N(R’)-, -NR’-(alkylene or substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or
substituted ne)-, -CSN(R’)-, -CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene
or substituted alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)-,
-N(R’)S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, 2-N=N-, and
-C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, alkyl, or substituted alkyl;
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted lkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each R21 is independently selected from the group consisting of H, halogen, alkyl, substituted alkyl,
-N(R’)2, -C(O)kR’ where k is l, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’, where each R’ is
independently H, alkyl, or substituted alkyl, and n is O to 8.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids are included:
0 3 NH
OH OH OH OH OH OH OH
H2N H2N H2N H2N H2N H2N H2N
o o o o o o o
7 7 7 7 7 7 7
and 0 wherein such compounds are optionally amino protected and carboxyl protected, or a
salt thereof, or may be incorporated into a non-natural amino acid polypeptide, polymer, polysaccharide,
or a polynucleotide and optionally post translationally modified.
In addition, the following amino acids haVing the structure of Formula HI) are
included:
0 O
A/ 1\L)KR
R1HNXClolR2
(XXXXVIII);
wherein:
A is optional, and when present is lower alkylene, substituted lower ne, lower cycloalkylene,
tuted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
alkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted e, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, lkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or cleotide;
X1 is C, S, or S(O); and L is alkylene, substituted alkylene, N(R’)(alkylene) or N(R’)(substituted
alkylene), where R’ is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, ccharide, or a polynucleotide and optionally post translationally
In addition, the following amino acids haVing the structure of a (XXXXIX) are
included:
0 O
A/ \L)kR
R1HNXClolR2
(XXXXIX)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower lene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, e, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted lene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
L is alkylene, substituted alkylene, N(R’)(alkylene) or N(R’)(substituted alkylene), where R’ is H, alkyl,
substituted alkyl, lkyl, or substituted cycloalkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid ptide, polymer, polysaccharide, or a cleotide and optionally post translationally
modified.
In addition, the following amino acids haVing the structure of Formula (XXXXX) are
included:
O 0
\S// A
KA/ \ R
R 1H N C (0 )R2
(XXXXX)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower lkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, lene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
L is ne, substituted alkylene, N(R’)(alkylene) or N(R’)(substituted alkylene), where R’ is H, alkyl,
substituted alkyl, cycloalkyl, or substituted cycloalkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, ccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids haVing the structure of Formula (XXXXXI) are
included:
0 o
l' A1
A/ \ R
X (c R ER 9)n
MN 0(0le
wherein:
A is optional, and when t is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino ting group, resin, amino acid, ptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
X1 is C, S, or S(O); and n is O, l, 2, 3, 4, or 5; and each R8 and R9 on each CRgR9 group is independently
selected from the group consisting of H, , alkylamine, halogen, alkyl, aryl, or any R8 and R9
can together form =0 or a cycloalkyl, or any to adjacent R8 groups can together form a cycloalkyl,
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
] In addition, the following amino acids haVing the structure of Formula (XXXXXH) are
included:
O O
é' A
A/ R X \(CR5R9>n
MN 0(0le
(XXXXXII)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower lene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted lene, aralkylene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, ptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
n is O, l, 2, 3, 4, or 5; and each R8 and R9 on each CRgR9 group is independently selected from the
group consisting of H, alkoxy, alkylamine, halogen, alkyl, aryl, or any R8 and R9 can together
form =0 or a cycloalkyl, or any to adjacent R8 groups can together form a cycloalkyl,
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post ationally
modified.
] In on, the following amino acids haVing the structure of Formula (XXXXXHI) are
included:
0 O 0
\S/ A
A/ \ R
X (c R ER 9)“
MN 0(0le (XXXXXIII)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower lene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted alkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted lene,
R is H, alkyl, tuted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
n is O, l, 2, 3, 4, or 5; and each R8 and R9 on each CRgR9 group is independently selected from the
group consisting of H, alkoxy, alkylamine, halogen, alkyl, aryl, or any R8 and R9 can together
form =0 or a cycloalkyl, or any to adjacent R8 groups can together form a cycloalkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post ationally
modified.
In addition, the following amino acids haVing the ure of Formula (XXXXXIV) are
included:
(XXXXXIV);
wherein:
A is al, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, lene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted e, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, ptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
X1 is C, S, or S(O); and L is ne, substituted ne, N(R’)(alkylene) or N(R’)(substituted
alkylene), where R’ is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl.
Such tural amino acids may be in the form of a salt, or may be incorporated into a tural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids haVing the structure of Formula (XXXXXV) are
included:
0 0
/C \
A N —|_ R
X R'
MIN 0(0le (XXXXXV)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, substituted e, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino ting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
L is alkylene, substituted alkylene, N(R’)(alkylene) or substituted alkylene), where R’ is H, alkyl,
substituted alkyl, cycloalkyl, or substituted cycloalkyl.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, the following amino acids haVing the structure of Formula (XXXXXVI) are
included:
0\S/ A0 o
A/ \N —L R
X R I
MIN 0(0le (XXXXXVI)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, lene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, arylene, tuted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester ting group, resin, amino acid, polypeptide, or polynucleotide;
L is alkylene, substituted alkylene, N(R’)(alkylene) or N(R’)(substituted ne), where R’ is H, alkyl,
substituted alkyl, cycloalkyl, or substituted cycloalkyl.
Such tural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, amino acids haVing the structure of Formula VII) are included:
O (XXXXXVII),
wherein:
A is optional, and when present is lower alkylene, tuted lower alkylene, lower cycloalkylene,
substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower
heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower
heterocycloalkylene, e, tuted arylene, heteroarylene, substituted heteroarylene, alkarylene,
substituted alkarylene, aralkylene, or substituted aralkylene;
(b) (b) (b)
"T” /R3 “I" “T" “I"
(b) (b) (b)
M is -C(R3)-, (a)E/C\—C\—g (b)R4 R4 (3)E/C=C\—éR4 (a)E/R—O—éR4 (a) is/C\—s—§R4
, , , ,
(b) (b)
(b) m R R
film /R3 l ”i
0—C—E/
s_ /_3C (b) (b)
_C_§ c=c—§ (b) g
(b) /
R /c\ R4 l I I
R4 JJJ m m m
(a) (a) (a) or (a) where (a) indicates
a , , ,
bonding to the A group and (b) indicates bonding to respective carbonyl groups, R3 and R4 are
independently chosen from H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
or R3 and R4 or two R3 groups or two R4 groups optionally form a cycloalkyl or a heterocycloalkyl;
R is H, halogen, alkyl, substituted alkyl, lkyl, or substituted cycloalkyl,
T3 is a bond, C(R)(R), O, or S, and R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or tuted
cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or cleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and ally post translationally
modified.
In addition, amino acids haVing the structure of a (XXXXXVIH) are included:
Ra T3\
R1\N R2
O (XXXXXVIH),
wherein:
(b) (b) (b)
WV‘ R3 m m m
<|:—c/—§ (b) (b) (b)
/ \ 0”
\ L—c—g é—o—g é—s—g \ / \
Mis -C(R3)-, (3) R4 R4 (a) 19/ — R4 (3) R4 (80 as/ \R4
, , , ,
(b) (b)
(b) (b)
m R
m R3 J‘ri /R3 Pr{
C=C— (b) O—C— (b) S—C— (b)
/C—C—3 <b> / I | I
R3 \R4 J‘s-5‘ R4
m m WU"
(a) (a) (a) or (a) Where (a) indicates
, , , ,
bonding to the A group and (b) indicates bonding to respective carbonyl groups, R3 and R4 are
independently chosen from H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl,
or R3 and R4 or two R3 groups or two R4 groups optionally form a cycloalkyl or a heterocycloalkyl;
R is H, halogen, alkyl, tuted alkyl, cycloalkyl, or substituted cycloalkyl,
T3 is a bond, ), O, or S, and R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted
cycloalkyl,
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each Ra is independently ed from the group consisting of H, halogen, alkyl, substituted alkyl,
-N(R’)2, R’ Where k is 1, 2, or 3, -C(O)N(R’)2, -OR’, and -S(O)kR’, Where each R’ is
independently H, alkyl, or substituted alkyl.
Such non-natural amino acids may be in the form of a salt, or may be orated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
] In addition, amino acids haVing the structure of Formula (XXXXXIX) are included:
R 0
wherein:
R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or tuted cycloalkyl; and
T3 is O, or S.
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, r, polysaccharide, or a polynucleotide and optionally post translationally
modified.
In addition, amino acids having the structure of Formula (XXXXXX) are included:
R O
O (XXXXXX),
wherein:
R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted lkyl.
] In addition, the ing amino acids having structures of Formula (XXXXXX) are
included:
0 O
O O
RPE R2 RDE R2
0 and 0
, .
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally
modified.
The carbonyl or dicarbonyl functionality can be reacted selectively With a ylamine-
containing reagent under mild conditions in aqueous solution to form the corresponding oxime linkage
that is stable under physiological conditions. See, e.g., Jencks, W. P., J. Am. Chem Soc. 81, 1
(1959); Shao, J. and Tam, J. P., J. Am. Chem. Soc. 117(14):3893-3899 (1995). Moreover, the unique
reactivity of the carbonyl or dicarbonyl group allows for selective modification in the presence of the
other amino acid side . See, e.g., Cornish, V. W., et al., J. Am. Chem. Soc. 118:8150-8151 (1996);
Geoghegan, K. F. & Stroh, J. G., Bioconjug. Chem. 3:138-146 (1992); Mahal, L. K., et al., e
276:1125-1128 (1997).
The synthesis of p-acetyl-(+/-)-phenylalanine and m—acetyl-(+/-)-phenylalanine is described in
Zhang, Z., et al., Biochemistry 42: 6735-6746 (2003), incorporated by reference. Other carbonyl- or
dicarbonyl-containing amino acids can be similarly ed.
In some embodiments, a polypeptide comprising a non-natural amino acid is chemically
modified to generate a reactive carbonyl or dicarbonyl functional group. For instance, an aldehyde
onality useful for conjugation ons can be generated from a functionality having adjacent amino
and hydroxyl groups. Where the biologically active le is a polypeptide, for example, an N—terminal
serine or threonine (which may be normally present or may be d Via chemical or enzymatic
digestion) can be used to generate an aldehyde functionality under mild oxidative cleavage ions
using periodate. See, e.g., Gaertner, et. al., Bioconjug. Chem. 3: 262-268 (1992); Geoghegan, K. & Stroh,
J., Bioconjug. Chem. 3:138-146 (1992); Gaertner et al., J. Biol. Chem. 269:7224-7230 (1994). r,
methods known in the art are restricted to the amino acid at the N—terminus of the peptide or protein.
Additionally, by way of example a non-natural amino acid bearing adjacent yl and
amino groups can be incorporated into a polypeptide as a “masked” aldehyde functionality. For example,
-hydroxylysine bears a hydroxyl group adjacent to the epsilon amine. Reaction conditions for generating
the aldehyde typically involve addition of molar excess of sodium riodate under mild conditions to
avoid oxidation at other sites within the polypeptide. The pH of the ion on is typically about
7.0. A typical reaction involves the addition of about 1.5 molar excess of sodium meta periodate to a
buffered solution of the polypeptide, followed by incubation for about 10 minutes in the dark. See, e. g.
US. Patent No. 6,423,685.
B. ure and sis 0fN0n-Natural Amino Acids: Dicarbonyl, Dicarbonyl-like,
Masked Dicarbonyl, and Protected Dicarbonyl Groups
Amino acids with an ophilic reactive group allow for a variety of reactions to link molecules
Via nucleophilic on reactions among others. Such ophilic reactive groups include a dicarbonyl
group (including a diketone group, a ketoaldehyde group, a ketoacid group, a ketoester group, and a
ketothioester group), a dicarbonyl-like group (which has reactiVity similar to a dicarbonyl group and is
structurally similar to a dicarbonyl group), a masked dicarbonyl group (which can be readily converted
into a onyl group), or a protected dicarbonyl group (which has reactiVity similar to a dicarbonyl
group upon deprotection). Such amino acids include amino acids having the structure of Formula
(xxxvn):
0 (XXXVH).
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
cycloalkylene, substituted lower cycloalkylene, lower alkenylene, substituted lower
lene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
substituted aralkylene,
B is optional, and when present is a linker linked at one end to a diamine ning moiety, the linker
ed from the group consisting of lower alkylene, tuted lower alkylene, lower
alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene,
-O-(alkylene or substituted alkylene)-, -S-(alkylene or substituted alkylene)-, -C(O)R”-, -
alkylene or substituted alkylene)-, where k is l, 2, or 3, -C(O)-(alkylene or substituted
alkylene)-, -C(S)-(alkylene or substituted alkylene)-, -NR”-(alkylene or substituted ne)-,
-CON(R”)-(alkylene or substituted alkylene)-, -CSN(R”)-(alkylene or substituted alkylene)-, and
-N(R”)CO-(alkylene or substituted alkylene)-, where each R” is independently H, alkyl, or
substituted alkyl,
0 0
0 o o
#2 Mkawk k /$71. 5,: Kisz' T1
\555 / 1 T2 \T \
T1 597
o 21 «duo Y 5&5\T3—T3—T2;?fi
a , where,
T1 is a bond, optionally substituted C1-C4 alkylene, ally substituted C1-C4 alkenylene, or
optionally substituted heteroalkyl;
wherein each optional substituents is independently selected from lower alkylene, substituted lower
alkylene, lower lkylene, substituted lower cycloalkylene, lower alkenylene, substituted
lower alkenylene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, tuted lower cycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
substituted aralkylene,
T2, is selected from the group consisting of lower alkylene, substituted lower alkylene, lower
alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene,
-O-, kylene or substituted alkylene)-, -S-, -S-(alkylene or substituted alkylene)-, -S(O)k-
where k is l, 2, or 3, -S(O)k(alkylene or substituted alkylene)-, , -C(O)-(alkylene or
substituted alkylene)-, , -C(S)-(alkylene or substituted alkylene)-, -N(R’)-, -NR’-(alkylene
or substituted alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene or tuted alkylene)-, -CSN(R’)-,
-CSN(R’)-(alkylene or substituted alkylene)-, -N(R’)CO-(alkylene or substituted ne)-,
_N(R’)C(O)O_a -S(O)kN(R’)-, _N(R’)C(O)N(R’)_a -N(R’)C(S)N(R’)-, 'N(R’)S(O)kN(R’)'a -N(R’)-
N=, -C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-,
where each R’ is independently H, alkyl, or substituted alkyl;
T ,5 ix): E “2352
, , or Where each X1 is
independently selected from the group consisting of -O-, -S-, -N(H)-, -N(R)-, -N(Ac)-, and —
N(OMe)-; X2 is —OR, -OAc, -SR, -N(R)2, -N(R)(Ac), -N(R)(OMe), or N3, and Where each R’ is
independently H, alkyl, or substituted alkyl;
R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted lkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
or the —A—B-K-R groups together form a bicyclic or tricyclic cycloalkyl or heterocycloalkyl
comprising at least one yl group, including a dicarbonyl group, protected carbonyl group,
ing a protected onyl group, or masked carbonyl group, including a masked dicarbonyl
group;
or the —K-R group together forms a monocyclic or bicyclic cycloalkyl or cycloalkyl comprising
at least one carbonyl group, including a dicarbonyl group, protected carbonyl group, including a
protected dicarbonyl group, or masked carbonyl group, including a masked dicarbonyl group.
] Non-limiting example of dicarbonyl amino acids haVing the structure of Formula
(X X XVII) include:
o o
0 O
OH OH
HZN HZN HZN
O O O
7 7 7
O 0
SM 0 O O O
HZNgM HZNWo’\ OH
O O O
7 7 7
O / O O
HZN iOH HzN OH OH
HZN HZN
O O O O
7 ' 7 7
O O
O O O O
O O
CF3 CHFZ
OH OH OH OH
HzN HZN HZN HZN
O 0 O O
OH OH OH
HZN H2N H2N
o o and 0
Such non-natural amino acids may be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, ccharide, or a polynucleotide and optionally post translationally
modified.
C. Structure and Synthesis of Non-Natural Amino Acids: Ketoalkyne, Ketoalkyne -
like, Masked Ketoalkyne, Protected Ketoalkyne , Alkyne, and
Cycloalkyne Groups
Amino acids containing reactive groups with dicarbonyl-like vity allow for the linking of
molecules Via philic addition reactions. Such electrophilic reactive groups include a ketoalkyne
group, a ketoalkyne-like group (which has reactivity r to a ketoalkyne group and is structurally
r to a kyne group), a masked kyne group (which can be readily converted into a
ketoalkyne group), or a protected ketoalkyne group (which has vity similar to a ketoalkyne group
upon deprotection). In some embodiments, amino acids containing reactive groups with a al alkyne,
al alkyne or cycloalkyne allow for linking of molecules Via cycloaddition reactions (e.g., 1,3-dipolar
cycloadditions, azide-alkyne Huisgen cycloaddition, etc.) Such amino acids include amino acids haVing
the structure of Formula (XXXXXXI-A) or (XXXXXXI-B):
R l H
3 A G—CEC—R
\B/ R3 A\ Q
R3 B
R (R19)q
R1\N 2 R1\N R2
H R4 H R
O (XXXXXXI-A), 4o (XXXXXXI-B),
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
cycloalkylene, substituted lower cycloalkylene, lower alkenylene, substituted lower
alkenylene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
arylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
substituted aralkylene,
B is optional, and when present is a linker linked at one end to a diamine containing moiety, the linker
selected from the group consisting of lower alkylene, substituted lower alkylene, lower
alkenylene, substituted lower alkenylene, lower heteroalkylene, tuted lower heteroalkylene,
-O-(alkylene or substituted alkylene)-, -S-(alkylene or substituted alkylene)-, -C(O)R”-, -
S(O)k(alkylene or substituted alkylene)-, where k is l, 2, or 3, -C(O)-(alkylene or tuted
alkylene)-, -C(S)-(alkylene or substituted ne)-, -NR”-(alkylene or substituted alkylene)-,
-CON(R”)-(alkylene or substituted alkylene)-, -CSN(R”)-(alkylene or substituted alkylene)-, and
-N(R”)CO-(alkylene or substituted alkylene)-, where each R” is ndently H, alkyl, or
substituted alkyl,
)K T
G is optional, and when present is Sonora/4);;
555% ix?“
T4 is a carbonyl protecting group including, but not limited to, \_/
55:2le Wm “Mn
XUCI cQ‘Z‘XZ 921/le2
; ; or where each X1 is independently selected from the group
ting of -O-, -S-, -N(H)-, -N(R)-, -N(Ac)-, and —N(OMe)-; X2 is —OR, -OAc, -SR, -N(R)2, -
N(R)(Ac), -N(R)(OMe), or N3, and where each R’ is independently H, alkyl, or substituted alkyl;
R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each of R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4 or
two R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
each R19 is ndently selected from the group ting of C1-C6 alkyl, C1-C6 alkoxy, ester,
ether, thioether, aminoalkyl, n, alkyl ester, aryl ester, amide, aryl amide, alkyl halide, alkyl
amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, halosulfonyl, nitrile, alkyl nitrile,
and nitro; and
qis 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10 or 11.
D. Structure and Synthesis ofNon-Natural Amino Acids: Ketoamine, Ketoamine-like,
Masked Ketoamine, and Protected Ketoamine Groups
]Amino acids containing reactive groups with dicarbonyl-like reactiVity allow for the linking of
molecules Via nucleophilic addition ons. Such reactive groups include a ine group, a
ketoamine-like group (which has reactiVity similar to a ketoamine group and is structurally r to a
ketoamine group), a masked ketoamine group (which can be readily converted into a ketoamine group), or
a protected ketoamine group (which has reactiVity similar to a ketoamine group upon deprotection). Such
amino acids include amino acids haVing the structure of Formula (XXXXXXH):
R3 A\B/G_T1\
N—R'
R1\N R2 R
H R4
0 (XXXXXXII)
wherein:
A is optional, and when present is lower alkylene, tuted lower alkylene, lower
cycloalkylene, tuted lower cycloalkylene, lower alkenylene, substituted lower
alkenylene, alkynylene, lower heteroalkylene, substituted alkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted lene, aralkylene, or
substituted aralkylene;
B is optional, and when present is a linker linked at one end to a diamine containing moiety, the linker
selected from the group consisting of lower ne, substituted lower alkylene, lower
lene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene,
-O-(alkylene or substituted alkylene)-, -S-(alkylene or substituted alkylene)-, -C(O)R”-, -
S(O)k(alkylene or substituted ne)-, where k is l, 2, or 3, -C(O)-(alkylene or substituted
alkylene)-, -C(S)-(alkylene or substituted alkylene)-, -NR”-(alkylene or tuted alkylene)-,
-CON(R”)-(alkylene or substituted alkylene)-, -CSN(R”)-(alkylene or substituted alkylene)-, and
-N(R”)CO-(alkylene or substituted alkylene)-, where each R” is ndently H, alkyl, or
substituted alkyl;
2* 5' T
" 2/ 4\ 5'S,
G is or ;
T1 is an optionally substituted C1-C4 alkylene, an optionally substituted C1-C4 alkenylene, or an
optionally substituted heteroalkyl;
555><9LL fir
T4 is a yl protecting group including, but not limited to, R'O OR' \_/
fyk “w
X X1 v 09-239 ‘12“11:
; ; or where each X1 is independently selected from the group
consisting of -O-, -S-, -N(H)-, -N(R’)-, -N(Ac)-, and —N(OMe)-; X2 is —OR, -OAc, -SR’, -N(R’)2,
-N(R’)(Ac), -N(R’)(OMe), or N3, and where each R’ is ndently H, alkyl, or substituted
alkyl;
R is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, ptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
each of R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4 or
two R3 groups optionally form a cycloalkyl or a heterocycloalkyl.
Amino acids haVing the structure of a (XXXXXXH) include amino acids haVing the
structure of Formula XHI) and Formula (XXXXXXIV):
Ra /Gfl
B /RV
Ra F O ’R’
R' N\
RE,1 a
R1\ R2 R1\ R2
N N
H H
O (XXXXXXIII), O (XXXXXXIV)
wherein each Ra is independently selected from the group consisting of H, halogen, alkyl, substituted
alkyl, -N(R’)2, -C(O)kR’ where k is 1, 2, or 3, -C(O)N(R’)2, -OR’, and R’, where each R’ is
ndently H, alkyl, or substituted alkyl.
E. Structure and sis ofNon-Natural Amino Acids: Diamine, Diamine-like, Masked
Diamine, Protected Amines and Azides
Amino acids with a nucleophilic reactive group allow for a variety of reactions to link
les Via electrophilic addition reactions among others. Such nucleophilic ve groups include a
diamine group (including a hydrazine group, an e group, an imine group, a l,l-diamine group, a
1,2-diamine group, a 1,3-diamine group, and a l,4-diamine group), a diamine-like group (which has
reactiVity similar to a diamine group and is structurally similar to a e group), a masked e
group (which can be readily ted into a diamine group), or a protected diamine group (which has
reactiVity similar to a diamine group upon deprotection). In some embodiments, amino acids containing
reactive groups with azides allow for linking of les Via cycloaddition reactions (e.g., 1,3-dipolar
cycloadditions, azide-alkyne Huisgen cycloaddition, etc.).
In another aspect are methods for the chemical synthesis of hydrazine-substituted molecules
for the derivatization of carbonyl-substituted dolastatin derivatives. In one embodiment, the hydrazine-
substituted molecule can dolastatin linked derivatives. In one embodiment are methods for the preparation
of hydrazine-substituted molecules suitable for the derivatization of carbonyl-containing non-natural
amino acid polypeptides, including by way of example only, ketone-, or aldehyde-containing non-natural
amino acid polypeptides. In a further or additional embodiment, the non-natural amino acids are
incorporated site-specifically during the in Vivo translation of proteins. In a further or additional
embodiment, the hydrazine-substituted dolastatin derivatives allow for the site-specific derivatization of
carbonyl-containing tural amino acids Via philic attack of each carbonyl group to form a
heterocycle-derivatized polypeptide, including a nitrogen-containing heterocycle-derivatized polypeptide
in a site-specific fashion. In a further or additional embodiment, the method for the preparation of
hydrazine-substituted dolastatin tives provides access to a wide variety of site-specifically
derivatized polypeptides. In a further or additional embodiment are s for synthesizing ine-
functionalized polyethyleneglycol (PEG) linked dolastatin derivatives.
Such amino acids include amino acids having the structure of Formula (XXXVII—A) or
(XXXVII-B):
R3 R3
A\ /K\ A\ /N 3
R3 B R R3 B
R1 \ R2 R \1 R2
N N
H R4 H R4
0 (XXXVII), o (XXXVII-B),
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
cycloalkylene, tuted lower cycloalkylene, lower alkenylene, substituted lower
lene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted e,
heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
substituted aralkylene;
B is optional, and when present is a linker linked at one end to a diamine ning moiety, the linker
selected from the group consisting of lower alkylene, substituted lower alkylene, lower
alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower alkylene,
-O-(alkylene or substituted ne)-, -S-(alkylene or substituted alkylene)-, ”-, -C(O)R”-
or substituted alkylene)-, where k is
, -S(O)k(alkylene l, 2, or 3, -C(O)-(alkylene or substituted
ne)-, -C(S)-(alkylene or substituted alkylene)-, -NR”-(alkylene or substituted alkylene)-,
-CON(R”)-(alkylene or tuted alkylene)-, -CSN(R”)-(alkylene or substituted alkylene)-, and
-N(R”)CO-(alkylene or substituted alkylene)-, where each R” is independently H, alkyl, or
substituted alkyl,
R R R2 H
R8 $9 $8 |9 H\N/8 Ill H‘ l;
| N\ /N\ \ \ /
N\ /N / T1 H T2 \R9
[.111 / \ T2
T1 \ \ / \ 55y
K IS ”LL!/ 555‘ J‘p’ “L21 ‘11.}. 555 01‘
a ’ ’ a
H\I\I\ I
1L1 ;where
R8 and R9 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted
lkyl, or amine protecting group;
T1 is a bond, optionally substituted C1-C4 ne, optionally substituted C1-C4 alkenylene, or
optionally substituted heteroalkyl,
T2 is optionally substituted C1-C4 ne, optionally substituted C1-C4 alkenylene, optionally
substituted heteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
wherein each optional substituents is independently selected from lower alkyl, substituted lower
alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower l, substituted lower alkenyl,
alkynyl, lower heteroalkyl, substituted heteroalkyl, lower heterocycloalkyl, substituted lower
heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted
alkaryl, aralkyl, or substituted aralkyl,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, ptide, or polynucleotide;
each of R3 and R4 is independently H, n, lower alkyl, or substituted lower alkyl, or R3 and R4 or
two R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
or the —A—B-K-R groups together form a bicyclic or tricyclic cycloalkyl or heterocycloalkyl
comprising at least one diamine group, protected diamine group or masked diamine
group;
or the —B-K-R groups together form a bicyclic or tricyclic cycloalkyl or cycloaryl or
cycloalkyl comprising at least one diamine group, protected diamine group or
masked diamine group;
or the —K-R group er forms a monocyclic or bicyclic cycloalkyl or heterocycloalkyl
sing at least one diamine group, protected diamine group or masked diamine
group;
wherein at least one amine group on —A—B-K-R is optionally a protected amine.
In one aspect are compounds comprising the structures 1 or 2:
NH 2
R3 R3A, 1% NH
3' \TI 2 R3 3A f
‘B’ 2NH2
Rl‘N R2 R1. R2
R N
H 4O H R40
1 2
wherein:
A is optional, and when t is lower alkylene, substituted lower alkylene, lower
cycloalkylene, substituted lower cycloalkylene, lower alkenylene, tuted lower
alkenylene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
arylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
tuted aralkylene,
B is al, and when present is a linker linked at one end to a diamine containing moiety, the
linker selected from the group consisting of lower alkylene, substituted lower alkylene,
lower alkenylene, substituted lower lene, lower heteroalkylene, substituted lower
alkylene, -O-(alkylene or substituted alkylene)-, -S-(alkylene or substituted
alkylene)-, -C(O)R”-,-S(O)k(alkylene or substituted alkylene)-, where k is l, 2, or 3,
-C(O)-(alkylene or substituted alkylene)-, -C(S)-(alkylene or substituted alkylene)-,
-NR”-(alkylene or substituted alkylene)-, -CON(R”)-(alkylene or substituted alkylene)-,
-CSN(R”)-(alkylene or substituted alkylene)-, and -N(R”)CO-(alkylene or substituted
alkylene)-, where each R” is independently H, alkyl, or substituted alkyl;
T1 is a bond or CH2; and T2 is CH;
wherein each optional substituents is independently selected from lower alkyl, substituted lower
alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower
alkenyl, alkynyl, lower heteroalkyl, substituted heteroalkyl, lower heterocycloalkyl,
substituted lower heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted
heteroaryl, alkaryl, substituted alkaryl, aralkyl, or substituted aralkyl;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester protecting group, resin, amino acid, ptide, or polynucleotide;
each of R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and
R4 or two R3 groups optionally form a cycloalkyl or a cycloalkyl;
or the —A—B-diamine ning moiety together form a ic cycloalkyl or heterocycloalkyl
comprising at least one diamine group, ted diamine group or masked diamine
group;
or the —B-diamine containing moiety groups together form a bicyclic or tricyclic cycloalkyl or
ryl or heterocycloalkyl comprising at least one diamine group, protected diamine
group or masked diamine group;
n at least one amine group on —A—B-diamine containing moiety is optionally a protected
amine;
or an active metabolite, salt, or a pharmaceutically acceptable prodrug or solvate thereof.
The following non-limiting es of amino acids having the structure of Formula (XXXVII)
are included:
qfiflfif NH2 NH2
7 7
If»?Ni
WO 66560
NH NH
NH2 NHz
OH OH OH OH
HZN HZN HZN HZN
NH2 OW
NH2 NH2
OH OH OH
HZN HZN HZN
O O and O
7 ,
Such non-natural amino acids may also be in the form of a salt or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and/or optionally post
translationally modified.
In certain embodiments, compounds of Formula (XXXVII) are stable in aqueous solution for at
least 1 month under mildly acidic conditions. In certain embodiments, compounds of Formula (XXXVII)
are stable for at least 2 weeks under mildly acidic conditions. In n embodiments, compound of
Formula (XXXVII) are stable for at least 5 days under mildly acidic conditions. In n embodiments,
such acidic conditions are pH about 2 to about 8.
In certain embodiments of compounds of Formula (XXXVII), B is lower alkylene, substituted
lower alkylene, O-(alkylene or substituted alkylene)-, C(R’)=NN(R’)-, -N(R’)CO-, C(O)-, =N—,
C(O)-(alkylene or substituted alkylene)-, CON(R’)(alkylene or substituted alkylene)-, -S(alkylene or
substituted alkylene)-, -S(O)(alkylene or substituted alkylene)-, or -S(O)2(alkylene or substituted
alkylene)-. In certain embodiments of compounds of Formula (XXXVII), B is —O(CH2)-, -CH=N—,
CH=NNH-, -NHCH2-, -NHCO-, C(O)-, C(O)(CH2)-, CONH(CH2)-, -SCH2-, CH2-, or -S(O)2CH2-.
In certain embodiments of compounds of a (XXXVII), R is C1-6 alkyl or cycloalkyl. In n
embodiments of compounds of Formula (XXXVII) R is —CH3, -CH(CH3)2, or ropyl. In certain
embodiments of compounds of Formula (XXXVII), R1 is H, tert-butyloxycarbonyl (Boc), 9-
Fluorenylmethoxycarbonyl (Fmoc), N—acetyl, tetrafluoroacetyl (TFA), or benzyloxycarbonyl (Cbz). In
certain embodiments of compounds of Formula (XXXVII), R1 is a resin, amino acid, polypeptide, or
cleotide. In certain embodiments of compounds of Formula (XXXVII), R1 is an antibody, antibody
fragment or monoclonal antibody. In certain embodiments of compounds of Formula (XXXVII), R2 is
OH, O-methyl, O-ethyl, or O-t-butyl. In n embodiments of compounds of Formula (XXXVII), R2 is
a resin, at least one amino acid, ptide, or polynucleotide. In certain embodiments of compounds of
Formula (XXXVII), R2 is an antibody, antibody fragment or monoclonal antibody.
] The ing non-limiting examples of amino acids haVing the structure of Formula (XXXVII)
are also included:
\NHZ
N 0vilk E‘NHz
02:21E H 5? NH2
oE OH
HZN Ez Ez
O O O
NH2 NH2
OH OH OH
HZN HZN HZN
o O
zE NH2
Om o: OH
H2N Ez H2N
O O 0
7 7 7
HzN NHZ
NH2 NH2
/ NH2 NH2
OH OH
H2N HzN H2N
O O O
7 7 7
NHz H N
H2N HzN
0 and 0%O
, ‘
Non—limiting examples of protected amino acids having the structure of Formula (XXXVII)
include:
’N= H H
N \ ,CH3 CH3
H CH3 N\ 0vN
N=c\ \N=C:
CH3 CH3
OH OH
H2N HZN HZN
O O O and
7 7 7
N\ ,CHs
N—C\_
F. ure and Synthesis 0fN0n-Natural Amino Acids: Aromatic Amines
Non-natural amino acids with nucleophilic reactive groups, such as, by way of example only,
an aromatic amine group (including ary and tertiary amine ), a masked aromatic amine
group (Which can be readily converted into a aromatic amine group), or a protected aromatic amine group
(Which has reactiVity similar to an aromatic amine group upon deprotection) allow for a variety of
reactions to link molecules via various reactions, including but not limited to, reductive alkylation
reactions with aldehyde containing dolastatin linker derivatives. Such ic amine containing non-
natural amino acids include amino acids having the structure of Formula (XXXXXXV):
(Ra>n\/A NH
R3 B
Rpg R2
o (XXXXXXV)
wherein:
is selected from the group consisting of a monocyclic aryl ring, a bicyclic aryl ring, a
multicyclic aryl ring, a clic heteroaryl ring, a bicyclic heteroaryl ring, and a yclic
heteroaryl ring;
A is independently CR,, or N;
B is independently CRa, N, O, or S;
each R2, is independently selected from the group consisting of H, halogen, alkyl, -N02, -CN, substituted
alkyl, -N(R’)2, -C(O)kR’, -C(O)N(R’)2, -OR’, and -S(O)kR’, where k is l, 2, or 3; andn is O, l, 2, 3, 4,
, or 6;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; and
R2 is OH, an ester ting group, resin, at least one amino acid, polypeptide, or polynucleotide;
each of R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4 or two
R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
M is H or —CH2R5; or the M-N—C(R5) moiety may form a 4 to 7 ed ring structure;
R5 is alkyl, substituted alkyl, alkenyl, substituted l, alkynyl, substituted alkynyl, alkoxy, substituted
alkoxy, alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, tuted polyalkylene oxide,
cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocycle, substituted heterocycle, alkaryl, tuted alkaryl, aralkyl, substituted aralkyl, -C(O)R”,
-C(O)OR”, -C(O)N(R”)2, -C(O)NHCH(R”)2, lene or substituted alkylene)-N(R”)2, -(alkenylene
or substituted alkenylene)-N(R”)2, -(alkylene or substituted alkylene)-(aryl or substituted aryl),
-(alkenylene or substituted alkenylene)-(aryl or substituted aryl), -(alkylene or substituted alkylene)-
ON(R”)2, -(alkylene or substituted alkylene)-C(O)SR”, -(alkylene or substituted alkylene)-S-S—(aryl
or substituted aryl), wherein each R” is independently hydrogen, alkyl, tuted alkyl, alkenyl,
substituted alkenyl, alkoxy, tuted alkoxy, aryl, substituted aryl, aryl, substituted
heteroaryl, heterocycle, tuted heterocycle, alkaryl, substituted alkaryl, aralkyl, substituted
aralkyl, or -C(O)OR’;
or two R5 groups optionally form a cycloalkyl or a heterocycloalkyl;
l 14
or R5 and any Ra optionally form a cycloalkyl or a heterocycloalkyl; and
each R’ is independently H, alkyl, or tuted alkyl.
Such non-natural amino acids may also be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally reductively
ted.
(Ron\/AQNH
The structure (as presented in all examples herein) does not present the relative
orientations of “A,” “B,” “NH-M” and “Ra”; rather these four features of this structure may be oriented in
any chemically-sound manner (along With other features of this structure), as illustrated by example
herein.
Non-natural amino acids containing an aromatic amine moiety haVing the structure of Formula
(A) include non-natural amino acids having the structures:
/A B-A1 \ v A
A/, B\‘
\A/ /:j::,'AAV R3 I
\ 2A
R3 A
R R
1\N 2
H R4
0 and
, ,
A‘=A‘
B \A‘
R3 A
R‘N R2
R4 M
0 ; Wherein, each A’ is independently selected from CRa, N, or C_NH, and
up to two A’ may be C_NH With the remaining A’ selected from CR,, or N.
Such non-natural amino acids may also be in the form of a salt, or may be incorporated into a non-natural
amino acid polypeptide, r, ccharide, or a polynucleotide and optionally ively
alkylated.
Non-limiting examples of non-natural amino acids containing an aromatic amine moiety
haVing the structure of a (XXXXXXV) include non-natural amino acids haVing the structure of
Formula (XXXXXXVI), and Formula (XXXXXXVII),
(XXXXXXVI), (XXXXXXVH), wherein; G is an
amine protecting group, including, but not limited to,
l 15
95.)" OVCC13 ,s‘“
1/ \fl/0\/ 0,5 OQ . fYoQ
; ; ‘g’ o
“1:3;O 555 CH CH
0 3 ’ 3
if $5_ ,5: 0 SiMe
—C Or it W 3
Such non-natural amino acids may be in the form of a salt, or may be orated into a tural
amino acid polypeptide, polymer, polysaccharide, or a polynucleotide and optionally reductively
alkylated.
] Non-natural amino acids containing an aromatic amine moiety have the following structures:
Wherein each Ra is independently selected from the group consisting of H, halogen, alkyl, -N02, -CN,
substituted alkyl, -N(R’)2, -C(O)kR’, -C(O)N(R’)2, -OR’, and -S(O)kR’, Where k is l, 2, or 3;
M is H or —CH2R5; or the M-N—C(R5) moiety may form a 4 to 7 membered ring structure;
R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide;
R5 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, l, substituted alkynyl, alkoxy, substituted
alkoxy, alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, substituted polyalkylene oxide,
cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
cycle, substituted heterocycle, alkaryl, substituted alkaryl, aralkyl, substituted aralkyl, -C(O)R”,
-C(O)OR”, -C(O)N(R”)2, HCH(R”)2, -(alkylene or substituted ne)-N(R”)2, -(alkenylene
or substituted alkenylene)-N(R”)2, -(alkylene or substituted alkylene)-(aryl or substituted aryl),
-(alkenylene or substituted alkenylene)-(aryl or substituted aryl), -(alkylene or substituted alkylene)-
2, -(alkylene or substituted alkylene)-C(O)SR”, -(alkylene or substituted alkylene)-S-S-(aryl
or substituted aryl), Wherein each R” is independently hydrogen, alkyl, tuted alkyl, alkenyl,
substituted alkenyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted
heteroaryl, heterocycle, substituted heterocycle, alkaryl, substituted l, aralkyl, tuted
aralkyl, or -C(O)OR’;
or R5 and any Ra optionally form a cycloalkyl or a heterocycloalkyl; and
each R’ is independently H, alkyl, or substituted alkyl. Such non-natural amino acids may also be in the
form of a salt, or may be incorporated into a non-natural amino acid polypeptide, polymer,
polysaccharide, or a polynucleotide.
Such tural amino acids of Formula (XXXXXXV) may be formed by reduction of
protected or masked amine moieties on the aromatic moiety of a non-natural amino acid. Such protected
or masked amine moieties include, but are not limited to, , hydrazines, nitro, or azide substituents.
The reducing agents used to reduce such protected or masked amine moieties include, but are not limited
to, TCEP, NaZS, Na2S204, LiAlH4, NaBH4 or NaBCNHg.
V. Non-Natural Amino Acid Linked Dolastatin Derivatives
In another aspect bed herein are methods, strategies and techniques for incorporating at least
one such atin linker derivatives into a non-natural amino acid. Also included With this aspect are
methods for ing, purifying, characterizing and using such dolastatin linker derivatives containing at
least one such non-natural amino acid. Also included With this aspect are compositions of and methods for
producing, purifying, characterizing and using oligonucleotides (including DNA and RNA) that can be
used to produce, at least in part, a dolastatin linker derivative containing at least one tural amino
acid. Also included With this aspect are compositions of and methods for producing, purifying,
characterizing and using cells that can express such oligonucleotides that can be used to produce, at least
in part, a atin linker derivative containing at least one non-natural amino acid.
Thus, dolastatin linker derivatives comprising at least one non-natural amino acid or modified
non-natural amino acid With a carbonyl, dicarbonyl, alkyne, cycloalkyne, azide, oxime or hydroxylamine
group are provided and described herein. In certain embodiments, dolastatin linker derivatives with at
least one non-natural amino acid or modified tural amino acid With a carbonyl, onyl, alkyne,
cycloalkyne, azide, oxime or hydroxylamine group include at least one post-translational modification at
some position on the polypeptide. In some embodiments the co-translational or post-translational
modification occurs via the cellular machinery (e. g., glycosylation, ation, acylation, lipid-
modification, palmitoylation, palmitate addition, orylation, ipid-linkage ation, and
the like), in many instances, such cellular-machinery-based co-translational or post-translational
modifications occur at the naturally occurring amino acid sites on the polypeptide, however, in certain
embodiments, the cellular-machinery—based co-translational or post-translational modifications occur on
the tural amino acid site(s) on the polypeptide.
In other ments, the post-translational modification does not utilize the cellular machinery,
but the onality is instead provided by attachment of a molecule (a polymer; a water-soluble polymer;
a derivative of polyethylene glycol; a second protein or ptide or polypeptide analog; an antibody or
antibody fragment; and any combination thereof) comprising a second reactive group to the at least one
non-natural amino acid comprising a first reactive group (including but not limited to, non-natural amino
acid containing a ketone, de, acetal, hemiacetal, alkyne, cycloalkyne, azide, oxime, or
hydroxylamine functional group) utilizing chemistry methodology described herein, or others suitable for
the ular reactive groups. In certain ments, the co-translational or post-translational
ation is made in vivo in a eukaryotic cell or in a karyotic cell. In certain embodiments, the
post-translational modification is made in vitro not utilizing the ar machinery. Also included With
this aspect are methods for ing, purifying, characterizing and using such dolastatin linker
derivatives containing at least one such co-translationally or post-translationally modified non-natural
amino acids.
Also included Within the scope of the methods, compositions, strategies and techniques described
herein are reagents capable of ng with a dolastatin linker derivative (containing a carbonyl or
dicarbonyl group, oxime group, alkyne, cycloalkyne, azide, hydroxylamine group, or masked or protected
forms thereof) that is part of a polypeptide so as to produce any of the aforementioned post-translational
modifications. In certain embodiments, the resulting post-translationally d dolastatin linker
derivative Will contain at least one oxime group; the ing modified oxime-containing dolastatin linker
derivative may undergo subsequent modification reactions. Also included with this aspect are methods for
producing, purifying, characterizing and using such reagents that are capable of any such post-
ational modifications of such dolastatin linker derivative(s).
In certain embodiments, the polypeptide or non-natural amino acid linked dolastatin derivative
includes at least one nslational or post-translational modification that is made in vivo by one host
cell, Where the post-translational modification is not normally made by another host cell type. In n
embodiments, the polypeptide includes at least one co-translational or post-translational modification that
is made in vivo by a eukaryotic cell, Where the co-translational or ranslational modification is not
normally made by a non-eukaryotic cell. Examples of such co-translational or ranslational
modifications include, but are not limited to, glycosylation, acetylation, acylation, lipid-modification,
palmitoylation, palmitate addition, orylation, glycolipid-linkage modification, and the like. In one
embodiment, the co-translational or ranslational modification comprises attachment of an
oligosaccharide to an asparagine by a GlcNAc-asparagine linkage (including but not limited to, Where the
oligosaccharide comprises (GlcNAc-Man)Z-Man-GlcNAc-GlcNAc, and the like). In another embodiment,
the co-translational or post-translational modification comprises attachment of an oligosaccharide
ding but not limited to, Gal-GalNAc, Gal-GlcNAc, etc.) to a serine or threonine by a GalNAc-
serine, a GalNAc-threonine, a GlcNAc-serine, or a GlcNAc-threonine linkage. In certain embodiments, a
protein or polypeptide can comprise a secretion or zation sequence, an epitope tag, a FLAG tag, a
polyhistidine tag, a GST fusion, and/or the like. Also included with this aspect are methods for producing,
purifying, characterizing and using such polypeptides containing at least one such co-translational or post-
translational ation. In other embodiments, the glycosylated non-natural amino acid polypeptide is
produced in a ycosylated form. Such a non-glycosylated form of a glycosylated non-natural amino
acid may be produced by methods that e chemical or enzymatic removal of oligosaccharide groups
from an isolated or substantially purified or unpurified glycosylated non-natural amino acid polypeptide;
production of the non-natural amino acid in a host that does not glycosylate such a non-natural amino acid
polypeptide (such a host including, prokaryotes or eukaryotes engineered or d to not glycosylate
such a polypeptide), the introduction of a glycosylation inhibitor into the cell culture medium in which
such a non-natural amino acid polypeptide is being produced by a eukaryote that normally would
glycosylate such a polypeptide, or a combination of any such methods. Also described herein are such
non-glycosylated forms of normally-glycosylated non-natural amino acid polypeptides (by normally-
glycosylated is meant a polypeptide that would be glycosylated when produced under conditions in which
naturally-occurring polypeptides are glycosylated). Of course, such non-glycosylated forms of normallyglycosylated
non-natural amino acid polypeptides (or indeed any polypeptide described herein) may be in
an unpurified form, a substantially purified form, or in an isolated form.
In certain embodiments, the non-natural amino acid polypeptide includes at least one post-
translational ation that is made in the ce of an accelerant, wherein the post-translational
modification is stoichiometric, stoichiometric-like, or near-stoichiometric. In other embodiments the
ptide is ted with a reagent of Formula (XIX) in the presence of an accelerant. In other
embodiments the accelerant is selected from the group consisting of:
::NH2 C:
OH 3:SH 0H [I \ NH2 NH2 H
CE N \(I
NSH OH
NH2 NH2 NH2 0H N NH2 N NH /\/NH2 NOH [53
2 H2N H2N H2N H N
7 7 7 7 7 7 7 7 7 7 7
and N.
A. Chemical Synthesis 0fN0n-Nataral Amino Acid Linked Dolastatin tives: Oxime-
Containing Linked atin Derivatives
Non-natural amino acid dolastatin linked derivatives containing an oxime group allow for reaction
with a variety of reagents that contain n reactive yl- or dicarbonyl- groups ding but not
limited to, s, aldehydes, or other groups with similar reactivity) to form new non-natural amino
acids comprising a new oxime group. Such an oxime exchange reaction allows for the further
functionalization of dolastatin linked tives. Further, the original dolastatin linked derivative
containing an oxime group may be useful in their own right as long as the oxime linkage is stable under
conditions necessary to incorporate the amino acid into a polypeptide (e.g., the in vivo, in vitro and
chemical synthetic methods described herein).
Thus, in certain ments described herein are non-natural amino acid dolastatin linked
derivatives with sidechains comprising an oxime group, an oxime-like group (which has reactivity similar
to an oxime group and is urally similar to an oxime group), a masked oxime group (which can be
readily converted into an oxime group), or a protected oxime group (which has reactivity similar to an
oxime group upon deprotection).
Such non-natural amino acid dolastatin linked tives include dolastatin linked derivatives
having the structure of Formula (VIII) or (IX):
(VH1)
(1X)
wherein:
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
cycloalkylene, substituted lower cycloalkylene, lower lene, substituted lower
alkenylene, alkynylene, lower heteroalkylene, substituted alkylene, lower
heterocycloalkylene, tuted lower heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, tuted alkarylene, aralkylene, or
substituted aralkylene;
B is optional, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower lene, substituted lower alkenylene, lower
heteroalkylene, substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -
S-, -S-(alkylene or substituted alkylene)-, -S(O)k- where k is l, 2, or 3, -S(O)k(alkylene or
substituted alkylene)-, -C(O)—, -C(O)-(alkylene or substituted alkylene)-, , -C(S)-
(alkylene or substituted alkylene)-, -N(R’)-, alkylene or substituted alkylene)-,
-C(O)N(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene
or substituted alkylene)-, -N(R’)CO-(alkylene or substituted alkylene)-, -N(R’)C(O)O-,
-S(0)kN(R’)-, C(0)N(R’)-, _N(R’)C(S)N(R’)_a -N(R’)S(O)kN(R’)-, -N(R’)-N=, -
C(R’)=N—, -C(R’)=N—N(R’)-, -C(R’)=N—N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where
each R’ is independently H, alkyl, or substituted alkyl,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;
R1 is H, an amino ting group, resin, at least one amino acid, ptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R3 and R4 are each independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4
or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
Z has the structure of:
‘7;\KKAr
R5 ;
R5 is H, CORg, C1-C6alkyl, or le;
R8 is OH
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or hydrogen;
L is a linker selected from the group ting of —alkylene—, —alkylene—C(O)—, —(alkylene—O)n—
alkylene—, —(alkylene—O)n—alkylene—C(O)—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nv~
C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, —(alkylene—O)n—alkylene—W—, —
alkylene—C(O)—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, and —(alkylene—O)n—
alkylene—U—alkylene—;
W has the structure of:
KTJK”
U has the ure of:
COZH
Mimi
each n, n', n", n'" and nH" are independently integers greater than or equal to one;
or an active metabolite, or a pharmaceutically acceptable prodrug or solvate thereof.
In certain embodiments of compounds of Formula (VIII) and (IX), R5 is thiazole. In certain
embodiments of compounds of Formula (VIII) and (IX), R6 is H. In n embodiments of compounds
of Formula (VIII) and (IX), Ar is phenyl. In certain ments of compounds of Formula (VIII) and
(IX), R7 is methyl. In certain embodiments of compounds of Formula (VIII) and (IX), n is an integer from
O to 20. In certain embodiments of compounds of Formula (VIII) and (IX), n is an integer from O to 10.
In certain embodiments of compounds of Formula (VIII) and (IX), n is an integer from O to 5.
In n embodiments of compounds of Formula (VIII) and (IX), R5 is thiazole. In n
embodiments of compounds of Formula (VIII) and (IX), R5 is hydrogen. In certain embodiments of
WO 66560
compounds of Formula (VIII) and (IX), R5 is methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl,
tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of Formula (VIII) and (IX), R5 is —
NH—(alkylene—O)n—NH2, wherein alkylene is —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2—, 2CHZCHZCHZCHZCHZCHZCH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CHZCH2CHZCHZCHZCHQCHZCHZCHZCH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In certain embodiments of Formula (VIII) and (IX),
ne is methylene, ethylene, propylene, butylenes, pentylene, hexylene, or heptylene.
In certain ments of compounds of Formula (VIII) and (IX), R5 is —NH—(alkylene—O)n—
NHZ, wherein n is 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
In certain embodiments of compounds of Formula (VIII) and (IX), R6 is H.
In certain embodiments of compounds of Formula (VIII) and (IX), Ar is .
In certain embodiments of compounds of a (VIII) and (IX), R7 is methyl, ethyl, propyl,
iso-propyl, butyl, sec-butyl iso-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of compounds
of Formula (VIII) and (IX), R7 is hydrogen.
In certain embodiments of compounds of Formula (VIII) and (IX), each L is independently a
cleavable linker or eavable linker. In n embodiments of compounds of Formula (VIII) and
(IX), each L is independently a oligo(ethylene glycol) derivatized linker.
In certain embodiments of compounds of Formula (VIII) and (IX), each alkylene, alkylene',
alkylene", and alkylene'" independently is —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CHZCHZCHZCHZCHZCHZCH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CHZCH2CHZCHZCHZCHQCHZCHZCHZCH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In certain embodiments of compounds of Formula
(VIII) and (IX), ne is ene, ethylene, propylene, nes, pentylene, hexylene, or heptylene.
In n embodiments of compounds of Formula (VIII) and (IX), each n, n', n", n'", and n""
independently is 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
In certain embodiments of compounds of Formula (VIII) or (IX), R1 is a polypeptide. In certain
embodiments of compounds of Formula (VIII) or (IX), R2 is a polypeptide. In certain embodiments of
compounds of Formula (VIII) or (IX), the polypeptide is an dy. In certain embodiments of
compounds of Formula (VIII) or (IX), the antibody is herceptin.
WO 66560
Such non-natural amino acid dolastatin linked derivatives include dolastatin linked derivatives
having the structure of Formula (X), (XI), (XII) 0r (XIII):
Me Lfl HMJ1:
R7 0 Me/_\MeMe OMeOM
R1” —N “j“ 0%;
B\A R7 0 M/KMeMe OMeO
R3 RO4
R3 R2
Me O Me/\MeMe OMeO OMeOA“”85:er R2 31
L1 (XI)
Me MNJL: \ R3
Me\ N 3 \ 3
N Y
Me o Me/KMeMe OMeO OMeOA R
IWNJL_ fiw
R7 0 Me/_\MeMe OMeOM N\H
,L1 Z
0 Me
R /N
Y N (X11)
L3—M meHJN Me
B\A 0 R7 0 Me/_\MeMe OMeoM
Me Me MeO NH
WO 66560
M321;£3;qu
R7 OMe/\MeMe OMeO OMe OA
R2 81
J\N \ R3
C? ’i R3
R7 OMe/\MeMe OMeO OMeOA R
R7 OMe/:\MeR12 OMeO OMeOA
A is optional, and when present is lower alkylene, substituted lower alkylene, lower
cycloalkylene, substituted lower lkylene, lower alkenylene, substituted lower
lene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower
heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or
substituted aralkylene;
B is optional, and when present is a linker selected from the group consisting of lower alkylene,
substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower
heteroalkylene, substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -
S-, -S-(alkylene or substituted alkylene)-, - where k is l, 2, or 3, -S(O)k(alkylene or
substituted alkylene)-, -C(O)—, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-
(alkylene or substituted alkylene)-, -, -NR’-(alkylene or substituted alkylene)-,
-C(O)N(R’)-, -CON(R’)-(alkylene or substituted alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene
or substituted alkylene)-, -N(R’)CO-(alkylene or tuted alkylene)-, -N(R’)C(O)O-,
-S(0)kN(R’)-, _N(R’)C(O)N(R’)_a -N(R’)C(S)N(R’)-, 'N(R’)S(O)kN(R’)'a -N(R’)-N=, -
C(R’)=N-, -C(R’)=N—N(R’)-, =N-N=, -C(R’)2-N=N-, and 2-N(R’)-N(R’)-, where
each R’ is independently H, alkyl, or substituted alkyl,
R is H, alkyl, substituted alkyl, cycloalkyl, or substituted lkyl;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R3 and R4 are each independently H, halogen, lower alkyl, or substituted lower alkyl, or R3 and R4
or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl;
Z has the structure of:
€Yé\(KAr
R5 ;
R5 is H, COZH, C1-C6alkyl, or thiazole;
R6 is OH or H;
Ar is phenyl or pyridine;
R7 is C1-C6alkyl or en;
L1, L2, L3, and L4 are each linkers independently selected from the group consisting of a bond, —
alkylene—, —(alkylene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —J—
(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—J—(alkylene—O)n'—alkylene—J'—, —
(alkylene—O)n—alkylene—J—alkylene'—, —W—, —alkylene—W—, alkylene'—J—(alkylene—NMe)n—
alkylene—W—, —J—(alkylene—NMe)n—alkylene—W—, ylene—NMe—alkylene'—NMe—
alkylene"—W—, and —alkylene—J—alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
ILWJUCVJK;
o NH2
each I and J' independently have the structure of:
aim/I51 \O/ii or J’S\Nj\e§
H H
, , ; and
each n and n' are independently integers greater than or equal to one.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R5 is thiazole or
ylic acid. In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R6 is H. In
certain embodiments of compounds of a (X), (XI), (XII) or (XIII), Ar is phenyl. In certain
embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R7 is methyl. In certain embodiments
of compounds of Formula (X), (XI), (XII) or (XIII), n and n' are integers from O to 20. In certain
embodiments of compounds of Formula (X), (XI), (XII) or (XIII), n and n' are integers from O to 10. In
certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), n and n' are rs from O to 5.
In certain ments of compounds of Formula (X), (XI), (XII) or (XIII), R5 is thiazole. In
certain ments of compounds of Formula (X), (XI), (XII) or (XIII), R5 is hydrogen. In certain
embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R5 is methyl, ethyl, propyl, iso-propyl,
butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of Formula
(X), (XI), (XII) or (XIII), R5 is —NH—(alkylene—O)n—NH2, wherein alkylene is —CH2—, —CH2CH2—, —
CH2CH2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CHZCH2CH2CHZCHZCHZCHZCHZCHZCH2—, or —CH2CH2CHZCH2CHZCHZCHZCHZCHgCHZCHZCH2—.
In certain embodiments of Formula (X), (XI), (XII) or (XIII), alkylene is methylene, ethylene, propylene,
butylenes, pentylene, hexylene, or heptylene.
In certain ments of compounds of Formula (X), (XI), (XII) or , R5 is —NH—
ene—O)n—NH2, wherein n is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R6 is H. In some
ments of nds of Formula (X), (XI), (XII) or , R6 is hydroxy.
] In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), Ar is phenyl.
In certain embodiments of compounds of a (X), (XI), (XII) or , R7 is methyl, ethyl,
propyl, opyl, butyl, sec-butyl iso-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of
compounds of Formula (X), (XI), (XII) or (XIII), R7 is en.
In n embodiments of compounds of Formula (X), (XI), (XII) or (XIII), each L1, L2, L3, and
L4 is independently a cleavable linker or non-cleavable linker. In certain embodiments of compounds of
Formula (X), (XI), (XII) or (XIII), each L1, L2, L3, and L4 is independently a oligo(ethylene glycol)
derivatized linker.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), each alkylene,
alkylene', alkylene", and alkylene'" independently is —CH2—, —CH2CH2—, —CH2CH2CH2—, —
CHZCHZCHgCH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—
, —CHQCH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CHZCHZCHZCHZCHZCHZCH2—,
CH2CH2CHZCHZCHZCHZCHZCHZCHZCH2—, —CH2CH2CH2CHZCHZCHZCHZCHZCHZCHZCH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In n embodiments of compounds of Formula
(X), (XI), (XII) or (XIII), alkylene is methylene, ethylene, propylene, butylenes, pentylene, hexylene, or
heptylene.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), each n and n'
ndently is 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R1 is a polypeptide.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), R2 is a polypeptide. In
certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), the polypeptide is an antibody.
In certain embodiments of compounds of Formula (X), (XI), (XII) or (XIII), the antibody is herceptin.
In certain embodiments, compounds of Formula (X), (XI), (XII) or (XIII) are stable in
aqueous solution for at least 1 month under mildly acidic conditions. In certain embodiments, compounds
of Formula (X), (XI), (XII) or (XIII) are stable for at least 2 weeks under mildly acidic conditions. In
certain embodiments, compound of Formula (X), (XI), (XII) or (XIII) are stable for at least 5 days under
mildly acidic conditions. In certain embodiments, such acidic conditions are pH 2 to 8. Such non-natural
amino acids may be in the form of a salt, or may be incorporated into a non-natural amino acid
polypeptide, polymer, polysaccharide, or a polynucleotide and optionally post translationally modified.
Oxime-based non-natural amino acids may be synthesized by methods already described in
the art, or by s described herein, ing: (a) reaction of a hydroxylamine-containing non-natural
amino acid with a carbonyl- or onyl-containing reagent; (b) reaction of a yl- or dicarbonyl-
containing non—natural amino acid with a hydroxylamine-containing reagent; or (c) reaction of an oxime-
ning non-natural amino acid with n carbonyl- or dicarbonyl-containing reagents.
B. al Structure and Synthesis of Non-Natural Amino Acid Linked Dolastatin
Derivatives: tea' Aromatic Amine Linked Dolastatin tives
] In one aspect are dolastatin linker derivatives for the chemical derivatization of non-natural
amino acids based upon the reactivity of an aromatic amine group. In further or additional embodiments,
at least one of the entioned non-natural amino acids is orated into a dolastatin linker
tive, that is, such embodiments are non-natural amino acid linked dolastatin derivatives. In further
or additional embodiments, the dolastatin linker derivatives are functionalized on their sidechains such
that their reaction with a derivatizing non-natural amino acid generates an amine linkage. In further or
additional embodiments, the dolastatin linker tives are selected from atin linker derivatives
having aromatic amine sidechains. In further or additional embodiments, the dolastatin linker tives
comprise a masked sidechain, including a masked ic amine group. In further or additional
embodiments, the non-natural amino acids are selected from amino acids having aromatic amine
sidechains. In further or additional embodiments, the non-natural amino acids comprise a masked
sidechain, including a masked aromatic amine group.
In another aspect are carbonyl-substituted dolastatin linker derivatives such as, by way of
example, aldehydes, and ketones, for the production of tized non-natural amino acid polypeptides
based upon an amine linkage. In a further embodiment are aldehyde-substituted dolastatin linker
derivatives used to derivatize aromatic amine-containing non-natural amino acid polypeptides via the
formation of an amine linkage between the derivatizing dolastatin linker and the aromatic amine-
containing non-natural amino acid polypeptide.
In r or additional ments, the non-natural amino acids comprise aromatic amine
sidechains where the aromatic amine is ed from an aryl amine or a heteroaryl amine. In a further or
additional embodiment, the non-natural amino acids resemble a natural amino acid in structure but contain
aromatic amine groups. In another or further embodiment the non-natural amino acids resemble
alanine or tyrosine (aromatic amino acids). In one embodiment, the non-natural amino acids have
properties that are distinct from those of the natural amino acids. In one embodiment, such ct
properties are the chemical reactivity of the sidechain; in a further embodiment this distinct chemical
reactiVity permits the sidechain of the non-natural amino acid to o a reaction while being a unit of a
polypeptide even though the sidechains of the naturally-occurring amino acid units in the same
ptide do not undergo the aforementioned reaction. In a further embodiment, the sidechain of the
non-natural amino acid has a chemistry orthogonal to those of the naturally-occurring amino acids. In a
r embodiment, the sidechain of the non-natural amino acid comprises a nucleophile-containing
moiety; in a further embodiment, the nucleophile-containing moiety on the sidechain of the non-natural
amino acid can undergo a reaction to te an amine-linked derivatized dolastatin. In a further
embodiment, the sidechain of the non-natural amino acid comprises an electrophile-containing moiety; in
a further embodiment, the electrophile-containing moiety on the sidechain of the non-natural amino acid
can undergo nucleophilic attack to generate an linked derivatized dolastatin. In any of the
aforementioned embodiments in this paragraph, the non-natural amino acid may exist as a separate
molecule or may be incorporated into a ptide of any length; if the latter, then the polypeptide may
further incorporate lly-occurring or non-natural amino acids.
Modification of non-natural amino acids described herein using reductive alkylation or
reductive amination reactions have any or all of the following advantages. First, aromatic amines can be
ively alkylated with carbonyl-containing compounds, including aldehydes, and ketones, in a pH
range of about 4 to about 10 (and in certain embodiments in a pH range of about 4 to about 7) to generate
substituted amine, including secondary and tertiary amine, linkages. Second, under these reaction
conditions the chemistry is selective for non-natural amino acids as the sidechains of naturally occurring
amino acids are unreactive. This allows for site-specific derivatization of polypeptides which have
incorporated non-natural amino acids containing aromatic amine moieties or protected aldehyde es,
including, by way of example, recombinant proteins. Such derivatized polypeptides and proteins can
thereby be prepared as defined neous products. Third, the mild conditions needed to effect the
reaction of an aromatic amine moiety on an amino acid, which has been incorporated into a polypeptide,
with an aldehyde-containing reagent generally do not rsibly destroy the ry structure of the
polypeptide ting, of , where the purpose of the reaction is to destroy such tertiary structure).
Similarly, the mild ions needed to effect the reaction of an aldehyde moiety on an amino acid,
which has been incorporated into a polypeptide and deprotected, with an aromatic amine-containing
reagent generally do not irreversibly destroy the tertiary structure of the polypeptide (excepting, of course,
where the purpose of the reaction is to destroy such tertiary structure). Fourth, the reaction occurs rapidly
at room temperature, which allows the use of many types of polypeptides or reagents that would otherwise
be unstable at higher temperatures. Fifth, the reaction occurs readily is aqueous conditions, again allowing
use of polypeptides and reagents incompatible (to any extent) with non-aqueous solutions. Six, the
reaction occurs y even when the ratio of polypeptide or amino acid to reagent is stoichiometric,
iometric-like, or near-stoichiometric, so that it is unnecessary to add excess reagent or polypeptide
to obufin a usefifl annnnn of reacfion product n the remflfing anfine can be produced
regioselectively and/or regiospecifically, ing upon the design of the amine and carbonyl portions of
the reactants. Finally, the reductive alkylation of aromatic amines with aldehyde-containing reagents, and
the reductive amination of aldehydes with aromatic amine containing reagents, generates amine, ing
secondary and tertiary amine, linkages which are stable under ical conditions.
Non-natural amino acids with nucleophilic reactive groups, such as, by way of example only,
an aromatic amine group (including secondary and tertiary amine groups), a masked aromatic amine
group (which can be readily converted into a aromatic amine group), or a protected aromatic amine group
(which has vity similar to a aromatic amine group upon deprotection) allow for a y of reactions
to link molecules via various reactions, including but not limited to, reductive alkylation reactions with
aldehyde containing dolastatin linked tives. Such alkylated non-natural amino acid linked atin
derivatives include amino acids having the structure of Formula (XXV), (XXVI), , (XXVHI),
(XXIX), or (XXX):
(R16)n—/TqNJ/L\NNZNILTUM;%Ne%I
R7 OMe/\MeMe OMeOM (XXV)
0 R2
Me Me
Me\NIN(N\)J\Ne Me
H Me
NH R6
N N
I : I Ar
HN R2 (XXVI)
R7 o A Me OMeO OM90
Me Me o N—L
\_H —M H
N \I—// R O4
(R16)n
L_NIMNenJ1jprOYkN
R7 OMe/\MeMe OMeO OMeO
\ NVL1
I Me
(R16)n|—\/, H (xxvrr)
Ri ‘R 1 Ls—w MHJDLNN
0 R2 R7 OMe/\MeMe OMeO OMeO
M3;viKNOWH
R7 OMe/\MeMe OMeO OMeOA R6 ,R1
H R2
H _ (XXVIH)
Me M eH Me \_
0 Me NAG R40 Me
\JL'?‘ H H
Me \ N N N
N N—L3 (R16)n
1 H
R7 0Me/\MeMe OMeO 0M6 OAr
gift?KWR7 OMe/\MeMe OMeOM N\H
\ N\/L1 Z
(R16) —|“ K7 H
NtR (XXIX)
R4 1L3—N Me
0 R2 R7 OMe/\MeMe OMe OM
0 Z
R7 OMe/\MeMe OMeOM NH
0 Z
R7 OMe/\MeMe OMeO OMeOA“MI—Jim R
, 1
HN R2
H —M
Nikki—L3o LBJ/Q R40
(R16)n (XXX)
R7 OMe/\MeMe OMeO OMeOAAr 6
Mka—L‘;O H R7 OMe/\MeMe OMeO r R5
wherein:
Z has the structure of:
R5 is H, COZH, C1-C6alkyl, or thiazole;
R6 is OH or H;
Ar is phenyl or pyridine;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, ptide, or polynucleotide;
R4 is H, halogen, lower alkyl, or tuted lower alkyl;
R7 is C1-C6alkyl or hydrogen;
L, L1, L2, L3, and L4 are each linkers selected from the group consisting of a bond, —alkylene—, —
alkylene—C(O)—, lene—O)n—alkylene—, lene—O)n—alkylene—C(O)—, —(alkylene—
O)n—(CH2)n~NHC(O) (CH2)nu C(Me)2 S S (CH2)nm NHC(O)—(alkylene—O)nmv—alkylene—, —
(alkylene—O)n—alkylene—W—, —alkylene—C(O)—W—, lene—O)n—alkylene—J—, —alkylene'—
J—(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—J—alkylene', —J—(alkylene—O)n—
alkylene—, —(alkylene—O)n—alkylene—J—(alkylene—O)n'—alkylene—J'—, —W—, —alkylene—W—,
alkylene'—J— (alkylene—NMe)n—alkylene—W—, and J— (alkylene—NMe)n—alkylene—W—, —
(alkylene—O)n—alkylene—U—alkylene—C(O)—, —(alkylene—O)n—alkylene—U—alkylene—; —J—
alkylene—NMe—alkylene'—NMe—alkylene"—W—, and —alkylene—J—alkylene'—NMe—alkylene"—
NMe—alkylene'"—W—;
W has the structure of:
Lwflfifk“;
U has the structure of:
COZH
mink
each J and J' independently have the structure of:
zit/iiN/‘Zi fiNiO/‘Zi or Jimi‘g
each n and n' are independently integers greater than or equal to one; and
each R16 is independently selected from the group consisting of hydrogen, halogen, alkyl, N02,
CN, and substituted alkyl.
Such alkylated non-natural amino acid linked dolastatin derivatives may also be in the form of a salt, or
may be incorporated into a non-natural amino acid polypeptide, polymer, polysaccharide, or a
polynucleotide and optionally reductively alkylated.
In certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), R5 is thiazole or ylic acid. In certain ments of compounds of Formula (XXV),
(XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), R6 is H. In n embodiments of compounds of
Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), Ar is phenyl. In certain embodiments
of compounds of a (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), R7 is methyl. In
certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX),
n is an r from O to 20. In certain embodiments of compounds of a (XXV), (XXVI),
(XXVII), (XXVIII), (XXIX), or (XXX), n is an r from O to 10. In certain embodiments of
compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or r (XXIV), n is an
integer from O to 5.
In n embodiments of nds of Formula (XXV), (XXVI), (XXVII), (XXVIII), ,
or (XXX), R5 is thiazole or carboxylic acid. In certain embodiments of compounds of Formula (XXV),
(XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), R5 is hydrogen. In certain embodiments of compounds
of Formula (XXV), (XXVI), ), I), (XXIX), or (XXX), R5 is methyl, ethyl, propyl, iso-
propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, or hexyl. In certain embodiments of compounds of
Formula ((XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), R5 is —NH—(alkylene—O)n—NH2,
Wherein alkylene is —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—, —CH2CHZCH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CHZCHgCHZCHQCHZCHQCHZCH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, or —CH2CHZCHZCHZCHZCHZCHZCHZCHZCHZCHQCH2—.
In certain embodiments of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), alkylene is
methylene, ethylene, propylene, butylenes, pentylene, hexylene, or heptylene.
In certain embodiments of nds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), R5 is —NH—(alkylene—O)n—NH2, Wherein n is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
or 100.
In certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), ,
or (XXX), R6 is H. In some embodiments of compounds of Formula (XXV), (XXVI), (XXVII),
(XXVIII), (XXIX), or (XXX), R6 is hydroxy.
In certain embodiments of compounds of Formula (XXV), , (XXVII), (XXVIII), (XXIX),
or (XXX), Ar is phenyl.
In certain ments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), R7 is methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl iso-butyl, tert-butyl, pentyl, or hexyl.
In certain ments of compounds of Formula (XXV), (XXVI), ), (XXVIII), , or
(XXX), R7 is hydrogen.
In certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), each L, L1, L2, L3, and L4 is independently a cleavable linker or non-cleavable linker. In
certain embodiments of compounds of a (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX),
each L, L1, L2, L3, and L4 is independently a oligo(ethylene glycol) derivatized linker.
In certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), each ne, alkylene', ne", and alkylene'" independently is —CH2—, H2—, -—
CH2CH2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, or —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—.
In certain embodiments of compounds of Formula (XIX), (XX), (XXI), (XXII), (XXIII) or ,
alkylene is methylene, ethylene, ene, butylenes, pentylene, hexylene, or heptylene.
In certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), each n, n', n", n'", and n"" independently is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or
100.
In certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX),
or (XXX), R1 is a ptide. In certain embodiments of compounds of a (XXV), (XXVI),
(XXVII), (XXVIII), (XXIX), or (XXX), R2 is a polypeptide. In certain embodiments of compounds of
Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX), the polypeptide is an dy. In
certain embodiments of compounds of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX),
the antibody is herceptin.
Compounds of Formula (XXV), (XXVI), ), (XXVIII), (XXIX), or (XXX) may be
formed by the reductive alkylation of aromatic amine nds With carbonyl containing reagents such
as, by way of example, ketones, esters, thioesters, and aldehydes.
In some embodiments, the masked amine moieties of non-natural amino acids contained in
polypeptides are lly reduced to give non-natural amino acids containing aromatic amine es
incorporated into non-natural amino acid polypeptides. Such aromatic amine moieties are then reductive
alkylated With carbonyl-containing reagents described above to give polypeptides containing non-natural
amino acids of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX). Such ons may
also be applied to non-natural amino acids incorporated into synthetic polymers, polysaccharides, or
polynucleotides. Additionally, such reactions may be applied to corporated tural amino
acids. By way of example the reducing agent used to reduce masked amine moieties includes, but is not
limited to, TCEP, NaZS, NaZSZO4, LiAlH4, B2H6, and NaBH4. By way of example only, reductive
tion may occur in aqueous buffers with a pH of about 4 to about 7 and using a mild reducing agent,
such as, by way of example only, sodium cyanoborohydride (NaBCNHg). In addition, other reducing
agents may be used for reductive alkylation including, but not limited to, TCEP, NaZS, NaZSZO4, ,
B2H6, and NaBH4.
A non-limiting exemplary syntheses of non-natural amino acid polypeptides containing amino
acids of Formula (XXV), (XXVI), (XXVII), (XXVIII), , or (XXX) by reductive alkylation of
secondary aromatic amine moieties, contained in non-natural amino acids, with carbonyl-containing
reagents described above. Such reductive alkylations give polypeptides containing non-natural amino
acids with tertiary aromatic amine es. Such reactions may also be applied to non-natural amino
acids orated into tic rs, polysaccharides, or polynucleotides. Additionally, such
reactions may be applied to non-incorporated non-natural amino acids. By way of example only, reductive
alkylation may occur in aqueous buffers with a pH of about 4 to about 7 and using a mild reducing agent,
such as, by way of example only, sodium cyanoborohydride (NaBCNHg). In addition, other reducing
agents may be used for reductive alkylation including, but not limited to, TCEP, NaZS, 4, LiAlH4,
B2H6, and NaBH4.
C. al Synthesis of Non-Natural Amino Acid Linked atin Derivatives:
Heteroaryl-Containing Linked Dolastatin Derivatives
In one aspect are non-natural amino acids for the chemical derivatization of dolastatin linked
derivatives based upon the reactivity of a dicarbonyl group, including a group containing at least one
ketone group, and/or at least one aldehyde groups, and/or at least one ester group, and/or at least one
carboxylic acid, and/or at least one thioester group, and wherein the dicarbonyl group can be a 1,2-
dicarbonyl group, a 1,3-dicarbonyl group, or a l,4-dicarbonyl group. In further or additional aspects are
non-natural amino acids for the chemical derivatization of dolastatin linked derivatives based upon the
vity of a diamine group, including a hydrazine group, an amidine group, an imine group, a 1,1-
diamine group, a 1,2-diamine group, a amine group, and a l,4-diamine group. In further or
additional embodiments, at least one of the aforementioned non-natural amino acids is incorporated into a
dolastatin linked derivative, that is, such embodiments are non-natural amino acid linked dolastatin
tives. In further or additional ments, the non-natural amino acids are functionalized on their
sidechains such that their reaction with a derivatizing molecule tes a linkage, ing a
cyclic-based linkage, including a nitrogen-containing heterocycle, and/or an aldol-based linkage. In
further or additional embodiments are non-natural amino acid polypeptides that can react with a
derivatizing dolastatin linker to generate a non-natural amino acid linked dolastatin derivatives containing
a linkage, including a heterocyclic-based linkage, including a nitrogen-containing heterocycle, and/or an
aldol-based linkage. In further or additional embodiments, the non-natural amino acids are selected from
amino acids having dicarbonyl and/or diamine sidechains. In r or additional embodiments, the non-
natural amino acids comprise a masked sidechain, including a masked diamine group and/or a masked
dicarbonyl group. In further or additional embodiments, the non-natural amino acids comprise a group
selected from: keto-amine (i.e., a group containing both a ketone and an amine); keto-alkyne (i.e., a group
ning both a ketone and an alkyne); and an one (i.e., a group containing a dicarbonyl group and
an alkene).
In r or additional ments, the non-natural amino acids comprise dicarbonyl
sidechains Where the carbonyl is selected from a ketone, an de, a carboxylic acid, or an ester,
including a thioester. In another embodiment are non-natural amino acids containing a onal group
that is capable of forming a heterocycle, ing a en-containing cycle, upon treatment With
an appropriately functionalized reagent. In a further or additional embodiment, the non-natural amino
acids resemble a natural amino acid in structure but contain one of the aforementioned functional groups.
In another or further embodiment the non-natural amino acids resemble phenylalanine or tyrosine
(aromatic amino acids); While in a separate embodiment, the tural amino acids resemble alanine
and leucine (hydrophobic amino acids). In one embodiment, the non-natural amino acids have properties
that are distinct from those of the natural amino acids. In one embodiment, such distinct properties are the
chemical reactivity of the sidechain, in a further ment this distinct al reactivity permits the
sidechain of the non-natural amino acid to undergo a reaction While being a unit of a polypeptide even
though the sidechains of the naturally-occurring amino acid units in the same polypeptide do not undergo
the aforementioned reaction. In a further embodiment, the sidechain of the non-natural amino acid has a
try orthogonal to those of the naturally-occurring amino acids. In a further embodiment, the
sidechain of the non-natural amino acid comprises an electrophile-containing moiety; in a further
ment, the electrophile-containing moiety on the sidechain of the non-natural amino acid can
undergo nucleophilic attack to generate a heterocycle-derivatized protein, including a nitrogen-containing
cycle-derivatized protein. In any of the aforementioned embodiments in this paragraph, the non-
natural amino acid may exist as a separate molecule or may be incorporated into a polypeptide of any
length; if the latter, then the polypeptide may further incorporate naturally-occurring or non-natural amino
acids.
In another aspect are e-substituted molecules, wherein the diamine group is selected
from a hydrazine, an amidine, an imine, a l,l-diamine, a l,2-diamine, a 1,3-diamine and a l,4-diamine
group, for the production of tized non-natural amino acid linked dolastatin derivatives based upon a
heterocycle, including a nitrogen-containing heterocycle, e. In a further embodiment are diamine-
substituted atin derivatives used to derivatize dicarbonyl-containing tural amino acid
polypeptides Via the formation of a heterocycle, including a nitrogen-containing heterocycle, linkage
between the derivatizing molecule and the dicarbonyl-containing non-natural amino acid polypeptide. In
further embodiments the aforementioned dicarbonyl-containing non-natural amino acid polypeptides are
diketone-containing non-natural amino acid polypeptides. In further or additional embodiments, the
dicarbonyl-containing non-natural amino acids comprise sidechains where the yl is selected from a
ketone, an aldehyde, a carboxylic acid, or an ester, including a thioester. In further or additional
embodiments, the diamine-substituted molecules comprise a group selected from a desired functionality.
In a further embodiment, the sidechain of the non-natural amino acid has a try orthogonal to those
of the lly-occurring amino acids that allows the non-natural amino acid to react selectively with the
diamine-substituted molecules. In a r embodiment, the sidechain of the non-natural amino acid
comprises an ophile-containing moiety that reacts selectively with the diamine-containing molecule;
in a further embodiment, the ophile-containing moiety on the sidechain of the non-natural amino
acid can undergo nucleophilic attack to generate a cycle-derivatized protein, including a nitrogen-
containing heterocycle-derivatized protein. In a further aspect related to the embodiments described in this
paragraph are the modified non-natural amino acid polypeptides that result from the reaction of the
derivatizing molecule with the non-natural amino acid ptides. Further embodiments include any
further modifications of the already modified non-natural amino acid polypeptides.
In another aspect are dicarbonyl-substituted molecules for the production of derivatized non-
natural amino acid polypeptides based upon a heterocycle, including a nitrogen-containing heterocycle,
linkage. In a further embodiment are dicarbonyl-substituted molecules used to derivatize diamine-
containing tural amino acid polypeptides via the formation of a cycle, including a nitrogen-
containing heterocycle group. In a further embodiment are dicarbonyl-substituted molecules that can form
such heterocycle, including a nitrogen-containing heterocycle groups with a diamine-containing non-
natural amino acid polypeptide in a pH range between about 4 and about 8. In a r embodiment are
dicarbonyl-substituted molecules used to tize diamine-containing non-natural amino acid
polypeptides via the formation of a heterocycle, including a nitrogen-containing heterocycle, linkage
between the derivatizing molecule and the diamine-containing non-natural amino acid polypeptides. In a
further ment the dicarbonyl-substituted molecules are diketone-substitued molecules, in other
aspects dehyde-substituted molecules, in other aspects id—substituted molecules, in other
aspects ketoester-substituted molecules, including ketothioester-substituted les. In further
embodiments, the dicarbonyl-substituted molecules comprise a group selected from a desired
functionality. In further or additional embodiments, the aldehyde-substituted molecules are aldehyde-
substituted polyethylene glycol (PEG) les. In a r embodiment, the sidechain of the non-
natural amino acid has a chemistry onal to those of the naturally-occurring amino acids that allows
the non-natural amino acid to react selectively with the carbonyl-substituted molecules. In a further
embodiment, the sidechain of the non-natural amino acid comprises a moiety (e. g., diamine group) that
reacts selectively with the dicarbonyl-containing molecule; in a further embodiment, the nucleophilic
moiety on the sidechain of the non-natural amino acid can undergo electrophilic attack to generate a
heterocyclic-derivatized protein, including a nitrogen-containing heterocycle-derivatized protein. In a
further aspect d to the embodiments described in this paragraph are the modified non-natural amino
acid polypeptides that result from the reaction of the derivatizing molecule with the non-natural amino
acid polypeptides. Further embodiments include any further modifications of the already modified non-
natural amino acid polypeptides.
In one aspect are methods to derivatize proteins Via the reaction of carbonyl and
hydrazine reactants to generate a heterocycle-derivatized protein, including a nitrogen-containing
heterocycle-derivatized dolastatin. ed Within this aspect are methods for the derivatization of
dolastatin linker derivatives based upon the condensation of carbonyl- and hydrazine-containing reactants
to generate a heterocycle-derivatized dolastatin, ing a nitrogen-containing heterocycle-derivatized
dolastatin. In additional or r embodiments are methods to derivatize ketone-containing dolastatin
derivatives or aldehyde-containing dolastatin derivatives With hydrazine-fiJnctionalized non-natural amino
acids. In yet additional or further aspects, the hydrazine-substituted molecule can include ns, other
rs, and small molecules.
In another aspect are methods for the chemical synthesis of hydrazine-substituted
molecules for the derivatization of carbonyl-substituted dolastatin derivatives. In one embodiment, the
hydrazine-substituted molecule is a atin linked derivative suitable for the tization of carbonyl-
containing non-natural amino acid polypeptides, including by way of example only, ketone-, or aldehyde-
ning non-natural amino acid polypeptides.
In one aspect are non-natural amino acids for the chemical derivatization of dolastatin analogs
based upon a quinoxaline or phenazine linkage. In further or additional embodiments, the non-natural
amino acids are onalized on their sidechains such that their on With a derivatizing dolastatin
linker generates a quinoxaline or phenazine linkage. In further or additional embodiments, the non-natural
amino acids are selected from amino acids haVing l,2-dicarbonyl or l,2-aryldiamine sidechains. In further
or additional embodiments, the non-natural amino acids are selected from amino acids haVing protected or
masked l,2-dicarbonyl or yldiamine sidechains. Further included are equivalents to l,2-dicarbonyl
sidechains, or protected or masked equivalents to l,2-dicarbonyl sidechains.
In r aspect are derivatizing molecules for the production of tized non-natural
amino acid polypeptides based upon quinoxaline or ine linkages. In one embodiment are l,2-
dicarbonyl substituted dolastatin linker tives used to derivatize yldiamine containing non-
natural amino acid polypeptides to form quinoxaline or phenazine es. In another embodiment are
yldiamine substituted dolastatin linker derivatives used to derivatize l,2-dicarbonyl containing non-
natural amino acid polypeptides to form quinoxaline or phenazine linkages. In a further aspect related to
the above embodiments are the modified non-natural amino acid polypeptides that result from the reaction
of the derivatizing dolastatin linker With the non-natural amino acid polypeptides. In one ment are
l,2-aryldiamine containing non-natural amino acid polypeptides derivatized With l,2-dicarbonyl
substituted dolastatin linker derivative to form quinoxaline or ine linkages. In another embodiment
are l,2-dicarbonyl containing non-natural amino acid polypeptides derivatized With l,2-aryldiamine
substituted dolastatin linker derivatives to form aline or phenazine linkages.
Provided herein in certain embodiments are tizing molecules for the production of toxic
compounds comprising non-natural amino acid polypeptides based upon triazole linkages. In some
embodiments, the reaction n the first and second reactive groups can proceed via a dipolarophile
reaction. In certain embodiments, the first reactive group can be an azide and the second reactive group
can be an alkyne. In further or alternative embodiments, the first reactive group can be an alkyne and the
second reactive group can be an azide. In some embodiments, the Huisgen cycloaddition reaction (see,
e.g., Huisgen, in l,3-DIPOLAR CYCLOADDITION CHEMISTRY, (ed. Padwa, A., 1984), p. 1-176)
provides for the incorporation of turally encoded amino acids bearing azide and alkyne-containing
side chains permits the resultant polypeptides to be modified with extremely high selectivity. In n
embodiments, both the azide and the alkyne functional groups are inert toward the twenty common amino
acids found in naturally-occurring polypeptides. When brought into close proximity, however, the
”spring-loaded” nature of the azide and alkyne groups is revealed and they react selectively and efficiently
Via Huisgen [3 2] ddition reaction to generate the corresponding triazole. See, e.g., Chin et al.,
Science 301:964-7 (2003); Wang et al., J. Am. Chem. Soc., 125, 193 (2003); Chin et al., J. Am.
Chem. Soc., 26-9027 (2002). Cycloaddition reaction involving azide or alkyne-containing
polypeptides can be carried out at room temperature under aqueous conditions by the addition of Cu(II)
(e. g., in the form of a tic amount of CuSO4) in the presence of a ng agent for reducing Cu(II)
to Cu(I), in situ, in tic amount. See, e.g., Wang et al., J. Am. Chem. Soc. 125, 193 (2003);
Tornoe et al., J. Org. Chem. 67:3057-3064 (2002); RostovtseV, Angew. Chem. Int. Ed. 41:2596-2599
(2002). Preferred reducing agents include ascorbate, metallic copper, quinine, hydroquinone, Vitamin K,
glutathione, cysteine, Fez, C02, and an applied electric potential.
Such tural amino acid heteroaryl-linked dolastatin derivatives include amino acids
haVing the structure of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI):
RNf,B\/L\:gf\)J\RRH 33
R7 O /\ Me OMeO
R2 MeO NH (XXXI)
HNIKAr
(XXXII)
OMe O
L2—'\Il N\Z
R7 OMe/\MeMe OMeO OMeO
H R3R3
N /B\
R/ /L1
1 fr:A D
(XXXIII)
R2 0 H
L3—'\Il \Z
R7 OMe/\MeMe OMeO OMeO
New NMHJ1lfimN“ANIFEWLZ
R7 OMe/\MeMe OMeO OMeOA
R3 R3N
L1\ DA/B\
Me AR4 NR1 (XXXIII)
R7 OMe/\MeMe OMeO OMeOA
Lz—Mngn-vfl%
R7 OMe/\MeMe OMeO—I\N3O§MER2
H R3 R3 NN;
R1/ EA/ELD/M Me
R2 0 L—Nlmn-fl“:pr0 (XXXV)
R7 eMe OMeOM
bfiw“TEEN:Me Ne
R7 OMe/\MeMe OMeOM NH
“AeINIJN .\
NfiNH
R7 OMe/\MeMe OMeO OMeO
r R5
R3 R3 H
L1\ /B\ N\
Me 0 R4
N 0 R2
u—Ls
OM6 0
Ar R5 (XXXVI)
j Me O
.~ H
R7 OMe/\MeMe OMe 0 OMe OAr
R6 -
wherein:
Z has the structure of:
‘7;\KKAr
R5 ;
R5 is H, COZH, C1-C6alkyl, or thiazole;
R6 is OH or H;
Ar is phenyl or pyridine;
R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide;
R4 is H, halogen, lower alkyl, or substituted lower alkyl;
R7 is C1-C6alkyl or en;
L, L1, L2, L3, and L4 are each linkers selected from the group ting of a bond, —alkylene—, —
alkylene—C(O)—, —alkylene—J—, —(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—C(O)—, —
(alkylene—O)n—J—, —(alkylene—O)n—J—alkylene—, —(alkylene—O)n—(CH2)n~NHC(O)—(CH2)nu—
C(Me)2—S—S—(CH2)nu~NHC(O)—(alkylene—O)nmv—alkylene—, —(alkylene—O)n—alkylene—W—, —
alkylene—C(O)—W—, lene—O)n—alkylene—J—, —alkylene'—J—(alkylene—O)n—alkylene—, —
(alkylene—O)n—alkylene—J—alkylene', —J—(alkylene—O)n—alkylene—, —(alkylene—O)n—alkylene—
J—(alkylene—O)n'—alkylene—J'—, —W—, ene—W—, alkylene'—J—(alkylene—NMe)n—alkylene—
W—, —J—(alkylene—NMe)n—alkylene—W—, —(alkylene—O)n—alkylene—U—alkylene—C(O)—, —
(alkylene—O)n—alkylene—U—alkylene—; —J—alkylene—NMe—alkylene'—NMe—alkylene"—W—, and
—alkylene—J—alkylene'—NMe—alkylene"—NMe—alkylene'"—W—;
W has the structure of:
LWJLKTJK“;
U has the structure of:
COZH
,nmiwr
each J and J' independently have the ure of:
zit/iiN/‘Zi fiNiO/‘Zi or
H {fimi‘i'
a a
each n and n' are independently integers greater than or equal to one;
D has the structure of:
each R17 is independently selected from the group consisting of H, alkyl, substituted alkyl,
l, tuted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy,
alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, substituted polyalkylene oxide,
aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl,
aralkyl, tuted aralkyl, -(alkylene or substituted alkylene)-ON(R”)2, -(alkylene or
substituted alkylene)-C(O)SR”, -(alkylene or substituted alkylene)-S-S-(aryl or
substituted aryl), -C(O)R”, -C(O)2R”, or -C(O)N(R”)2, n each R” is independently
hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, , substituted alkoxy,
aryl, substituted aryl, aryl, l, substituted alkaryl, aralkyl, or substituted
each 21 is a bond, CR17R17, O, S, NR’, CR17R17-CR17R17, CR17R17-O, O-CR17R17, CR17R17-S,
S-CR17R17, CR17R17-NR’, or NR’-CR17R17;
each R’ is H, alkyl, or substituted alkyl;
each 22 is selected from the group consisting of a bond, -C(O)-, -C(S)-, optionally substituted
C1-C3 alkylene, optionally substituted C1-C3 alkenylene, and optionally tuted
heteroalkyl;
each 23 are independently selected from the group ting of a bond, optionally substituted
C1-C4 alkylene, optionally substituted C1-C4 alkenylene, optionally substituted
heteroalkyl, -O-, -S-, -C(O)-, -C(S)-, and -N(R’)-;
each T3 is a bond, C(R”)(R”), O, or S; With the o that When T3 is O or S, R” cannot be
halogen;
each R” is H, halogen, alkyl, substituted alkyl, cycloalkyl, or substituted lkyl;
m and p are 0, l, 2, or 3, provided that at least one ofm or p is not 0;
(b) (b)
| ‘A'I'V‘ /R3 if; nlnr
/C\— E03) /C—C\(b—E)
(577R4 /C=C\—E(b) /C—O—Emlnn (b) /C\—5—§ (b)
M2 is (a) R3 R4 (a5; R4 M3 (201K:
(b) (b) (b)
(b) M J‘ri R fi R
3 3
m R3 I / /
R3/i—d—é
/C=C—E (b) O—T—E (b) s—T—E (b) (b)
\R4 >44“ R4 mIJu‘ w m
(a) (a) (a) or (a) Where (a) indicates
a , , ,
bonding to the B group and (b) indicates bonding to respective positions Within the
heterocycle group;
(b) (b) (b) (b) “if” /R3
mi: 3(1)) —c/R3—§(b) b)§ c—s—E (b) (f—ng (b) / / R M3 is (3)3? (a)$??/||— CR\R4 (352% (3)3/ 4
Where (a) indicates bonding to the B group and (b) indicates bonding to respective
positions Within the heterocycle group;
(b) (b) ”$3“ (b) (b)
“I: “l” R—c'2—c=§ I— —g '— :31)
/C\_q=g (b) 3 (b) 0
1|?4 >5: C}; (b) S
/C—§(b) CE‘Nm)
R3 M41s (3)19 (a) R3 (a) (a) or (a)
, , a , 7
Where (a) indicates bonding to the B group and (b) indicates bonding to respective
positions Within the heterocycle group;
each R19 is independently selected from the group ting of C1-C6 alkyl, C1-C6 ,
ester, ether, thioether, lkyl, halogen, alkyl ester, aryl ester, amide, aryl amide,
alkyl halide, alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester,
halosulfonyl, nitrile, alkyl nitrile, and nitro;
qis 0,1, 2, 3, 4, 5, 6, 7, 8, 9,10 or 11; and
each R16 is independently selected from the group consisting of hydrogen, halogen, alkyl, N02,
CN, and substituted alkyl.
In some embodiments, the compound of Formula (XXXI) include compounds having the
structure of a (XXXI-A):
R7 OMe/\M eMe OMeOM (XXXI—A)
R3 3R40
“'1“
R1 R2
In n embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), ),
, or (XXXVI), R5 is thiazole or carboxylic acid. In certain embodiments of compounds of
Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), R6 is H. In certain embodiments
of nds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), Ar is phenyl.
In certain embodiments of compounds of a (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or
(XXXVI), R7 is methyl. In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII),
(XXXIV), (XXXV), or (XXXVI), n is an integer from O to 20. In certain embodiments of compounds of
Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), n is an integer from O to 10. In
certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or
(XXXVI), n is an integer from O to 5.
In certain embodiments of nds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), R5 is thiazole or carboxylic acid. In certain embodiments of compounds of
Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), R5 is hydrogen. In certain
embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI),
R5 is methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, utyl, pentyl, or hexyl. In certain
ments of compounds of a (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI),
R5 is —NH—(alkylene—O)n—NH2, wherein alkylene is —CH2—, —CH2CH2—, —CH2CH2CH2—, —
CHZCHZCHZCH2—, —CH2CH2CH2CH2CH2—, 2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2—
, ZCHZCHZCHZCHZCHZCH2—, —CHZCH2CHZCHZCHZCHZCHZCHZCH2—,
CHZCH2CH2CHgCHgCHgCHZCHZCHZCH2—, —CH2CH2CH2CH2CHZCHZCHZCHZCHZCHZCH2—, or —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—. In certain embodiments of a (XXXI),
(XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), alkylene is methylene, ethylene, propylene,
butylenes, pentylene, hexylene, or heptylene.
In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), R5 is —NH—(alkylene—O)n—NH2, n n is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14,15,16,17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68,
69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, or 100.
In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or ), R6 is H. In some embodiments of compounds of a (XXXI), (XXXII),
(XXXIII), (XXXIV), (XXXV), or (XXXVI), R6 is hydroxy.
In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), Ar is phenyl.
] In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), ),
(XXXV), or (XXXVI), R7 is methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl iso-butyl, tert-butyl,
pentyl, or hexyl. In n embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII),
(XXXIV), (XXXV), or (XXXVI), R7 is hydrogen.
In certain embodiments of compounds of Formula , (XXXII), I), ),
(XXXV), or (XXXVI), each L, L1, L2, L3, and L4 is independently a cleavable linker or non-cleavable
linker. In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), each L, L1, L2, L3, and L4 is independently a oligo(ethylene glycol) derivatized
linker.
] In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), each alkylene, alkylene', alkylene", and alkylene'" independently is —CH2—, -—
CH2CH2—, H2CH2—, —CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2—, —CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2—, 2CH2CH2CH2CH2CH2CH2CH2CH2—, —
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—, or —CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2—.
In certain embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), , or
(XXXVI), alkylene is methylene, ethylene, propylene, butylenes, pentylene, ne, or heptylene.
In certain embodiments of nds of a (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), each n, n', n", n'", and n"" independently is O, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,
70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,
98, 99, or 100.
WO 66560
] In n embodiments of compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), R1 is a polypeptide. In n embodiments of compounds of Formula ,
(XXXII), (XXXIII), (XXXIV), (XXXV), or ), R2 is a polypeptide. In certain embodiments of
compounds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), the polypeptide is
an antibody. In certain embodiments of compounds of a (XXXI), ), (XXXIII), (XXXIV),
(XXXV), or (XXXVI), the antibody is herceptin.
nds of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI) may
be formed by the reductive alkylation of aromatic amine compounds with carbonyl containing reagents
such as, by way of example, s, esters, thioesters, and des.
The formation of such non-natural amino acid heterocycle-linked dolastatin derivatives haVing the
structure of Formula (XXXI), ), (XXXIII), (XXXIV), , or (XXXVI) includes, but is not
limited to, (i) reactions of diamine-containing non-natural amino acids with dicarbonyl-containing
dolastatin linked derivatives or reactions of diamine-containing non-natural amino acids with ketoalkyne-
containing dolastatin linked derivatives, (ii) reactions of dicarbonyl-containing non-natural amino acids
with either e-containing dolastatin linked tives or reactions of onyl-containing non-
natural amino acids with ketoamine-containing dolastatin linked derivatives, (iii) reactions of ketoalkyne-
containing non-natural amino acids with diamine-containing dolastatin linked derivatives, or (iV) reactions
of ketoamine-containing non-natural amino acids with dicarbonyl-containing V.
Modification of dolastatin linked derivatives described herein with such reactions have any or all
of the following advantages. First, diamines undergo condensation with dicarbonyl-containing compounds
in a pH range of about 5 to about 8 (and in further embodiments in a pH range of about 4 to about 10, in
other embodiments in a pH range of about 3 to about 8, in other embodiments in a pH range of about 4 to
about 9, and in further embodiments a pH range of about 4 to about 9, in other embodiments a pH of
about 4, and in yet another embodiment a pH of about 8) to generate cycle, including a nitrogen-
containing heterocycle, es. Under these conditions, the sidechains of the naturally occurring amino
acids are unreactive. Second, such selective chemistry makes possible the site-specific derivatization of
recombinant proteins: derivatized proteins can now be prepared as defined homogeneous products. Third,
the mild conditions needed to effect the reaction of the diamines described herein with the dicarbonyl-
containing polypeptides described herein generally do not irreversibly destroy the tertiary structure of the
polypeptide (excepting, of course, where the e of the reaction is to destroy such tertiary structure).
Fourth, the reaction occurs rapidly at room temperature, which allows the use of many types of
polypeptides or reagents that would be unstable at higher temperatures. Fifth, the reaction occurs readily
is aqueous ions, again allowing use of polypeptides and ts incompatible (to any extent) with
non-aqueous solutions. Six, the reaction occurs readily even when the ratio of polypeptide or amino acid
to reagent is stoichiometric, near stoichiometric, or stoichiometric-like, so that it is unnecessary to add
excess reagent or polypeptide to obtain a useful amount of reaction product. Seventh, the resulting
heterocycle can be produced regioselectively and/or regiospecif1cally, depending upon the design of the
diamine and onyl portions of the reactants. Finally, the condensation of diamines with dicarbonyl-
containing molecules tes heterocycle, including a nitrogen-containing heterocycle, linkages which
are stable under biological conditions.
V1 Location 0fn0n-nataral amino acids in dolastatin linker derivatives
The methods and compositions described herein include incorporation of one or more non-natural
amino acids into a dolastatin linker derivative. One or more non-natural amino acids may be incorporated
at one or more particular positions which do not disrupt activity of the dolastatin linker derivative. This
can be achieved by making “conservative” substitutions, including but not limited to, substituting
hydrophobic amino acids with non-natural or l hydrophobic amino acids, bulky amino acids with
tural or natural bulky amino acids, hydrophilic amino acids with non-natural or natural hilic
amino acids) and/or inserting the non-natural amino acid in a location that is not required for activity.
A variety of biochemical and ural approaches can be employed to select the desired sites for
substitution with a non-natural amino acid within the dolastatin linker derivative. In some embodiments,
the non-natural amino acid is linked at the inus of the dolastatin derivative. In other embodiments,
the tural amino acid is linked at the N—terminus of the dolastatin derivative. Any position of the
dolastatin linker derivative is suitable for selection to incorporate a non-natural amino acid, and selection
may be based on rational design or by random selection for any or no particular desired purpose. Selection
of d sites may be based on producing a non-natural amino acid polypeptide (which may be r
modified or remain unmodified) having any desired property or activity, including but not limited to a
receptor binding modulators, receptor activity modulators, modulators of binding to binder partners,
binding r activity modulators, binding partner conformation modulators, dimer or multimer
formation, no change to ty or property ed to the native molecule, or manipulating any
physical or chemical property of the ptide such as solubility, aggregation, or ity.
Alternatively, the sites identified as critical to biological activity may also be good ates for
substitution with a non-natural amino acid, again depending on the desired activity sought for the
polypeptide. Another alternative would be to simply make serial substitutions in each position on the
polypeptide chain with a non-natural amino acid and observe the effect on the activities of the
polypeptide. Any means, technique, or method for selecting a position for substitution with a non-natural
amino acid into any polypeptide is suitable for use in the s, techniques and compositions described
herein.
The structure and activity of naturally-occurring mutants of a polypeptide that contain deletions
can also be examined to determine regions of the protein that are likely to be tolerant of substitution with
a non-natural amino acid. Once residues that are likely to be intolerant to substitution with non-natural
amino acids have been eliminated, the impact of proposed tutions at each of the remaining positions
can be examined using methods including, but not limited to, the three-dimensional structure of the
relevant polypeptide, and any associated ligands or binding proteins. X-ray crystallographic and NMR
structures of many polypeptides are available in the Protein Data Bank (PDB, WV}?
centralized database containing three-dimensional structural data of large molecules of proteins and
nucleic acids, one can be used to identify amino acid positions that can be substituted with non-natural
amino acids. . In addition, models may be made investigating the secondary and tertiary structure of
polypeptides, if three-dimensional structural data is not available. Thus, the identity of amino acid
positions that can be substituted with non-natural amino acids can be readily obtained.
Exemplary sites of incorporation of a non-natural amino acid include, but are not limited to, those
that are ed from potential or g regions, or regions for binding to binding proteins or
ligands may be fully or partially t exposed, have minimal or no hydrogen-bonding interactions with
nearby residues, may be minimally exposed to nearby reactive residues, and/or may be in regions that are
highly flexible as ted by the three-dimensional crystal structure of a particular polypeptide with its
associated receptor, ligand or binding ns.
A wide variety of tural amino acids can be substituted for, or incorporated into, a given
position in a polypeptide. By way of example, a particular non-natural amino acid may be selected for
incorporation based on an examination of the three dimensional crystal structure of a polypeptide with its
associated , receptor and/or binding proteins, a preference for vative substitutions
In one ment, the methods described herein include incorporating into the dolastatin linker
derivative, where the dolastatin linker derivative comprises a first reactive group; and contacting the
dolastatin linker derivative with a molecule (including but not d to a second protein or polypeptide
or polypeptide analog; an antibody or antibody fragment; and any combination thereof) that comprises a
second reactive group. In certain embodiments, the first reactive group is a hydroxylamine moiety and the
second reactive group is a carbonyl or onyl moiety, whereby an oxime linkage is formed. In certain
ments, the first reactive group is a carbonyl or onyl moiety and the second reactive group is
a hydroxylamine moiety, whereby an oxime linkage is formed. In certain ments, the first reactive
group is a carbonyl or dicarbonyl moiety and the second reactive group is an oxime moiety, whereby an
oxime exchange reaction occurs. In certain embodiments, the first reactive group is an oxime moiety and
the second reactive group is carbonyl or dicarbonyl moiety, whereby an oxime exchange reaction .
In some cases, the dolastatin linker derivative incorporation(s) will be combined with other
additions, substitutions, or deletions within the polypeptide to affect other chemical, physical,
pharmacologic and/or biological traits. In some cases, the other additions, substitutions or deletions may
increase the stability (including but not limited to, resistance to proteolytic degradation) of the polypeptide
or se affinity of the polypeptide for its appropriate receptor, ligand and/or binding proteins. In some
cases, the other additions, substitutions or deletions may increase the solubility (including but not limited
to, when expressed in i cili or other host cells) of the polypeptide. In some embodiments sites are
selected for substitution with a naturally encoded or non-natural amino acid in addition to r site for
oration of a non-natural amino acid for the purpose of sing the polypeptide solubility
following expression in E coli, or other recombinant host cells. In some embodiments, the polypeptides
comprise another addition, substitution, or deletion that modulates y for the associated ligand,
2012/039472
binding proteins, and/or receptor, modulates (including but not limited to, increases or decreases) receptor
dimerization, stabilizes receptor dimers, modulates circulating half-life, tes release or bio-
bility, facilitates purification, or improves or alters a particular route of administration. Similarly,
the non-natural amino acid polypeptide can comprise chemical or enzyme cleavage sequences, protease
cleavage ces, reactive groups, antibody-binding domains (including but not limited to, FLAG or
poly-His) or other affinity based sequences (including but not limited to, FLAG, poly-His, GST, etc.) or
linked molecules (including but not limited to, biotin) that improve detection (including but not d to,
GFP), purification, transport thru tissues or cell membranes, prodrug release or activation, size reduction,
or other traits of the polypeptide.
VII. HER2 Gene as Exemplar
The methods, compositions, strategies and ques described herein are not limited to a
particular type, class or family of polypeptides or proteins. Indeed, Virtually any polypeptides may be
designed or modified to include at least one “modified or unmodified” non-natural amino acids containing
dolastatin linker derivative bed . By way of example only, the polypeptide can be homologous
to a therapeutic protein ed from the group consisting of: alpha-l antitrypsin, angiostatin,
antihemolytic factor, antibody, antibody fragment, monoclonal antibody (e. g., bevacizumab, cetuximab,
panitumumab, infliximab, adalimumab, basiliximab, daclizumab, omalizumab, ustekinumab, etanercept,
gemtuzumab, alemtuzumab, rituximab, trastuzumab, nimotuzumab, palivizumab, and abciximab),
apolipoprotein, apoprotein, atrial natriuretic factor, atrial natriuretic polypeptide, atrial peptide, C-X-C
chemokine, T39765, NAP-2, ENA—78, gro-a, gro-b, gro-c, IP-10, GCP-2, NAP-4, SDF-l, PF4, MIG,
calcitonin, c-kit ligand, cytokine, CC ine, monocyte chemoattractant n-l, monocyte
chemoattractant protein-2, monocyte chemoattractant protein-3, monocyte inflammatory protein-l alpha,
monocyte inflammatory n-i beta, , 1309, R83915, R91733, HCCl, T58847, ,
T64262, CD40, CD40 ligand, c-kit ligand, collagen, colony stimulating factor (CSF), complement factor
5a, complement inhibitor, complement receptor 1, cytokine, epithelial neutrophil activating peptide-78,
MIP-l6, MCP-l, epidermal grth factor (EGF), lial neutrophil activating peptide, erythropoietin
(EPO), exfoliating toxin, Factor IX, Factor VII, Factor VIII, Factor X, fibroblast grth factor (FGF),
fibrinogen, fibronectin, four-helical bundle protein, G-CSF, glp-l, GM-CSF, erebrosidase,
gonadotropin, grth factor, grth factor receptor, grf, hedgehog n, hemoglobin, hepatocyte
grth factor (hGF), hirudin, human grth hormone (hGH), human serum albumin, ICAM-l, ICAM-l
receptor, LFA—l, LFA—l receptor, insulin, insulin-like grth factor (IGF), IGF-I, IGF-II, interferon
(IFN), IFN—alpha, IFN—beta, IFN—gamma, interleukin (IL), IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-11, IL-12, keratinocyte grth factor (KGF), lactoferrin, leukemia inhibitory factor,
luciferase, neurturin, neutrophil inhibitory factor (NIF), oncostatin M, osteogenic protein, oncogene
product, tonin, parathyroid hormone, F, PDGF, peptide hormone, pleiotropin, protein A,
protein G, pth, pyrogenic exotoxin A, pyrogenic in B, nic exotoxin C, pyy, n, renin,
SCF, small biosynthetic protein, soluble complement receptor I, soluble I-CAM l, soluble interleukin
receptor, e TNF receptor, medin, somatostatin, somatotropin, streptokinase, superantigens,
lococcal enterotoxin, SEA, SEB, SECl, SEC2, SEC3, SED, SEE, steroid hormone receptor,
superoxide dismutase, toxic shock syndrome toxin, thymosin alpha 1, tissue plasminogen tor, tumor
growth factor (TGF), tumor necrosis factor, tumor necrosis factor alpha, tumor necrosis factor beta, tumor
necrosis factor or (TNFR), VLA—4 protein, VCAM-l protein, vascular endothelial growth factor
(VEGF), urokinase, mos, ras, raf, met, p53, tat, fos, myc, jun, myb, rel, estrogen receptor, progesterone
receptor, testosterone receptor, aldosterone receptor, LDL receptor, and corticosterone.
In one embodiment is a method for treating solid tumor which overexpresses HER-2 selected
from the group consisting of breast cancer, small cell lung oma, ovarian cancer, prostate cancer,
gastric carcinoma, cervical cancer, esophageal carcinoma, and colon cancer. In another embodiment, the
solid tumor is breast cancer. In a further embodiment the solid tumor is ovarian cancer.
Thus, the following description of trastuzumab is provided for rative purposes and by way of
example only, and not as a limit on the scope of the methods, compositions, strategies and techniques
described herein. Further, reference to trastuzumab in this application is intended to use the generic term
as an example of any antibody. Thus, it is understood that the modifications and tries described
herein with reference to trastuzumab can be equally applied to any antibody or monoclonal antibody,
including those ically listed herein.
Trastuzumab is a zed monoclonal dy that binds to the domain IV of the extracellular
t of the HER2/neu receptor. The HER2 gene (also known as HER2/neu and ErbB2 gene) is
amplified in 20-30% of early-stage breast cancers, which makes it overexpressed. Also, in , HER2
may send s without mitogens arriving and binding to any receptor, making it overactive.
HER2 extends through the cell membrane, and s signals from outside the cell to the inside.
In healthy people, signaling compounds called mitogens arrive at the cell membrane, and bind to the
outside part of other members of the HER family of receptors. Those bound receptors then link (dimerize)
with HER2, activating it. HER2 then sends a signal to the inside of the cell. The signal passes through
different biochemical pathways. This includes the PI3K/Akt y and the MAPK pathway. These
signals promote invasion, survival and growth of blood vessels (angiogenesis) of cells.
Cells treated with zumab undergo arrest during the G1 phase of the cell cycle so there is
reduced proliferation. It has been suggested that zumab induces some of its effect by downregulation
of HER2/neu leading to disruption of receptor dimerization and signaling h the downstream PI3K
cascade. P27Kipl is then not phosphorylated and is able to enter the nucleus and inhibit cdk2 activity,
causing cell cycle arrest. Also, trastuzumab suppresses angiogenesis by both induction of antiangiogenic
factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth
ed in cancer could be due to proteolytic cleavage of HER2/neu that results in the release of the
extracellular domain. Trastuzumab has been shown to inhibit HER2/neu main cleavage in breast
cancer cells.
VIII. Cellular uptake 0fn0n-natural amino acids
Non-natural amino acid uptake by a eukaryotic cell is one issue that is typically ered
when designing and selecting non-natural amino acids, including but not limited to, for incorporation into
a protein. For example, the high charge density of oc-amino acids suggests that these compounds are
unlikely to be cell ble. l amino acids are taken up into the eukaryotic cell via a collection of
protein-based transport systems. A rapid screen can be done which assesses which non-natural amino
acids, if any, are taken up by cells (examples 15 & l6 herein illustrate non-limiting examples of tests
which can be done on tural amino acids). See, e. g., the toxicity assays in, e. g., the US. Patent
Publication No. 2004/198637 entitled “Protein Arrays,” which is herein orated by reference in its
entirety, and Liu, D.R. & Schultz, PG. (1999) Progress toward the evolution of an organism with an
expanded genetic code. PNAS United States 96:4780-4785. Although uptake is easily analyzed with
s assays, an alternative to designing non-natural amino acids that are amenable to cellular uptake
pathways is to provide biosynthetic pathways to create amino acids in vivo.
Typically, the non-natural amino acid produced via cellular uptake as described herein is
produced in a concentration sufficient for efficient protein biosynthesis, ing but not limited to, a
natural cellular amount, but not to such a degree as to affect the concentration of the other amino acids or
exhaust cellular resources. Typical concentrations produced in this manner are about 10 mM to about 0.05
IX. Biosynthesis 0fN0n-Natural Amino Acids
Many biosynthetic pathways already exist in cells for the production of amino acids and other
compounds. While a biosynthetic method for a particular non-natural amino acid may not exist in nature,
including but not limited to, in a cell, the methods and compositions described herein provide such
methods. For e, thetic pathways for non-natural amino acids can be generated in host cell by
adding new enzymes or modifying existing host cell pathways. Additional new enzymes include naturally
occurring enzymes or ially d s. For example, the biosynthesis of p-
aminophenylalanine (as presented in an example in ed “In vivo incorporation of
unnatural amino acids”) relies on the addition of a combination of known enzymes from other organisms.
The genes for these enzymes can be introduced into a eukaryotic cell by transforming the cell with a
plasmid comprising the genes. The genes, when expressed in the cell, provide an enzymatic pathway to
size the desired nd. Examples of the types of enzymes that are optionally added are
provided herein. Additional s sequences are found, for example, in Genbank. Artificially evolved
enzymes can be added into a cell in the same manner. In this manner, the ar machinery and resources
of a cell are manipulated to produce non-natural amino acids.
] A variety of methods are available for producing novel enzymes for use in biosynthetic
pathways or for evolution of existing ys. For example, recursive ination, including but not
limited to, as developed by Maxygen, Inc. (available on the world wide web at www.maxygen.com), can
be used to develop novel enzymes and pathways. See, e. g., Stemmer (1994), Rapid evolution of a protein
in vitro by DNA Shuflling, ):389-391; and, Stemmer, (1994), DNA Shuflling by random
fragmentation and reassembly: In vitro recombination for molecular evolution, Proc. Natl. Acad. Sci.
M, 91:10747-10751. Similarly DesignPathTM, developed by Genencor (available on the world wide
web at genencor.com) is optionally used for metabolic pathway engineering, ing but not d to,
to engineer a pathway to create a tural amino acid in a cell. This technology reconstructs existing
ys in host organisms using a combination of new genes, including but not limited to those
identified through functional genomics, molecular evolution and design. Diversa Corporation (available
on the world wide web at diversa.com) also provides technology for rapidly screening libraries of genes
and gene pathways, including but not d to, to create new pathways for biosynthetically producing
non-natural amino acids.
lly, the non-natural amino acid produced with an engineered biosynthetic pathway as
bed herein is produced in a concentration sufficient for efficient protein biosynthesis, including but
not limited to, a natural cellular amount, but not to such a degree as to affect the concentration of the other
amino acids or exhaust cellular resources. Typical concentrations produced in vivo in this manner are
about 10 mM to about 0.05 mM. Once a cell is transformed with a plasmid sing the genes used to
produce enzymes desired for a specific pathway and a tural amino acid is generated, in vivo
selections are optionally used to further ze the production of the non-natural amino acid for both
mal protein synthesis and cell growth.
X. Additional tic Methodology
The non-natural amino acids described herein may be synthesized using methodologies
described in the art or using the techniques described herein or by a combination thereof. As an aid, the
following table provides s starting electrophiles and nucleophiles which may be combined to create
a desired functional group. The information provided is meant to be illustrative and not limiting to the
synthetic techniques described herein.
Table 1: Examples of Covalent Linkages and Precursors Thereof
Oximes aldehydes or ketones Hydroxylamines
Alkyl amines alkyl halides amines/anilines
Esters alkyl halides carboxylic acids
Thioethers alkyl halides Thiols
Ethers alkyl halides alcohols/phenols
hers alkyl sulfonates Thiols
Esters alkyl sulfonates carboxylic acids
Ethers alkyl sulfonates alcohols/phenols
Esters Anhydrides alcohols/phenols
Carboxamides Anhydrides amines/anilines
Thiophenols aryl halides Thiols
Aryl amines aryl halides Amines
Thioethers Azindines Thiols
te esters Boronates Glycols
amides carboxylic acids amines/anilines
Esters carboxylic acids Alcohols
hydrazines Hydrazides carboxylic acids
N—acylureas or Anhydrides carbodiimides carboxylic acids
Esters diazoalkanes carboxylic acids
Thioethers es Thiols
Thioethers haloacetamides Thiols
Ammotriazines halotriazines amines/anilines
Triazinyl ethers iazines alcohols/phenols
Amidines imido esters /anilines
Ureas lsocyanates amines/anilines
Urethanes lsocyanates alcohols/phenols
Thioureas isothiocyanates amines/anilines
Thioethers Maleimides Thiols
Phosphite esters phosphoramidites Alcohols
Silyl ethers silyl halides ls
Alkyl amines sulfonate esters amines/anilines
Thioethers ate esters Thiols
Esters ate esters carboxylic acids
Ethers sulfonate esters Alcohols
Sulfonamides sulfonyl halides amines/anilines
Sulfonate esters sulfonyl halides phenols/alcohols
] In general, carbon electrophiles are susceptible to attack by complementary nucleophiles,
including carbon nucleophiles, wherein an attacking nucleophile brings an electron pair to the carbon
electrophile in order to form a new bond between the nucleophile and the carbon electrophile.
Non-limiting examples of carbon nucleophiles include, but are not limited to alkyl, l,
aryl and alkynyl Grignard, organolithium, organozinc, , alkenyl , aryl- and alkynyl-tin reagents
(organostannanes), alkyl-, alkenyl-, aryl- and alkynyl-borane reagents (organoboranes and
organoboronates); these carbon nucleophiles have the advantage of being kinetically stable in water or
polar organic solvents. Other non-limiting es of carbon nucleophiles include phosphorus ylids,
enol and enolate reagents; these carbon nucleophiles have the advantage of being relatively easy to
generate from precursors well known to those skilled in the art of synthetic organic chemistry. Carbon
nucleophiles, when used in conjunction with carbon electrophiles, engender new carbon-carbon bonds
between the carbon nucleophile and carbon electrophile.
Non-limiting examples of non-carbon nucleophiles suitable for coupling to carbon
electrophiles include but are not limited to y and secondary amines, thiols, thiolates, and hers,
alcohols, alkoxides, azides, semicarbazides, and the like. These non-carbon nucleophiles, when used in
conjunction with carbon electrophiles, typically generate heteroatom linkages (C-X-C), wherein X is a
hetereoatom, including, but not limited to, oxygen, sulfur, or nitrogen.
EXAMPLES
Example 1: Synthesis ofCompound 1
Scheme 1
/\/0\/\0/\/0H 1_2
1-1 :9:NoN0\/\O/\/0\/\O/\,0H
DIAD PPh;.,
HCI “\H H
N0 o
0 /\ OMe O OMe O
/ l1:
1-5 N\—/_S
1 NaBH3CN
eamwnwxgtf0 OMe o OMe o
NH2NH2
xfla?OMeO OMe O
Compound 1-3: Tetra (ethylene glycol ) 1-1 (10g, 51.5mmol), N—hydroxyphthalimide 1-2 (
8.4g, 51.15mmol) and triphenylphosphine ( 17.6g, 67mmol) were dissolved in 300 mL of tetrahydrofiJran
followed by addition of DIAD (12.8 mL, 61.78 mol) at 0°C. The ing solution was d at room
temperature overnight, and then trated to dryness. The residue was purified by flash column
chromatography to give 5.47g (31%) of compound 1-3.
Compound 1-4: To a on of compound 1-3 (200mg, 0.59mmol) in 15mL
dichloromethane was added Dess-Martin Periodinane , 0.71 mmol). The reaction mixture was
stirred at ambient temperature overnight. The reaction was ed with the solution of sodium bisulfite
in 15 mL of saturated sodium bicarbonate. The e was separated. The organic layer was washed with
saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered and concentrated in vacuo. The
residue was purified by flash column chromatography to give 150mg (75%) of compound 1-4.
Compound 1-6: To a on of monomethyldolastatin hydrochloride salt 1-5 (50mg, 0.062
mmol) in lmL of DMF was added compound 1-4 (63mg, 0.186mmol) and 70uL of acetic acid, followed
by addition of 8 mg of sodium cyanoborohydride. The resulting mixture was d at ambient
temperature for 2 hours. The reaction mixture was diluted with water and purified by HPLC to give 60mg
(80%) of nd 1-6. MS (ESI) m/z 547 , 1092 [M+H].
Compound 1: Compound 1-6 (60mg, 0.05mmol) was dissolved in 1 mL of DMF. 32 uL of
hydrazine was added. The resulting solution was stirred at ambient temperature for 1 hour. The reaction
was quenched with 1N hydrochloride solution. The reaction mixture was purified by HPLC to give 33 mg
(55%) of compound 1. MS (ESI) m/z 482 [M+2H], 962 [M+H].
Example 2: sis ofCompound 2
Scheme 2
HO\/\o/\/0\/\OH 6:10 03>:Noo\/\ /\/o\/\0 OH
2-1 DIAD PPh3
HCIHEN/{kRM
N’o\/\o/\/o\/§o
OMe O OMeO 21:" \
o 2-3
flewwwnummmfNaBH3CN OMe O OMe 0
Compound 2 was synthesized via a similar synthetic route as described in e 1. MS
(ESI) m/z 460 [M+2H], 918 [M+H].
Example 3: Synthesis ofCompound 3
Scheme 3
NOH o
o 6:10 o/\/°H
HO/\/1\/\OH \
DIAD PPh3 0 3-2
OMe O OMe ON
Qmwwmfw?NaBH3CNOMe O OMe O
‘ NHZNHZ
“wing:$494M.5OMeO OMe 0
Compound 3 was synthesized Via similar synthetic route to Example 1. MS (ESI) m/z 438
[M+2H], 974 [M+H].
Example 4: Synthesis ofCompound 4
Compound 4-2: To a on of Val -OH.HCl 4-1 (1 g, 4.77 mmol) and
bromoethanol (304.7 uL, 4.3 mmol) in 10 mL of DMF was added 1.68 ml of DIEA. The reaction mixture
was stirred at room temperature for 2 days. 4.8 mmol of BocZO was added to the reaction mixture,
followed by 0.84 mL of DIEA. The reaction mixture was stirred at room temperature for 2 days. The
reaction e was concentrated in vacuo and extracted with ethyl acetate, and washed with water,
brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash column
chromatography to give 0.66 g of compound 4-2.
Scheme 4
0 Bco O Bco O
°J< JED—0’ HO’VNEAO —>/\/Br I J< / “VA/“$0| J<
:15.“ ; I ocz
/\ /=\ O 4'3 /\
4-1 i
HATU
o H“EJL'TI H H
N/o\/\|}l N N
\ Bee 0
/\ OMe O OMeO
o OtBu
o /\ OMeO
HCI OMeoo OH
HCHO
o HNgkN H H
N N
\ N/O\/\lil g
o I
A OMe o OMe o
O OH
o NHZNHZl 4-8
.mwfiflfifiwofléoH H H
o /\ OMeO OMeO
0 OH
Compound 4-3: To a solution of compound 4-2 (500 mg, 1.58 mmol), N-hydroxyphthalimide
(261 mg, 1.6 mmol) and triphenylphosphine (538 mg, 2.05 mmol) in 15 mL THF was added DIAD (394
uL, 1.9 mol) at at 0°C. The resulting solution was stirred at room temperature ght, and then
concentrated in vacuo. The residue was purified by flash column chromatography to give 0.68 g of
compound 4-3.
nd 4-4: Compound 4-3 was dissolved in 15 mL 4N HCl/Dioxane. The reaction
mixture was stirred at room temperature for 2 days and concentrated in vacuo. The residue was dissolved
in DMF and treated with BocZO (230 uL, 1 mmol) and DIEA (352 uL, 2 mmol). The reaction mixture
was stirred at room temperature for 2 days. The reaction mixture was d by HPLC to give 100 mg of
compound 4-4.
] Compound 4-5: To a solution of nd Boc-Val-Dil-methleap-OH in DMF is added
phe(OtBu)-OH.HCl, HATU and N—methylmorpholine. The reaction mixture is d at room
temperature for 4 hours. The reaction e is concentrated in vacuo and extracted with ethyl acetate
(100 mLXl, 50 mL X2). The organic layer is ed and washed with brine, dried over sodium sulfate
and concentrated in vacuo. The residue is purified by flash chromatography. The resulting compound is
treated with HCl/EtOAC to give compound 4-5.
Compound 4-6: To a solution of compound 4-5 in DMF is added compound 4-4, HATU and
DIEA. The reaction mixture is stirred at room temperature for 4 hours. The reaction e is
concentrated in vacuo and extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer is
combined and washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue is
d by flash chromatography to give compound 4-6.
] Compound 4-7: Compound 4-6 is dissolved in 15 mL 4N HCl/Dioxane. The reaction mixture
is stirred at room temperature for 2 hours and concentrated in vacuo to give compound 4-7.
Compound 4-8: To a solution of compound 4-7 in 1 mL of DMF is added formylaldehyde
and acetic acid, followed by addition of sodium cyanoborohydride. The resulting mixture is stirred at
t temperature for 2 hours. The reaction mixture is d with water and purified by HPLC to give
compound 4-8.
Compound 4: Compound 4-8 is dissolved in 1 mL of DMF. Hydrazine is added. The
resulting solution is stirred at ambient temperature for 1 hour. The reaction is quenched with lN
hydrochloride solution. The reaction mixture is purified by HPLC to give Compound 4.
Example 5: sis ofCompound 5
Compound 4-7 is dissolved in 1 mL of DMF. Hydrazine is added. The resulting solution is
stirred at ambient temperature for 1 hour. The reaction is quenched with lN hydrochloride solution. The
reaction mixture is purified by HPLC to give Compound 5.
Example 6: Synthesis ofCompound 6
Scheme 6
”‘3'
e.HC|
X0YNJLT; OH —. ()qu —. HZNJKN
OMe O OMe O OMe o OMe 00 OMe O OMe O COOMe
Boc-N--methyl--Va|
3°C 0 /'\ OMeO OMeO COOMe Boc o /\ OMeO OMe 0 COOH
CW\/\0
Ir“:RQN“‘61?6°
o A OMeO OMeO COOH
6-6 I NaBH3CN
N~M\/O\/\o/\/0\/\ (DH/:31,“
ZNHZ OMe o OMe oo
0-090909%99%0995
OMe O OMe O
Compound 6-2: To a solution of compound 6-1 (500 mg, 0.875 mmol) in 3 mL of DMF was
added 283 mg of phenylalanine hydrochloride, 433mg of HATU and 581 uL of N—methylmorpholine. The
reaction mixture was stirred at room temperature for 4 hours. The reaction e was concentrated in
vacuo and extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer was combined and
washed with brine, dried over sodium sulfate and trated in vacuo. The residue was purified by flash
chromatography to give 560 mg (76%) of compound 6-2.
Compound 6-3: Compound 6-2 was dissolved in 15 mL 4N HCl/Dioxane. The reaction
e was stirred at room temperature for 2 hours and concentrated in vacuo to give 511 mg of
compound 6-3.
Compound 6-4: To a solution of compound 6-3 (368 mg, 0.55 mmol) in 3 mL of DMF was
added 255 mg of Boc-N—methyl valine, 314mg of HATU and 303 uL of ylmorpholine. The
reaction mixture was stirred at room ature for 4 hours. The reaction mixture was concentrated in
vacuo and extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer was combined and
washed with brine, dried over sodium sulfate and trated in vacuo. The residue was purified by flash
chromatography to give 370 mg (79%) of compound 6-4.
Compound 6-5: To a solution of compound 6-4 (170mg) in 10 mL MeOH was added 5eq of
1N LiOH. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was
ed by lNHCl and extracted with ethyl acetate washed with brine, dried over sodium sulfate and
concentrated in vacuo to give 150 mg (90%) of compound 6-5.
Compound 6-6: Compound 6-5 was dissolved in 4N HCl/Dioxane. The reaction mixture was
stirred at room temperature for 2 hours and concentrated in vacuo and purified by HPLC to give 150mg of
compound 6-6.
Compound 6-7: To a solution of compound 6-6 (50mg, 0.062 mmol) in lmL of DMF was
added compound 1-4 (63mg, 0.186mmol) and 70uL of acetic acid, followed by addition of 8 mg of
sodium cyanoborohydride. The resulting mixture was stirred at ambient temperature for 2 hours. The
reaction mixture was diluted with water and purified by HPLC to give 60mg (80%) of compound 6-7.
Compound 6: Compound 6-7 (60mg, 0.05mmol) was dissolved in 1 mL of DMF. 32 [LL of
ine was added. The resulting solution was stirred at ambient ature for 1 hour. The reaction
was quenched with 1N hydrochloride solution. The reaction mixture was purified by HPLC to give 33 mg
(55%) of nd 6.
Example 7: Synthesis ofCompound 7
Scheme 7
urifOMe O OMe O 6x13?“
l NaBH3CN
CgowwwiwfifwOMeO OMe O
l NHZNHZ
“Wm;fifiwOMeo OM 00e
nd 7 was synthesized via similar synthetic route to Compound 1. MS (ESI) m/z 440
[M+2H], 879 [M+H].
Example 8: Synthesis ofCompound 8
Scheme8
HCI “\Jx .nH N’°\/\o/\7o
HN N
; \
l o/‘\‘ OMeO + 0 3'3
OMeoo
N‘lTlO/Vo\/\ oniN/8-1\I\HNHZNHZOMeO OMeoo
”2”°N°$“In“dlfflrofidw
OMeO OMeoo
Compound 8 was synthesized Via similar synthetic route to Compound 1. MS (ESI) m/z 418
[M+2H], 835 [M+H].
2012/039472
Example 9: Synthesis ofCompound 9
Scheme 9
drag/1W MM:0.o 0”
/\ OMe o OMe o NV\O+
9-1 /5\
HATUl
»wj§fi$w%Boc O A OMe O OMe O
/\ OMe O OMe O /N
NH2NH2
HzN/ \/\N N \
I .
AI l
OMe o OMe o /N
Compound 9-1: To a solution of compound Boc-Val-Dil-methleap-OH in DMF is added 4-
(2—Aminoethyl) pyridine, HATU and ylmorpholine. The reaction mixture is stirred at room
temperature for 4 hours. The reaction mixture is trated in vacuo and extracted With ethyl acetate
(100 mLXl, 50 mL X2). The organic layer is combined and washed With brine, dried over sodium sulfate
and concentrated in vacuo. The residue is purified by flash chromatography. The ing compound is
treated with HCl/EtOAC to give compound 9-1.
Compound 9-2: To a solution of compound 9-1 in DMF is added compound 4-4, HATU and
DIEA. The reaction mixture is stirred at room temperature for 4 hours. The reaction mixture is
concentrated in vacuo and extracted With ethyl acetate (100 mLXl, 50 mL X2). The organic layer is
combined and washed With brine, dried over sodium sulfate and concentrated in vacuo. The residue is
purified by flash chromatography to give compound 9-2.
Compound 9-3: Compound 9-2 is dissolved in 15 mL 4N HCl/Dioxane. The reaction
mixture is d at room temperature for 2 hours and concentrated in vacuo to give compound 9-3.
Compound 9-4: To a solution of compound 9-3 in lmL of DMF is added formylaldehyde
and acetic acid, followed by addition of sodium cyanoborohydride. The resulting mixture is stirred at
ambient temperature for 2 hours. The reaction mixture is diluted With water and purified by HPLC to give
compound 9-4.
] Compound 9: Compound 9-4 is ved in 1 mL of DMF. ine is added. The
resulting solution is d at ambient temperature for 1 hour. The reaction is quenched With lN
hydrochloride solution. The reaction mixture is purified by HPLC to give compound 9.
Example 10: Synthesis ound 10
Scheme 10
o NIOWHIl/NWJLN
H “\H H
N N
\ I |
o /=\ OMeO OMeO IN
NH2NH2
é)12%Z:3:0 Z Z:
IN2\ —Z
Compound 10: Compound 9-3 is dissolved in 1 mL of DMF. Hydrazine is added. The
resulting solution is stirred at ambient temperature for 1 hour. The reaction is quenched With lN
hydrochloride solution. The on mixture is purified by HPLC to give Example 10.
Example 11: Synthesis ofCompound 11
Scheme 11
O N
Vk \
OtBu 11-2 0
H0\/\o/\/0\/\o/\/OH H°\/\o/\/O\/\o/\/0\/\[rOtBu—>11 -4 Na! THF DIAD PPh3 THF
11-1 11-3 0
N’°\/\o/\/°\/\o/\/° OtBu Dioxane
0 11-5 0
N’O\/\ /\/O\/\o o/\/ \/\n/OH0 +
o OMe O OMe 0
O o'q/lijiN
11-6
117 N\/:/s
PyBroP
No/\/ \/\o/\/ weO O /\/U\N o”\)kN OMe o OMe o
N S
NH2NH2
~°wo~°on*~119*XQN
CF3COOH OMe O OMe O
N/N\:/S
Compound 11-3: To a solution of tetra (ethylene glycol) 11-1 (40.6 mL, 235 mmol) in 100
mL of tetrahedrofuran was added 47 mg of . 12 mL of tert-butylacrylate was added after sodium
was ved. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture
was concentrated in vacuo and quenched with 2 mL of 1 N HCl. The e was suspended in brine and
extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer was combined and washed with
brine, dried over sodium sulfate and concentrated in vacuo to give 6.4 g (23%) of compound 11-3.
Compound 11-5: Compound 11-3 (1.0 g, 3.12 mmol), N—hydroxyphthalimide 11-4 (611 mg,
3.744 mmol) and triphenylphosphine (1.23 g, 4.68 mmol) were dissolved in 20 mL of tetrahydrofuran
followed by addition of DIAD (0.84 mL, 4.06 mol) at 0°C. The resulting solution was stirred at room
temperature overnight, and then concentrated to dryness. The residue was purified by flash column
chromatography using ep Cartridges (80g), g with 0-100% ethyl acetate/hexanes, to give 1.0 g
(100%) of compound 11-5.
Compound 11-6: Compound 11-5 was dissolved in 15 mL 4N HCl/Dioxane. The reaction
mixture was stirred at room temperature for 2 hours and concentrated in vacuo to give 1.0 g of nd
11-6.
Compound 11-8: To a solution of 30 mg (0.0372 mmol) of monomethyldolastatin
hydrochloride, 31 mg 4 mmol) of compound 11-6 and 38.2 mg (0.082 mmol) of PyBroP in 1 mL of
DMF was added 33 [LL (0.186 mmol) of diisopropylethylamine. The reaction mixture was stirred at room
temperature for 5 hours. The reaction mixture was purified by HPLC to give 28mg (65%) of compound
11-8. MS (ESI) m/z 785 [M+2H], 1164[M+H].
Compound 11: Compound 11-8 (28 mg, 0.024 mmol) was dissolved in 1 mL of DMF. 23 [LL
(0.72mmol) of ous hydrazine was added. The resulting solution was stirred at room temperature
for 1 hour. The on was quenched with 1N hloride solution. The reaction e was
purified by preparative HPLC, eluting with 20-70%CH3CN/H2O in 20 min at 254 nm, to give 20 mg
(66%) of Compound 11. MS (ESI) m/z 518 [M+2H], 1034[M+H].
Example 12: Synthesis ofCompound 12
Scheme 12
mwmfiwwMmQaE—wmla?OMeO OMeO OMeO OMeO OMeO OMeO COOMe
121 12-2
Bee o A OMeO OMeO COOMe Bee o A OMeO OMeO NZ/No COOH
12-5
No/\/ \/\NH2o
I;51%ng 31%ng
OMe o OMe 0 COOH OMe 0 COOH
\ITNfimQArN O
\ NHzNHz \ENdeYQRWT
OMe o OMe oo N/Vo\/\ON OMe o OMe 00 ”WeNH2
12-11
@111—CH12-9 < 2:0l
0 Bee
How \/\u No/\/0\/\NH2
1. DIAD PPhalTHF
12-8 12'1°
2. 4N HClIDioxane
Compound 12-2: To a solution of compound 12-1 (500 mg, 0.875 mmol) in 3 mL of DMF
was added 283 mg of alanine hydrochloride, 433mg of HATU and 581 uL of ylmorpholine.
The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated
in vacuo and extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer was ed and
washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash
chromatography to give 560 mg (76%) of compound 12-2.
Compound 12-3: Compound 12-2 was dissolved in 15 mL 4N oxane. The reaction
mixture was stirred at room temperature for 2 hours and concentrated in vacuo to give 511 mg of
compound 12-3.
Compound 12-4: To a solution of compound 12-3 (368 mg, 0.55 mmol) in 3 mL of DMF
was added 255 mg of Boc-N—methyl valine, 314mg of HATU and 303 uL of N—methylmorpholine. The
reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated in
vacuo and extracted with ethyl e (100 mLXl, 50 mL X2). The organic layer was combined and
washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was d by flash
chromatography to give 370 mg (79%) of compound 12-4.
Compound 12-5: To a solution of compound 12-4 (170mg) in 10 mL MeOH was added Seq
of 1N LiOH. The reaction mixture was stirred at room temperature for 2 hours. The on mixture was
acidified by 1NHCl and extracted with ethyl acetate washed with brine, dried over sodium sulfate and
concentrated in vacuo to give 150 mg (90%) of compound 12-5.
Compound 12-6: Compound 12-5 was ved in 4N HCl/Dioxane. The reaction mixture
was stirred at room temperature for 2 hours and concentrated in vacuo and purified by HPLC to give
150mg of compound 12-6.
Compound 12-7: To a solution of compound 12-6 in DMF was added formylaldehyde (3eq)
and 20 eq of acetic acid, followed by addition of 2 eq of sodium cyanoborohydride. The resulting mixture
was stirred at ambient temperature for 2 hours. The reaction mixture was diluted with water and purified
by HPLC to give compound 12-7.
nd 12-10: tert—Butyl 2-(2-hydroxyethoxy)ethylcarbamate (2.05 g, 10 mmol), N-
hydroxyphthalimide (1.8 g, 11 mmol) and triphenylphosphine (3.67 g, 14 mmol) were dissolved in 100
mL of tetrahydrofuran followed by on of DIAD (2.48 mL, 12 mol) at 0°C. The resulting solution
was stirred at room temperature overnight, and then concentrated to dryness. The residue was d with
50 mL of 4N HCl/dioxane. The mixture was stirred at room temperature for 2 hours. The solvent was
removed in vacuo. The residue was d with ether, filtered, washed with ether and dried in vacuo to
get 2.6 g (91%) of compound 12-10. MS (ESI) m/z 251 [M+H].
Compound 12-11: To a solution of compound 12-10 (20 mg, 0.026 mmol) in 1 mL of DMF
was added 11.2 mg of compound 12-10, 15 mg of HATU and 23 [LL of DIEA. The reaction mixture was
stirred at room temperature for 2 hours. The reaction mixture was purified by HPLC to give 20 mg (70%)
of compound 12-4. MS (ESI) m/z 490 , 978[M+H].
Compound 12: Compound 12-11 (20 mg, 0.0183 mmol) was ved in 1 mL of DMF. 18
ML (0.56mmol) of anhydrous hydrazine was added. The resulting solution was stirred at room
temperature for 1 hour. The reaction was quenched with 1N hydrochloride solution. The reaction mixture
was purified by preparative HPLC, eluting with 20-70%CH3CN/H2O in 20 min at 254 nm, to give 14 mg
(72%) of nd 12. MS (ESI) m/z 425 , H].
Example 13: Synthesis ofCompound 13
° [1°kaOtBu NOWOH
HOMOtBu—. 4N HCIIDioxane
13-1 DIAD PPh3 13-3
HOSu DCCCine
$QAOH ValCItPABOH 13.5 :NoOM:N
36- HNJ/
1lBNP,DIEA02“NH2
0A HCI
o M nJ1 Q”°
N’0 11”9
N N OMeO OMeO
\ H : H
0 13-8
13-7
A HOBt,D|EA
o NH2
0 0 OH
JK H \H H
N -‘ N
N.0\/\/\)J\N o _
/\ 0M9 O 0M9 °
\ H N\/U\H:
0 13-9
O NH2 NH2NH2
o 0 OH
H “H H
o o
N\)LNH
OJKNjng$Nj/\I:W(%N| 5 ‘
/\ OMe o OMe o
H N’o\/\/\/U\N2
H H
of 13
0%NH2
Compound 13-2: Tert-butyl 6-hydroxyhexanoate 13-1 (1.5 g, ol), N-
hydroxyphthalimide ( 1.42g, 8.76mmol) and triphenylphosphine ( 2.82g, 10.76 mmol) were dissolved in
50 mL of tetrahydrofuran ed by addition of DIAD (2 mL, 9.564 mol) at 0°C. The resulting
solution was stirred at room temperature overnight, and then concentrated to dryness. The residue was
purified by flash column chromatography to give 2.5g (95%) of compound 13-2.
Compound 13-3: The compound 13-2 was treated with 15 mL 4N HCl in dioxane. The
reaction mixture was stirred at t temperature for 12 hours and concentrated to s in vacuo to
give 900mg (100%) of compound 13-3.
Compound 13-4: To a solution of compound 13-3 (900mg, 3.0mmol) in 10 mL of THF was
added 397 mg of N—hydroxysuccinimide, followed by adding 669 mg of DCC. The reaction mixture was
stirred at ambient ature overnight and filtered. The filtration was concentrated and treated with 10
mL of DCM. The DCM solution was stayed at ambient temperature for 1 hour and filtered. The filtration
was concentrated and purified by flash column chromatography to give 800mg (71%) of compound 13-4.
] Compound 13-6: The mixture of compound 13-4 (435 mg, 1.16 mmol) and Val-Cit-PABOH
13-51 (400mg, 1.054 mmol) in 12 mL of DMF was stirred at ambient temperature for 24 hours. The
solvent was removed in vacuo. The residue was treated with ether, filtered and washed with ether. The
solid was dried in vacuo to give 660mg (98%) of nd 13-6.
Compound 13-7: To the solution of compound 13-6 (200mg, 0.313 mmol) in 6 mL of DMF
was added bis (p-nitrophenyl) carbonate (286 mg, 0.94 mmol), followed by addition of 110.2 uL of
DIEA. The reaction mixture was stirred at ambient temperature for 5 hours and concentrated. The residue
was treated with ether and filtered. The collected solid was washed with ether, 5% citric acid, water, ether
and dried in vacuo to give 210mg (83%) compound 13-7.
nd 13-9: To a solution of thylauristatin hydrochloride salt 13-8 (100mg,
0.1325 mmol) in 2mL of DMF was added compound 13-7 (159mg, 0.2mmol) and 10 mg of HOBt,
followed by addition of 35.2 uL of DIEA. The ing mixture was stirred at ambient temperature for 2
days. The reaction mixture was diluted with water and purified by HPLC to give 93mg (51%) of
nd 13-9. MS (ESI) m/z 692 [M+2H], 1382 [M+H].
Compound 13: The compound 13-9 (50mg, 0.036mmol) was dissolved in 1 mL of DMF. 23
[LL of hydrazine was added. The resulting solution was stirred at ambient temperature for 3 hours. The
reaction was quenched with 1N hydrochloride solution. The reaction mixture was purified by HPLC to
give 32mg (65%) of Compound 13. MS (ESI) m/z 638.5 [M+Na+2H], 1253.3 [M+H], 1275.8 [M+Na].
Example 14: Synthesis ofCompound 14
Scheme 14
0 &°N \Aogaufld \
14.4 o
H0\/\o/\/ \/\o/\/ —.0 0H HO\/\°/\/ /°\/\n/013u —.0 N—°\/\°/\/°\/\o/\/° OtBu
Na, THF DIAD, PPh3, THF \ W
0 °
14.1 23% 100% 0 14-5
14-3
Dioxane \ 100%
“\iN N--Hydroxysuccinimide
No 0 DCC, THF
N \/\°/\/ / We)”O 0
N— \/\°/\/°\/\o/\/°WOH
100% \
of 0
0 14-6
ogNNH2
92% DMF
/ N:/\/°\/\o/\/°\/\o/\iN 0N?”go” BNP, DIEAIDMF
/ N:/\/°\/\°/\,o\/\°/\iN OHEiN/©/\°N HNJ/ 14-10 HNJ/
14-9 0%NH2 02W”:
DIEA
wwwmmwaemf\=/
HNJ/ 14-11
o NH2 NHZNHZ
81/0
1{(13%WE
HZNo/Vowo/VowoA/Lkujggrj/3i”mo OMeO OMeO
CF3COOH N\_/s—
HNJ/ 14
o NH2
Compound 14-3: To a solution of tetra (ethylene glycol) 14-1 (40.6 mL, 235 mmol) in 100
mL of tetrahedrofuran was added 47 mg of . 12 mL of tert-butylacrylate was added after sodium
was dissolved. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture
was concentrated in vacuo and quenched with 2 mL of 1 N HCl. The residue was ded in brine and
extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer was combined and washed with
brine, dried over sodium sulfate and concentrated in vacuop to give 6.4 g (23%) of compound 14-3.
Compound 14-5: Compound 14-3 (1.0 g, 3.12 mmol), N—hydroxyphthalimide 14-4 (611 mg,
3.744 mmol) and triphenylphosphine (1.23 g, 4.68 mmol) were dissolved in 20 mL of ydrofuran
followed by addition of DIAD (0.84 mL, 4.06 mol) at 0°C. The resulting solution was stirred at room
temperature overnight, and then concentrated to dryness. The residue was purified by flash column
chromatography using ep Cartridges (80g), eluting with 0-100% ethyl acetate/hexanes, to give 1.0 g
(100%) of compound 14-5.
Compound 14-6: Compound 14-5 was dissolved in 15 mL 4N HCl/Dioxane. The reaction
mixture was stirred at room temperature for 2 hours and concentrated in vacuo to give 1.0 g of compound
14-6.
Compound 14-7: To a solution of compound 6 (1.93 g, 4.68 mmol) and N-
hydroxysuccinimide (646 mg, 5.616 mmol) in 20 mL of tetrahedrofuran was added 1.062 g (5.148 mmol)
of DCC. The reaction mixture was stirred at room temperature overnight and filtered. The filtration was
trated and purified by flash column chromatography using SiliaSep Cartridges (80g), g with
0-100% ethyl acetate/hexanes to give 2.37g (100%) of compound 14-7.
Compound 14-8: Compound 14- 8 was made ing to the literature (Bioconjugat Chem.
2002, 13 (4), 855-869.)
Compound 14-9: To a solution of compound 14-8 (200 mg, 0.527 mmol) in 2 mL of DMF
was added 295 mg (0.58 mmol) of compound 14-7. The reaction mixture was stirred at room temperature
overnight and trated in vacuo. The residue was treated with ether, filtered, washed with ether and
dried in vacuo to give 402 mg (98%) of compound 14-9.
Compound 14-10: To a solution of compound 14-9 (406 mg, 0.527 mmol) and bis(p-
henol) carbonate (481 mg, 1.58 mmol) in 10 mL of DMF was added 0.186 mL(1.054 mmol) of
diisopropylethylamine. The reaction e was stirred at room temperature for 5 hours. The solvent was
d in vacuo. The residue was treated with ether, filtered, washed with ether, 5% citic acid, water,
ether and dried in vacuo to give 350 mg (72%) of compound 14-10.
] Compound 14-11: To a solution of 50 mg (0.062 mmol) of monomethyldolastatin
hydrochloride, 87.2 mg (0.093 mmol) of compound 14-10 and 4.7 mg (0.031 mmol) of HOBt in 1 mL of
DMF was added 22 [LL (0.124 mmol) of diisopropylethylamine. The reaction mixture was stirred at room
temperature for 16 hours. The reaction mixture was purified by HPLC to give 41mg (42%) of compound
14-11. MS (ESI) m/z 785 [M+2H].
Compound 14: Compound 14-11 (41 mg, 0.026 mmol) was dissolved in 1 mL of DMF. 17
ML (0.52mmol) of ous ine was added. The resulting solution was stirred at room
temperature for 1 hour. The reaction was quenched with 1N hydrochloride solution. The reaction mixture
was purified by preparative HPLC, eluting with 20-70%CH3CN/H2O in 20 min at 254 nm, to give 22 mg
(58%) of compound 14. MS (ESI) m/z 720 [M+2H].
2012/039472
Example 15: Synthesis ofCompound 15
Scheme 15
Jk o
o HCI \AJLN \H
O N N
N’°\/\/\)LN HN
O /=\ I OMe O OMeO
\ H N’ S
o f \=/
'1 13'7
DIEAIHOBt
o NH2
O O
H “H H
o o OAOATIfVLaQ/VWN
NEJkNH O OMeO
Compound 15-2: To a on of 50 mg (0.062 mmol) of monomethyldolastatin
hydrochloride, 75 mg (0.093 mmol) of compound 13-7 and 4.7 mg (0.031 mmol) of HOBt in 1 mL of
DMF was added 22 uL (0.124 mmol) of diisopropylethylamine. The reaction e was stirred at room
temperature for 16 hours. The reaction mixture was purified by HPLC to give 41mg (42%) of compound
-2. MS (ES1)m/z 718 [M+2H], 1435 [M+H].
Compound 15-2: Compound 15-2 (41 mg, 0.026 mmol) was dissolved in 1 mL of DMF. 17
uL (0.52mmol) of anhydrous hydrazine was added. The resulting solution was stirred at room
temperature for 1 hour. The reaction was quenched with 1N hydrochloride solution. The reaction mixture
was purified by preparative HPLC, g with 20-70%CH3CN/H20 in 20 min at 254 nm, to give 22 mg
(58%) of example 15. MS (ESI) m/z 653 [M+2H], 1305 [M+H].
Example 16: Synthesis ofCompound 16
Scheme 16
A 16-8
0 NH2
HO\/\OH
16-1
DMF BNP,DIEA
VLOtBu NO
Na THF 0
16-2 Jk
o o o
HO W/\/O OtBu Fmoc\N N \)J\NDA
H : H
163. o o
o f
@ 16-9
N—OH DIAD, PPh3, THF OANHZ
16-40
MMD, HOBt
DIEAIDMF
N’owo/Qkomu
< \i
‘0 16-5 (3)111fo$RQJWT§>N
\ 4NHC|IDioxane Fmoc~b‘j;(“\:/(l)J\N/©/\o OMe O OMe O
16-10
o 0
N )J\OH HN
16-6
0 ogNNH2 l DiethylamineTHF
0 o
O o/\iop
+ HZEH¢kN/©/\o11:1:1:12:15OMeO OMeO
16-7 I 16-11
1 NHZ
HNJ/ 16-12
Compound 16-3: To a solution of ne glycol 16-1 (13.1 mL, 235 mmol) in 100 mL of
tetrahedrofuran was added 47 mg of sodium. 12 mL of tert-butylacrylate was added after sodium was
dissolved. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was
concentrated in vacuo and quenched with 2 mL of 1 N HCl. The residue was suspended in brine and
extracted with ethyl acetate (100 mLXl, 50 mL X2). The organic layer was combined and washed with
brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash column
chromatography to give 5.2 g (24%) of compound 16—3.
Compound 16—5: Compound 16-3 (2.0 g, 10.5 mmol), oxyphthalimide (2.05 g,
12.6 mmol) and triphenylphosphine (3.58 g, 13.65 mmol) were dissolved in 50 mL of tetrahydrofuran
followed by addition of DIAD (3.26 mL, 15.75 mol) at 0°C. The resulting solution was stirred at room
temperature overnight, and then trated to dryness. The residue was d by flash column
chromatography to give compound 16—5.
] Compound 16—6: Compound 16—5 was dissolved in 15 mL 4N HCl/Dioxane. The reaction
mixture was stirred at room temperature for 2 hours and concentrated in vacuo to give compound 16—6.
Compound 16—7: To a on of compound 16—6 (5.16 mmol) and N—hydroxysuccinimide
(722 mg, 6.7 mmol) in 20 mL of tetrahedrofuran was added 1.28 g (6.2 mmol) of DCC. The reaction
mixture was stirred at room temperature overnight and filtered. The filtration was concentrated and
purified by flash column chromatography to give 500mg of compound 16—7.
nd 16—8: Compound 16— 8 was made according to the literature (Bioconjugat Chem.
2002, 13 (4), 9.)
Compound 16—9: To a solution of compound 16—8 (5.0 g, 8.3 mmol) and bis(p-nitrophenol)
carbonate (7.6 g, 25 mmol) in 100 mL of DMF was added 2.92 mL(16.6 mmol) of diisopropylethylamine.
The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed in vacuo.
The residue was d with ether, filtered, washed with ether, 5% citic acid, water, ether and dried in
vacuo to give 5.0 g (81%) of compound 16—9.
Compound 16—10: To a solution of 1.0 g (1.24 mmol) of monomethyldolastatin
hydrochloride, 1.42 g (1.8575 mmol) of compound 16-9 and 95 mg (0.62 mmol) of HOBt in 10 mL of
DMF was added 437 uL (2.48 mmol) of diisopropylethylamine. The reaction mixture was stirred at room
temperature for 16 hours. The reaction mixture was purified by HPLC to give 1.0 g (58%) of compound
16-10. MS (ESI) m/z 700 [M+2H], 1398 [M+H].
Compound 16—11: To a solution of compound 16—10 (1.0 g, 0.715 mmol) in 15 mL of
tetrahedrofuran was added 5 mL (48 mmol) of diethylamine. The reaction mixture was stirred at room
temperature for 1.5 hours and concentrated in vacuo. The residue was dissolved in 20 mL of DCM, treated
with 200 mL of ether and filtered, wshed with ether and dried in vacuo to give 860 mg of nd 16-
11. MS (ESI) m/z 589 [M+2H], 1176 [M+H].
Compound 16: To a on of 50 mg (0.0425 mmol) of compound 16-11 in 1 mL of DMF
was added 32 mg (0.085 mmol) of compound 16—7. The on mixture was stirred at room temperature
for 16 hours. The HPLC and MS showed reaction done. 27.2 uL (0.85 mmol) of anhydrous hydrazine was
added to the reaction mixture. The on was done in 2 hours. The reaction mixture was acidified with
1N HCl and purified by HPLC to give 40mg (66%) of nd 16. MS (ESI) m/z 654 [M+2H],
1307[M+H].
Example I 7: Synthesis ofCompound I 7
Scheme 17
o O
0 17-1
‘HOSu
OLNIrVgfiYWYNo o
H “H H
° o
0%" HQK lo 5 I OMeO OMeO
N’ o‘ + H2" N A
N/ S
\ H
0 or \:l
16-11
17-2
l 06km2
O O
°1NOJLIW1J1©A° l
O g1 OMe O OMe O
\ H a H
0 HNJ/ 17-3
o NH2
1 o o
HZNDJLEH$N©AO O 1‘ .
0 AT OMe o OMe o
N ’s
H E H
CF3COOH 0
06km2
] Compound 17-2: To a solution of compound 17-1 (1.0 g, 4.52 mmol) and N-
hydroxysuccinimide (572 mg, 4.97 mmol) in 20 mL of tetrahedrofiiran was added 1.12 g (5.424 mmol) of
DCC. The reaction e was stirred at room temperature overnight and filtered. The filtration was
trated to give compound 17-2.
Compound 17: To a solution of 50 mg (0.0425 mmol) of compound 16-11 in 1 mL of DMF
was added 41 mg (0.1275 mmol) of compound 17-2. The reaction mixture was stirred at room
temperature for 16 hours. The HPLC and MS showed reaction done. 20 uL (0.625 mmol) of anhydrous
hydrazine was added to the reaction mixture. The reaction was done in 2 hours. The reaction mixture was
acidified with 1N HCl and purified by HPLC to give 35mg (60%) of compound 17. MS (ESI) m/z 625
[M+2H], 1249[M+H].
Example 18: Synthesis ofCompound 18
Scheme 18
Wwwwwfir*0mg1.19m
HNJ/ 0 OH
14—10 A
o NH2
a H
J/ 18-1
0 NH2 1 NHZNHZDMF
H2N\ONO\A0~O\Ao/\)kr\I(N\-ANO H gxxmxOMeO
OMe O
H 5
Of 18
o¢L\NH2
Compound 18-1: To a solution of compound 6-6, mg (0.062 mmol) of compound 14-10 and
HOBt in 1 mL of DMF was added diisopropylethylamine. The reaction mixture was stirred at room
temperature for 16 hours. The reaction e was purified by HPLC to give compound 18-1.
] Compound 18: Compound 18-1 was ved in 1 mL of DMF. Anhydrous ine was
added. The resulting solution was stirred at room temperature for 1 hour. The reaction was quenched
with 1N hydrochloride solution. The reaction mixture was purified by preparative HPLC, eluting with 20-
70%CH3CN/H20 in 20 min at 254 nm, to give compound 18.
Example 19: Synthesis ofCompound 19
Scheme 19
iokflo/VOWONOWOHO Dess-Martin i
DC—TM OMONOWONO\/§o
~o\/\N,Boc 14-3 19-5
19-1
1.NaBH;CN,DMF MMD
1.D|AD,PPhg/THF 1 N—0H
2. 4N HCI/Dioxane
ofNHZ >LOMONO\AONO\/\MEN/:51mm‘rn
/_/ OMe o OMe o é:/
l N—o N\_/s_
19-6
3°01 NH2
Lys-(Boc)2-OH Hc. 4N HCI/Dioxane
EDC, HOBt
o o
4N HCI/Dioxane .3: o
—. >—\ H
ofNH NH ofNH 0\/\ /\/°\/\N N
+ o
o Boc o NH2
/—’o H HCI ONEiN OMe o OMe o
N / s
l N-o l N-0 \—/
19-3 194 19-7
0 O
HATU/DIEA 75%
wow°$“Id/{LI\ 1%;
Z”; OMe o OMe o
CF3c00H N,
o /—/o—/— Lowowowow11:ng“\iRQAH‘‘CF3c00H o /'\ OMe o OMe o
l N-o N S
19-8
NHZNHZIDMF 71%
HNNONOWO/Vo‘AMEN/figmmrH—s
OMe o OMe o
CF3c00H N/
HII‘NJJ\/\o/\/°\/\o/\/°\/\MEN?RQAVHS
CF3COOHO OMe o OMe o
HZN—O/—/
CF3COOH 19
Compound 19-2: tert—Butyl 2-(2-hydroxyethoxy)ethylcarbamate 13 (2.05 g, 10 mmol), N-
hydroxyphthalimide (1.8 g, 11 mmol) and triphenylphosphine (3.67 g, 14 mmol) were dissolved in 100
mL of tetrahydrofuran followed by addition of DIAD (2.48 mL, 12 mol) at 0°C. The resulting solution
was d at room temperature overnight, and then concentrated to dryness. The residue was treated with
50 mL of 4N HCl/dioxane. The e was stirred at room temperature for 2 hours. The solvent was
removed in vacuo. The residue was d with ether, filtered, washed with ether and dried in vacuo to
get 2.6 g (91%) of compound 19-2. MS (ESI) m/z 251 [M+H].
] Compound 19-3: To the mixture of compound 19-2 (315 mg, 1.1 mmol), Boc-Lys(Boc)-OH
(365 mg, 1 mmol), EDC (382 mg, 2 mmol) and HOBt (306 mg, 2 mmol) in 10 mL of DCM was added
2012/039472
1.056 mL (6 mmol) of diisopropylethylamine. The on mixture was stirred at room temperature for 3
hours and extracted with ethyl acetate, washed with 5% citric acid, saturate sodium bicarbonate, brine,
dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified flash column
tography using SiliaSep Cartridges (40g), eluting with 0-100% ethyl acetate/hexanes, to give 405
mg (70%) of compound 19-3.
] Compound 19-4: Compound 19-3 was dissolved in 15 mL 4N HCl/Dioxane. The reaction
e was stirred at room temperature for 2 hours and concentrated in vacuo to give 315 mg (98%) of
compound 19-4. MS (ESI) m/z 379 [M+H].
Compound 19-5: To a solution of compound 14-3 (322 mg, 1 mmol) in 20 mL
dichloromethane was added artin Periodinane (636 mg, 1.5 mmol). The reaction mixture was
d at room temperature for 3 hours. The reaction was quenched with a solution of sodium thiosulfate
(1.4 g, 8.85 mmol) in 15 mL of saturated sodium bicarbonate. The mixture was separated. The organic
layer was washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered and
concentrated in vacuo. The residue was purified by flash column chromatography using SiliaSep
Cartridges (40g), eluting with 0-100% ethyl e/hexanes to give 170mg (53%) of compound 19-5.
Compound 19-6: To a solution of thyldolastatin hydrochloride 1.0 g (1.24 mmol) in
mL of DMF was added 1.19 g (3.72 mmol) of compound 17 followed by 1.4 mL (24.8 mmol) of acetic
acid and 156 mg (2.48 mmol) of sodium cyanoborohydride. The resulting mixture was stirred at room
temperature for 2 hours. The solvent was removed in vacuo. The residue was adjusted to pH 8 by sodium
bicarbonate and extracted with DCM, washed with brine, dried over sodium e, filtered and
concentrated in vacuo. The residue was purified by flash column chromatography using SiliaSep
Cartridges (40g), eluting with 0-5% methanol/DCM to give 680mg (51%) of compound 19-6. MS (ESI)
m/z 538 [M+2H], 1075 [M+H].
Compound 19-7: To a solution of compound 19-6 (680 mg, 0.632 mmol) in 5 mL of DCM
was added 20 mL of 4N HCl/dioxane. The reaction mixture was d at room temperature for 2 hours
and concentrated in vacuo. The e was treated with ether, filtered, washed with ether and dried in
vacuo to give 660 mg (98%) of compound 19-7. MS (ESI) m/z 510 [M+2H], 1019 [M+H].
Compound 19-8: To a solution of compound 19-7 (280 mg, 0.257 mmol), compound 19-4
(38 mg, 0.0857 mmol) and ylmorpholine (0.283 mL, 2.57 mmol) in 5 mL of N-
methylmpyrrolidinone was added 98 mg (0.257 mmol) of HATU. The reaction mixture was stirred at
room temperature for 1 hour. The reaction mixture was purified by HPLC to give 160mg (71%) of
nd 19-8. MS (ESI) m/z 596 [M+4H], 794[M+3H], 1191 [M+2H].
Compound 19: Compound 19-8 (160 mg, 0.0613 mmol) was dissolved in 1.5 mL of DMF.
ML (0.613mmol) of anhydrous hydrazine was added. The resulting solution was stirred at room
temperature for 1 hour. The reaction was quenched with 1N hloride solution. The reaction mixture
was purified by preparative HPLC, eluting with 20-70% CH3CN/H2O in 20 min at 254 nm, to give 120
mg (75%) of compound 19. MS (ESI) m/z 451[M+5H], 563[M+4H], 751 [M+3H], 1126 [M+2H].
Example 20: Synthesis ofCompound 20
Scheme 20
NaH,THF .
Ho/\/o\/\o/\/o\/\OH T T35~o/\/°\/\o/\/°\/\0H m. \/O\/\o/\,O\/§o
-1 20.2 20-3
1. NaBH3CN, MMD, DMF
2. HF. pyridine \
\/\o/\/o\/\NENEiRQI/Rrh‘
OMe O OMe O
204 NS\=/
HCI cool2
o o_/—NH NHZ Clio/\/O\/\o/\/O\/\PINK/N?RQArN
/_/ HCI OMe O OMe O
l N-0 NS\:/
-5
o l DCM, DIEA
0wo~0w0~~3§~w9%%~0 0 CM 0
A CMe e /_S
CFchOH N\_/
0 2H
/—/°f °=<°wo~0wo~~
@_0 ”j:EYOYLH:5CMe 0 0M9 o
38 CF3c00Ho
NHZNHZ
H .\H H
O\/\o/\/ \/\o/\/‘o NEN$$QHWNi 1
O 0 /\ OMeO OMeON,s
NH CFchOH \=,
MEI—{NH
O O=<
/_/ “\jL
°\/\o/\/°\/\o/\/N
H2N‘0 a
CFSCOOHO OMe O OMe ON
CFchOH 39 N\=/s
Compound 20-2: To a solution of tetra (ethylene glycol) 20-1 (8.0 g, 41.2 mmol) in 100 mL
of tetrahedrofuran was added 1.65 g of sodium hydride at 0°C. The on mixture was stirred at room
temperature for 30min. 6.21 g of TBS-Cl was added to this solution. The reaction e was stirred at
room temperature overnight. The reaction mixture was trated in vacuo and quenched with 2 mL of
1 N HCl. The residue was suspended in brine and extracted with ethyl acetate (100 mLXl, 50 mL X2).
The organic layer was combined and washed with brine, dried over sodium sulfate and concentrated in
vacuo. The residue was purified by flash column chromatography to give 5.7g of nd 20-2.
Compound 20-3: To a solution of compound 20-2 (500 mg, 1.62 mmol) in 30 mL
dichloromethane was added artin Periodinane (1.03 g, 2.43 mmol). The reaction mixture was
stirred at room temperature for 3 hours. The reaction was quenched with a solution of sodium thiosulfate
(1.4 g, 8.85 mmol) in 15 mL of saturated sodium bicarbonate. The mixture was separated. The organic
layer was washed with ted sodium onate, brine, dried over sodium sulfate, filtered and
concentrated in vacuo. The residue was purified by flash column chromatography to give 400mg of
compound 20-3.
Compound 20-4: To a on of monomethyldolastatin hydrochloride 213 mg (0.263
mmol) in 4 mL of DMF was added 245 mg (0.75 mmol) of compound 20-3 followed by 0.303 mL (5
mmol) of acetic acid and 34 mg (0.5 mmol) of sodium cyanoborohydride. The resulting mixture was
stirred at room temperature for 2 hours. The solvent was removed in vacuo. 3 mL of 60% acetonitrile was
added, followed by 0.2 mL of HF.Pyridine at 00C. The resulting solution was stirred at room temperature
for 2 hours. The organic solvent was removed in vacuo. The residue was adjusted to pH 8 by sodium
onate and extracted with DCM, washed with brine, dried over sodium sulfate, filtered and
concentrated in vacuo. The residue was purified by flash column chromatography to give 160mg of
compound 20-4. MS (ESI) m/z 474 [M+2H], 947[M+H].
] Compound 20-5: To a on of compound 20-4 (50mg, 0.062 mmol) in 4 mL ofDCM was
added 0.3 mL of phosgene/toluene at 0°C. The reaction mixture was stirred at 0°C for 3 hours and
concentrated in vacuo for next step t purification.
Compound 20-6: To a solution of compound 19-4 (7.6 mg, 0.017 mmol) and compound 20-5
(0.062 mmol) was added 25 [LL of diisopropylethylamine. The reaction mixture was stirred at room
temperature for 1 hour. The reaction e was purified by HPLC, eluting with 20-70% CH3CN/H2O
in 20 min at 254 nm, to give 33 mg of compound 20-6. MS (ESI) m/Z 582[M+4H], 775[M+3H],
1 163 [M+2H].
Compound 20: Compound 20-6 (33 mg, 0.014 mmol) was dissolved in 1 mL of DMF. 14 uL
(0.43mmol) of anhydrous hydrazine was added. The resulting solution was d at room temperature
for 1 hour. The reaction was quenched with 1N hydrochloride solution. The reaction mixture was
d by preparative HPLC, eluting with 20-70%CH3CN/H2O in 20 min at 254 nm, to give 10 mg of
compound 20. MS (ESI) m/z 549[M+4H], 732[M+3H], 1098[M+2H].
Example 21: sis ofCompound 21
Scheme 21
\i J< o
| \ 1
HN\/\1|1H 2 Xor/Nwwmkok
21-1 21 2
4NHCIIDioxane I 1"Ir“fiNfiWNQK'W“
”°1,NH“CY\1“*HCIOOHDECPK+H2jgf/Nr-H\ijLNDAD OMeO OMeO
HN/r 16-11
21-3
NHZ OANHz
2H0 NMP
OH; DH
HOWNwN/Jngfj/\ijLN OMeO OMeO
N,_s
o of"” NH2 + o
Efi‘N-O/—/ Hc' HNJ/ 21-4
19.4 OANHz
HATU
NMP \
1I.grow5
,N\/\rf/\/U\Nj;r-o1 H\jLrm)
OMeO OMeO
NHZNHZ
..“rsiMIMrWIMROflOMeo OMe o ,
CFchOH
° o2NNH2
ofNH | CFchOH Ni orig“
/_/ HNY\/N\/\NNAN MED/w“ OMS O OMe O
HzN-O 0
CF3COOH
CF COOH of
3 21
0 NH2
Compound 21-2: The mixture of N, N’-Dimethy1ene diamine 21-1 (5 mL, 46.5 mmol) and
tert-butyl acrylate 13 mL (116 mmol) was heated at 85 0C for 1 hour. Another 13 mL (116 mmol) of tertbutyl
acrylate was added. The reaction mixture was continuely heated at 85°C for 1 hour and stirred at
room temperature overnight. The reaction mixture was concentrated in vacuo. The residue wasdiluted
with hexanes and purified by flash column tography using SiliaSep Cartridges (120g), eluting with
0-5% ol/DCM to give 10.1 g (62%) of compound 21-2. MS (ESI) m/z 345 [M+H].
] Compound 21-3: To a solution of compound 21-2 (5.0 g, 14.5 mmol) in 50 mL of DCM was
added 40 mL of 4N HCl/dioxane. The reaction mixture was stirred at room temperature for 2 days and
concentrated in vacuo. The e was treated with ether, d, washed with ether and dried in vacuo
to give 4.3 g (97%) of compound 21-3.
] Compound 21-4: To a solution of 166 mg(0.544 mmol) of compound 21-3 and 0.15 mL of
N—methylmorpholine in 10 mL of N—methylpyrrolidinone was added 160 mg of compound 16—11,
followed by 0.068 mL (0.408 mmol) of DECP. The on mixture was stirred at room temperature for 1
hour. The reaction mixture was purified by preparative HPLC, eluting with 35-70% CH3CN/H2O in 20
min at 254 nm, to give 100 mg (50%) of compound 21-4. MS (ESI) m/z 464[M+3H], 696 [M+2H], 1391
[M+H].
Compound 21-5: To a solution of compound 19-4 (11 mg, 0.025 mmol), compound 21-4 (115
mg, 0.077 mmol) and N—methylmorpholine (0.028 mL, 0.25 mmol) in 1.5 mL thylmpyrrolidinone
was added 29.3 mg (0.077 mmol) of HATU. The reaction mixture was stirred at room temperature for 1
hour. The reaction mixture was purified by HPLC, eluting with 20-70% CH3CN/H2O in 20 min at 254
nm, to give 60 mg (67%) of compound 21-5. MS (ESI) m/z 625 [M+5H], 781 [M+4H], 1041[M+3H].
] Compound 21: Compound 21-5 (60 mg, 0.014 mmol) was dissolved in 1 mL of DMF. 7 uL
(0.21mmol) of anhydrous hydrazine was added. The resulting solution was stirred at room temperature
for 1 hour. The on was quenched with 1N hydrochloride solution. The reaction mixture was
purified by preparative HPLC, eluting with 20-70% CH3CN/H2O in 20 min at 254 nm, to give 29 mg
(58%) of compound 21. MS (ESI) m/z 599[M+5H], 749[M+4H], 998 [M+3H].
Example 22: sis ofCompound 22
Scheme 22
H H H o
\N NJN N N + O
HICI o /i\ I OMeO OMeO c00H NNOV‘O’N
H 0
12-7 19-4 :3“
HATU i
\thrNdLNoH H H
N N
I 3
o I
A OMe0 OMeO N”
CFacOOH 0
JENIROVHo o
H H H \
~~°w°'“
I I H
o /\ OMeO OMeO 0
CF3COOH H
NHZNHZl
‘INNJIoH H
I MNH
o/'\I OMeO 0Meoo NH
CFacOOH
\T 2
i 'i‘ ”N \/\or
o A OMeO OMeO N
CFacOOH 0
Compound 22-1: To a on of nd 19-4 (7.6 mg, 0.017 mmol), compound 12-7 (40
mg, 0.051 mmol) and DIEA (0.030 mL, 0.17 mmol) in 2 mL of DMF was added 32 mg (0.085 mmol) of
HATU. The reaction mixture was stirred at room temperature for 2 hour. The reaction e was
purified by HPLC, eluting with 20-70% CH3CN/H2O in 20 min at 254 nm, to give 24 mg (68%) of
compound 22-1. MS (ESI) m/z 612 [M+3H], 917 [M+2H], 1834[M+H].
Compound 22: Compound 22-1 (24 mg, 0.012 mmol) was dissolved in 1 mL of DMF. 12 uL
(0.36mmol) of anhydrous hydrazine was added. The resulting solution was stirred at room temperature
for 1 hour. The on was quenched with 1N hydrochloride solution. The reaction mixture was
purified by preparative HPLC, eluting with 20-70% CH3CN/H2O in 20 min at 254 nm, to give 15 mg
(58%) of Example 21. MS (ESI) m/z 569[M+3H], 852[M+2H], 1726[M+2H].
Example 23: Synthesis ofCompound 23
Scheme 23
o O
>LOMONTA’TONOWOH fl» NOWO/VOW(:5;
23-1
Naml
\IKO/Nme“15> HZNNOWONOwo/\j\oJ<‘_H2/Pd-c >LChe/:owo/VOWNS
OMe o OMe 0 COOH
23_3
HCI l
3%217%wi o
CF3COOHO OMe o OMe o o
o ”WOVEN \/\o/\)koJ<
H H H “
\N NdLN N N
I O
I I I +
O /\ OMe O OMe O
o N’VOV‘O’VOwo’QkOH
23_ H ”(:NOworN
HATU
CF3COOHO OMe OWE OMe O N/VOw Now/QK° °
$Y%N
CF3COOHO OMe O OMe O
O M/VowoA/Owo“)1”:in«AK/m}?
23-6
QAE; [ NHZNHZ
CF3COOHO OMeO OMeO N~o% ~O\/\ VkNH° °
H/tioLN O CF3COOH
N/\/O\/\O,NH2
0M9 0 0MB 00 ”NOWONOWO H
CF3COOH
Compound 23-1: To a solution of compound 14-3 (4.0 g, 12.4 mmol) and 6.6 mL (37.2
mmol) of DIEA in 50 mL of DCM was added 3.31 g of tolunenesulfonyl chloride at 0°C. The on
mixture was stirred at room temperature for 2 days. The reaction mixture was extracted with ethyl acetate.
The organic layer was combined and washed with 5% citric acid, water, brine, dried over sodium sulfate
and concentrated in vacuo. The residue was purified by flash column chromatography to give 3.5g of
compound 23-1.
Compound 23-2: To a solution of compound 23-1 (3.5 g, 7.34 mmol) in 20 mL DMF was
added solium azide (1.44 g, 22.02 mmol). The reaction mixture was stirred at 50°C for 2 days. The
reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, brine, dried
over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column
chromatography to give 2.1 g of compound 23-2.
Compound 23-3: To a solution of compound 23-2 (2.1 g, 6.05 mmol) in 50 mL MeOH was
added 400 mg (10%) of Pd—C. The resulting mixture was stirred at room temperature under 1 atm Hg for
24 hours. The reaction mixture was filtered and concentrated in vacuo to give 2.1 g of compound 23-3.
MS (ESI) m/z 322[M+H].
Compound 23-4: To a solution of compound 23-3 (33mg, 0.102 mmol), compound 12-7 (40
mg, 0.051 mmol) and 54 [LL of diisopropylethylamine in 1 mL of DMF was added 38 mg of HATU. The
reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was d by HPLC
to give 52 mg of compound 23-4. MS (ESI) m/z 525[M+2H], 1049[M+H].
Compound 23-5: Compound 23-4 (52 mg, 0.045 mmol) was ved in 5 mL 4N
HCl/Dioxane. The reaction mixture was stirred at room ature for 2 hours and concentrated in vacuo
to give 52 mg (100%) of compound 23-5. MS (ESI) m/z 497[M+2H], 993[M+H].
Compound 23-6: To a solution of compound 19-4 (7.6 mg, 0.017 mmol), nd 23-6 (52
mg, 0.051 mmol) and DIEA (0.030 mL, 0.17 mmol) in 2 mL of DMF was added 32 mg (0.085 mmol) of
HATU. The reaction mixture was stirred at room temperature for 2 hour. The reaction mixture was
purified by HPLC, eluting with 20-70% CH3CN/H2O in 20 min at 254 nm, to give 26 mg (61%) of
compound 23-6. MS (ESI) m/z 583[M+4H], 777[M+3H], 1165[M+2H].
Compound 23: Compound 23-6 (26 mg, 0.01 mmol) was dissolved in 1 mL of DMF. 10 [LL
mol) of anhydrous hydrazine was added. The resulting solution was d at room temperature
for 1 hour. The reaction was quenched with 1N hydrochloride solution. The reaction mixture was
purified by preparative HPLC, eluting with 20-70% H2O in 20 min at 254 nm, to give 10 mg
(40%) of Example 23. MS (ESI) m/z 550[M+4H], 733[M+3H], +2H].
Table 1. Structures of Compounds 1-23
Structure
Example
"'2No/\/0\/\o/\/0\/\NIH-IL\ijkRQI/‘WVN
OMe O OMe O
N/N\=/S
2 HZN’O\/\o/\/O\/\NIrH-jLN
OMe o W158OMe 0
N\=IS
WO 66560
2012/039472
0\/\ H “\H
N H
HZN’ H \
g Ii] I
/'\ OMeO OMeO /N
11 H2N\o/\/O\/\o/\/O\/\o/\)LN N\_)LNH H H
\\\ N N
| i |
/\ OMeO OMe O
N/ S
H H H
12 \\ ‘
\N NgLN N N
I o A I OMeO OMeoo N/\/0\/\O,NH2
(AMENo 0 OH
H ”\H H
o o _ mMH/kfi:
“WON“ N\/U\NH | 5 I
o /\ OMeO OMeO
H i H
13 of
o)\NH2
o o
H H H
H2N\o/\/O\/\o/\/0V\O/\)LN NEJL” I I
14 O A OMeO OMeO
H a
HNJ/O
O NH
i H\i H H
N N N
O O m N N
H I I
O /i\ OMeO OMeO
H [WOMEN. N
2 N/ S
H of: H \=/
O NH
i H\i H H
N N N
O O m
H T i T
16 H2N’o\/\0/\)LN N o OMeO OMeO
. N N/ s
H of: H \=/
O NH
WO 66560
17 HZN’OdLN
0 NH
0 o
OJKN HN$N “H H
N N
o O
/\)L “\JL I i I
18 HN2 ‘oNOV‘o’VOV‘o o OMeO OM o
/\ e
I u 0 CH
0 NH
O O
H H H
HNMONOV\ONOV\T¥NEJL%MN:
O I
A OMeO OMeO \3
N I S
19 \:l
o o
H \H H
ofNH HNJVONOWONO$NITN9LNW$YMN
o /=\ I OMeO OMeO
HzN-O N,’_ S,
U »“ H
~ ~
oV‘o/VowO/Vl 5 'i‘
O O /\ OMeO OMeO
N’ S
NH \=I
°>—N
pfNH=<4H o H
N N¢LH N n
OWONOWO’VI ! Iii
H H H
" "
I AIM
N 9*? W
HN OMeO OMeO
‘g’\’N\/\ A
'l H H ’_S
0 if
l o NH2 0 o
H H H
o O/Nokv N%%%N \ o
ofNjH
/_, ”NYVNWN’QL”l N; °/\_ OMeO
H owneoN’s
HZN-O | _
o of
o NH2
NQLNH H H
\N N N
I O/‘\|i OMeO OMeO NH
O :2
H 12
Example 24: Analysis 0fHER-t0x binding to HER2 receptor
Her2-Fc was immobilized on CMS chip to a density of N 280 RU. Flow rate was adjusted to
50 ul/min with HBS-EP as buffer. HerTox ts were injected for 3 min with 15 dissociation phase.
30sec pulse of 20mM HCl was used for regeneration. The Bivalent Analyte model was utilize to fit the
data (Figure 1). Analysis of the data indicates that HerTox HA121-NC2D: Kd N 60 pM (chi2=4) and
HerTox HA121-NC1D: Kd N 300 pM (chi2=l4).
Example 25: ent Transfection
WO 66560 2012/039472
CHO-S culture is seeded at 0.75x10A6/mL approximately 16 hours pre-transfection in
FreeStyle Cho medium. Cells are ready to transfect the next day when the cell count has d 1.4 —
1.6x10A6/mL. When cells reach target count, 400 mM pAF stock is added to a 1.4mM final culture
concentration. PEI/DNA complex is prepared as described: DNA (1.42 ug/1x10A6 cells) is dissolved in
RPMI (5% (v/v) of total culture volume), DNA/RPMI mixture is incubated at room temperature for 2
minutes, PEI stock (1 mg/mL) is added to DNA solution at a 3:1 ratio (mL PEI/ug DNA), and the mixture
is incubated at room ature for 5 min. The culture is gently added to the mixture and swirled. The
flasks are transferred to a 32°C incubator. At day 6 ransfection, a western blot analysis is performed.
At day 7 post-transfection, the atant is harvested.
Example 26: Anti-Her2 variant expression test
30 ml shaker cultures, CHO-S in yle medium; 56 ug DNA in PEI reagent were used.
1.5 mM pAF was also used. At day 6, the supernatant was harvested. Titer was determined by Fc
ELISA. (Figures 2 and 3)
Example 27: In vitro Inhibition ofProliferation Assay
At day 1, the cells were seeded. The media was aspirated and the T-225 culture flasks of cells
was rinsed with 30mL PBS -/. PBS was aspirated and 6 mL of 0.25% Trypsin—EDTA was added to each
flask. The flasks were incubated at 37C, 5%CO2 for 2-5 minutes. Adherent cells were dislodged by
hitting flask and trypsin was neutralized by adding 14mL culture medium. The cell suspension was mixed
and transered to a 50 mL conical tube. The cells were spun down at 1200 rpm, 5 min, room temperature.
The resultant cell pellet was resuspended in 12 mL of e medium. The cells were counted in a
hemacytometer. Cells were seeded at appropriate cell densities into 96-well flat-bottom, clear plates and
incubated overnight at 37°C, 5% C02 to allow cells to attach. Plating volume was 80uL/well. 80uL/well
of culture medium was utilized as the “no cell” control.
Cell plating density es include:
BT474 (high Her2) — 20,000 cells/well in Fl2k/DMEM (50/50), 10% FBS, P/S
MDA—MB-468 (Her2 ve) — 6,000 cells/well in Fl2k/DMEM (50/50), 10% FBS, P/S
HCC1954 — 5,000 cells/well in RPMI 1640, 10% FBS, P/S
SKOV-3 — 6,000 cells/well in RPMI 1640, 10% FBS, P/S
HT29 — 20,000 cells/well in McCoy’ s 5A, 10% FBS, P/S
At day 2, the test samples were added to the cells. The test samples were diluted in culture
medium to a 9x stock concentration in Column 2 of a round-bottom 96-well plate. 3x serial dilutions
were made from Column 2 to Column 11 with a channel or. 10uL/well of the above samples
was added in duplicate to the appropriate wells of the seeded plate. The total volume in the wells was
about 90uL/well. 10uL/well of culture medium was added to avoid edge s for sample wells. Media
Control wells were ed in the inner wells where no sample was added (just 10uL/well of culture
medium) to be used in proliferation calculations. The plates were incubated at 37°C, 5%C02 for 72 hrs.
WO 66560
At day 5, proliferation readout occurred. To detect cell proliferation, lOuL/well of WST-8
reagent was added (Cell Counting Kit-8, cat# CKO4-20, o Labs) to all wells. The plate was
incubated for 4 hrs at 37°C, 5%C02. The plates were measured for absorbance at OD 450nm. Calculation
of proliferation inhibition of test samples: subtract the “no cell control” OD450 value from all wells’
OD450 ; calculate average of the Media Control (untreated) wells; calculate each sample’s %
Media Control value using the formula: (OD450 sample/OD450 avg % Media Control) *100; calculate
the average, standard deviation, and %CV of each ’s duplicate % Media Control values; plot each
samples average % Media l value against sample concentration; calculate ICSO values using 4-
parameter logistic fit regression analysis to determine potency of test samples.
Figure 4 and Figure 5 illustrate results from the in Vitro proliferation assay with dolastatin
linker derivatives and breast cancer line HCCl954, HER2 +++. Figures 6 and 7 illustrate results from the
in Vitro proliferation assay with dolastatin linker derivatives and ovarian cancer line SKOV-3, HER2 +++.
s 8 and 9 illustrate results from the in Vitro proliferation assay with dolastatin linker derivatives and
breast cancer line MDS-MB-468, HER2 negative.
TABLE 2. x Proliferation Assay Summary: IC50 Values [nM] after 72hr drug treatment
Data Set I
Experiment
Date 9/4/10 9/4/10 9/4/10 9/4/10 9/4/10 9/4/10 9/13/10 0 9/13/10
HER2 exp.
(literature/in
house) +++/+++ +++/+++ ?/+++ +++/++++ + +++/++++ +++/+++ +++/+++ ?
In vivo
sensitivity to
Herceptin + + - ? - ? + - ?
HCC195
4 NCI-N87 ZR30
Dolastatin 0.1 0.06 0.2 >30 0.2 >30 0.1 0.1 no fit
NC-Dl 2.7 0.9 11 >100 3.7 >100 2.9 2.1 no fit
NC-D2 2.4 1.5 5.2 >100 3.4 >100 2.8 2.3 no fit
PHC-D2
Herceptin >300 >300 >300 >300 >300 >300 >300 >300 >300
Mab HA121-
NC-Dl 0.2 0.1 >10 >10 (0.04)* >10 0.2 no fit 0.3
Mab HA121-
NC-D2 1.0 0.3 >10 >10 0.3 >10 0.4 no fit 0.7
Mab HA121-
PHC-D2
-——-——-==—-
Fab K136-NC-
m III-I...-
Data Set 11
ment Date 9/24/10 9/24/10 10/8/10 10/8/10 10/8/10
HER2 exp. (literature/in
house) ++/? H/H: H/H: :H/H: -/?
In vivo sensitivity to
Herceptin unlikely -- --
- ?
Sa_mpl_e HT29 BT474 HCC1954 SKOV-3 MDA-MB-468
NC-Dl 4 (45)* <0.01 <0.1 <0.1
NC-D2 4 3 <0.01 (0.1)* 0.3
PHC-D2 12 7 2 8 2
Herceptin >300 >300 >300 >300 >300
Mab HA121-
NC-Dl >10 1 0.2 1.3 >30
Mab HA121-
NC-D2 >10 0.8 0.03 (1.3)* >30
Mab HA121-
PHC-D2 5* 2 0.1 0.3 (5.8)*
Fab K136pAF
Fab K136-NC-D1
TABLE 3. In vitro Cellular Data
-----SmallMolecule, IC50, nM ADC, IC50, nM
EGFR C225—HC- C225—NC-
Cancer Cell Line KRAS BRAF MMD NC-D-l C-D-l NC-D-2 C-D-1
expression D-1 D-2
WO 66560
HCT-116 mut wt 0.13 2.14 24.86 5.7 51.73 >100 62.8
HT-29 wt mut 0.1 4.3 1.7 36.9 16.7
SW620 mut wt - 0.14 5 3.2 121 56.8
HCT-15 mut wt ++ 2.65 31.03 >100 >100 >300 >300
A549* mut wt --+ 0.19 6.44 39.82 39.82 >100 >100
Lung H2122 mut wt -- 0.11 12.71 31.76 31.76 >100 >100
H460 mut wt + 0.48 10.4 95.1 95.1 >300 >300
Prostate DU145 wt wt --+ 0.24 4.8 20.51 20.51 >100 >100
Example 28: In vivo anti-tumor efficacy 0fHer2-ADCs in HCCI954 (human breast
carcinoma) xenograft animal model
4 (human breast carcinoma) cells were obtained from American Type Culture
Collection (Manassas, VA) and cultured in RPMI + 10% FBS, 37°C, 5% C02 until 80% confluent. Cells
were harvested by trypsinization and suspended in PBS at 1 X 108 cells/mL.
Female, SClD—beige mice, 5—8 weeks old, were obtained from Charles River Laboratories.
HCCl954 cells (human, breast carcinoma, ATCC, # 38) were mixed l:l with Matrigel (BD
Biosciences, Bedford MA) and injected subcutaneously into the mice. When tumors reached an average
size of 100—200 mm3, mice were sorted into groups of 9—10 mice each. r measurements were taken
twice weekly until the end of the study. To estimate tumor volume, two orthogonal diameters were
measured with calipers and the values entered into the formula, (L X W X W)./2=V, (Where W=the shortest
diameter, L=the longest diameter and V=volume), to obtain an estimated volume. The tumor volume was
ted to tumor weight in the Excel data file by assuming 1 mm3 = l mg. Endpoint was based on a
study design of tumor growth inhibition (TGl). When the mean tumor volume of the control group
reached . 1,000 mm3 all mice were ized or day 28, whichever came first.
Mice were given a single IV injection (tail vein) on day 1 of dosing. Test article was
ved at 4 mg/mL, 2 mg/mL and 0.66 mg/mL and administered at a dose volume of 5 mL/kg to
deliver 20, 10 and 3.3 mg/kg. Test articles were: Herceptin® al grade (Trastuzumab), Her2-HS122-
NCD1 (Ab:Drug ratio = 1:2, non-cleavable linker), and Her2-HS122/LK145-HCD1 (Ab:Drug ratio = 1:4,
cleavable linker) See Figure 16.
Example 29: In vivo Studies 0fHer2-Dolastatin linked Derivative
HCCI954 cells were utilized for this study with 107 cells/mouse in Matrigel, SC in the right
flank. Mice were SCID-bg female 4-8 weeks. Grouping was performed at day 5 after cell implantation
(tumors ~100 mm3): sorted into 11 groups of 10 mice each. A single IV dose was given on day 1 of
dosing with each compound at 3 dose levels, 20 mg/kg, 10 mg/kg and 3.3 mg/kg. Tumor volume was
monitored until the endpoint was reached (1,000 mm3 or 60 days). (Figure 10) Paclitaxel 25 mg/kg, 1V,
qod X 5 was employed as the l herapy. The vehicle = 50 mM histamine, 0.1 M NaCl, 5%
trehalose, pH 6. Herceptin® clinical grade (Trastuzumab), Her2-HS122-NCD1 (non-cleavable linker)
and Her2-HS122/LK145-HCD1 (cleavable linker) were tested. (Figures lland 12)
Table 4. ation of T/C (Treated / Control) for the HCC1954 study at day 28
Median
Tumor
olume
Group 11 Schedule (mm3) T/C
1# 10 vehicle - iv qd x 1 486 --
2 10 trastuzumab 3.3 iv qd x 1 405 0.833
3 10 trastuzumab 10 iv qd x 1 446 0.918
4 10 trastuzumab 20 iv qd x 1 385 0.792
10 Her-HS122-NC1D-002 3.3 iv qd x 1 40 0.082
6 10 122-NC1D-002 10 iv qd x 1 14 0.029
7 10 Her-HS122-NC1D-002 20 iv qd x 1 18 0.037
8 10 Her-HS122/LK145-HC1D-001 3.3 iv qd x 1 40 0.082
9 10 Her-HS122/LK145-HC1D-001 10 iv qd x 1 25 0.051
10 Her-HS122/LK145-HC1D-001 20 iv qd x 1 18 0.037
11 10 paclitaxel 25 iv qod x 5 18 0.037
Example 30: Pharmacokinetic studies
Assay was performed that detected antibody binding to ErbB2 receptor. (Figure 13) Assay was
performed that detected at least two dolastatins linked to an antibody (Figure 14).
Figure 15.
Example 31: entfor Breast Cancer
Human Clinical Trial of the Safety and/0r Efficacy of Trastuzumab-Linked Dolastatin Derivative
for Breast Cancer y
Objective: To compare the safety and pharmacokinetics of administered composition comprising
trastuzumab-linked dolastatin derivative.
Study Design: This study will be a Phase I, -center, open-label, randomized dose escalation
study followed by a Phase II study in breast cancer patients. Patients should not have had exposure to
trastuzumab-linked dolastatin derivative prior to the study entry. Patients must not have ed
treatment for their cancer within 2 weeks of beginning the trial. Treatments include the use of
chemotherapy, hematopoietic growth s, and ic therapy such as monoclonal antibodies.
Patients must have recovered from all ties (to grade 0 or 1) associated with previous treatment. All
subjects are evaluated for safety and all blood collections for pharmacokinetic analysis are collected as
led. All studies are performed with institutional ethics committee approval and patient consent.
Phase 1: Patients receive i.v. zumab-linked dolastatin derivative on days 1, 8, and 15 of each
28-day cycle. Doses of trastuzumab-linked dolastatin derivative may be held or modified for toxicity
based on assessments as outlined below. Treatment repeats every 28 days in the absence of unacceptable
toxicity. Cohorts of 3-6 patients receive escalating doses of trastuzumab-linked dolastatin derivative until
the maximum tolerated dose (MTD) for zumab-linked dolastatin derivative is determined. The MTD
is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Dose limiting toxicities are determined according to the definitions and standards set by the National
Cancer Institute (NCI) Common ology for Adverse Events (CTCAE) Version 3.0 (August 9,
2006).
Phase 11: Patients e trastuzumab-linked dolastatin tive as in phase I at the MTD
determined in phase 1. Treatment repeats every 4 weeks for 2-6 courses in the absence of disease
progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve
a complete or partial response may receive an additional 4 courses. ts who maintain stable disease
for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses
at the time of disease ssion, provided they meet al eligibility criteria.
Blood Sampling Serial blood is drawn by direct vein puncture before and after administration
of trastuzumab-linked dolastatin derivative. Venous blood samples (5 mL) for determination of serum
concentrations are obtained at about 10 minutes prior to dosing and at imately the ing times
after dosing: days 1, 8, and 15. Each serum sample is divided into two aliquots. All serum samples are
stored at -20°C. Serum samples are shipped on dry ice.
Pharmacokinetics: Patients undergo plasma/serum sample tion for pharmacokinetic
evaluation before beginning treatment and at days 1, 8, and 15 . Pharmacokinetic parameters are
calculated by model independent methods on a Digital Equipment Corporation VAX 8600 computer
system using the latest version of the BIOAVL software. The following pharmacokinetics parameters are
determined: peak serum concentration (Cmax); time to peak serum concentration (tmax); area under the
concentration-time curve (AUC) from time zero to the last blood sampling time (AUC 042) calculated with
the use of the linear oidal rule; and terminal ation half-life (t1/2), computed from the
elimination rate constant. The elimination rate constant is ted by linear sion of consecutive
data points in the al linear region of the log-linear concentration-time plot. The mean, standard
deviation (SD), and coefficient of variation (CV) of the pharmacokinetic parameters are calculated for
each treatment. The ratio of the parameter means (preserved ation/non—preserved formulation) is
calculated.
Patient se to combination therapy: Patient response is assessed via imaging with X-
ray, CT scans, and MRI, and imaging is performed prior to beginning the study and at the end of the first
cycle, with additional imaging performed every four weeks or at the end of subsequent cycles. Imaging
modalities are chosen based upon the cancer type and feasibility/availability, and the same imaging
modality is ed for similar cancer types as well as throughout each patient’s study course. Response
rates are determined using the RECIST criteria. (Therasse et al, J. Natl. Cancer Inst. 2000 Feb 2;
92(3):205-l6; http://ctep.cancer.gov/forms/TherasseRECISTJNCIpdf). ts also undergo
/tumor biopsy to assess changes in progenitor cancer cell phenotype and clonogenic growth by flow
cytometry, Western blotting, and IHC, and for changes in cytogenetics by FISH. After tion of
study treatment, patients are followed periodically for 4 weeks.
Example 32: Treatmentfor Breast Cancer
Human Clinical Trial of the Safety and Efficacy of Trastuzumab-Linked Dolastatin
Derivative for Breast Cancer Therapy
Objective: Compare the efficacy and toxicity of trastuzumab-linked atin derivative
alone followed at e progression by combination trastuzumab and paclitaxel vs first-line combination
trastuzumab and paclitaxel in women with verexpressing metastatic breast cancer.
Study Design: This study is a randomized, multicenter study. Patients are stratified according to
degree of HER2/neu-overexpression (2+ vs 3+), prior anthracycline-containing adjuvant treatment (no
prior treatment vs prior treatment without radiotherapy to left chest wall vs prior treatment with
radiotherapy to left chest wall), estrogen-receptor status (positive vs negative vs unknown), prior therapy
(first-line vs second/third-line), and center. Patients are randomized to one of two treatment arms. Arm I:
Patients receive zumab-linked dolastatin derivative IV over 30-90 minutes weekly. At time of
disease progression, ts receive combination trastuzumab-linked dolastatin derivative IV and
paclitaxel IV as in arm II. Arm II: Patients receive trastuzumab-linked dolastatin derivative IV over 30-90
minutes . Paclitaxel is administered IV over 1 hour weekly for 3 weeks followed by 1 week of rest.
Treatment continues in both arms in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and day l of s 2, 3, 4, 5, 6, 8, 10, and 12. Patients are
followed at l, 3, and 6 months and then every 6 months thereafter.
e 33: Treatmentfor Bladder Cancer
Objective: Determine the acute toxicity of paclitaxel and radiotherapy with or without a atin
derivative bed herein in patients who have undergone prior transurethral bladder resection for
muscle-invasive transitional cell carcinoma of the bladder.
Disease Characteristics: Histologically or cytologically is confirmed y tional cell
carcinoma (TCC) of the bladder; histologic ce of muscularis propria invasion; meets l of the
following stage criteria: stage T2-4a; NX, NO, or N1; and M0 disease or clinical stage Tl, grade 3/3
disease AND requires definitive local therapy; tumor involvement of the prostatic urethra allowed
ed the following ia are met: tumor is visibly completely resected; no evidence of stromal
invasion of the prostate, no evidence of distant metastases by chest x-ray or CT scan AND
abdominal/pelvic CT scan; has undergone transurethral bladder resection (as thorough as is judged safely
possible) within the past 3-8 weeks, including bimanual examination with tumor mapping; sufficient
tumor tissue available for HER2/neu analysis; not a candidate for radical cystectomy.
Study Design: This study is a ndomized, multicenter study. Patients are assigned to 1 of 2
treatment groups according to HER2/neu status (HER2/neu 2+ or 3+ staining [group 1] vs HER2/neu O or
1+ ng [group 2]).
Group 1: Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and a
dolastatin tive described herein Via IV over 90 minutes on day 1 and then over 30 minutes on days
8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26,
29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable
toxicity.
Group 2: Patients receive axel and undergo radiotherapy as in group 1. After completion of
study treatment, patients are followed at 4-5 weeks, every 3 months for 1 year, every 4 months for 1 year,
every 6 months for 3 years, and then annually thereafter.
Example 34: Treatmentfor Ovarian Cancer
Human Clinical Trial of the Safety and y of aDolastatin Derivative described herein
for Ovarian Cancer Therapy
Objective: Evaluate the safety and efficacy of a four week once weekly IV dosage of
ition sing a dolastatin derivative described herein in women with HER2-overexpressing
ovarian cancer.
Study Design: This study is a non-randomized, open-label, 11 week, enter study. This study
will evaluate the safety profile of four once weekly IV dosage, the MTD, PK and immunogenicity of
trastuzumab-linked dolastatin derivative. Patients are assigned to a single group. Patients receive one
dose of trastuzumab-linked dolastatin derivative once a week for 4 weeks. Trastuzumab-linked dolastatin
derivative will be administered by IV infusion on Study Days 1, 8, 15, and 22. Urine s will be
taken on days 1 and 22.
Blood Sampling Serial blood is drawn by direct vein puncture before and after administration
of the atin derivative. Venous blood samples (5 mL) for determination of serum concentrations are
obtained at about 10 minutes prior to dosing and at approximately the following times after dosing: days
1, 2, 4, 5, 8, 15, 22, 36, 43 and 50. Each serum sample is diVided into two aliquots. All serum samples are
stored at -20°C. Serum samples are shipped on dry ice.
Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of
life is ed at baseline and day 1 of courses 2, 3, 4, 5, 6, 8, 10, and 12. Patients are followed on days
29. 36, 43, and 50. Patients will be asked about adverse events. Patients will have an imaging scan and
ECG to evaluate tumor siz and heart function (day 43). At the termination of the study ts will have
a physical exam day 50). ts with evidence of disease regression may receive continued therapy until
evidence of ssion of disease is documented.
Claims (53)
1. A compound, of Formula (I) or salt thereof: Me Me Me O Me H H L N N Me (I) Y N N R7 O Me OMe O Me Me MeO NH O Z ; 5 wherein: Z has the structure of: R5 ; R5 is H, COR8, C1-C6alkyl, or thiazole; R8 is OH or –NH–(alkylene–O)n–NH2; 10 R6 is OH or H; Ar is phenyl or pyridine; R7 is C1-C6alkyl or hydrogen; Y are each selected from the group consisting of an hydroxylamine, methyl, aldehyde, protected aldehyde, ketone, protected ketone, thioester, ester, dicarbonyl, 15 ine, amidine, imine, diamine, azide, keto-amine, keto-alkyne, alkyne, cycloalkyne, and ene-dione; L is a linker selected from the group consisting of ene–, –alkylene–C(O)–, – (alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–C(O)–, –(alkylene–O)n– '–NHC(O)–(CH2)n''–C(Me)2–S–S–(CH2)n'''–NHC(O)–(alkylene–O)n''''– 20 alkylene–, –(alkylene–O)n–alkylene–W–, –alkylene–C(O)–W–, –(alkylene–O)n– alkylene–U–alkylene–C(O)–, and –(alkylene–O)n–alkylene–U–alkylene–; provided that when R5 is H, C1-C6alkyl or le or R8 is OH, L is not alkylene or – (alkylene-O)n-alkylene; W has the structure of: Me Me O O O N N H H O NH2 ; U has the structure of: CO2H O ; or L is , Y is , R5 is COR8, and R8 is –NH–(alkylene–O)n–NH2; 5 and each n, n', n'', n''' and n'''' are independently integers greater than or equal to one.
2. The compound of claim 1, wherein R5 is thiazole.
3. The compound of claim 1, wherein R6 is H.
4. The compound of claim 1, wherein Ar is phenyl. 10
5. The compound of claim 1, wherein R7 is methyl.
6. The compound of claim 1, where n is an integer from 0 to 20.
7. The compound of claim 1, where n is an integer from 0 to 10.
8. The compound of claim 1, where n is an integer from 0 to 5.
9. The compound of claim 1, wherein Y is cyclooctyne. 15
10. The nd of claim 9, wherein the cyclooctyne has a structure of: (R19)q ; each R19 is independently selected from the group ting of C1-C6 alkyl, C1-C6 alkoxy, ester, ether, thioether, aminoalkyl, halogen, alkyl ester, aryl ester, amide, aryl amide, alkyl halide, alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, 20 sulfonyl ester, halosulfonyl, nitrile, alkyl nitrile, and nitro; and q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.
11. The compound of claim 1, wherein Y is azide.
12. The compound of claim 1, comprising Formula (II): Me Me Me O Me H H H2N L N N Me (II) O N N R7 O Me OMe O Me Me MeO NH N Ph 5
13. The compound of claim 12, wherein L is –(alkylene–O) n–alkylene–C(O)–.
14. The compound of claim 13, wherein each alkylene is –CH2CH2–, n is equal to 4, and R7 is methyl.
15. The compound of claim 12, wherein L is lene–O) n–(CH2)n'–NHC(O)–(CH2)n''– C(Me)2–S–S–(CH2)n'''–NHC(O)–(alkylene–O)n''''–alkylene–. 10
16. The compound of claim 15, n each alkylene is –CH2CH2–, n is equal to 1, n' is equal to 2, n'' is equal to 1, n ''' is equal to 2, n'''' is equal to 4, and R7 is methyl.
17. A compound of Formula (III), (IV), (V) or (VI), or salt thereof,: Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z Me Me Me (III) Y O Me H H N N L3 N N Me R7 O Me OMe O Me Me MeO NH O Z ; Me Me Me O Me H H Me N N N N Me Me O Me OMe O Me Me MeO NH O Ar HN L2 Me Me Me (IV) O Me R6 H H Me N N Me L1 N N Me O Me OMe O V Me Me MeO NH HN L3 Ar O R6 ; Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z Y Me Me Me O Me H H (V) N N L3 N N Me R7 O Me OMe O Me Me MeO NH J O Z Me Me Me O Me H H N N L4 N N Me R7 O Me OMe O Me Me MeO NH O Z ; Me Me Me O Me H H Me N N N N Me Me O Me OMe O Me Me MeO NH O Ar HN L2 Me Me Me O Me R6 H H Me N N L1 N N Me Me O Me OMe O Me Me MeO NH HN L3 (VI) Ar O Me Me Me O Me R6 H H J Me N N N N Me Me O Me OMe O Me Me MeO NH HN L4 Ar O wherein: Z has the structure of: R5 ; 5 R5 is H, COR8, C1-C6alkyl, or le; R8 is OH; R6 is OH or H; Ar is phenyl or pyridine; R7 is C1-C6alkyl or hydrogen; 10 Y and V are each selected from the group consisting of an hydroxylamine, methyl, aldehyde, protected de, ketone, protected ketone, thioester, ester, dicarbonyl, hydrazine, amidine, imine, diamine, azide, keto-amine, lkyne, alkyne, cycloalkyne, and ene-dione; L1, L2, L3, and L4 are each linkers independently selected from the group consisting of 15 a bond, –alkylene–, –(alkylene–O)n–alkylene–J–, –alkylene'–J–(alkylene–O)n– alkylene–, –J–(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–J–(alkylene– O)n'–alkylene–J'–, –(alkylene–O)n–alkylene–J–alkylene'–, –W–, –alkylene–W–, alkylene'–J–(alkylene–NMe)n–alkylene–W–, –J–(alkylene–NMe)n–alkylene–W–, – J–alkylene–NMe–alkylene'–NMe–alkylene''–W–, and –alkylene–J–alkylene'– NMe–alkylene''–NMe–alkylene'''–W–; 5 W has the structure of: Me Me O O O N N H H O NH2 ; each J and J' independently have the structure of: O O O N N O or N H , H , H ; and each n and n' are independently integers greater than or equal to one. 10
18. The compound of claim 17, wherein the compound is of a (VII): Me Me Me O Me H H Me N N N N Me Me O Me OMe O Me Me MeO NH O Ar HN L2 Me Me Me (VII) O Me R6 H H Me N N L1 N N Me Me O Me OMe O V Me Me MeO NH HN L3 Ar O R6 .
19. The nd of claim 18, wherein L1 is –(alkylene–O)n–alkylene–J–, L2 is –alkylene'–J'– (alkylene–O)n'–alkylene–, L3 is –J''–(alkylene–O)n''–alkylene–, alkylene is –CH2CH2–, alkylene' is –(CH2)4–, n is 1, n' and n'' are 3, J has the structure of H , J' and J'' have N O the structure of H , and R7 is methyl.
20. The nd of claim 18, wherein the compound is of Formula (IV) and wherein L1 is – J–(alkylene–O)n–alkylene–, L2 is –(alkylene–O)n'–alkylene–J'–alkylene'–, L3 is –(alkylene– 5 O)n''–alkylene–J''–, alkylene is –CH2CH2–, alkylene' is –(CH2)4–, n is 1, n' and n'' are 4, and J, J' and J'' have the structure of H .
21. A compound of Formula (VIII) or (IX): Me Me Me O Me H H L N N O N N Me R N R7 O Me OMe O Me Me (VIII) MeO NH B O Z A O R3 R4 R3 R2 R1 ; Me Me Me O Me H H Me R6 Me N N N N N (IX) Me O Me OMe O Me Me OMe O O NH R3 R3 R1 L NH O A N B O R2 R ; 10 wherein: A is al, and when present is lower alkylene, lower lkylene, lower alkenylene, lene, lower heteroalkylene, lower heterocycloalkylene, arylene, heteroarylene, alkarylene, aralkylene; B is optional, and when present is a linker selected from the group consisting of lower 15 alkylene, lower alkenylene, lower heteroalkylene, -O-, -O-(alkylene)-, -S-, -S- (alkylene)-, -S(O)k- where k is 1, 2, or 3, -S(O)k(alkylene)-, -C(O)-, -C(O)- (alkylene)-, -C(S)-, -C(S)-(alkylene)-, -N(R’)-, -NR’-(alkylene)-, -C(O)N(R’)- , -CON(R’)-(alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene)-, -N(R’)CO-(alkylene)- , -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)- , S(O)kN(R’)-, -N(R’)-N=, -C(R’)=N-, -C(R’)=N-N(R’)-, -C(R’)=N- 5 N=, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where each R’ is independently H,or alkyl; R is H, alkyl, or cycloalkyl; R1 is H, an amino ting group, resin, at least one amino acid, polypeptide, or polynucleotide; 10 R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; R3 and R4 are each independently H, halogen, lower alkyl, or R 3 and R4 or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl; Z has the structure of: 15 R5 ; R5 is H, COR8, lkyl, or thiazole; R8 is OH; R6 is OH or H; Ar is phenyl or ne; 20 R7 is C1-C6alkyl or en; L is a linker selected from the group consisting of–alkylene–C(O)–, –(alkylene–O)n– alkylene–C(O)–, –(alkylene–O)n–(CH2)n'–NHC(O)–(CH2)n''–C(Me)2–S–S–(CH2)n'''– NHC(O)–(alkylene–O)n''''–alkylene–, –(alkylene–O)n–alkylene–W–, –alkylene– C(O)–W–, –(alkylene–O)n–alkylene–U–alkylene–C(O)–, and –(alkylene–O)n– 25 alkylene–U–alkylene–; W has the structure of: Me Me O O O N N H H O NH2 ; U has the structure of: CO2H O ; and each n, n', n'', n''' and n'''' are independently integers greater than or equal to one; 5 or solvate thereof.
22. The compound of claim 21, wherein R1 is a polypeptide.
23. The compound of claims 22, wherein the polypeptide is an antibody.
24. The nd of claim 23, wherein the antibody is zumab.
25. The compound of claim 21, wherein R2 is a polypeptide. 10
26. The compound of claims 25, wherein the polypeptide is an dy.
27. The compound of claim 26, wherein the antibody is trastuzumab.
28. A compoundof Formula (X), (XI), (XII) or (XIII) or salt thereof: Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z Me Me Me O O Me (X) R N H H N N L3 N N Me A O R7 O Me OMe O Me Me MeO NH R3 R4 R2 O Z R1 ; Me Me Me O Me Me O H H H Me N N N N N N L2 Me O Me OMe O OMe O Me Me Ar R6 R2 R1 L1 (XI) Me Me Me R3 O Me Me O A H O H H R3 Me N N N N B N N N L3 Me O Me OMe O OMe O R Me Me Ar R6 ; Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z Me Me Me O O Me R N H H N N (XII) L3 N N Me A O R7 O Me OMe O R3 R4 Me Me MeO NH R2 J Me O Z R3 Me Me HN O Me R1 H N N L4 N N Me R7 O Me OMe O Me Me MeO NH O Z ; Me Me Me O Me Me O H H H Me N N N N N N L2 R7 O Me OMe O OMe O Me Me Ar R6 R2 R1 L1 (XIII) Me Me Me R3 O Me Me O O A H H H R3 Me N N N N B N N N L3 R7 O Me OMe O H OMe O R Me Me Ar R6 Me Me Me O Me Me O H H H Me N N N N N N L4 R7 O Me OMe O H OMe O Me Me Ar R6 5 n: A is optional, and when present is lower alkylene, lower cycloalkylene, lower alkenylene, alkynylene, lower heteroalkylene, lower heterocycloalkylene, arylene, heteroarylene, lene, or aralkylene; B is optional, and when present is a linker selected from the group consisting of lower 5 alkylene, lower alkenylene, lower heteroalkylene, -O-, -O-(alkylene)-, -S-, -S- (alkylene)-, -S(O)k- where k is 1, 2, or 3, -S(O)k(alkylene)-, -C(O)-, -C(O)- (alkylene)-, -C(S)-, -C(S)-(alkylene)-, -N(R’)-, -NR’-(alkylene)-, -C(O)N(R’)- , -CON(R’)-(alkylene)-, -CSN(R’)-, -CSN(R’)-(alkylene)-, -N(R’)CO-(alkylene)- , -N(R’)C(O)O-, -S(O)kN(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(S)N(R’)- 10 , -N(R’)S(O)kN(R’)-, -N(R’)-N=, =N-, -C(R’)=N-N(R’)-, -C(R’)=NN =, -C(R’)2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, or alkyl; R is H, alkylor cycloalkyl; R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or 15 polynucleotide; R2 is OH, an ester ting group, resin, at least one amino acid, polypeptide, or polynucleotide; R3 and R4 are each independently H, halogen, lower alkyl, or R 3 and R4 or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl; 20 Z has the structure of: R5 ; R5 is H, CO2H, C1-C6alkyl, or thiazole; R6 is OH or H; Ar is phenyl or ne; 25 R7 is C1-C6alkyl or hydrogen; L1, L2, L3, and L4 are each s ndently ed from the group consisting of a bond, –alkylene–, –(alkylene–O)n–alkylene–J–, –alkylene'–J–(alkylene–O)n– alkylene–, –J–(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–J–(alkylene– O)n'–alkylene–J'–, –(alkylene–O)n–alkylene–J–alkylene'–, –W–, –alkylene–W–, ne'–J–(alkylene–NMe)n–alkylene–W–, –J–(alkylene–NMe)n–alkylene–W–, – J–alkylene–NMe–alkylene'–NMe–alkylene''–W–, and –alkylene–J–alkylene'– NMe–alkylene''–NMe–alkylene'''–W–; W has the structure of: Me Me O O O N N H H 5 O NH2 ; each J and J' independently have the structure of: O O O N N O or N H , H , H ; and each n and n' are independently integers r than or equal to one. 10
29. The compound of claim 28, n R1 is a polypeptide.
30. The compound of claims 29, wherein the polypeptide is an dy.
31. The compound of claim 30, wherein the antibody is trastuzumab.
32. The compound of claim 28, wherein R2 is a polypeptide.
33. The compound of claims 32, wherein the polypeptide is an antibody. 15
34. The compound of claim 33, wherein the antibody is trastuzumab.
35. A method for derivatizing a dolastatin analog of Formula (I), (III), (IV), (V), or (VI) so as to produce a derivative of said dolastatin analog, the method comprising contacting the dolastatin analog with a reagent of Formula (XXXVII), wherein Formula (I), (III), (IV), (V), or (VI) correspond to: Me Me Me O Me H H L N N Me (I) Y N N R7 O Me OMe O Me Me MeO NH 20 O Z ; Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z Me (III) Y Me Me O Me H H N N L3 N N Me R7 O Me OMe O Me Me MeO NH O Z ; Me Me Me O Me H H Me N N N N Me Me O Me OMe O Me Me MeO NH O Ar HN L2 Me Me Me (IV) O Me R6 H H Me N N N N Me L1 Me O Me OMe O V Me Me MeO NH HN L3 Ar O R6 ; Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z Y Me Me Me O Me H H (V) N N L3 N N Me R7 O Me OMe O Me Me MeO NH J O Z Me Me Me O Me H H N N L4 N N Me R7 O Me OMe O Me Me MeO NH O Z ; Me Me Me O Me H H Me N N N N Me Me O Me OMe O Me Me MeO NH O Ar HN L2 Me Me Me O Me R6 H H Me N N L1 N N Me Me O Me OMe O Me Me MeO NH HN L3 (VI) Ar O Me Me Me O Me R6 H H J Me N N N N Me Me O Me OMe O Me Me MeO NH HN L4 Ar O R6 ; Z has the structure of: R5 ; 5 R5 is H, COR8, C1-C6alkyl, or thiazole; R8 is OH or –NH–(alkylene–O)n–NH2; R6 is OH or H; Ar is phenyl or pyridine; R7 is C1-C6 alkyl or hydrogen; 10 Y is NH2–O– or methyl; L, L1, L2, L3, and L4 are each linkers selected from the group consisting of a bond, – alkylene–, –alkylene–C(O)–, –(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene– C(O)–, –(alkylene–O)n–(CH2)n'–NHC(O)–(CH2)n''–C(Me)2–S–S–(CH2)n'''– NHC(O)–(alkylene–O)n''''–alkylene–, –(alkylene–O)n–alkylene–W–, –alkylene– 15 C(O)–W–, –(alkylene–O)n–alkylene–J–, –alkylene'–J–(alkylene–O)n–alkylene–, – (alkylene–O)n–alkylene–J–alkylene', kylene–O)n–alkylene–, –(alkylene–O)n– alkylene–J–(alkylene–O)n'–alkylene–J'–, –W–, –alkylene–W–, alkylene'–J– (alkylene–NMe)n–alkylene–W–, and J– (alkylene–NMe)n–alkylene–W–, – (alkylene–O)n–alkylene–U–alkylene–C(O)–, –(alkylene–O)n–alkylene–U– alkylene–; –J–alkylene–NMe–alkylene'–NMe–alkylene''–W–, and –alkylene–J– 5 alkylene'–NMe–alkylene''–NMe–alkylene'''–W–; W has the structure of: Me Me O O O N N H H O NH2 ; U has the structure of: CO2H 10 O each J and J' independently have the ure of: O O O N N O or N H , H , H or L is absent, Y is methyl, V is selected from the group consisting of an hydroxylamine, methyl, aldehyde, protected aldehyde, , ted 15 ketone, thioester, ester, dicarbonyl, hydrazine, amidine, imine, diamine, azide, keto-amine, lkyne, alkyne, cycloalkyne, and ene-dione; R5 is COR8, and R8 is –NH–(alkylene–O)n–NH2; and each n, n', n'', n''' and n'''' are independently integers greater than or equal to one; 20 wherein Formula (XXXVII) corresponds to: A K R3 B R (XXXVII) R1 R2 H R4 wherein: A is optional, and when present is lower alkylene, tuted lower alkylene, lower alkenylene, substituted lower alkenylene, arylene, substituted arylene, 5 heteroarylene, substituted heteroarylene, lene, substituted alkarylene, aralkylene, or substituted aralkylene; B is optional, and when present is a linker selected from the group consisting of lower alkylene, lower alkenylene, -O-, -O-()-, -S-, -S-(alkylene)-, - where k is 1, 2, or 3, -S(O)k(alkylene)-, -C(O)-, -C(O)-(alkylene)-, -C(S)-, -C(S)-(alkylene)-, - 10 N(R’)-, -NR’-(alkylene)-, -C(O)N(R’)-, -CON(R’)-(alkylene)-, -CSN(R’)- , -CSN(R’)-(alkylene)-, -N(R’)CO-(alkylene)-, -N(R’)C(O)O-, -S(O)kN(R’)- , C(O)N(R’)-, C(S)N(R’)-, -N(R’)S(O)kN(R’)-, -N(R’)-N=, - C(R’)=N-, -C(R’)=N-N(R’)-, -C(R’)=N-N=, 2-N=N-, and -C(R’)2-N(R’)-N(R’)-, where each R’ is independently H, or alkyl; 15 each R’ is independently H or alkyl; O O S OR' SR' R' O O K is , O , , , , , O , or O R' R is H, alkyl or cycloalkyl; R1 is H, an amino protecting group, resin, at least one amino acid, or polynucleotide; 20 R2 is OH, an ester protecting group, resin, at least one amino acid, or polynucleotide; R3 and R4 are each independently H, halogen, lower alkyl, or R 3 and R4 or two R3 groups optionally form a cycloalkyl or a heterocycloalkyl.
36. The method of claim 35, wherein the derivative of said dolastatin analog is at least one oxime containing amino acid having the ure of Formula (VIII), (IX), (X), (XI), (XII), or (XIII): Me Me Me O Me H H L N N O N N Me R N R7 O Me OMe O Me Me (VIII) MeO NH B O Z A O R3 R4 R3 R2 Me Me Me O Me H H Me R6 Me N N N N N (IX) Me O Me OMe O Me Me OMe O O NH R3 R3 R1 L NH O A N B O R2 5 R Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z O Me Me O Me (X) R N H H N N L3 N N Me A O R7 O Me OMe O Me Me MeO NH R3 R4 R2 O Z Me Me Me O Me Me O H H H Me N N N N N N L2 Me O Me OMe O OMe O Me Me Ar R6 R2 R1 L1 (XI) Me Me Me R3 O Me Me O A H O H H R3 Me N N N N B N N N L3 Me O Me OMe O OMe O R Me Me Ar R6 ; Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH L1 O Z O Me Me O Me R N H H N N (XII) L3 N N Me A O R7 O Me OMe O Me Me R3 R4 MeO NH J O Z R3 R2 Me Me Me HN O R1 H N N L4 N N Me R7 O Me OMe O Me Me MeO NH O Z ; Me Me Me O Me Me O H H H Me N N N N N N L2 R7 O Me OMe O OMe O Me Me Ar R6 R2 R1 L1 (XIII) Me Me Me R3 O Me Me O O A H H H R3 Me N N N N B N N N L3 R7 O Me OMe O H OMe O R Me Me Ar R6 Me J Me Me O Me Me O H H H Me N N N N N N L4 R7 O Me OMe O H OMe O Me Me Ar R6 5
37. The method of claim 35, wherein the dolastatin analog is contacted with the t of Formula (XXXVII) in aqueous solution under mildly acidic conditions.
38. A nd of Formula (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), or (XXX): Me Me Me O Me H H H N L N N N N Me (R16)n H N R7 O Me OMe O R1 Me Me MeO NH (XXV) R4 O Z O R2 ; Me Me Me O Me H H Me R6 Me N N N N N R1 R7 O Me OMe O HN R2 (XXVI) Me Me OMe O O N L H H N R4 O (R16)n Me Me Me O Me Me H H H N N N L2 N N Z R7 O Me OMe O OMe O Me Me N L1 (R16)n Me Me Me H O Me (XXVII) H Me N H H R1 N N N R4 L3 N N Z O R2 R7 O Me OMe O 5 OMe O Me Me Me Me Me O Me Me O H H H Me N N N N N N L2 R7 O Me OMe O OMe O Me Me Ar R6 R1 HN R2 L1 (XXVIII) Me Me Me H O Me R4 O Me O N H H H Me N N N N N N L3 (R16)n R7 O Me OMe O H OMe O Me Me Ar R6 Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O Me Me MeO NH N L1 O Z (R16)n Me Me Me H O Me N H H (XXIX) R1 N N R4 L3 N N Me O R2 R7 O Me OMe O Me Me MeO NH J O Z Me Me Me O Me H H N N L4 N N Me R7 O Me OMe O Me Me MeO NH O Z Me Me Me O Me Me O H H H Me N N N N N N L2 R7 O Me OMe O OMe O Me Me Ar R6 R1 HN R2 Me Me Me H O Me Me O N R4 O H H H Me N N N N N N L3 (R16)n (XXX) R7 O Me OMe O OMe O Me Me Ar R6 Me Me Me O Me Me O H H H Me N N N N N N L4 R7 O Me OMe O OMe O Me Me Ar R6 5 n: Z has the structure of: R5 ; R5 is H, CO2H, C1-C6alkyl, or thiazole; R6 is OH or H; 10 Ar is phenyl or pyridine; R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; 5 R4 is H, halogen, or lower alkyl; R7 is C1-C6alkyl or hydrogen; L, L1, L2, L3, and L4 are each linkers selected from the group consisting of a bond, – alkylene–, –alkylene–C(O)–, ene–J–, –(alkylene–O)n–alkylene–, –(alkylene– O)n–alkylene–C(O)–, –(alkylene–O)n–J–, lene–O)n–J–alkylene–, lene– 10 O)n–(CH2)n'–NHC(O)–(CH2)n''–C(Me)2–S–S–(CH2)n'''–NHC(O)–(alkylene–O)n''''– alkylene–, –(alkylene–O)n–alkylene–W–, –alkylene–C(O)–W–, –(alkylene–O)n– alkylene–J–, –alkylene'–J–(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–J– alkylene', –J–(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–J–(alkylene– lkylene–J'–, –W–, –alkylene–W–, alkylene'–J–(alkylene–NMe)n–alkylene– 15 W–, –J–(alkylene–NMe)n–alkylene–W–, –(alkylene–O)n–alkylene–U–alkylene– C(O)–, –(alkylene–O)n–alkylene–U–alkylene–; –J–alkylene–NMe–alkylene'– NMe–alkylene''–W–, and –alkylene–J–alkylene'–NMe–alkylene''–NMe– alkylene'''–W–; 20 W has the structure of: Me Me O O O N N H H O NH2 ; U has the structure of: CO2H each J and J' independently have the structure of: O O O N N O or N H , H , H ; each n and n' are independently integers greater than or equal to one; and each R16 is ndently selected from the group ting of hydrogen, halogen, alkyl, NO2, and CN. 5
39. The compound of claim 38, wherein R1 is a polypeptide.
40. The compound of claims 39, wherein the polypeptide is an antibody.
41. The compound of claim 40, wherein the antibody is trastuzumab.
42. The compound of claim 38, wherein R2 is a polypeptide.
43. The compound of claims 42, wherein the polypeptide is an antibody. 10
44. The compound of claim 43, wherein the dy is trastuzumab.
45. A compound of Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI): Me Me Me O Me H R3 R3 H H N B L N N R1 A D N N Me R7 O Me OMe O R2 O Me Me MeO NH (XXXI) O Z ; Me Me Me O Me H H Me R6 Me N N N N N Ar ) R7 O Me OMe O Me Me OMe O O NH R3 R3 H L B N D A R1 O R2 ; Me Me Me O Me Me H H H N N N L2 N N Z R7 O Me OMe O OMe O R3 R3 Me Me N B L1 R1 A D R4 Me Me Me (XXXIII) O Me H Me R2 O H N N N L3 N N Z R7 O Me OMe O OMe O Me Me 15 ; Me Me Me O Me Me O H H H Me N N N N N N L2 R7 O Me OMe O OMe O Me Me Ar R6 R3 R3 L1 H B N Me Me Me D A R1 (XXXIII) O Me Me O R4 H H H Me N N N O R2 N N N L3 R7 O Me OMe O OMe O Me Me Ar R6 Me Me Me O Me H H N N L2 N N Me R7 O Me OMe O H R3 R3 Me Me MeO NH N B L1 O Z R1 A D Me Me Me R4 O Me H H R2 O N N (XXXV) L3 N N Me R7 O Me OMe O Me Me MeO NH J O Z Me Me Me O Me H H N N L4 N N Me R7 O Me OMe O Me Me MeO NH O Z Me Me Me O Me Me O H H H Me N N N N N N L2 R7 O Me OMe O OMe O Me Me Ar R6 R3 R3 H L1 B N Me Me Me D A R1 O Me Me O R4 H H H Me N N N O R2 N N N L3 R7 O Me OMe O OMe O Me Me Ar R6 ) Me Me Me O Me Me O H H H Me N N N N N N L4 R7 O Me OMe O OMe O Me Me Ar R6 5 ; wherein: Z has the structure of: R5 ; R5 is H, CO2H, C1-C6alkyl, or thiazole; R6 is OH or H; 5 Ar is phenyl or pyridine; R1 is H, an amino protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; R2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide, or polynucleotide; 10 R4 is H, halogen or lower alkyl; R7 is C1-C6alkyl or hydrogen; L, L1, L2, L3, and L4 are each linkers ed from the group consisting of a bond, – alkylene–, –alkylene–C(O)–, –alkylene–J–, –(alkylene–O)n–alkylene–, –(alkylene– O)n–alkylene–C(O)–, –(alkylene–O)n–J–, –(alkylene–O)n–J–alkylene–, –(alkylene– 15 O)n–(CH2)n'–NHC(O)–(CH2)n''–C(Me)2–S–S–(CH2)n'''–NHC(O)–(alkylene–O)n''''– alkylene–, –(alkylene–O)n–alkylene–W–, –alkylene–C(O)–W–, –(alkylene–O)n– alkylene–J–, ene'–J–(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–J– alkylene', –J–(alkylene–O)n–alkylene–, –(alkylene–O)n–alkylene–J–(alkylene– O)n'–alkylene–J'–, –W–, –alkylene–W–, ne'–J–(alkylene–NMe)n–alkylene– 20 W–, –J–(alkylene–NMe)n–alkylene–W–, –(alkylene–O)n–alkylene–U–alkylene– C(O)–, –(alkylene–O)n–alkylene–U–alkylene–; –J–alkylene–NMe–alkylene'– NMe–alkylene''–W–, and –alkylene–J–alkylene'–NMe–alkylene''–NMe– alkylene'''–W–; 25 W has the structure of: Me Me O O O N N H H O NH2 ; U has the structure of: CO2H each J and J' independently have the structure of: O O O N N O or N 5 H , H , H ; each n and n' are independently integers greater than or equal to one; D has the structure of: R17 R17 R17 Z1 Z1 Z1 Z1 N N N Z1 R17 N N N N N Z1 N M3 NH Z2 N Z2 T , Z2 N , , Z2 T , Z3 T , R17 R17 R17 R17 R17 R17 R17 T3 R17 N R17 N R18 H Z1 Z3 R18 H N (R18)p M4 N M2 N N T3 , T3 , , R17 R17 m(R18) , H H H N N N N N or N , , N N H H , H (R19)q each R17 is independently ed from the group consisting of H, alkyl, alkenyl, 10 alkynyl, alkoxy, alkylalkoxy, polyalkylene oxide, aryl, heteroaryl, alkaryl, aralkyl, -(alkylene)-ON(R”)2, -(alkylene)-C(O)SR”, -(alkylene)-S-S- (aryl), -C(O)R”, -C(O)2R”, or -C(O)N(R”)2, wherein each R” is ndently hydrogen, alkyl, l, alkoxy, aryl, heteroaryl, alkaryl, or aralkyl; each Z1 is a bond, CR17R17, O, S, NR’, CR17R17-CR17R17, 7-O, O-CR17R17, CR17R17-S, S-CR17R17, CR17R17-NR’, or NR’-CR17R17; each R’ is H or alkyl; each Z2 is selected from the group consisting of a bond, -C(O)-, , C1-C3 5 alkylene, C1-C3 alkenylene, and heteroalkyl; each Z3 are independently selected from the group consisting of a bond, C1-C4 alkylene, C1-C4 lene, heteroalkyl, -O-, -S-, -C(O)-, -C(S)-, and -N(R’)-; each T3 is a bond, C(R’’)(R’’), O, or S; with the proviso that when T3 is O or S, R’’ cannot be halogen; 10 each R’’ is H, halogen, alkyl or cycloalkyl; m and p are 0, 1, 2, or 3, provided that at least one of m or p is not 0; (b) (b) C (b) C C (b) C C (b) C O (b) M2 is (a) R3 , (a) R4 R4 , (a) R4 , (a) R4 , (b) (b) (b) R3 C C (b) O C (b) C C (b) C S (b) R3 R4 (a) R4 , (a) , (a) , (a) , or S C (b) (a) , where (a) tes bonding to the B group and (b) indicates 15 bonding to respective positions within the heterocycle group; (b) (b) (b) (b) C (b) C C (b) C O (b) C S (b) M3 is (a) , (a) R4 , (a) , (a) , or C C (b) (a) , where (a) indicates bonding to the B group and (b) indicates bonding to respective positions within the heterocycle group; (b) (b) (b) R3 C C (b) O C (b) C (b) C C (b) M4 is (a) , (a) R3 R3 , (a) , (a) , or S C (b) (a) , where (a) indicates bonding to the B group and (b) indicates g to tive positions within the heterocycle group; each R19 is independently ed from the group ting of C1-C6 alkyl, C1-C6 5 alkoxy, ester, ether, thioether, aminoalkyl, halogen, alkyl ester, aryl ester, amide, aryl amide, alkyl halide, alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, halosulfonyl, nitrile, alkyl nitrile, and nitro; q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and each R18 is independently selected from the group consisting of hydrogen, n, 10 alkyl, NO2, CN, and alkyl.
46. The compound of claim 45, wherein R1 is a polypeptide.
47. The compound of claims 46, wherein the polypeptide is an antibody.
48. The compound of claim 47, wherein the antibody is zumab.
49. The compound of claim 45, wherein R2 is a polypeptide. 15
50. The compound of claims 49, wherein the polypeptide is an antibody.
51. The compound of claim 50, wherein the antibody is trastuzumab.
52. The compound of claim 45, wherein the compound is of Formula (XXXI-A): Me Me Me O Me H H L N N Me B N N N R3 A N N R7 O Me OMe O Me Me MeO NH (XXXI-A) R3 R4 O Z R1 R2 .
53. A pharmaceutical composition comprising a compound of any of claims 1-34 and 38-52 20 and a pharmaceutically acceptable carrier, excipient, or binder.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161491146P | 2011-05-27 | 2011-05-27 | |
US61/491,146 | 2011-05-27 | ||
PCT/US2012/039472 WO2012166560A1 (en) | 2011-05-27 | 2012-05-24 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ618079A NZ618079A (en) | 2016-04-29 |
NZ618079B2 true NZ618079B2 (en) | 2016-08-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020217337B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | |
AU2017216489B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | |
AU2017200877A1 (en) | Prostate-specific membrane antigen antibody drug conjugates | |
NZ618079B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | |
NZ618261B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |